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Genetic loci associated with heart rate variability
and their effects on cardiac disease risk
Ilja M. Nolte et al.#
Reduced cardiac vagal control reﬂected in low heart rate variability (HRV) is associated with
greater risks for cardiac morbidity and mortality. In two-stage meta-analyses of genome-wide
association studies for three HRV traits in up to 53,174 individuals of European ancestry, we
detect 17 genome-wide signiﬁcant SNPs in eight loci. HRV SNPs tag non-synonymous SNPs
(in NDUFA11 and KIAA1755), expression quantitative trait loci (eQTLs) (inﬂuencing GNG11,
RGS6 and NEO1), or are located in genes preferentially expressed in the sinoatrial node
(GNG11, RGS6 and HCN4). Genetic risk scores account for 0.9 to 2.6% of the HRV variance.
Signiﬁcant genetic correlation is found for HRV with heart rate (0.74orgo0.55) and
blood pressure (0.35orgo0.20). These ﬁndings provide clinically relevant biological
insight into heritable variation in vagal heart rhythm regulation, with a key role for genetic
variants (GNG11, RGS6) that inﬂuence G-protein heterotrimer action in GIRK-channel induced
pacemaker membrane hyperpolarization.
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H
eart rate variability (HRV) is a physiological variation in
cardiac cycle duration. When measured under supine or
sitting conditions, resting HRV is most prominently
centred around the frequency of respiration (B0.25Hz) and the
intrinsic blood pressure rhythm (B0.1Hz). This reﬂects
modulation of tonic activity in the cardiac vagal nerves
originating in cortical and subcortical nuclei1 by oscillatory
input at the brainstem level from cardiorespiratory coupling, lung
stretch-reﬂexes, and arterial chemo- and baroreceptors1,2.
This vagal gating gives rise to oscillatory vagal effects on
the pacemaker potentials in the sinoatrial node that scales with
the tonic activity in the vagal nerves and provides a source of
beat-to-beat variation in heart rate. Due to its good
reproducibility3 and ease of measurement, HRV is a widely
used non-invasive research and clinical tool to quantify the
degree of vagal control of heart rate4.
Loss of cardiac vagal control as indexed by low HRV is
associated with mortality in patients with cardiovascular disease5.
Animal research further supports a role for cardiac vagal activity
in preventing sudden death and ventricular ﬁbrillation6. In
addition, hypertension7, end-stage renal disease8 and diabetes9
are all associated with low HRV. Although the above associations
may partly reﬂect impaired cardiac vagal control caused by these
diseases, lowered HRV does not simply indicate disease severity
as it also predicts all-cause mortality10 and cardiac morbidity and
mortality11,12 in apparently healthy individuals.
Large inter-individual differences in HRV exist in the basal
resting state. Family and twin studies have uniformly conﬁrmed a
substantial genetic contribution to resting HRV with heritability
estimates between 25 and 71% (ref. 13). Candidate gene studies
based on current knowledge of parasympathetic nervous system
biology have not yielded results that hold up in replication14.
To improve our understanding of the genetic basis of HRV,
we performed a two-stage meta-analysis of genome-wide
association studies (GWAS) in up to 53,174 individuals
of European ancestry on three HRV traits (the s.d. of the
normal-to-normal inter beat intervals (SDNN), the root mean
square of the successive differences of inter beat intervals
(RMSSD) and the peak-valley respiratory sinus arrhythmia or
high frequency power (pvRSA/HF)). These HRV traits were
measured during resting, basal recordings ranging in length from
ultrashort 10-s electrocardiograms (ECGs) to up to 90min of
sitting or from 2 to 12 h of daytime recording. Relevance of the
identiﬁed loci for other ethnicities was examined in data from
11,234 Hispanic/Latino and 6,899 African-American individuals.
In silico post-GWAS analyses were performed to test for
association with cardiac disease risk factors and disease
outcomes and to provide insights into the biological
mechanisms by which the identiﬁed loci inﬂuence cardiac vagal
control and its effect on HRV.
We detect 17 SNPs in eight loci harbouring several genes
preferentially expressed in the sinoatrial node and signiﬁcant
negative genetic correlations of HRV with heart rate and blood
pressure. These ﬁndings provide clinically relevant biological
insight into heritable variation in vagal heart rhythm regulation,
with a key role for genetic variants in proteins (RGS6, GNG11)
known to inﬂuence G-protein heterotrimer action in
GIRK-channel induced pacemaker membrane hyperpolarization.
Results
New loci associated with HRV. We meta-analysed results from
GWAS on three HRV traits (see Methods section for details)
performed by 20 cohorts of European ancestry in up to 28,700
individuals (Fig. 1; Supplementary Figs 1–3; Supplementary
Tables 1–4). Using a signiﬁcance threshold of 1 10 6,
23 single-nucleotide polymorphism (SNPs) in 14 loci that were
associated with one or more of these HRV traits were taken
forward for wet-lab genotyping or in silico replication in 11
cohorts including up to 24,474 additional individuals of European
ancestry, followed by a second stage meta-analysis
(Supplementary Data 1).
After stage 2, we identiﬁed 17 lead SNPs (11 independent)
in eight loci (Table 1) that reached genome-wide signiﬁcance
(Po5 10 8). The loci on chromosomes 14 and 15 contained
three and two independent signals, respectively, (Supplementary
Fig. 3). Conditional analysis conﬁrmed the presence of
independently associated variants in these loci (Supplementary
Table 5). In total, nine independently associated SNPs in seven
loci were detected for SDNN, nine independently associated SNPs
in eight loci for RMSSD, and ﬁve independently associated SNPs
in ﬁve loci for pvRSA/HF. Many of the SNPs were associated with
at least two of the HRV traits (Supplementary Data 1). In four
loci, the lead SNPs differed between traits but were in linkage
disequilibrium (LD) with each other (0.24or2o0.90) (Table 1).
Forest plots show little heterogeneity in the genetic associations
across the entire set of cohorts for all SNPs (Supplementary
Fig. 4). Sex-stratiﬁed analyses did not show differences in SNP
effects between men and women for the genome-wide associated
loci (Supplementary Table 6). Separately meta-analysing across
cohorts with short laboratory rest recordings versus longer term
ambulatory recordings did not suggest sensitivity of the results to
these different recording methods (Supplementary Table 7).
Results of VEGAS gene-based analyses corroborated those of the
SNP-based analyses (Supplementary Note 1).
Variance explained. Weighted genetic risk scores based on the
independent SNPs that reached genome-wide signiﬁcance after
the second stage meta-analysis were computed for the three HRV
traits and used to predict RMSSD, SDNN and pvRSA/HF in
adults from the Lifelines (n¼ 12,101) and NESDA (n¼ 2,218)
cohorts, adolescents from the TRAILS-Pop cohort (n¼ 1,191),
and children from the ABCD cohort (n¼ 1,094) (Table 2).
The multi-SNP genetic risk scores were all signiﬁcantly associated
with HRV and the percentages of variance explained for the
corresponding traits were 1.0–1.4% for SDNN, 1.1–2.4% for
RMSSD, and 0.9–2.6% for pvRSA/HF. Cross-trait explained
variances of genetic risk scores were close to those for the
corresponding trait.
To test the contribution of SNPs that did not reach
genome-wide signiﬁcance, we performed polygenic risk score
analyses using increasingly more lenient signiﬁcance thresholds
and determined the percentages of explained HRV in the same
four cohorts (Supplementary Fig. 5; Table 3). Maximal variance
explained by the polygenic risk score was 0.8–1.4% for SDNN,
0.9–2.3% for RMSSD and 0.9–2.3% for pvRSA/HF. This was
reached at relatively small numbers of SNPs (r71) with
additional SNPs adding more noise than signal.
The total variance explained by common SNPs (SNP-based
heritability) estimated by Genomic Restricted Maximum
Likelihood or LD score regression analysis varied between 10.8
and 13.2%, with only small differences in estimates across
methods and HRV traits (Supplementary Note 2).
Generalization to other ethnicities. In data from up to 11,234
Hispanic/Latino individuals, ﬁve SNPs in ﬁve of the eight loci
identiﬁed for RMSSD, seven SNPs in six of the seven loci for
SDNN and three SNPs in three of the ﬁve loci for pvRSA/HF
showed a statistically signiﬁcant association that was consistent in
direction with the association in individuals of European ancestry
(Table 4). In data from 6,899 African–Americans, four SNPs from
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four of the eight loci were associated with RMSSD, three SNPs in
three of the seven loci with SDNN and none with pvRSA/HF. In
the combined meta-analysis in a maximum of 71,675 participants
from all ethnicities, one SNP (rs6123471 on chromosome 20) was
no longer signiﬁcant (Table 4).
Correcting HRV for heart rate. The strong inverse association
between HRV and heart rate reﬂects the well-established
simultaneous biological effect of cardiac vagal activity on heart
rate15 and HRV16, but it also expresses a mathematical
dependency of the variance in inter beat interval (IBI) on the
mean IBI that is unrelated to the underlying biology. We
conducted three analyses to test whether the association of the
HRV SNPs was robust to correction of the HRV traits for heart
rate (Supplementary Table 8). First, we used a recently developed
analytical technique17 to obtain the meta-analysis for the
coefﬁcient of variation of SDNN and RMMSD from the
summary statistics of the HRV and resting heart rate
meta-analyses18. The coefﬁcient of variation detects the amount
of IBI variability relative to the mean IBI of each subject, and
deals with the proportionality-based dependence of HRV on
heart rate19. Second, we established the effect of the 17 HRV
SNPs on the coefﬁcients of variation for SDNN and RMSSD in
the Lifelines, NESDA and TRAILS-Pop cohorts, and
meta-analysed the results. Third, we use a mediation analysis in
these same cohorts to see how much of the SNP effects on the
three HRV measures was mediated by heart rate. In all three
analyses, we ﬁnd some attenuation of the HRV SNP associations.
The average mediation of the association by heart rate was
B28%. However, the correction for heart rate left most of the
HRV SNP associations intact, particularly in the ﬁrst analysis that
used the full discovery sample.
Association of the HRV SNPs with resting heart rate. Because
the HRV traits reﬂect cardiac vagal activity, we expected the HRV
SNPs to have an effect on resting heart rate. We performed a
lookup of the 17 HRV SNPs in a GWAS meta-analysis on resting
heart rate in 85,787 individuals18. Out of the 17 HRV lead SNPs,
11 were associated with heart rate after correcting for multiple
testing (Supplementary Table 9, panel a). All effects were in the
expected direction such that the HRV decreasing allele was
associated with higher heart rate (Supplementary Fig. 6). Six of
the HRV SNPs were not signiﬁcantly associated with heart rate,
including our top hit on chromosome 19 (rs12974991 in
NDUFA11: p RMSSD¼ 4.6 10 46; p heart rate¼ 0.18).
Analysis of summary statistics of the HRV and heart rate meta-
analyses as implemented in the gtx R package showed that multi-
SNP genetic risk scores for HRV were signiﬁcantly associated
with heart rate (Supplementary Table 9, panel b).
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Figure 1 | Manhattan plots of the meta-analyses of stage 1 GWAS results. (a) SDNN, (b) RMSSD and (c) pvRSA/HF in up to 28,700 individuals of
European ancestry. Only SNPs with a minor allele frequency41% and that were present in at least 1/3 of the sample are plotted. Signiﬁcant loci are shown
in blue, suggestive ones in red. The blue horizontal line represents the genome-wide signiﬁcance threshold. Genes closest to the lead SNPs are indicated for
the loci that were genome-wide signiﬁcantly associated with the trait after the stage 1þ 2 combined meta-analysis.
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In addition, genetic risk scores based on the independent
genome-wide signiﬁcant HRV SNPs from the combined stage 1
and 2 meta-analysis were tested for association with heart rate in
the Lifelines, NESDA, TRAILS-Pop and ABCD cohorts
(Supplementary Table 9, panel b). The three multi-SNP risk
scores of the HRV traits explained a small, but mostly signiﬁcant
percentage of variance in heart rate (0.09–1.13%). Polygenic
risk score analysis showed that adding HRV SNPs below the
genome-wide signiﬁcance threshold did not further increase the
variance explained in heart rate (Supplementary Fig. 5;
Supplementary Table 9, panel c).
The reverse question, whether SNPs with effects on heart rate
are associated with HRV, was also investigated. The 21 heart rate
SNPs identiﬁed by the GWAS meta-analysis on heart rate18
explained between 0.2 and 0.9% of the variance in the three HRV
traits (Supplementary Table 10).
Association with cardiometabolic traits and diseases.
In addition to heart rate, we examined the association of the 17
HRV-associated SNPs with other conﬁrmed risk factors for
cardiac, metabolic and renal disease traits and endpoints using
data from large-scale GWAS meta-analyses (Supplementary
Table 11). Multi-SNP risk scores were computed based on our
17 top SNPs and we tested their association with the outcomes.
No effects of risk scores using the 17 HRV SNPs were observed
for systolic or diastolic blood pressure, body mass index,
renal function, heart failure, sudden cardiac death, coronary
artery disease, atrial ﬁbrillation or type 2 diabetes. Only for
atrial ﬁbrillation we observed individually signiﬁcant SNPs. These
two highly signiﬁcant SNPs (rs10842383 near LINC00477,
P¼ 3.45 10 7 and rs2680344 in HCN4, P¼ 4.34 10 7
(Supplementary Table 12) had large opposite effects on atrial
ﬁbrillation, while both decreased HRV. In addition to these
lookups that were restricted to genome-wide signiﬁcant SNPs, we
employed bivariate LD score regression20 that uses the full GWAS
summary statistics of the HRV and cardiometabolic traits and
diseases to compute genetic correlations. The genetic correlations
systematically pointed to an overlap in the genetic variants
causing low HRV and increased risk for disease (that is, negative
Table 1 | Stage 1þ 2 combined meta-analysis results for SDNN, RMSSD and pvRSA/HF of loci that were genome-wide signiﬁcant
(Po(5 108)/3) in the analysis of individuals of European ancestry.
Locus Chr SNP Position
(bp)
(build 36)
Closest gene Annotation Trait Allele Stage 1þ2
E/O N EAF b (s.e.) P value
1 19 rs12974991* 5845584 NDUFA11 IN RMSSD A/G 43,205 0.078 0.116(0.008) 4.57E-46
rs12974440* 5845386 IN pvRSA/HFw A/G 29,527 0.073 0.244(0.019) 1.91E-41
rs12980262* 5844058 M SDNN A/G 46,046 0.076 0.060(0.006) 2.30E-23
2 12 rs10842383 24663234 LINC00477 (C12orf67) IG, HRi SDNN C/T 47,808 0.863 0.049(0.004) 9.33E-31
RMSSD 43,223 0.862 0.065(0.006) 2.45E-29
pvRSA/HFw 31,085 0.865 0.124(0.013) 1.20E-25
3 6 rs236349 36928543 PPIL1 IG SDNN G/A 51,379 0.651 0.033(0.003) 3.70E-25
RMSSD 46,795 0.655 0.035(0.004) 9.10E-17
pvRSA/HFw 33,654 0.645 0.069(0.009) 3.16E-15
4 12 rs7980799z 33468257 SYT10 IN, HRii RMSSD A/C 44,210 0.390 0.039(0.004) 3.19E-20
rs1351682z 33490042 IG, HRiii pvRSA/HFw G/A 30,643 0.437 0.073(0.009) 5.70E-15
rs1384598z 33514166 IG, HRiv SDNN T/A 47,358 0.432 0.023(0.003) 7.37E-13
5 7 rs4262y 93389364 GNG11 UTR5, Q, HRv SDNN C/T 49,005 0.390 0.028(0.003) 4.26E-17
pvRSA/HFw 31,281 0.388 0.050(0.010) 1.84E-11
rs180238y 93388383 UP, Q, HRvi RMSSD C/T 44,420 0.333 0.034(0.004) 7.99E-16
6 14b rs4899412|| 71534015 RGS6 IN, Q SDNN T/C 48,252 0.253 0.026(0.004) 3.13E-13
rs2052015|| 71556806 RMSSD T/C 45,492 0.165 0.036(0.006) 3.56E-10
14c rs2529471 71883022 IN SDNN C/A 49,619 0.429 0.021(0.003) 1.88E-12
14a rs36423 71422955 IG SDNN T/G 48,182 0.129 0.033(0.005) 6.25E-13
RMSSD 45,419 0.127 0.040(0.006) 5.36E-11
7 15a rs2680344 71440538 HCN4 IN, HRvii SDNN A/G 51,370 0.777 0.024(0.004) 4.88E-11
15b rs1812835 71294557 NEO1 IN, Q RMSSD A/C 44,421 0.418 0.025(0.004) 5.18E-10
8 20 rs6123471 36273570 KIAA1755 UTR3, HRviii RMSSD T/C 46,789 0.534 0.024(0.004) 1.30E-08
Allele E/O, effect allele/other allele; bp, base pair position based on build 36 (hg18); Chr, chromosome; EAF, effect allele frequency; HR, HRV SNPs that are in pairwise LD (based on SNAP, HapMap
release 22 CEU) with identiﬁed loci associated with heart rate (HR) from den Hoed et al.18; IG, intergenic variant; IN, intronic variant; N, sample size; M, missense variant; Q, associated with an eQTL;
s.e., standard error of b; UTR3, variant in the 30 untranslated region; UTR5, variant in the 50 untranslated region; UP, upstream variant (within 2kb); b, effect size.
NOTE: Only SNPs that were independently associated (that is, lead SNPs) to the traits are shown. At some loci lead SNPs were the same for the different traits, at other loci there were different
(dependent) lead SNPs for the different traits. SNPs are sorted according to P value of the combined meta-analysis per locus. Genome-wide signiﬁcant association (two-sided Po5 108), corrected for
testing three traits (that is, Po5 108/3), is shown in bold. Effect alleles were chosen to reﬂect an increased risk for low levels of HRV, hence b’s are all negative.
i r2¼ 1 between rs10842383 and rs17287293[HR]; ii same SNP; iii r2¼0.782 between rs1351682 and rs7980799[HR]; iv r2¼0.695 between rs1384598 and rs7980799[HR]; v r2¼0.570 between
rs4262 and rs180242[HR]; vi r2¼0.893 between rs180238 and rs180242[HR]; vii r2¼0.505 between rs2680344 and rs4489968[HR]; viii r2¼ 1 between rs6123471 and rs6127471[HR].
*these SNPs are all in perfect LD (r2¼ 1).
wP value, allele, EAF, N from P value weighted meta-analysis of all cohorts using METAL and b, s.e. from inverse-variance meta-analysis of only HF cohorts using GWAMA.
zr2¼0.782 between rs7980799 and rs1351682; r2¼0.695 between rs7980799 and rs1384598; r2¼0.903 between rs1351682 and rs1384598.
yr2¼0.600 between rs4262 and rs180238.
||r2¼0.237 between rs4899412 and rs2052015.
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correlations with systolic and diastolic blood pressure, coronary
artery disease, heart failure, sudden cardiac death, BMI and type 2
diabetes) compatible with clinical relevance of the HRV SNPs
identiﬁed, although signiﬁcance was reached only for systolic and
diastolic blood pressure after correction for number of outcomes
tested (Supplementary Table 11).
Potential functional impact of the HRV variants. To identify
functional variants tagged by the 17 HRV SNPs, we performed
various post-GWAS annotation (Supplementary Fig. 7). In silico
annotation (Supplementary Data 2) showed that the lead SNP for
SDNN on chromosome 19 was a non-synonymous SNP
(rs12980262 in NDUFA11) and that the lead SNPs for RMSSD
(rs12974991) and pvRSA/HF (rs12974440) were in perfect LD
with this SNP (Table 1; Supplementary Data 2). SNP rs129080262
was characterized as deleterious, with a sorting intolerant from
tolerant (SIFT) score of 0.01 and a polymorphism phenotyping
(PolyPhen) score of 0.753 indicating a possibly damaging effect.
Functional variant analyses using RegulomeDB conﬁrmed that
rs12980262 and rs12974440 in NDUFA11 on chromosome 19
likely have functional consequences (Supplementary Table 13) by
binding to transcription factors or inﬂuencing the chromatin
state. SNP rs6123471 in the locus on chromosome 20 was in
high LD with two non-synonymous SNPs in the KIAA1755
gene (rs3746471 [r2¼ 0.94] and rs760998 [r2¼ 0.55]) that are
predicted to yield tolerated, benign amino acid changes
(Supplementary Data 2).
We examined if the 17 HRV SNPs were eQTLs in a large whole
blood database. Four of the HRV SNPs were signiﬁcantly (false
discovery rate o5%) associated with gene expression in blood
(Supplementary Table 14): rs1812835 with expression of NEO1,
rs4899412 with expression of RGS6, and rs180238 and rs4262
with expression of GNG11. These four SNPs were all in strong LD
with the top eQTL SNPs for these genes (r240.70) and lost
signiﬁcance after conditioning on the corresponding top eQTL.
The eQTLs for NEO1 and RGS6 were replicated in at least one
other whole blood eQTL study (Supplementary Table 14). The
eQTL for GNG11 was replicated in the medulla (P¼ 2.8 10 4)
and the anterior tibialis artery (P¼ 8.1 10 9). None of the 17
SNPs reached signiﬁcance in a smaller heart eQTL database.
Nine of the 17 HRV SNPs were in high LD (r240.70) with
SNPs associated with methylation level of one or multiple CpG
sites (methylation quantitative trait loci [mQTLs]) in whole blood
(Supplementary Table 15). Two of the HRV SNPs that were
eQTLs also inﬂuenced methylation of the same gene in whole
blood, strongly suggestive of a regulatory function for those SNPs.
eQTL rs1812835 in NEO1 was associated with methylation level
of cg11357013, cg19281068, cg11552023 and cg17150474. eQTL
rs4262 was associated with methylation level of cg08038054 and
cg06439941 in GNG11. The other two eQTL SNPs did not
achieve genome-wide signiﬁcance level for an association with
methylation, but eQTL rs4899412 in RGS6 was in high LD with a
proxy SNP (rs2238280) that was associated with methylation level
of cg19493789, which is located in a CpG island shelf near RGS6.
Five other HRV SNPs were (in high LD with) mQTLs but were
not themselves eQTLs. For example, HRV SNPs rs12974991,
rs12974440 and rs12980262 (chromosome 19) were associated
with methylation level of multiple CpG sites (cg22854549,
cg03715305 and cg19211619) located in or nearby NDUFA11,
but were not associated with expression level of NDUFA11 in
whole blood. Such mQTLs may well exert a regulatory effect on
NDUFA11 in other tissues. DEPICT tissue enrichment analysis
(Supplementary Data 3; Supplementary Table 16, Supplementary
Fig. 8) showed NDUFA11 expression was weak in blood, but
enriched in heart, sensory and endocrine tissues.
Discussion
This meta-analysis of GWAS for HRV yielded 17 lead SNPs
(11 independent) in eight loci that were genome-wide
signiﬁcantly associated, six of which generalized to individuals
of African-American and Hispanic/Latino ethnicity. Various
ways that correct HRV for its mathematical dependency on
resting heart rate attenuated the SNP effects, but largely left the
associations intact. Together, the hits in the eight loci explained
0.9–2.6% of the variance in resting HRV in four independent
cohorts of European ancestry. Details of known biological
functions of the genes closest to these loci are given in the
Supplementary Note 6.
We noted a strong enrichment of our HRV loci in a
previously conducted meta-analysis of GWAS for resting heart
rate18, a known risk factor for cardiac morbidity and
mortality21,22. SNPs in ﬁve of the 21 resting heart rate loci
(that is, LINC00477 (C12orf67), SYT10, GNG11, HCN4 and
KIAA1755) were associated with HRV at genome-wide
signiﬁcance level and six more attained nominal signiﬁcance,
with associations always in the expected direction. Genetic risk
Table 2 | Explained variance in HRV traits in the Lifelines (n¼ 12,101), NESDA (n¼ 2,118), TRAILS-Pop (n¼ 1,191) and ABCD
(n¼ 1,094) cohorts by the weighted multi-SNP genetic risk score based on the independent genome-wide signiﬁcant SNPs in the
stage 1þ 2 meta-analysis.
Lifelines NESDA TRAILS-Pop ABCDTrait Risk score
No. SNPs P value DR2 No. SNPs P value DR2 No. SNPs P value DR2 No. SNPs P value DR2
SDNN SDNN 9 6.3E-33 1.00% 9 4.9E-10 1.39% 10 8.0E-05 1.28% 10 7.8E-04 1.03%
SDNN RMSSD 7 1.1E-30 0.93% 11 7.5E-10 1.35% 11 6.3E-06 1.69% 11 3.5E-05 1.56%
SDNN pvRSA/HF 5 6.4E-25 0.75% 5 5.2E-07 0.89% 5 8.7E-07 1.99% 4 4.3E-03 0.75%
RMSSD SDNN 9 8.3E-37 1.13% 9 2.0E-11 1.54% 10 4.4E-06 1.73% 10 4.7E-04 1.11%
RMSSD RMSSD 7 8.8E-37 1.13% 11 6.1E-12 1.62% 11 5.3E-08 2.42% 11 2.5E-06 2.01%
RMSSD pvRSA/HF 5 1.5E-30 0.93% 5 2.0E-11 1.54% 5 2.1E-09 2.92% 4 8.1E-04 1.02%
pvRSA/HF SDNN 7 NA NA 9 1.5E-13 1.58% 10 4.3E-05 1.38% 10 2.0E-03 0.87%
pvRSA/HF RMSSD 6 NA NA 11 7.1E-14 1.62% 11 1.3E-06 1.93% 11 1.5E-05 1.70%
pvRSA/HF pvRSA/HF 5 NA NA 5 7.7E-17 2.01% 5 1.4E-08 2.64% 4 1.8E-03 0.89%
NA, not available.
NOTE: DR2 is the difference in percentage of explained variance by the multi-SNP genetic or polygenetic risk score between the models with and without the risk score while adjusting both for age, sex
and principal components.
For Lifelines, NESDA and TRAILS-Pop the weights (that is, effects sizes) and number of genome-wide signiﬁcant SNPs included in the risk score were adjusted by analytically extracting the cohort’s effect
size and s.e. from the meta effect size and s.e., respectively, and recalculating the P value based on these adjusted effect sizes and s.e.’s, since these cohorts were included in stage 1 and/or 2.
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scores for HRV traits were also signiﬁcantly associated with
heart rate and LD score regression conﬁrmed that the allelic
variants that decrease HRV in parallel increase heart rate. This
suggests to us that part of the HRV SNPs exert their effect on
heart rate through oscillatory modulation of pacemaker activity
by the vagal nerves.
Supplementary Fig. 9 depicts the two routes by which
acetylcholine released by the vagal nerves in the sinoatrial node
is known to inﬂuence heart rate, both of which are supported
by our results in GNG11, RGS6 and HCN4. By binding
the muscarinic type 2 receptor (M2R) and dissociating the
G-protein heterotrimer (Gabg) into a Gai/o subunit and a Gbg
component, acetylcholine inhibits the ongoing depolarization
of the pacemaker cells by b1/b2-adenylatecyclase activation of
funny (If) channels and calcium channels23. In parallel, it acts
to actively hyperpolarize the pacemaker cells by activation of
the GIRK1/4 channel. Each route accounts for about half of the
tonic decrease in heart rate upon vagal stimulation23, but
the response time for M2R-GIRK effects on the sinus rate is
much shorter than for the M2R-HCN2/4 or the
b1/b2-adenylatecyclase signalling pathways. Only signalling
through the Gbg component is fast enough (B0.3 s) to rapidly
track changes in vagal outﬂow to the sinoatrial node, for
example, as they occur within the duration of a single
respiration (B4.5 s), whereas signalling through the a subunit
is too slow (43 s) to track such phasic changes in acetylcholine
release1,24. GIRK signalling, therefore, accounts for most of
HRV due to the phasic oscillation in vagal activity24, but it
accounts for only half of the tonic vagal effects on heart rate.
The above leads to HRV only partially capturing the vagal
effects on heart rate. Additional reasons for the imperfect relation
between HRV and vagal effects on heart rate1,2 are individual
differences in: (i) resting respiration rate and depth; (ii) the
amplitude of the intrinsic 0.1Hz oscillations related to both vagal
Table 3 | Explained variance in HRV traits in the Lifelines (n¼ 12,101), NESDA (n¼ 2,118), TRAILS-Pop (n¼ 1,191) and ABCD
(n¼ 1,094) cohorts by the optimal polygenic risk scores computed at the P value threshold that explained the largest percentage
of phenotypic variance.
Trait Risk score Cohort P cutoff No. SNPs P value DR2
SDNN SDNN Lifelines o5E-7 13 6.8E-27 0.82%
NESDA o5E-8 6 2.6E-08 1.16%
TRAILS-Pop o5E-5 64 1.1E-04 1.23%
ABCD o5E-5 71 9.4E-05 1.39%
SDNN RMSSD Lifelines o5E-8 8 2.4E-23 0.71%
NESDA o5E-6 23 1.2E-07 1.05%
TRAILS-Pop o5E-8 8 1.2E-04 1.23%
ABCD o5E-7 13 2.8E-06 2.00%
SDNN pvRSA/HF Lifelines o5E-8 7 3.1E-19 0.58%
NESDA o5E-8 4 3.5E-05 0.64%
TRAILS-Pop o5E-7 6 9.7E-06 1.61%
ABCD o5E-5 67 9.2E-04 1.01%
RMSSD SDNN Lifelines o5E-7 13 8.9E-31 0.95%
NESDA o5E-8 6 1.6E-10 1.46%
TRAILS-Pop o5E-8 7 8.3E-06 1.63%
ABCD o5E-5 71 1.6E-04 1.30%
RMSSD RMSSD Lifelines o5E-7 12 2.8E-30 0.94%
NESDA o5E-7 10 2.7E-10 1.43%
TRAILS-Pop o5E-7 11 3.4E-07 2.13%
ABCD o5E-7 13 3.8E-07 2.34%
RMSSD pvRSA/HF Lifelines o5E-8 7 1.4E-25 0.78%
NESDA o5E-8 4 3.6E-09 1.25%
TRAILS-Pop o5E-7 6 3.7E-08 2.47%
ABCD o5E-8 67 8.4E-04 1.02%
pvRSA/HF SDNN NESDA o5E-8 6 1.1E-12 1.52%
TRAILS-Pop o5E-8 7 5.0E-05 1.36%
ABCD o5E-5 71 5.4E-04 1.09%
pvRSA/HF RMSSD NESDA o5E-7 10 5.6E-14 1.69%
TRAILS-Pop o5E-7 11 3.3E-06 1.78%
ABCD o5E-7 13 1.9E-06 2.06%
pvRSA/HF pvRSA/HF NESDA o5E-8 4 4.4E-13 1.58%
TRAILS-Pop o5E-7 6 1.6E-07 2.25%
ABCD o5E-5 67 1.6E-03 0.90%
NA, not available.
NOTE: Weighted polygenic risk score was determined based on independent SNPs in the stage 1 meta-analysis. For NESDA and TRAILS-Pop the weights (that is, effects sizes) and P values were adjusted
by analytically extracting the cohort’s effect size and s.e. from the meta effect size and s.e., respectively, and recalculating the P value based on these adjusted effect size and s.e., since these cohorts were
included in stage 1.
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and sympathetic blood pressure regulation through the baroreﬂex
loops; (iii) mechanotransduction or intracellular pathways
stimulated by sinoatrial stretch or (iv) the efﬁciency of the
actual vagal gating process. These processes can have a strong
impact on HRV, but less so on mean heart rate. We found six
SNPs in four loci, including our top hit (rs12974991 in
NDUFA11), that may act on the individual differences in these
processes as they had no discernible effect on heart rate, in spite
of their signiﬁcant impact on HRV.
The genome-wide signiﬁcant SNPs in GNG11, RGS6 and NEO1
were eQTLs and in strong LD with the top mQTLs and eQTLs for
the corresponding genes. Two of these (GNG11, RGS6) readily
provide a biological hypothesis to account for the associations
detected in the meta-analysis. The C alleles of rs4262 and
rs180238 of GNG11 coding for the g11 subunit of the
heterotrimeric G-protein complex Gabg cause decreased
expression of this subunit and were associated with lower HRV.
The effects of the GNG11 eQTLs associated with lower HRV are
likely to lower the availability of the g11 subunit, thereby
reducing Gbg component-induced GIRK activation. This
potentially blunts the heart rate change in response to the
oscillatory changes in cardiac vagal activity.
The regulator of heterotrimeric G-protein complex signalling,
type 6 (RGS6) gene on chromosome 14 was found to be linked
to three independent signals for SDNN and RMSSD. RGS6 acts as
a critical negative regulator of M2R signalling in the sinoatrial
node of the heart rapidly terminating Gbg signalling and thus
curtailing vagal lowering of the heart rate25,26. The results of our
meta-analysis are consistent with a role for RGS6 in decreasing
HRV previously hinted at by animal experimentation23,27 and a
human case report27,28. The T allele of our eQTL RGS6 SNP
(rs4899412) causes increased expression of RGS6. By increasing
RGS6 expression, the T allele acts as a gain-of-function mutation
that gives rise to a decrease in GIRK-channel signalling
and the observed decrease in HRV. Of note, Rgs6 / mice,
that show the expected increase in HRV, are characterized by
a strong bradycardia and an increased susceptibility to AV
block and atrial ﬁbrillation which is attributed to an enhancement
of GIRK-induced sinoatrial and atrioventricular node
hyperpolarization by removing the negative regulation of Gbg
by RGS6 (refs 23,26,28).
The association of the rs2680344 SNP in HCN4 is puzzling
because HCN signalling does not involve the fast M2R-GIRK
channels and cannot translate rapid vagal ﬂuctuation into
beat-to-beat variation in IBI length, that is, HRV. The effect of
the HCN4 SNP on HRV may be secondary to its effects on the
average slope of the diastolic depolarization29. The HCN4 protein
is a key component of the If channel30–32 that generates the
pacemaker potential by a gradual depolarization of the sinoatrial
myocyte cell membrane during diastole. This ‘pacemaker
depolarization’ phase is known to be slowed by loss-of-function
mutations in the HCN4 that lead to lower heart rate31 and the
If is the known site of action for ivabradine and other therapeutic
agents used to slow heart rate in angina patients32. Of note, both
ivabradine treatment33 and loss-of-function mutations increase
the risk for atrial ﬁbrillation34. In contrast, gain-of-function
mutations in the sensitivity of HCN4 for cAMP lead to higher
heart rate30. This leads us to hypothesize that the A allele of
rs2680344 in HCN4 either is itself a gain-of-function mutation or
tags such a mutation because it increases heart rate18.
High HRV is associated with lower morbidity and mortality in
patients with cardiovascular disease5, hypertension7, end-stage
Table 4 | Meta-analysis results for the identiﬁed loci in other ethnicities and combined meta-analysis results with European
ancestry.
Locus Chr SNP Trait Allele Hispanic/Latino African American EURþHISþAfAm
E/O N EAF b (s.e.) P value N EAF b (s.e.) P value P value
1 19 rs12974991 RMSSD A/G 11,233 0.065 0.162 (0.018) 7.05E-20 6,673 0.455 0.077 (0.033) 1.10E-02 1.86E-63
rs12974440 pvRSA/HF* A/G 404 0.048 0.518 (0.174) 3.06E-03 1900 0.019 0.189 (0.158) 3.41E-01 4.53E-41
rs12980262 SDNN A/G 11,233 0.048 0.161 (0.070) 1.04E-02 6675 0.093 0.046 (0.030) 6.48E-02 1.57E-24
2 12 rs10842383 SDNN C/T 11,233 0.854 0.053 (0.012) 2.45E-06 6676 0.955 0.056 (0.026) 9.83E-01 7.61E-33
RMSSD 11,233 0.854 0.064 (0.012) 1.38E-07 6673 0.955 0.065 (0.030) 9.86E-01 4.23E-32
pvRSA/HF* 404 0.830 0.140 (0.095) 1.40E-01 1901 0.959 0.068 (0.104) 6.79E-01 4.98E-25
3 6 rs236349 SDNN G/A 11,234 0.684 0.034 (0.009) 6.15E-05 6676 0.724 0.017 (0.011) 6.57E-02 1.76E-28
RMSSD 11,234 0.684 0.034 (0.009) 1.67E-04 6673 0.724 0.021 (0.013) 4.79E-02 5.88E-20
pvRSA/HF* 404 0.704 0.164 (0.080) 4.13E-02 1901 0.729 0.004 (0.043) 4.87E-01 4.64E-15
4 12 rs7980799 RMSSD A/C 11,234 0.269 0.031 (0.010) 1.23E-03 6488 0.097 0.029 (0.021) 7.70E-02 1.57E-22
rs1351682 pvRSA/HF* G/A 404 0.348 0.166 (0.077) 3.19E-02 1901 0.142 0.082 (0.058) 6.91E-02 2.00E-14
rs1384598 SDNN T/A 11,234 0.307 0.026 (0.009) 1.80E-03 6676 0.146 0.024 (0.015) 5.41E-02 2.88E-15
5 7 rs4262 SDNN C/T 11,234 0.427 0.016 (0.008) 2.39E-02 6676 0.608 0.028 (0.011) 5.87E-03 5.36E-19
pvRSA/HF* 404 0.410 0.014 (0.074) 8.46E-01 1901 0.618 0.055 (0.043) 1.15E-01 1.50E-11
rs180238 RMSSD C/T 11,234 0.367 0.024 (0.009) 4.05E-03 6673 0.474 0.032 (0.011) 2.77E-03 8.07E-19
6 14b rs4899412 SDNN T/C 11,234 0.329 0.012 (0.009) 8.27E-02 6676 0.419 0.009 (0.010) 1.86E-01 5.96E-13
rs2052015 RMSSD T/C 11,234 0.173 0.015 (0.012) 9.94E-02 6673 0.098 0.001 (0.020) 4.83E-01 1.94E-09
14c rs2529471 SDNN C/A 11,233 0.485 0.018 (0.008) 1.38E-02 6676 0.543 0.003 (0.010) 3.83E-01 2.08E-12
14a rs36423 SDNN T/G 11,234 0.193 0.021 (0.011) 2.41E-02 6676 0.160 0.030 (0.015) 1.79E-02 1.60E-14
RMSSD 11,234 0.193 0.017 (0.011) 7.05E-02 6673 0.160 0.034 (0.016) 1.72E-02 1.02E-11
7 15a rs2680344 SDNN A/G 11,234 0.681 0.005 (0.009) 2.97E-01 6676 0.450 0.024 (0.011) 1.32E-02 2.90E-11
15b rs1812835 RMSSD A/C 11,234 0.426 0.012 (0.009) 8.83E-02 1388 0.140 0.009 (0.033) 3.98E-01 5.30E-10
8 20 rs6123471 RMSSDw T/C 11,234 0.560 0.001 (0.009) 4.40E-01 6673 0.739 0.020 (0.013) 5.67E-02 5.14E-06
AfAm, African American; Allele E/O, effect allele/other allele; Chr, chromosome; bp, base pair position based on build 36 (hg18); EAF, effect allele frequency; EUR, European; HIS, Hispanic/Latino;
N, sample size; s.e., standard error of b; b, beta/effect size.
NOTE: SNPs sorted as in Table 1 according to the European ancestry combined meta-analysis P value per locus. Signiﬁcant Ps are shown in bold (see text for criteria). Effect alleles were chosen to reﬂect
an increased risk for low levels of HRV, hence b’s are all negative.
*P value, allele, EAF, N from z-score weighted meta-analysis of all cohorts using METAL and b, s.e. from inverse-variance meta-analysis of only HF cohorts using GWAMA.
wb of participants of European ancestry differs signiﬁcantly from that of participants from African-American (diff b¼0.044, P¼0.0012) or Hispanic/Latino ancestry (diff b¼ 0.023, P¼0.0195).
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renal disease8 and diabetes9, but also in apparently healthy
individuals11,12. Using LD score regression on meta-GWAS
summary statistics from various risk factors and endpoints
we ﬁnd some evidence for overlap in the genetic variants causing
low HRV and increased risk for disease, but signiﬁcance was
reached only for systolic and diastolic blood pressure after
correction for multiple outcomes tested. These genetic
correlations are compatible with causal effects of cardiac vagal
control in the aetiology of disease, but they could also be ascribed
to reversed causality, where the disease process leads to lower
cardiac vagal control. A strength of this study in this regard is that
analyses were conﬁned to individuals in good cardiac health, that
is, cohorts excluded patients with existing cardiovascular diseases
or medication potentially impacting HRV. Because we selected
individuals in good cardiac health reverse effects of disease on
HRV seem less likely, although some latent pathology could have
been present. However, an alternative explanation that is harder
to rule out is that the genetic correlation derives from pleiotropic
effects of genetic variants common to both outcomes.
Further strengths of this study were the consistency of results
across the different HRV traits used to capture cardiac vagal
control and the generalization of the HRV SNP effects to different
ancestries, in spite of known ethnic differences in absolute resting
HRV35. Results also held in men and women separately and
across a very large range of mean cohort ages spanning from early
childhood to the late middle ages; in spite of a strong reduction in
HRV values with aging36. Although effects of age and sex on
HRV were taken into account in the analyses, many other factors
were not. The ideal design would have corrected for the known
effects of respiration depth and rate on HRV, which are
independent of vagal activity37. These could not be added as
covariates because they were not available in most cohorts. We
were liberal in excluding other covariates like BMI, smoking and
exercise in the GWAS analyses. These traits are substantially
heritable themselves and adjusting for heritable covariates can
bias the genome-wide association effects38 or even induce
non-existing associations through collider bias39. Finally,
instructions on pre-ECG recording behaviours like physical
activity, and caffeine, alcohol or nicotine use were not
rigorously standardized across cohorts.
Direct clinical relevance of most current GWAS ﬁndings is still
low and our study is no exception. Potential future clinical use of
our ﬁndings hinges on the ability of our genetic variants to
capture (sub)cortical, brainstem and medullary transmission of
tonic vagal activity to the sinoatrial node, not just the impact of
that activity on heart rate. Subcortical generation of tonic vagal
activity is an important biomarker for cardiovascular health and
potentially modiﬁable by interventions on psychosocial stress40
and lifestyle habits41. It can even be a transdiagnostic biomarker
for psychopathology and executive cognitive functioning possibly
by reﬂecting the integrity of prefrontal cortex functioning42.
Genetic markers for HRV may prove useful as instrumental
variables in Mendelian randomization43 to test causal hypotheses
on the effects of centrally generated vagal activity on behavioural
and health outcomes.
In conclusion, this meta-analysis detects a critical role for
genetic variation in Gbg and HCN signalling in explaining
individual differences in HRV. The HRV variants detected can
help guide further investigations of the functional consequences
and potential therapeutic implications of individual differences in
sinoatrial Gbg signalling.
Methods
Study cohorts. Appropriate IRB approval and informed consent from participants
in all participating cohorts was obtained. Full information on consent procedures
and details of the IRB boards are provided in the Supplementary Note 8.
HRV measurement. In this study, we investigated three HRV traits: SDNN, the
RMSSD and pvRSA or HF. SDNN and RMSSD were derived from the IBI time
series obtained from the R waves in the ECG4. HF was calculated from Wavelet or
Fourier decomposition with power obtained from a high frequency band of either
0.15–0.40Hz or 0.15–0.50Hz. A time domain measure of RSA was derived by
pvRSA using a respiratory signal co-registered with the ECG. Estimates of pvRSA
are obtained by subtracting the shortest IBI during heart rate acceleration in the
inspiration phase from the longest IBI during heart rate deceleration in the
expiration phase.
HRV traits were extracted from the IBI time series preferably based on
2–10min periods of ECG in a standardized setting, at rest and in a sitting/supine
position. If ambulatory data were available, we advised cohorts to extract a period
of sitting still in the evening, when this proved feasible. Supplementary Table 2 lists
the actual way HRV was assessed by the participating cohorts. For the cohorts
analysed in stage 2, we extended our HRV measurements to include cohorts with
10 s and/or 20 s ECG recordings, as RMSSD and SDNN based on these ultra-short
recordings have shown a good agreement with 4–5min recordings3. Furthermore,
since IBI time series require reliable detection of the R-wave only, a three-lead ECG
was considered sufﬁcient while the use of more leads was encouraged. For pvRSA,
an additional respiration signal of sufﬁcient quality to detect beginning and end of
inspiration and expiration was needed.
SDNN and RMSSD have prevailed in epidemiological studies because they are
more easily assessed in large cohorts and, as noted above, can be obtained even
from short ECG recordings. HF and pvRSA were available in fewer cohorts, but
they better reﬂect the cardiorespiratory coupling that drives the oscillatory
modulation of vagal effects in the sinoatrial node. In the typical resting respiratory
frequency range, these time- and frequency-domain measures of RSA are much less
contaminated by oscillations in cardiac sympathetic control than SDNN (and other
measures of HRV that span a broader frequency range). This is due to the temporal
dynamics of the sinoatrial node signalling pathway that acts as a low pass ﬁlter
allowing only oscillations in vagal effects to translate into HRV, whereas for
sympathetic effects or vagal effects at progressively higher respiratory frequencies
the node acts as a leaky integrator causing more tonic changes in heart rate1. Phasic
modulation of vagal effects is therefore captured most purely by pvRSA or HF.
Because pvRSA and HF are conceptually similar and highly correlated with each
other (r40.80) across a wide range of values for respiration and heart rates44,
we grouped the analyses on pvRSA and HF under the label pvRSA/HF.
Study population. Cohorts that had data on at least one of the three HRV traits
and genome-wide data were invited to participate in the ﬁrst (discovery) stage of
the Genetic Variance in Heart Rate Variability (VgHRV) consortium. The stage 1
discovery analysis was performed in up to 28,700 individuals of European ancestry
from a maximum of 20 cohorts. Independent cohorts with either genome-wide or
gene-centred array data or with the ability to perform wet-lab genotyping on the
single-nucleotide polymorphism (SNPs) taken forward from the ﬁrst stage were
included in the second (replication) stage. This stage included additional data from
up to 24,474 individuals from 11 cohorts of European ancestry (see Supplementary
Tables 1–4 for cohort descriptions and details).
Association analysis: stage 1 (discovery). The following exclusion criteria were
applied a priori: (1) individuals with heart disease (for example, angina, past
myocardial infarction, left ventricular failure) and (2) individuals known to use
antidepressants (particularly tricyclic antidepressants) and all anticholinergic
agents (for example, digoxin, atropine and acetylcholinesterase inhibitors) because
of the strong effects that these drugs have on HRV. Individuals reporting over the
counter use of anticholinergic agents were not excluded.
Imputation of SNPs was done to extend and create similar SNP databases
between cohorts using different genotyping platforms. Most of the cohorts used the
HapMap Phase II release 22 CEU panel as reference, but later releases (for example,
release 24) or other reference data sets (for example, 1000 Genomes) were also used
(Supplementary Table 4).
Each cohort performed linear regression analyses on all available HRV traits
using an additive SNP model adjusting for age at the time of ECG recording,
sex, principal components—to adjust for population stratiﬁcation—and other
study-speciﬁc parameters; all HRV traits were log-transformed because of the
skewness of their distributions. Only autosomal associations were examined.
Analyses were performed for all individuals as well as for men and women
separately.
Stage 1 meta-analysis. Before meta-analysis, quality control of all uploaded
cohort ﬁles was performed using the QCGWAS package45. In case of issues the
cohorts were notiﬁed and problems were solved. Using the QCGWAS results,
speciﬁc imputation quality and allele frequency thresholds were set for each cohort.
An inverse-variance, ﬁxed-effects meta-analysis was performed for RMSSD and
SDNN for which SNPs of the different cohorts were merged based on rs-id. For
pvRSA/HF, we performed a sample size weighted meta-analysis using z-scores with
METAL46, since we combined results of two HRV phenotypes (pvRSA and HF)
that have different units and ranges, and therefore incomparable SNP effect sizes.
To get an idea of the size of the SNP effect on pvRSA/HF, we obtained effect sizes
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and s.e.’s from an additional ﬁxed-effect meta-analysis on the GWAS results of the
(majority of) cohorts that measured HF. Results of the meta-analyses were double
genomic control corrected47 to control for potential inﬂation as a result of
population stratiﬁcation within and between cohorts. The results included all SNPs
that met the following selection criteria: (a) a minor allele frequency in the meta-
analysis of41%, and (b) present in at least one third of the cohorts. This resulted
in 2,555,913 SNPs being analysed for SDNN, 2,534,714 SNPs for RMSSD and
2,628,894 SNPs for pvRSA/HF. For each trait separately, SNPs with a Po1 10 6
were clumped for LD using pairwise LD checking in SNAP48 to ascertain
independent primary and secondary signals (r2o0.1). A total of 23 lead SNPs in 14
loci were selected for follow-up in the second (replication) stage.
Stage 2 meta-analysis. Stage 2 cohorts applied the same exclusion criteria and
performed the same association analysis as in the discovery stage, but analyses were
restricted to the 23 lead SNPs. If a SNP was not available in a cohort, the best
available proxy was used instead based on strongest LD according to the 1000
Genomes database. To verify homogeneity of the results in the stage 2 cohorts with
those in the stage 1 cohorts, the stage 1 meta-analysis effect sizes of the 23 SNPs
were correlated to the effect sizes obtained in each cohort for each of the HRV
traits. If a negative correlation (ro0) was found, the cohort/trait pair was excluded
from stage 2 analysis. For this reason results from one cohort for SDNN were
excluded. The replication results were then meta-analysed per trait using an
inverse-variance ﬁxed-effects meta-analysis for RMSSD and SDNN and a sample
size P weighted meta-analysis using z-scores in METAL46 for pvRSA/HF. SNPs
were matched based on rs-id. Next the association results from both stages were
combined in the same way. A SNP was only considered to be signiﬁcantly
associated to HRV if it satisﬁed the following criteria: (1) it had Po1 10 6 in
stage 1, (2) it had a one-sided Po0.05 in the stage 2 meta-analysis congruent with
the direction of effect in the stage 1 meta-analysis and (3) it had a genome-wide
signiﬁcant Po5 10 8/3 (two-sided) in the combined meta-analysis of stage 1
and 2 results, correcting for the testing of three separate traits.
Conditional analysis. In the discovery stage independent SNPs were selected
for follow-up based on LD clumping (r2o0.1). To conﬁrm independence between
these SNPs within the loci on chromosome 14 and 15, we applied the
conditional-and-joint analysis as implemented in the Genome-wide Complex Trait
Analysis software package49 to the stage 1 summary statistics of RMSSD and
SDNN with the genotype data of the NESDA cohort50 of 1,925 individuals as the
LD reference data set. In addition, cohort-level individual data on log-transformed
RMSSD and SDNN of 12,101 individuals from the Dutch Lifelines cohort51 were
analysed using linear regression analysis with age and sex as covariates conditioned
on the other associated SNP(s) within the locus.
Gene-based association analysis (VEGAS). We performed gene-based testing
with the full set of B2.5M HapMap SNPs from GWAS results of all three
phenotypes, using VEGAS (Supplementary Table 17). This software has the
advantage of accounting for LD structure and the possibility to deﬁne a range
beyond the gene bounds to include promoter, 50UTR, intronic and 30UTR regions
into the analysis. We deﬁned a 50 kb extra window beyond the genes, considered
every SNP in this window for the gene-based analysis, and ran the analyses per
chromosome with up to 106 permutations. A Po2.5 10 6 (¼ 0.05/B20,000
genes) was considered as the threshold for signiﬁcance.
Variance explained. The Lifelines and NESDA cohorts were used for genetic risk
score and polygenic risk score analyses to determine the percentage of variance
explained by independent HRV SNPs that were genome-wide signiﬁcant, and by
SNPs meeting increasingly lenient signiﬁcance thresholds, respectively. Lifelines
and NESDA represent examples of a population-based cohort and a cohort
ascertained on case-control status (for major depressive disorder). Both recruited
adult participants. To test the stability of explained variance across the life span, we
repeated this analysis in two other Dutch cohorts, the adolescent TRAILS-Pop
cohort52 (age 10–18) and the ABCD cohort consisting of young children (age 5–7)
(ref. 53).
For the genetic risk score, stage 1þ 2 summary statistics were used for the
selection of HRV SNPs. No correction was needed for ABCD as genotyping in this
cohort had ﬁnished only after completion of the meta-analyses. However, the
NESDA cohort had been included in both stage 1 and 2, TRAILS-Pop in stage 1,
and Lifelines in stage 2, so the effect sizes and s.e.’s of the HRV SNPs were
corrected to subtract the effects of those cohorts to obtain independent validation
cohorts54. Also, only SNPs were used in the genetic risk score if they remained
genome-wide signiﬁcant after analytically subtracting these cohort’s effects from
the meta-analysis. Genetic risk scores of the remaining SNPs (Lifelines: SDNN(9),
RMSSD(7), pvRSA/HF(5); NESDA: SDNN(9), RMSSD(11), pvRSA/HF(5);
TRAILS-Pop: SDNN(10), RMSSD(11), pvRSA/HF(5)) weighted by the adjusted
effect size were calculated for the participants of all four cohorts and regressed on
the three HRV traits (pvRSA/HF was not available in Lifelines). Explained variance
was computed as the change in R2 from a model with and without the genetic risk
score, while adjusting both for age, sex and principal components.
To compute the polygenic risk scores, the imputed genotypes were ﬁrst
converted to best-guess genotypes. This was done regardless of the imputation
quality, since it was previously shown that even low-quality SNPs might contribute
to the variance explained by SNPs (ref. 54). The SNP set was further pruned for LD
using PriorityPruner (http://prioritypruner.sourceforge.net/) to select independent
SNPs, taking the signiﬁcance of the SNP in the discovery meta-analysis of each of
the HRV traits into account. This provided three LD-pruned SNP sets. Polygenic
risk scores were then calculated in PLINK55 using signiﬁcance thresholds of
5 10 8, 5 10 7, 5 10 6, 5 10 5, 5 10 4, 0.005, 0.05, 0.5 and 1 and
associated with the three HRV traits and resting heart rate in the Lifelines, NESDA,
TRAILS-Pop and ABCD cohorts. For NESDA and TRAILS-Pop pruning and
polygenic risk score analysis was based on analytically corrected results, since these
cohorts were part of stage 1 of our study54.
Heritabilities and genetic correlations. We applied genomic restricted
maximum likelihood analysis implemented in the Genomic Complex Trait
Analysis software package56 in the Lifelines cohort (Supplementary Table 18) to
estimate the percentages of additive phenotypic variance that can be explained by
common SNPs (that is, common SNP heritability denoted as h2SNP). For this
analysis, SNPs from the HapMap Phase 3 project were selected to obtain a set of
independent SNPs. We further used LD score regression to estimate the
heritabilities of the three HRV traits and the genetic correlation among HRV traits
and with heart rate20. The GWAS meta-analysis summary statistics for RMSSD,
SDNN and pvRSA/HF were obtained from stage 1 of the current study, and the
GWAS meta-analysis summary statistics for heart rate from the discovery stage of a
recent GWAS meta-analysis for heart rate18. The LD scores required by the method
were computed using 1000 Genomes data of Europeans. The heritabilities of the
three HRV measurements were estimated using the univariate model of this
method. Cross-phenotype LD score regression analysis was performed using the
LDSC tool (LD SCore) to estimate genetic correlations between pairs of
phenotypes20.
In addition, we used the Oman Family Study57 to perform univariate and
bivariate analyses in ﬁve multigenerational highly inbred pedigrees to estimate the
heritabilities for and the genetic correlations between log-transformed RMSSD,
SDNN, HF and heart rate using SOLAR (v7.2.5) (ref. 58).
Generalization to other ethnicities. We further examined the generalization of
loci identiﬁed after meta-analysis of stage 1 and 2 results to other ethnicities using
data from 11,234 individuals of two Hispanic/Latino cohorts, and 6,899 individuals
from ﬁve African-American cohorts (Supplementary Tables 1–4). Stage 3
meta-analyses were performed in the same way as in stage 2 of this study to assess
the effect of the HRV-associated SNPs in individuals of Hispanic/Latino and
African-American ancestry, in the combined set of European and Hispanic/Latino
ancestry, in the combined set of European and African-American ancestry, and in
all three ethnicities combined. Here, we applied the same criteria for signiﬁcance as
in stage 2 described above, that is, a SNP was only considered to be signiﬁcantly
associated to HRV if: (1) it had Po1 10 6 in stage 1 meta-analysis in European
individuals, (2) it had a one-sided Po0.05 in the new ethnicity speciﬁc
meta-analysis congruent with the direction of effect in the stage 1 meta-analysis in
European individuals and (3) it had a genome-wide signiﬁcant Po5 10 8/3
(two-sided) in the combined meta-analysis.
Correcting HRV for heart rate. The well-known inverse association between
HRV and heart rate in part reﬂects a dependency of the variance in IBI on the
mean IBI that is unrelated to cardiac vagal activity59. That is, the slower the heart
rate, the longer the IBI, and therefore, any proportionally minor beat-to-beat
differences in IBI are more pronounced at slower heart rates. This occurs on top of
the well-established dual effect of cardiac vagal activity that lowers heart rate and
increases HRV15,16. Although these two mechanisms (biological, mean-variance
dependency) are impossible to completely separate, we conducted three analyses to
test whether the HRV SNPs were robust to correction for the mean IBI.
First, we corrected SDNN and RMSSD for their dependency on mean IBI by
using the coefﬁcient of variation, which is a more parsimonious solution19 than the
logarithmic approach suggested by Monfredi et al.29. We obtained the summary
statistics for the resting heart rate GWAS meta-analysis18 from: https://
walker05.u.hpc.mssm.edu/ and used the GWIS procedure17 to infer a GWA
analysis of the coefﬁcient of variation of the SDNN and the RMSSD. We
approximated the coefﬁcients of variation by (SDNN/X) 100% and
(RMSSD/X) 100%, respectively, where X equals 60,000 per heart rate.
Transformation from heart rate to IBI is required as both terms in the coefﬁcient of
variation (HRV and IBI) are in milliseconds, whereas the heart rate GWAS
meta-analysis used heart rate in beats per minute. As the coefﬁcients of variation
were skewed, we used a log-transformation. As an example of the linear
approximation by GWIS we assume that the increaser effect of one allele for an
SDNN SNP is þ 0.2 with the same SNP reducing heart rate by  0.1. Given a
mean SDNN of 100 and mean heart rate of 60, we can then approximate (omitting
some nuances adequately explained in Nieuwboer et al.17) the effect of the SNP on
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the coefﬁcient of variation of the SDNN as:
ln
100þ 0:2
60;000=ð60 0:1Þ
 
 ln 100
60;000=ð60Þ
 
¼ 0:00033
We used the delta method to approximate a s.e. for the effect of the SNP given that
we know the s.d.’s for the SNP effects on SDNN and HR, and their dependence. We
obtain the dependence from analysis with LD score regression20.
Second, we performed association analyses for our 17 top SNPs on the actual
log-transformed coefﬁcients of variation of SDNN and RMSSD computed in the
Lifelines, NESDA and TRAILS-Pop cohorts and then meta-analysed these results.
Because pvRSA and HF are expressed on different scales, such a meta-analysis was
not feasible for pvRSA/HF.
Third, we repeated the association analysis for our 17 top SNPs on SDNN,
RMSSD and pvRSA/HF in the Lifelines, NESDA and TRAILS-Pop cohorts with
and without adjusting for heart rate as a covariate and performed mediation tests
with the Sobel test to assess the mediation effect of heart rate on the HRV SNP
association. Signiﬁcance of the Sobel t-value was determined using a bootstrap
procedure (n¼ 10,000 permutations). The mediation P values of the three cohorts
for SDNN and RMSSD and two for pvRSA/HF (as this was not available in
Lifelines) were next meta-analysed to determine the signiﬁcance of mediation and
to compute the percentage of the SNP effect on HRV that was mediated through its
effects on heart rate. We note that this is likely an overcorrection because the HRV
SNPs are expected to inﬂuence heart rate through a common biological
mechanism, that is, changes in cardiac vagal activity.
Association of the HRV SNPs with heart rate. We conducted a lookup of the 17
(11 independent) HRV lead SNPs identiﬁed in this study using the results of a
recent GWAS meta-analysis for heart rate18. A HRV-associated SNP was
considered to be signiﬁcantly associated with resting heart rate if the GWAS
meta-analysis result for heart rate was o0.05/11¼ 0.0045. Three separate HRV
weighted multi-SNP genetic risk scores were calculated from 10 (SDNN), 11
(RMSSD) and ﬁve (pvRSA/HF) HRV SNPs, respectively, (based on all
genome-wide signiﬁcant SNPs for the respective HRV trait in the stage 1þ 2
meta-analysis). These were tested for their effect a on resting heart rate using the
gtx package in R (https://cran.r-project.org/web/packages/gtx), which
approximated a by (Sob seb 2)/(So2 seb 2) with seaDO(1/So2 seb 2),
where o is the effect of the SNP on HRV, b is the effect of the SNP on heart rate
and seb is the s.e. of b. This approximation requires only single SNP association
summary statistics extracted from GWAS results60. The effects of the multi-SNP
genetic risk scores were considered as statistically signiﬁcant when the P was less
than 0.0045 (correcting for 11 traits; heart rate and the 10 cardiometabolic traits
described below).
In addition to these lookups that were restricted to genome-wide signiﬁcant
SNPs, we employed LD score regression20 that uses the full summary statistics of
the HRV and heart rate GWAS meta-analyses to compute genetic correlations.
We further examined the variance in resting heart rate explained by multi-SNP
genetic risk scores (based on the lead SNPs only) and of the full polygenic risk
scores for HRV in the four Dutch cohorts Lifelines, NESDA, TRAILS-Pop and
ABCD. The identical approach was used as done previously for the computation of
variance explained in the HRV traits themselves.
Association of heart rate SNPs with HRV. We also performed reverse analyses to
detect the effects of heart rate SNPs on the HRV traits. In our GWAS meta-analysis
results for SDNN, RMSSD and pvRSA/HF, we performed a lookup for the 21
previously identiﬁed heart rate SNPs by den Hoed et al.18. A heart rate associated
SNP was considered to be signiﬁcantly associated with HRV if the P was o0.05/
21¼ 0.0024. The 21 heart rate SNPs were tested in a multi-SNP risk score for their
effect on the HRV traits using the gtx approach as described above.
To examine the variance explained in the HRV traits by the 21 heart rate SNPs,
multi-SNP genetic risk scores and polygenetic risk scores based on the heart rate
SNPs were computed in the Lifelines, NESDA, TRAILS-Pop and ABCD cohorts
and these were tested for association with the available HRV traits. For the
multi-SNP genetic risk scores weights were either the original SNP effect sizes on
heart rate (for NESDA, TRAILS-Pop and ABCD) or corrected because of
participation of the cohort in the GWAS meta-analysis (Lifelines). Only 15 of the
21 SNPs were used in the Lifelines cohort because ﬁve SNPs lost genome-wide
signiﬁcance after subtracting the SNP effects of the Lifelines cohort. One other SNP
(rs826838) was removed because it was in LD (r2¼ 0.15) in Lifelines with a more
signiﬁcant heart rate SNP (rs7980799).
Association with cardiometabolic traits and diseases. We estimated the joint
effect of the HRV SNPs on cardiometabolic and renal disease traits and endpoints.
The traits included were systolic and diastolic blood pressure, body mass index and
urinary albumin excretion as well as estimated glomerular ﬁltration rate based on
creatinine. The clinical outcomes used were heart failure, coronary artery disease,
atrial ﬁbrillation, sudden cardiac death and type 2 diabetes. The relevant consortia
(Supplementary Table 11) and/or corresponding authors of the studies were
contacted with the request to perform a lookup and provide summary GWAS
meta-analysis results for our list of 17 SNPs.
The association analyses consisted of the same three steps as used for heart rate.
First, we checked the P of our HRV SNPs (or their proxies) in the cardiometabolic
trait or disease GWAS meta-analysis results. Second, three separate HRV weighted
genetic risk scores were calculated from 11 (RMSSD), 10 (SDNN) and ﬁve
(pvRSA/HF) HRV SNPs, respectively (based on all genome-wide signiﬁcant SNPs
for the respective HRV trait in the stage 1þ 2 meta-analysis). These were tested for
their effect on the clinical outcomes using a regression model in the gtx package in
R as described above for the association of the HRV SNPs with heart rate. The
effects of the genetic risk scores were considered as statistically signiﬁcant when the
P was less than 0.0045 (0.05/11, correcting for heart rate and the 10 traits and
diseases).
In addition to these lookups that were restricted to genome-wide signiﬁcant
SNPs, we employed LD score regression20 that uses the full GWAS summary
statistics of the HRV and cardiometabolic traits and diseases to compute genetic
correlations.
Search for known functional SNPs (in silico annotation). We followed an in
silico bioinformatics-based approach61 to search and annotate SNPs in the regions
surrounding the 17 identiﬁed HRV SNPs. For this purpose SNP positions were
converted from National Center for Biotechnology Information (NCBI) build 36,
Human Genome 18, to NCBI build 37, Human Genome 19, (GRCh37/hg19)
using the NCBI Genome Remapping service tool (http://www.ncbi.nlm.nih.gov/
genome/tools/remap). For ±1Mb regions surrounding the SNPs, we downloaded
the according variance call format ﬁle from the 1000 Genomes Project. We used
data of 503 European ancestry individuals from 1000 Genomes Project Phase 3
(version 5.a.) to calculate LD between the HRV SNP and all other SNPs within the
area. SNPs in moderate to high LD (r2Z0.5) were subsequently selected and
annotated by ANNOVAR software62 for functionality. For all non-synonymous
SNPs loss-of-function and gain-of-function was determined by using the SIFT and
PolyPhen prediction scores. A SNP was categorized as deleterious if the SIFT score
was r0.05 or the PolyPhen score was between 0.957 and 1 (probably damaging).
We used RegulomeDB to integrate results from the RoadMap Epigenomics and
ENCODE projects to identify variants that are likely to have functional
consequences using the lead SNPs identiﬁed for the three HRV traits. We distilled
information on transcription factor binding and chromatin states for SNPs that
showed most evidence of being functional, that is, for SNPs with a RegulomeDB
score o4.
Finally, all the HRV SNPs and those that were in high LD (r2Z0.8) with them
were looked up in the National Human Genome Research Institute GWAS
catalogue to check for association with other complex traits or diseases identiﬁed in
previous GWAS studies63.
eQTL analyses. We performed expression quantitative trait locus (eQTL) analysis
in whole blood to identify regulatory variants that were associated with the HRV
SNPs using the gene-expression database from NESDA50 and NTR64 cohorts. The
sample used for this analysis consisted of 4,896 individuals of European ancestry.
For complete details on the sample and the procedures, see65.
eQTL effects were tested with a linear model approach using MatrixeQTL66
with expression level as dependent variable and SNP genotype values as
independent variable. In this study we only tested cis effects for our HRV SNPs,
meaning that the probe was at a distance o1Mb from the SNP on the genome
according to GRCh37/hg19. For each probe set that displayed a statistically
signiﬁcant association with at least one SNP in the cis region, we identiﬁed the most
signiﬁcantly associated SNP (top eQTL). Conditional eQTL analysis was carried
out by ﬁrst residualizing probe set expression using the corresponding top eQTL
and then repeating the eQTL analysis using the residualized data.
All HRV SNPs with signiﬁcant results in the NESDA/NTR eQTL data were
looked up in two other independent whole blood eQTL databases, eQTLs in
lymphoblastoid cell lines, eQTLs in 10 different brain regions, and a heart eQTL
database.
mQTL analyses. We obtained mQTL results from a previously published study67.
In short, genome-wide DNA methylation data were generated using Illumina 450 k
arrays for 3,841 whole blood samples. Corresponding genotype data were imputed
using the Genome of The Netherlands68 reference panel. To determine the effect of
nearby genetic variation on methylation levels (cis-mQTLs) a Spearman rank
correlation and corresponding P value was computed for each CpG-SNP pair, in
which the CpG and SNP location were no further than 250 kb apart. To control for
multiple testing, we used a permutation procedure to empirically control the false
discovery rate at 5%. The distribution of observed P values was compared to the P
value distribution obtained from the analyses on permuted data. For a permutation
the sample identiﬁers of the genotype data set were shufﬂed, breaking the link
between the genotype data set and the methylation data set. This was repeated 10
times to obtain a stable distribution of P values under the null hypothesis. To
determine the false discovery rate only the strongest effect per CpG in both the real
analysis and in the permutations were selected.
Gene prioritization using four bioinformatics approaches. Potentially causal
genes for the associations identiﬁed by GWAS were identiﬁed using four previously
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described bioinformatics tools: ToppGene, Endeavour, MetaRanker and DEPICT
(Supplementary Table 19). To this end, we ﬁrst retrieved positional coordinates for
all lead SNPs according to GRCh37/hg19. These coordinates were used to extract
all genes located within ±40 kb of lead SNPs using the UCSC genome browser.
The identiﬁed genes subsequently served as input for ToppGene and Endeavour,
together with two genes with established roles in sinus node function (HCN4)
and synaptic signal transmission (ACHE) that served as training genes. For
MetaRanker, we ﬁrst combined results of the stage 1þ 2 meta-analyses of GWAS
for the three HRV traits, retained the association with the lowest P for lead SNPs
that were identiﬁed for multiple traits, and subsequently provided SNPs, P values,
and the same two test genes (HCN4 and ACHE) as input. For DEPICT—arguably
the most powerful and informative of the four methods—we used results from the
stage 1 meta-analysis for all SNPs that reached a P for associationo10 5 as input,
for each of the three HRV outcomes separately. In order for genes to be prioritized
by the combined four approaches, they needed to be either: (1) selected by DEPICT
for at least one of the three HRV outcomes; or (2) identiﬁed by at least two of the
three remaining tools (ToppGene, Endeavour and/or MetaRanker).
Network and functional enrichment analyses. We performed gene network and
enrichment analysis using the GeneMANIA algorithm, which uses data resources on
genetic interactions, protein–protein, co-expression, shared protein domains and co-
localization networks. To build a functional interaction network, we selected genes as
input for this analysis using the following criteria: (a) genes implicated by gene
prioritization using the four bioinformatics approaches described above, (b) the genes
closest to our 17 HRV SNPs, (c) genes to which linked (r240.50) non-synonymous
SNPs mapped, (d) genes to which other linked (r240.80) SNPs mapped, (e) genes
identiﬁed by VEGAS, and (f) expression probe gene names signiﬁcantly associated
with HRV eQTLs (false discovery rateo0.01). The input gene list was extended to 100
by their most strongly interacting genes and a weighted composite functional asso-
ciation network was constructed61. Subsequently, functional enrichment analysis of all
genes of the constructed interaction network against Gene Ontology (GO) terms was
performed to ﬁnd the most enriched GO terms (Supplementary Table 20).
Signiﬁcantly enriched GO terms (false discovery rate o0.10) were visualized as
highlighted boxes within their corresponding GO tree depicted by the RamiGO R
package69 (Supplementary Fig. 10).
Tissue and gene-set enrichment analyses. We used DEPICT for a tissue
enrichment analysis to tabulate tissues that are enriched for expression of genes
located within ±40 kb of SNPs with a Po10 5 association with the HRV traits.
DEPICT calculates the likelihood of every known gene to be a member of, amongst
others, KEGG, GEO or REACTOME-based gene sets (N¼ 14,461) to create
reconstituted gene sets. It then determines which of these reconstituted gene
sets are enriched for the HRV genes. A graphical representation of DEPICT’s
reconstituted gene-set enrichment analysis (Po0.05 after Bonferroni correction for
examining three HRV traits) was generated using a script that is based on an
afﬁnity propagation clustering algorithm by Frey et al.70. Interactions between gene
sets are considered signiﬁcant if the Pearson coefﬁcient, which is based on the
number of genes that are shared between gene sets, is 40.3.
Data availability. Summary statistics of the meta-analyses are available on request
from the corresponding authors after a formal data access request procedure and
approval by the VgHRV consortium.
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SUPPLEMENTARY FIGURES  
 
Supplementary Figure 1: VgHRV GWA meta-analysis study design. 
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Supplementary Figure 2: Quantile-quantile-plots of the three meta-analyses of GWAS results of (a) SDNN, (b) RMSSD, and (c) 
pvRSA/HF for the stage 1 meta-analysis on individuals of European ancestry. 
NOTE: Expected –log10(p-values) assuming a normal distribution are shown on the x-axis. The y-axis depicts the observed –log10(p-
values). Only SNPs with a minor allele frequency >1% and that were present in at least 1/3 of the sample are shown. 
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Supplementary Figure 3: Regional association plots of the 17 HRV SNPs from the stage 1 
meta-analysis on individuals of European ancestry. 
NOTE: Lead SNP and HRV trait are indicated in the top line. In the plots rs-numbers of the lead 
SNPs are given. Color coding reflects the LD (r
2
) of the SNP with this lead SNP according to the 
legend. The left y-axis represent -log10(p-value) of association; the right y-axis indicates 
recombination rate. The x-axis depicts the position on the chromosome (Mb) and lists known 
genes near the locus. Symbols annotation: framestop (triangle), splice (triangle), non-
synonymous (inverted triangle), synonymous (square), UTR (square), TFBScon [in a conserved 
region predicted to be a transcription factor binding site] (eight pointed star), MCS44 [in a region 
highly conserved within placental mammals] (square with two diagonal lines) and none-of-the-
above (filled circle). 
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Supplementary Figure 3 (continued) 
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Supplementary Figure 4: Forest plots of the 17 HRV SNPs showing the effect sizes from the 
individual cohorts and from the stage 1, 2, and 3 meta-analyses on individuals of European 
ancestry, Hispanic/Latino ancestry, and African American ancestry.  
NOTE: Meta-analysis derived effect sizes and 95% CI are given per stage and ancestry. The 
lower lines represent the heterogeneity test and the overall effect size based on all individuals 
from all ethnicities. 
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Supplementary Figure 4 (continued) 
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Supplementary Figure 4 (continued) 
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Supplementary Figure 4 (continued) 
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Supplementary Figure 4 (continued)  
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Supplementary Figure 4 (continued) 
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Supplementary Figure 5: Explained variance in HRV traits and heart rate by polygenic risk 
scores (PRS) for HRV in the Lifelines (n=12,101), NESDA (n=2,118), TRAILS-Pop (n=1,191), 
and ABCD (n=1,094) cohorts. 
NOTE: Significance thresholds to include HRV SNPs in the polygenic risk scores are shown on 
the x-axis and were p < 5.0x10
-8
; p < 5.0x10
-7
; p < 5.0x10
-6
; p < 5.0x10
-5
; p < 5.0x10
-4
; p < 
5.0x10
-3
; p < 0.05; p < 0.5; and p < 1. The y-axis depicts the percentage of variance explained by 
the polygenic risk score.  
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Supplementary Figure 6: Diagnostic plot for the association between genetic risk alleles for the 
HRV traits and heart rate. 
NOTE: Each SNP is plotted by its decreasing effect on HRV per risk effect allele (x-axis) versus 
the estimated effect of that allele on the risk for high heart rate (y-axis). A solid red line shows 
the effect size estimate, called α, for the risk score on HRV. The 95% CI of α is represented by 
red dashed lines. The grey vertical lines indicate the 95% confidence interval (CI) of the effect on 
heart rate for each individual SNP. The estimated effects on heart rate are in beats per minute 
(bpm). Graphs from top to bottom are for SDNN, RMSSD, and pvRSA/HF, respectively. 
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Supplementary Figure 7: Flowchart depicting the post-GWAS steps to annotate the HRV SNPs 
using public online resources: SIFT 
1
, PolyPhen 
2
, RegulomeDB 
3
 , VEGAS 
4
,  MetaRanker 
5
, 
DEPICT, 
6
, ToppGene 
7
, Endeavour 
8
, and GeneMANIA 
9
. 
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Supplementary Figure 8: Tissue enrichment and reconstituted gene set enrichment analysis using DEPICT for (a-b) SDNN; (c-d) 
RMSSD; and (e-f) pvRSA/HF. 
NOTE: In panels (a), (c), and (e) graphical representations of DEPICT's tissue enrichment analysis are provided, highlighting 
annotated tissues that are enriched for expression of genes located within ±40kb of SNPs associated with p < 10
-5
 to SDNN, RMSSD, 
and pvRSA/HF, respectively (enrichment in orange p < 0.05). In panels (b), (d), and (f) graphical representations of DEPICT’s 
reconstituted gene set enrichment analysis are shown (p < 0.05 after Bonferroni correction) for examining SDNN, RMSSD, and 
pvRSA/HF, respectively. DEPICT calculates every gene’s likelihood to be a member of KEGG, GEO, or REACTOME-based gene 
sets amongst others (N=14,461) resulting in reconstituted gene sets. Shown are the reconstituted gene sets enriched for genes in 
SDNN-, RMSSD-, and pvRSA/HF-associated loci (nodes), respectively, and the significant interactions between these gene sets 
(edges). 
  
(a) (b) 
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Supplementary Figure 8 (continued) 
(c) 
(d) 
(e) (f) 
16 
 
 
 
Supplementary Figure 9: A schematic representation of known cardiac vagal effects on the sinoatrial node and the potential roles of 
HRV SNPs in GNG11, RGS6, and HCN4. See for more details on next page. 
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Various pathways convey the effects of cardiac autonomic activity on heart rate regulation
10, 11
. To these known pathways we added 
the hypothesized effects of some of the HRV SNPs. 
Green colored pathway: The vagal nerve releases acetylcholine (ACh), which binds to the muscarinic (M2R) receptor. This dissociates 
the inactive G protein heterotrimer (Gαβγ) composed of three subunits (α, β, and γ) into two components, namely the α subunit and a 
Gβγ component. The Gβγ component then interacts and activates the G protein-gated inwardly rectifying potassium (GIRK) channel, 
which is a potassium channel (IKACh) composed of GIRK1 and GIRK4 subunits. This causes potassium ions (K
+
) to permeate 
outwardly, which results in a membrane hyperpolarization slowing pacemaker depolarization and subsequently decreasing heart rate.  
We hypothesize that HRV SNPs in GNG11 may lower the availability of the γ11 subunit and could reduce Gβγ component induced 
GIRK activation, which is expected to blunt the effects of phasic changes in cardiac vagal activity, thereby decreasing HRV.  
Red colored pathway: RGS6 binds with G-protein β5 to create the RGS6/Gβ5 dimer complex, which activates GTPase activating 
proteins (GAPs), regulatory proteins that hydrolyze guanosine triphosphate (GTP) breaking a phosphate bond (Pi) to make guanosine 
diphosphate (GDP) on the α subunit. This causes the Gαi/o subunit and a Gβγ component to rejoin into the inactive Gαβγ heterotrimer. 
This ends GIRK channel activation and leads to an increase in heart rate.  
We hypothesize the HRV SNP in RGS6 to increase the availability of RGS6, which gives rise to a decrease in GIRK channel signaling, 
blunting the effects of phasic changes in cardiac vagal activity, thereby decreasing HRV. 
Purple colored pathway: Catecholamine-mediated activation of β-adrenergic receptors also act as a guanine nucleotide exchange factor 
to dissociate the Gαβγ, with the GTP-Gαs then causing adenylate-cyclase to catalyze cAMP production. cAMP-dependent protein 
kinases then activate the L-type Ca,1,2 channels that increase depolarization of the pacemaker membrane, which leads to an increase in 
tonic heart rate.  
Blue colored pathway: Through this same adenylate/cAMP signaling pathway, vagal activation of the M2R also impacts on the funny 
channels (If) of which the hyperpolarization-activated cyclic nucleotide-gated channel isoform 4 (HCN4) is the predominant molecular 
constituent. The If is permeable to K
+
, Na
+
 and Ca
++
 yielding a net inward current that plays a key role in the generation of the 
pacemaker potential
12, 13
. The unique property of reverse voltage dependence of the funny channel causes a spontaneous gradual 
depolarization of the pacemaker membrane until the action potential threshold, at which potential the systolic phase of the next 
heartbeat commences, whereas the sympathetic Gαs subunit speeds up If diastolic depolarization, the vagal Gαi/o subunit counters this 
by slowing the If diastolic depolarization.  
We hypothesize the HRV SNP in HCN4 to increase permeability of the HCN channel to speed up depolarization of the pacemaker 
membrane, thereby increasing tonic heart rate and reducing HRV. 
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(a) See VgHRV_Supplementary_Figure10a.png 
 
(b) See VgHRV_Supplementary_Figure10b.png 
 
Supplementary Figure 10: Functional enrichment analysis based on 24 query genes resulting from the GWAS meta-analyses and 
post-GWAS analyses on the three HRV traits. 
NOTE: The following genes were used as input for GeneMANIA: NDUFA11, FUT5, CAPS, PPIL1, C6orf89, SYT10, GNG11, 
GNGT1, RGS6, HCN4, NEO1, KIAA1755, CCDC141, TFPI2, ALG10, ALG10B, CPNE8, NRTN, FUT6, FUT3, VMAC, RFX2, 
RANBP3, and CPNE5. The resulting significantly enriched gene ontology terms (false discovery rate<0.10) are visualized as 
highlighted boxes within their corresponding gene ontology tree depicted by RamiGO R package, as (a) yellow category: terms related 
to cell membrane signal transduction, and (b) green category: terms related to cellular anabolic, catabolic, and respiratory processes. 
The relations between the boxes have standard color scheme: green, red, black, blue, and light blue represent ‘positively regulates’, 
‘negatively regulates’, ‘regulates’, ‘is a’, and ‘part of’, respectively (http://www.geneontology.org/GO.ontology-ext.relations.shtml). 
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SUPPLEMENTARY TABLES 
 
 
Supplementary Table 1: Description of stage 1 discovery, stage 2 replication, stage 3 other ethnicity lookup, and post-GWAS cohorts 
and lookup trait/disease consortia used in the VgHRV analyses. 
  
Study acronym Study full name Study design Country Ethnicity Study reference 
STAGE 1 DISCOVERY COHORTS 
ARIC 
Atherosclerosis Risk 
in Communities 
study 
prospective population-based 
cohort study 
USA EUR PMID: 2646917 
CHS 
Cardiovascular 
Health Study 
prospective population-based 
cohort study 
USA EUR PMID: 1669507 
FHS 
Framingham Heart 
Study 
prospective population-based 
cohort study 
USA EUR PMID: 14819398 
FINGESTURE 
FINnish GEnetic 
STUdy of 
aRrhythmic Events 
prospective case-control study 
(cases: post-AMI patients) 
Finland EUR 
ClinicalTrials.gov Identifier: 
NCT02075866 
FLEMENGHO-EPOGH 
FLEMish study on 
Environment, Genes 
and Health Outcomes 
– European Project 
on Genes in 
Hypertension 
prospective population-based 
cohort study 
Belgium, Romania, 
Poland, Italy, Russian 
Federation and Czech 
Republic  
EUR PMID: 12640246 & 22184326 
GenR Generation R Study 
prospective population-based 
cohort study of infants 
Netherlands EUR PMID: 16826450 
GTR 
Groningen Twin 
Registry 
prospective twin study Netherlands EUR PMID: 23186546 
KORA S4 
KOoperative 
gesundheitsforschung 
in der Region 
Augsburg – Survey 4 
prospective population-based 
cohort study 
Germany EUR PMID: 16032513 & 16032514 
MESA 
Multi-Ethnic Study 
of Atherosclerosis 
prospective population-based 
cohort study 
USA EUR PMID: 12397006 
MRS 
Marine Resiliency 
Study 
prospective population-based 
cohort study 
USA EUR 
DOI: 
http://dx.doi.org/10.5888/pcd9.1
10134; PMID: 25456346  
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NESDA 
Netherlands Study of 
Depression and 
Anxiety 
prospective case-control study 
(cases: MDD patients) 
Netherlands EUR PMID: 18763692 
NTR 
Netherlands Twin 
Register 
prospective twin-family study Netherlands EUR PMID: 12537867 
PIVUS 
Prospective 
Investigation of the 
Vasculature in 
Uppsala Seniors 
prospective population-based 
cohort study 
Sweden EUR PMID: 16141402 
PREVEND 
Prevention of Renal 
and Vascular ENd-
stage Disease 
prospective population-based 
cohort study enriched for 
individuals with 
microalbuminuria 
Netherlands EUR PMID: 11004219 
RS(1+2) Rotterdam Study 
prospective population-based 
cohort study 
Netherlands EUR PMID: 24258680 
TRAILS-CC 
TRacking 
Adolescents 
Individual Lives 
Survey – CliniCal 
cohort 
prospective high-risk cohort 
study of adolescents     
Netherlands EUR PMIDs: 25431468, 25066533 
TRAILS-Pop 
TRacking 
Adolescents 
Individual Lives 
Survey – POPulation 
cohort 
prospective population-based 
cohort study of adolescents 
Netherlands EUR see TRAILS-CC 
ULSAM 
Uppsala Longitudinal 
Study of Adult Men 
prospective population-based 
cohort study 
Sweden EUR 
PMID: 1216390; 
http://www2.pubcare.uu.se/ULS
AM/ 
YFS 
Cardiovascular Risk 
in Young Finns 
Study 
prospective population-based 
cohort study 
Finland EUR 
PMID: 18263651; 
http://youngfinnsstudy.utu.fi/ 
      
STAGE 2 REPLICATION COHORTS 
CARLA 
CARdiovascular 
disease, Living and 
Ageing in Halle 
prospective population-based 
cohort study 
Germany EUR PMID: 19199053 
FINCAVAS 
FINnish 
CArdioVAscular 
Study 
prospective population-based 
cohort study 
Finland EUR PMID: 16515696 
KORA S4 
KOoperative 
gesundheitsforschung 
prospective population-based 
cohort study 
Germany EUR PMID: 16032513 
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in der Region 
Augsburg – Survey 4 
Lifelines 
Lifelines Cohort 
Study 
prospective population-based 
cohort study 
Netherlands EUR PMID: 18075776 
MRC NSHD 
Medical Research 
Council National 
Survey of Health and 
Development 
prospective population-based 
birth cohort study 
UK EUR 
PMID: 21345808; 
http://www.nshd.mrc.ac.uk 
NESDA 
Netherlands Study of 
Depression and 
Anxiety 
prospective case-control study 
(cases: MDD patients) 
Netherlands EUR PMID: 18763692 
NFBC 1966 
Northern Finland 
Birth Cohort 1966 
prospective population-based 
birth cohort study 
Finland EUR PMID 19060910 
UCSD TWINS 
University of 
California San Diego 
TWINS 
prospective twin study USA EUR PMID: 22676942 
WHI CT – GARNET 
Women’s Health 
Initiative Clinical 
Trials (Genomics 
And Randomized 
Trials Network) 
controls 
prospective cohort study USA EUR 
PMID: 9492970 and 
http://www.genome.gov/275411
19 
WHI CT – MOPMAP 
Women’s Health 
Initiative Clinical 
Trials (Modification 
Of PM-Mediated 
Arrhythmogenesis in 
Populations) controls 
prospective cohort study USA EUR 
PMID: 9492970 and 
http://projectreporter.nih.gov/pr
oject_info_description.cfm?aid=
7984809& 
icde=19283008 
WHII Whitehall-II study 
prospective population-based 
cohort study 
UK EUR PMID: 15576467 
      STAGE 3 LOOKUP COHORTS OF OTHER ETHNICITY 
HCHS/SOL 
Hispanic Community 
Health Study/Study 
of Latinos 
multicenter community-based 
cohort study 
USA HIS PMID: 20609343, 20609344 
MRS 
Marine Resiliency 
Study 
prospective population-based 
cohort study 
USA HIS 
DOI: 
http://dx.doi.org/10.5888/pcd9.1
10134; PMID: 25456346 
      
ARIC 
Atherosclerosis Risk 
in Communities 
study 
prospective population-based 
cohort study 
USA AfAm PMID: 2646917 
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HANDLS 
Healthy Aging in 
Neighborhoods of 
Diversity across Life 
Span 
prospective community-based 
study 
USA AfAm PMID: 20828101 
MESA 
Multi-Ethnic Study 
of Atherosclerosis 
prospective population-based 
cohort study 
USA AfAm PMID: 12397006 
MRS 
Marine Resiliency 
Study 
prospective population-based 
cohort study 
USA AfAm 
DOI: 
http://dx.doi.org/10.5888/pcd9.1
10134; PMID: 25456346 
WHI CT – SHARe 
Women’s Health 
Initiative Clinical 
Trials (Single 
nucleotide 
polymorphism 
Health Association 
Resource) 
prospective cohort study USA AfAm 
PMID: 9492970 and 
https://www.nhlbi.nih.gov/resou
rces/geneticsgenomics/programs
/share.htm 
      POST-GWAS COHORTS & CONSORTIA providing lookups 
ABCD 
Amsterdam Born 
Children and their 
Development 
population-based Netherlands EUR PMID: 20813863 
OFS Oman Family Study five large inbred pedigrees Oman Arabic PMID: 15767758 
      
CHARGE-HF 
CHARGE-Heart 
Failure Working 
Group 
GWAS Consortium multiple EUR PMID 20445134 
CKDGen 
CKDGen 
Consortium 
GWAS Consortium multiple EUR PMID: 21355061, 22479191 
ICBP 
International 
Consortium for 
Blood Pressure  
GWAS Consortium multiple EUR PMID: 21909115 
AFGen Consortium AFGen Consortium GWAS Consortium multiple EUR PMID: 22544366 
CHARGE-SCD 
CHARGE-SCD 
Consortium 
GWAS Consortium multiple EUR PMID:21738491 
EUR: European; HIS: Hispanic/Latino; AfAm: African American; PMID: PubMed ID; NCT: ClinicalTrails.gov identifier; DOI: digital 
object identifier.  
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Supplementary Table 2: Phenotyping information of stage 1 discovery, stage 2 replication, stage 3 other ethnicity lookup, and post-
GWAS cohorts used in the VgHRV analyses. 
 
Study acronym 
Analysis  
sample size 
(N) 
HRV assessment method HRV measurement 
 Female/male 
participation 
STAGE 1 DISCOVERY COHORTS 
ARIC 8262 3-lead ECG; 2 minutes; supine RMSSD; SDNN; HF Men and women 
CHS 759 24hr Holter monitor RMSSD; SDNN; HF Men and women 
FHS 1944 2hr ambulatory ECG RMSSD; SDNN; HF Men and women 
FINGESTURE 494 24hr Holter monitor SDNN; HF Men and women 
FLEMENGHO-
EPOGH 
196 
12-lead ECG & nasal thermistor for RSA: PSA to estimate 
HF ranges ; ECG recording for 15 min ; supine 
pvRSA Men and women 
GenR 392 
3-pole ECG & breathing pattern using a piëzo-electric 
transducer ; 100-180 seconds ; sitting 
HF Men and women 
GTR 134 
type II 3-lead ECGs & respiration with a flexible band 
around upper thorax; 5 minutes; sitting 
RMSSD; SDNN; HF Women 
KORA S4 1617 2-lead  ECG ; 5 minutes ; supine RMSSD; SDNN; HF Men and women 
MESA 2401 
12-lead ECG; average from 3 sequential 10-second ECGs; 
supine; resting 
RMSSD; SDNN Men and women 
MRS 1383 finger photoplethysmograph ; 5 minutes ; sitting RMSSD; SDNN; HF Men 
NESDA 1740 
type II, 3-lead ECG & breathing recorded from thorax 
impedance ; ~90 minutes ; sitting 
RMSSD; SDNN; pvRSA Men and women 
NTR 439 
type II, 3-lead ECG & breathing recorded from respitrace ; 8 
minutes ; sitting 
RMSSD; SDNN; pvRSA Men and women 
PIVUS 766 
6-precordial-lead ECG & breathing recorded using custom-
made impedance device ; 5-minutes ;  supine ;  controlled 
breathing (12 breaths/min)  
SDNN; pvRSA Men and women 
PREVEND 2793 
beat-to-beat blood pressure pulse wave recording on middle 
finger (Portapres); 15 minutes; supine 
RMSSD; SDNN; HF Men and women 
RS1 972 12-lead ECG ; 10 seconds; resting RMSSD; SDNN Men and women 
RS2 985 12-lead ECG ; 10 seconds; resting RMSSD; SDNN Men and women 
TRAILS-CC 307 type II 3-lead ECG; 4 minutes (T1); supine  RMSSD; SDNN; HF Men and women 
TRAILS-Pop 1222 type II 3-lead ECG; 4 minutes (T1), 5 minutes (T3); supine RMSSD; SDNN; HF Men and women 
ULSAM 67 
6-precordial-lead ECG & breathing recorded using custom-
made impedance device from a 24hr recording during 
normal activity 
SDNN; pvRSA Men 
YFS 1827 2-lead ECG ; 3 minutes ; supine RMSSD; SDNN; HF Men and women 
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STAGE 2 REPLICATION COHORTS 
CARLA 1367 12-lead  ECG ; 5 minutes for HRV analysis ; supine  RMSSD; SDNN; HF Men and women 
FINCAVAS 542 12-lead ECG ; 1 minute ; supine RMSSD; SDNN; HF Men and women 
KORA S4 1959 2-lead  ECG ; 5 minutes ; supine RMSSD; SDNN; HF Men and women 
Lifelines 12101 12-lead ECG; 10 seconds; supine RMSSD; SDNN Men and women 
MRC NSHD 1127  3 lead ECG ; 6 minutes ; supine RMSSD; SDNN; HF Men and women 
NESDA 606 
type II, 3-lead ECG & breathing recorded from thorax 
impedance ; ~90 minutes ; sitting 
RMSSD; SDNN; pvRSA Men and women 
NFBC 1966 1941 lead-II ECG recording ; 3 minutes ; sitting SDNN; HF Men and women 
UCSD TWINS 230 3 lead ECG ; 5 minutes; sitting HF Men and women 
WHI CT – GARNET 1648 12-lead ECG; 10 seconds; resting; supine RMSSD; SDNN Women 
WHI CT – MOPMAP 1198 12-lead ECG; 10 seconds; resting; supine RMSSD; SDNN Women 
WHII 1755 12-lead ECG; 5 minutes;  resting; supine SDNN; HF Men and women 
     
STAGE 3 LOOKUP COHORTS OF OTHER ETHNICITY 
HCHS/SOL 10830 12-lead ECG; one 10-second ECG; supine; resting RMSSD; SDNN Men and women 
MRS 404 
finger photoplethysmograph & (simultaneous)2-lead ECG 
recording ; 5 minutes ; sitting 
RMSSD; SDNN; HF Men 
ARIC 1582 3-lead ECG; 2 minutes; supine RMSSD; SDNN; HF Men and women 
HANDLS 188 
Portapres ambulatory HR and BP monitor; 5 minutes; 
sitting 
RMSSD; SDNN; HF Men and women 
MESA 1480 
12-lead ECG; average from 3 sequential 10-second ECGs; 
supine; resting 
RMSSD; SDNN Men and women 
MRS 131 finger photoplethysmograph ; 5 minutes ; sitting RMSSD; SDNN; HF Men 
WHI CT – SHARe 3518 12-lead ECG; 10 seconds; supine RMSSD; SDNN Women 
     
POST-GWAS COHORTS 
ABCD 1094 
 type II, 3-lead ECG & breathing recorded from thorax 
impedance ; ~4 minutes ; sitting 
RMSSD; SDNN; pvRSA Men and women 
OFS 1326 type II, 6-lead ECG ; 10 minutes; supine RMSSD; SDNN; HF Men and women 
ECG: electrocardiogram; RSA: respiratory sinus arrhythmia; PSA: proportion of specific agreement; HF: high frequency; HR: heart 
rate; BP: blood pressure.  
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Supplementary Table 3: Clinical characteristics of stage 1 discovery, stage 2 replication, and stage 3 other ethnicity, and post-GWAS 
cohorts used in the VgHRV analyses.         
Study 
acronym 
Analysis 
sample size 
(N) 
Women 
(%) 
  Age SDNN ln(SDNN) RMSSD ln(RMSSD) pvRSA/HF ln(pvRSA/HF) 
  Mean (SD) 
STAGE 1 DISCOVERY COHORTS 
ARIC 8.262 54.9 
overall 54.04 (5.65) 37.58 (19.14) 3.52 (0.46) 27.87 (21.73) 3.15 (0.58) 16.89 (44.33) 2.03 (1.27) 
women 53.74 (5.63) 36.27 (18.16) 3.49 (0.45) 27.96 (20.37) 3.16 (0.58) 17.96 (37.96) 2.16 (1.24) 
men 54.41 (5.66) 39.18 (20.16) 3.56 (0.46) 27.75 (23.28) 3.14 (0.58) 15.59 (51.00) 1.87 (1.29) 
CHS 759 58.1 
overall 71.2 (4.5) 96.7 (28.4) 4.5 (0.3) 21.5 (11.8) 2.9 (0.4) 115.8 (172.1) 4.3 (0.8) 
women 70.6 (4.1) 93.1 (25.4) 4.5 (0.3) 20.3 (9.1) 2.9 (0.4) 104.9 (116.6) 4.3 (0.8) 
men 72.0 (4.9) 101.6 (32.0) 4.6 (0.3) 23.2 (14.8) 3.0 (0.5) 130.8 (227.7) 4.3 (0.9) 
FHS 1.944 53.86 
overall 51.70 (12.85) 91.76 (27.97) 4.47 (0.31) 33.54 (16.61) 3.41 (0.44) 34.07 (38.51) 5.44 (0.88) 
women 52.23 (13.06) 93.60 (27.79) 4.45 (0.32) 33.94 (16.76) 3.40 (0.44) 33.91 (37.67) 5.44 (0.89) 
men 51.09 (12.60) 89.61 (28.18) 4.49 (0.30) 33.08 (16.43) 3.42 (0.44) 34.26 (39.47) 5.43 (0.86) 
FINGESTURE 494 23.68 
overall 61 (9.96) 97.84 (31.86) 4.53 (0.34) n.a. n.a. 525.4 (885.4) 5.83 (0.84) 
women 64 (9.56) 87.88 (32.36) 4.41 (0.36) n.a. n.a. 630.8 (1400.1) 5.85 (0.89) 
men 60 (9.89) 100.72 (31.17) 4.58 (0.32) n.a. n.a. 493.7 (661.1) 5.82 (0.83) 
FLEMENGHO
-EPOGH 
196 48.98 
overall 52.74 (11.44) n.a. n.a. n.a. n.a. n.a. 3.07 (0.40) 
women 53.00 (10.54) n.a. n.a. n.a. n.a. n.a. 3.02 (0.37) 
men 52.50 (12.30) n.a. n.a. n.a. n.a. n.a. 3.11 (0.41) 
GenR 392 49.49 
overall 1.22 (0.08) n.a. n.a. n.a. n.a. n.a. 2.85 (0.42) 
women 1.22 (0.08) n.a. n.a. n.a. n.a. n.a. 2.86 (0.44) 
men 1.22 (0.07) n.a. n.a. n.a. n.a. n.a. 2.84 (0.38) 
GTR 134 100 
overall  23.43 (3.39) 51.05 (20.96) 3.86 (0.39) 37.17 (25.04) 3.45 (0.55) 1034.68 (1684.47) 6.29 (1.1) 
women 23.43 (3.39) 51.05 (20.96) 3.86 (0.39) 37.17 (25.04) 3.45 (0.55) 1034.68 (1684.47) 6.29 (1.1) 
men n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
KORA S4 1.617 51.64 
overall 53.46 (8.82) 35.93 (19.15) 3.47 (0.46) 25.26 (19.11) 3.04 (0.61) 61.20 (215.59) 3.25 (1.25) 
women 53.26 (8.77) 35.36 (19.34) 3.46 (0.46) 25.79 (19.32) 3.06 (0.60) 61.43 (106.10) 3.37 (1.24) 
men 53.68 (8.87) 36.54 (18.94) 3.49 (0.46) 24.69 (18.89) 3.01 (0.61) 60.96 (290.09) 3.12 (1.26) 
MESA 2.401 52.35 
overall 62.3 (10.1) 33.6 (16.4) 2.9 (0.6) 25.0 (22.5) 3.0 (0.66) n.a. n.a. 
women 62.3 (10.2) 22.5 (14.5) 2.9 (0.6) 25.3 (19.5) 3.0 (0.64) n.a. n.a. 
men 62.4 (9.9) 22.6 (18.1) 2.9 (0.6) 24.7 (25.4) 2.9 (0.67) n.a. n.a. 
MRS 1.383 0 
overall 22.75 (3.48) 65.43 (27.43) 4.10 (0.41) 59.51 (34.98) 3.94 (0.54) 4304.72 (5277.67) 7.86 (1.04) 
women n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
men 22.75 (3.48) 65.43 (27.43) 4.10 (0.41) 59.51 (34.98) 3.94 (0.54) 4304.72 (5277.67) 7.86 (1.04) 
NESDA 1.740 68.05 
overall 41.88 (12.59) 61.19 (25.20) 4.11 (3.23) 33.14 (20.66) 3.50 (3.03) 42.95 (24.23) 1.57 (0.24) 
women 40.95 (12.69) 60.31 (24.43) 4.10 (3.20) 33.96 (20.83) 3.53 (3.04) 45.65 (24.60) 1.60 (0.23) 
men 43.86 (12.15) 63.07 (26.71) 4.14 (3.29) 31.38 (20.20) 3.45 (3.01) 37.19 (22.35) 1.50 (0.25) 
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NTR 439 65.15 
overall 30.83 (14.42) 77.09 (32.75) 4.21 (0.46) 61.02 (34.41) 3.97 (0.55) 76.73 (46.56) 4.18 (0.58) 
women 29.84 (14.71) 60.65 (34.16) 3.98 (0.54) 75.22 (31.28) 4.24 (0.44) 79.52 (45.94) 4.23 (0.57) 
men 32.67 (7.84) 81.28 (35.47) 4.30 (0.50) 61.80 (41.20) 3.97 (0.59) 71.51 (47.41) 4.09 (0.62) 
PIVUS 766 53.66 
overall 70.20 (0.18) 34.56 (18.19) 3.43 (0.46) n.a. n.a. 243.20 (385.89) 4.79 (1.20) 
women 70.27 (0.15) 34.60 (18.61) 3.44 (0.45) n.a. n.a. 240.6 (335.90) 4.84 (1.17) 
men 70.13 (0.18) 34.52 (17.73) 3.43 (0.47) n.a. n.a. 246.2 (437.10) 4.73 (1.24) 
PREVEND 2.793 49.48 
overall 53.22 (11.68) 35.64 (17.46) 3.47 (0.45) 29.35 (19.70) 3.24 (0.51) 438.32 (1089.07) 5.39 (1.13) 
women 53.90 (12.06) 36.15 (18.19) 3.48 (0.47) 28.11 (19.76) 3.19 (0.51) 398.76 (1109.34) 5.27 (1.13) 
men 52.55 (11.25) 35.14 (16.71) 3.46 (0.44) 30.57 (19.58) 3.28 (0.51) 477.12 (1067.78) 5.50 (1.12) 
RS1 972 37.55 
overall 79.13 (4.79) 36.70 (31.39) 3.37 (0.64) 35.66 (45.39) 3.13 (0.86) n.a. n.a. 
women 78.80 (4.47) 43.07 (39.77) 3.48 (0.71) 43.30 (57.93) 3.23 (3.23) n.a. n.a. 
men 79.23 (4.97) 79.23 (4.97) 3.31 (0.59) 31.06 (35.05) 5.66 (3.08) n.a. n.a. 
RS2 985 58.78 
overall 72.13 (5.00) 35.10 (27.72) 3.38 (0.56) 31.91 (45.54) 3.07 (0.77) n.a. n.a. 
women 72.25 (5.18) 32.87 (25.68) 3.33 (0.52) 29.49 (44.97) 3.03 (0.72) n.a. n.a. 
men 71.96 (4.71) 38.27 (30.15) 3.44 (0.60) 35.34 (46.18) 3.12 (0.85) n.a. n.a. 
TRAILS-CC 307 30.62 
overall 11.11 (0.48) 75.79 (38.05) 6.51 (0.50) 89.21 (54.25) 4.31 (0.62) 4277.19 (5828.07) 7.64 (1.27) 
women 11.07 (0.55) 73.52 (30.44) 6.51 (0.44) 82.15 (42.75) 4.26 (0.59) 3509.59 (3736.52) 7.60 (1.16) 
men 11.13 (0.45) 76.79 (40.98) 6.51 (0.52) 92.31 (58.41) 4.33 (0.64) 4619.12 (6526.94) 7.65 (1.31) 
TRAILS-Pop 1.222 52.7 
overall 11.46 (1.57) 70.74 (35.84) 4.13 (0.51) 77.61 (51.06) 4.14 (0.68) 3715.66 (5230.48) 7.47 (1.32) 
women 11.42 (1.54) 67.49 (33.42) 4.09 (0.49) 73.04 (48.02) 4.09 (0.66) 3327.63 (4981.83) 7.36 (1.30) 
men 11.50 (1.60) 74.34 (38.05) 4.18 (0.53) 82.69 (53.83) 4.20 (0.69) 4145.51 (5465.12) 7.58 (1.35) 
ULSAM 67 0 
overall 71.05 (0.46) 163.81 (52.87) 5.05 (0.31) n.a. n.a. 11.37 (6.60) 2.25 (0.54) 
women n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
men 71.05 (0.46) 163.81 (52.87) 5.05 (0.31) n.a. n.a. 11.37 (6.60) 2.25 (0.54) 
YFS 1.827 55.12 
overall 31.68 (4.99) 50.76 (23.36) 3.83 (0.44) 48.48 (32.34) 3.69 (0.62) 1010 (1497) 6.26 (1.18) 
women 31.68 (4.98) 50.6 (24.35) 3.82 (0.46) 50.05 (34.74) 3.70 (0.65) 1161 (1759) 6.37 (1.23) 
men 31.68 (4.99) 50.97 (22.1) 3.84 (0.42) 46.56 (29.03) 3.67 (0.58) 823.8 (1063) 6.13 (1.11) 
Stage 1 discovery 
total 
28.700 
 
STAGE 2 REPLICATION COHORTS 
CARLA 1.367 47.7 
overall 62.74 (9.77) 30.55 (15.89) 3.30 (0.48) 23.25 (19.14) 2.94 (0.61) 291.60 (557.22) 4.88 (1.22) 
women 62.56 (9.59) 31.61 (16.18) 3.35 (0.45) 24.94 (19.35) 3.03 (0.58) 343.60 (623.83) 5.14 (1.14) 
men 62.91 (9.93) 29.58 (15.57) 3.27 (0.49) 21.70 (18.82) 2.86 (0.62) 244.00 (484.18) 4.65 (1.25) 
FINCAVAS 542 44.83 
overall 52.90 (12.94) 28.96 (15.35) 3.22 (0.57) 20.95 (12.15) 2.89 (0.56) 102.48 (190.76) 3.80 (1.29) 
women 54.51 (11.94) 27.29 (14.05) 3.16 (0.56) 19.98 (11.07) 2.85 (0.55) 91.89 (137.72) 3.76 (1.27) 
men 51.59 (13.57) 30.31 (16.23) 3.26 (0.58) 21.74 (12.92) 2.92 (0.57) 111.09 (224.71) 3.83 (1.32) 
KORA S4 1.959 50.89 
overall 44.98 (15.85) 42.40 (23.38) 3.62 (0.51) 33.76 (23.98) 3.30 (0.68) 105.48 (191.06) 3.80 (1.41) 
women 44.21 (15.41) 42.85 (24.47) 3.63 (0.51) 35.37 (25.40) 3.35 (0.67) 117.80 (220.36) 3.94 (1.37) 
men 45.78 (16.26) 41.94 (22.20) 3.61 (0.52) 32.09 (22.30) 3.25 (0.68) 92.71 (154.03) 3.65 (1.43) 
27 
 
 
 
Lifelines 12.101 58.59 
overall 48.01 (11.14) 33.42 (24.22) 3.29 (0.66) 33.41 (28.13) 3.26 (0.71) n.a. n.a. 
women 48.00 (11.10) 33.84 (24.22) 3.31 (0.65) 34.87 (29.06) 3.30 (0.70) n.a. n.a. 
men 48.00 (11.21) 32.84 (24.22) 3.27 (0.68) 31.35 (26.62) 3.19 (0.72) n.a. n.a. 
MRC NSHD 1.127 55.72 
overall 63.3 (1.0) 32.3 (13.1) 3.4 (0.4) 21.2 (12.2) 2.9 (0.5) 227.3 (1.3) 4.7 (1.0) 
women 63.4 (1.0) 31.7 (12.3) 3.4 (0.4) 21.8 (12.2) 2.9 (0.5) 240.0 (4.7) 4.8 (1.0) 
men 63.3 (1.1) 33.1 (14.0) 3.4 (0.4) 20.5 (12.1) 2.9 (0.5) 162.9 (207.8) 4.6 (1.0) 
NESDA 606 64.36 
overall 42.33 (14.32) 77.01 (34.27) 4.25 (0.43) 45.34 (35.24) 3.57 (0.68) 47.78 (32.08) 3.68 (0.64) 
women 42.06 (14.17) 75.41 (31.94) 4.24 (0.42) 45.12 (33.08) 3.59 (0.65) 50.38 (32.43) 3.76 (0.60) 
men 42.82 (14.62) 79.90 (38.02) 4.28 (0.45) 45.76 (38.92) 3.54 (0.74) 43.08 (30.95) 3.54 (0.69) 
NFBC 1966 1.941 54.97 
overall 46.6 (0.6) 32.5 (14.3) 3.4 (0.4) n.a. n.a. 264.6 (407.9) 4.8 (1.3) 
women 46.6 (0.6) 32.3 (13.5) 3.4 (0.4) n.a. n.a. 304.8 (447.2) 5.0 (1.3) 
men 46.6 (0.6) 32.9 (15.3) 3.4 (0.5) n.a. n.a. 215.6 (348.2) 4.6 (1.3) 
UCSD TWINS 230 76.52 
overall 41.03 (16.53) 61.89 (32.41) 3.98 (0.6) n.a. n.a. 152.16 (364.59) 3.96 (1.60) 
women 41.27 (16.38) 61.52 (33.14) 3.98 (0.6) n.a. n.a. 165.10 (407.87) 4.02 (1.59) 
men 38.78 (16.96) 63.07 (30.18) 4.00 (0.63) n.a. n.a. 110.01 (150.62) 3.77 (1.60) 
WHI  CT– 
GARNET 
(controls) 
1.648 100 
overall 65.26 (6.77) 19.73 (15.63) 2.76 (0.65) 21.09 (19.74) 2.79 (0.68) n.a. n.a. 
women 65.26 (6.77) 19.73 (15.63) 2.76 (0.65) 21.09 (19.74) 2.79 (0.68) n.a. n.a. 
men n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
WHI  CT– 
MOPMAP 
(controls) 
1.198 100 
overall 63.11 (6.61) 20.29 (15.93) 2.79 (0.65) 22.26 (20.86) 2.84 (0.69) n.a. n.a. 
women 63.11 (6.61) 20.29 (15.93) 2.79 (0.65) 22.26 (20.86) 2.84 (0.69) n.a. n.a. 
men n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
WHII 1.755 24.22 
overall 60.30 (5.85) 38.73 (27.04) 3.53 (0.47) n.a. n.a. 382.48 (2618.92) 4.76 (1.20) 
women 60.64 (5.83) 40.81 (28.20) 3.52 (0.46) n.a. n.a. 484.38 (2851.76) 5.02 (1.22) 
men 60.19 (5.83) 38.06 (25.19) 3.56 (0.48) n.a. n.a. 349.92 (2697.58) 4.67 (1.19) 
Stage 2 replication 
total 
24.474 
 
STAGE 3 LOOKUP COHORTS OF OTHER ETHNICITY 
HCHS/SOL 10.830 59.41 
overall 45.18 (13.61) 29.75 (22.53) 3.16 (0.69) 35.79 (29.25) 3.31 (0.73) n.a. n.a. 
women 45.91 (13.41) 29.89 (22.03) 3.18 (0.67) 36.98 (29.56) 3.36 (0.72) n.a. n.a. 
men 44.11 (13.83) 29.55 (23.23) 3.14 (0.71) 34.04 (28.70) 3.25 (0.75) n.a. n.a. 
MRS 404 0 
overall 22.51 (3.12) 62.90 (24.84) 4.06 (0.40) 58.57 (32.98) 3.93 (0.52) 4069.94 (4706.06) 7.82 (1.02) 
women n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
men 22.51 (3.12) 62.90 (24.84) 4.06 (0.40) 58.57 (32.98) 3.93 (0.52) 4069.94 (4706.06) 7.82 (1.02) 
Total HIS  11.234 
 
ARIC 1.582 63.15 
overall 53.06 (5.76) 38.00 (19.77) 3.5 (0.52) 34.20 (24.54) 3.33 (0.63) 22.84 (37.44) 2.38 (1.31) 
women 52.94 (5.63) 36.93 (19.10) 3.48 (0.52) 34.51 (24.38) 3.34 (0.64) 23.98 (37.10) 2.45 (1.30) 
men 53.28 (5.98) 39.84 (20.77) 3.56 (0.51) 33.67 (24.82) 3.32 (0.62) 20.90 (38.00) 2.28 (1.33) 
HANDLS 188 54.79 
overall 47.32 (8.90) 32.79 (13.91) 3.40 (0.43) 34.04 (13.67) 3.45 (0.41) 483.87 (604.08) 5.68 (1.01) 
women 47.59 (9.17) 32.56 (12.55) 3.41 (0.40) 35.96 (13.79) 3.51 (0.92) 541.57 (566.36) 5.86 (0.97) 
men 47.04 (8.61) 33.06 (15.46) 3.39 (0.47) 31.68 (13.23) 3.37 (0.41) 413.94 (643.31) 5.47 (1.02) 
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MESA 1.480 54.73 
overall 61.9 (10.0) 26.72 (19.78) 3.08 (0.64) 32.72 (27.80) 3.24 (0.70) n.a. n.a. 
women 61.84 (9.95) 26.71 (18.53) 3.09 (0.62) 33.33 (25.74) 3.27 (0.68) n.a. n.a. 
men 61.95 (10.14) 26.74 (20.99) 3.07 (0.65) 31.99 (30.11) 3.20 (0.72) n.a. n.a. 
MRS 131 0 
overall 23.74 (4.73) 59.83 (22.94) 4.03 (0.37) 58.76 (28.53) 3.96 (0.48) 3804.05 (4239.97) 7.87 (0.91) 
women n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
men 23.74 (4.73) 59.83 (22.94) 4.03 (0.37) 58.76 (28.53) 3.96 (0.48) 3804.05 (4239.97) 7.87 (0.91) 
WHI CT - 
SHARe 
3.518 100 
overall 60.84 (6.70) 22.03 (17.67) 2.86 (0.68) 26.79 (24.92) 3.01 (0.73) n.a. n.a. 
women 60.84 (6.70) 22.03 (17.67) 2.86 (0.68) 26.79 (24.92) 3.01 (0.73) n.a. n.a. 
men n.a. n.a. n.a. n.a. n.a. n.a. n.a. 
Total AfAm  6.899 
 
 
Stage 3 other ethnicity 
total 
18.133 
 
 
POST-GWAS COHORTS 
ABCD 1.094 0.51 
overall 5.51 (0.38) 73.10 (30.95) 4.2 (0.43) 80.87 (45.91) 4.23 (0.59) 121.39 (62.42) 4.66 (0.54) 
women 5.51 (0.39) 72.42 (30.95) 4.19 (0.43) 79.22 (46.19) 4.21 (0.59) 120.72 (62.65) 4.66 (0.53) 
men 5.50 (0.37) 73.80 (30.96) 4.21 (0.43) 82.58 (45.60) 4.25 (0.60) 122.09 (62.23) 4.67 (0.55) 
OFS 1.326 56.03 
overall 33.41 (15.73) 61.92 (32.46) 4.02 (0.45) 41.39 (22.66) 3.57 (0.56) 197.43 (2569.48) 10.58 (1.49) 
women 33.98 (14.90) 55.27 (29.54) 3.91 (0.44) 39.34 (23.34) 3.50 (0.59) 97.78 (233.66) 10.35 (1.54) 
men 32.68 (16.73) 70.24 (34.01) 4.16 (0.43) 43.96 (21.53) 3.67 (0.51) 318.79 (3816.42) 10.87 (1.38) 
SD: standard deviation; n.a.: not available.   
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Supplementary Table 4: Technical information on the genotyping and imputation method of stage 1 discovery, stage 2 replication, 
stage 3 other ethnicity lookup, and post-GWAS cohorts used in the VgHRV analyses.  
Study acronym Array(s) 
Calling 
Algorithm 
QC filters for 
exclusion of 
genotyped SNPs 
QC filters for 
exclusion of 
individuals 
Imputation 
software 
Imputation 
reference panel 
(build) 
Total SNPs 
after 
imputation 
Statistical 
software 
Genomic 
control lambda 
SDNN / RMSSD 
/ pvRSA/HF 
STAGE 1 DISCOVERY COHORTS 
ARIC 
Affymetrix 
GeneChip SNP 
Array 6.0 
Birdseed 
call rate ≤ 95%; 
MAF <1%; 
pHWE< 1E-6 
call rate <95% 
MaCH 
v1.0.16 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.543.887 Probabel 
1.015 / 1.011 / 
1.012 
CHS 
Illumina 
370CNV 
BeadStudio 
call rate <97%; 
MAF: n.a. - 
excluded SNPs 
with 0 
heterozygotes; 
pHWE< 1E-5 
call rate<=95% or if 
their genotype was 
discordant with 
known sex or prior 
genotyping 
BIMBAM 
v0.99 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.318.082 R 
1.011 / 1.009 / 
1.016 
FHS 
Affymetrix 
500K, 
Affymetrix 
50K 
supplemental 
BRLMM 
call rate ≤ 97%; 
MAF: n.a.; 
pHWE< 1E-6 
call rate <90% 
Mach1 
v1.0.15 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.466.720 PLINK, R 
1.012 / 1.010 / 
1.014 
FINGESTURE Affymetrix 6.0 
Birdseed (as 
implemented in 
Affymetrix 
powertools 
1.10.2 package) 
call rate < 95%; 
MAF < 0.01; 
pHWE: n.a. 
Sample genotyping 
rate ≤97% 
MACH 
1.0.15 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.543.888 
MACH2QTL 
V1.0.4 
0.997/ - / 1.006 
FLEMENGH
O-EPOGH 
ILLUMINA 
1M 
ILLUMINA 
Genome Studio 
call rate< 99%; 
MAF <0.01; 
pHWE< 1E-08 
call rate <99%; sex 
mismatch; 
heterozygosity > 4SD 
from mean; non-
Caucasians 
MACH 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.581.944 PLINK, R - / - / 1.003 
GenR 
Ilumina 610 
Quad array 
Genomestudio 
2009 V.1.1.9 
call rate <95%; 
MAF <1%; 
pHWE< 1E-6 
Call rate <97,50%; 
Heterozygosity > 
4SD from mean; 
Caucasian only, 
ethnic outliers 
excluded based on 
PCA 
MACH 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
25.438.877 PLINK - / - / 1.007 
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GTR 
Illumina Cyto 
SNP12 v2 
GenomeStudio 
call rate < 95%; 
MAF <1%; 
pHWE< 1E-4 
call rate <95%; sex 
mismatch; 
heterozygosity > 4SD 
from mean; non-
Caucasians 
IMPUTE 
v2 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.631.501 
SNPTEST 
v2.2.0 
1.013 / 1.022 / 
1.017 
KORA S4 Affymetrix 6.0 Birdseed v2 
call rate< 93%; 
HapMap SNPs 
only 
call rate< 93%; sex 
mismatch 
MACH 
v1.0.15 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.543.887 
MACH2QTL 
v1.0.8 
1.022 / 1.012 / 
1.007 
MESA Affymetrix 6.0 Birdseed v2 
call rate < 95%; 
MAF: n.a.; 
pHWE: n.a; 
heterozygosity > 
53%. 
sex mismatches, 
expected and 
unexpected 
duplicates, call rate < 
95% 
IMPUTE 
v2.1.0 
HapMap Phase I 
and II CEU 
individuals release 
24 (build36) 
3.854.661 R 0.994 / 0.998 / - 
MRS 
Illumina 
HumanOmniEx
pressExome 
array (HOEE 
12v1.0) 
Genome Studio 
call rate< 95%; 
MAF: n.a.; 
pHWE< 5E-08 
call rate <98%; 
heterozygosity 
<0.211 or >0.302; 
non-Caucasians 
IMPUTEv2 
1000Genomes 
global panel phase 
1 release v3 (build 
37) 
32.179.008 
SNPTEST 
v2.4.1 
0.999 / 1.008 / 
1.003 
NESDA 
Perlegen-
Affymetrix 5.0; 
Affymetrix 6.0 
907K 
Proprietary 
call rate ≤ 95%; 
MAF <0.01; 
pHWE: n.a. 
Non-Caucasians, XO 
and XXY samples, 
and samples with a 
call rate <95%, high 
genome-wide homo- 
or heterozygosity, 
excess IBS 
IMPUTE 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.135.543 
SNPTEST 
v1.1.4 
1.008 / 1.000 / 
0.998 
NTR 
Affymetrix-
Perlegen; 
Illumina 370, 
660, 1M Omi; 
Affymetrix 6.0 
Proprietary 
Affymetrix 
Calling 
Algorithms, 
Birdsuite 1 & 
2. 
callrate SNPs < 
90%, MAF < 
0.01, HWE < 
0.00001 
Callrate < 90%, Sex 
/IBD mismatch, F(st) 
> 0.10 or F < 0.10,  
Ethnicity based on 
PCs (deviating from 
maximum European 
PC values), 
Mendelian 2 error 
rate in relation to 
family member >  
2% 
IMPUTE 
HapMap Phase II 
CEU B36 rel 24. 
2.401.535 
SNPTEST 
v1.1.4 
0.998 / 1.002 / 
1.015 
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PIVUS 
Illumina 
OmniExpress + 
Metabochip 
Proprietary 
call rate< 95%; 
MAF< 0.01; 
pHWE< 1E-6 
Call rate <95%; 
heterozygosity, 
gender check and 
relatedness 
IMPUTE 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.616.874 PLINK 1.004 / - / 1.006 
PREVEND 
Illumina 
HumanCytoSN
P12 v2 
beadchip assay 
Illumina 
Genome Studio 
software 
call rate < 0.95; 
MAF <0.01; 
pHWE <E-5 
call rate < 0.95; sex 
mismatch; non-
Caucasians 
BEAGLE 
v3.3.1 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.269.099 PLINK 
1.014 / 1.000 / 
1.001 
RS1 
Illumina, 
HumanHap550
- chip v3.0 
BeadStudio 
call rate < 98%; 
MAF <1%; 
pHWE< 1E-6 
excess autosomal 
heterozygosity, sex 
mismatch or outlying 
identity-by-state 
clustering estimates 
Mach1 
v1.0.15 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.543.887 ProbABEL,R 1.006 / 1.011 / - 
RS2 
Illumina550K 
Duo, 
610KQuad 
GenomeStudio 
call rate < 98%; 
MAF <1%; 
pHWE< 1E-6 
excess autosomal 
heterozygosity, sex 
mismatch or outlying 
identity-by-state 
clustering estimates 
Machv1.0.1
6 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.543.887 ProbABEL, R 0.995 / 1.007 / - 
TRAILS-CC 
Illumina Cyto 
SNP12 v2 
GenomeStudio 
call rate < 95%; 
MAF <1%; 
pHWE< 1E-4 
call rate <95%; sex 
mismatch; 
heterozygosity > 4SD 
from mean; non-
Caucasians 
IMPUTE 
v2 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.631.501 
SNPTEST 
v2.2.0 
1.014 / 1.012 / 
1.011 
TRAILS-Pop 
Illumina Cyto 
SNP12 v2 
GenomeStudio 
call rate < 95%; 
MAF <1%; 
pHWE< 1E-4 
call rate <95%; sex 
mismatch; 
heterozygosity > 4SD 
from mean; non-
Caucasians 
IMPUTE 
v2 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.631.501 
SNPTEST 
v2.2.0 
0.994 / 0.994 / 
0.992 
ULSAM 
Illumina 
OMNI2.5 + 
Metabochip 
Proprietary 
call rate< 99%%; 
MAF <0.01; 
pHWE: n.a. 
Call rate <95%; 
heterozygosity, 
gender check and 
relatedness 
IMPUTE 
v2 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
3.126.254 PLINK v1.07 1.005 / - / 1.007 
YFS 
Illumina 670k 
custom 
Illuminus 
call rate ≤ 95%; 
MAF<0.01; 
pHWE< 1E-6 
Call rate <95%; 
heterozygosity, 
gender check and 
relatedness 
MACH 1.0 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.543.887 
ProbABEL 
v0.1-3 
1.006 / 1.013 / 
1.015 
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STAGE 2 REPLICATION COHORTS                
CARLA 
TaqMan® 
(Applied 
Biosystems, 
Darmstadt, 
Germany) 
Sequence 
Detection 
Software SDS 
2.3 
call rate< 95%; 
MAF <0.01; 
pHWE: n.a. 
non-Caucasians n.a. n.a. n.a. R - 
FINCAVAS Metabochip GenomeStudio 
call rate ≤ 95%; 
MAF <0.01; 
pHWE< 1E-6 
Call rate <95%; 
heterozygosity, 
gender check and 
relatedness 
SHAPEIT 
v2 / 
IMPUTE 
2.3.0 
1000Genomes 
global panel phase 
1 release v3 (build 
37) 
38.943.535 
SNPTEST 
v2.5 
- 
KORA S4 
Affymetrix 
Axiom 
Affymetrix 
Software 
call rate ≤ 98%; 
MAF: <1%; 
pHWE< 1E-6 
call rate ≤ 97%; sex 
mismatch; 
heterozygosity >5SD 
from mean; non-
Caucasian; 
population outliers; 
participant in stage 1 
SHAPEIT 
v2, 
IMPUTE 
v2.3.0 
1000Genomes 
global panel phase 
1 release v3 (build 
37) 
30.067.091 R - 
Lifelines 
Illumina 
Cyto 
SNP12 v2 
GenomeStudio 
call rate < 98%; 
MAF <1%; 
pHWE< 1E-5 
call rate <95%; sex 
mismatch; 
heterozygosity > 4SD 
from mean; non-
Caucasians 
MACH 
minimac 
1000Genomes 
global panel phase 
1 release v3 (build 
37) 
28.681.763 PLINK v1.07 - 
MRC NSHD LGC KASP Proprietary 
call rate < 90%; 
MAF <1%; 
pHWE< 0.05 
call rate < 90%, n.a. n.a. n.a. SAS - 
NESDA 
Affymetrix 
6.0 907K 
Birdseed 
call rate< 95%; 
MAF <0.01; 
pHWE<1E-5.; 
unmapped; allele 
frequency 
difference with 
reference >20%; 
ambiguous SNPs 
with allele 
frequency>35% 
call rate<90%; 
heterozygosity 
abs(PLINK F)>0.1; 
sex mismatch; 
unexpected 
relatedness 
Minimac 
1000Genomes 
global panel phase 
1 release v3 (build 
37) 
3.000.779 
SNPTEST 
v2.4.1 
- 
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NFBC 1966 
Illumina 
HumanCN
V‐370DUO 
Analysis 
BeadChip 
Beadstudio 
call rate < 95%; 
MAF <1%; 
pHWE< 1E-07 
call rate <95% 
IMPUTE 
v2 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
3.855.963 
SNPTEST 
2.4.1 
- 
UCSD TWINS 
Illumina 
610 Quad 
genotyping 
array 
Proprietary 
call rate< 95%; 
MAF <0.01; 
pHWE: n.a. 
call rate <95% MaCH 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.587.522 PLINK - 
WHI – GARNET 
Human 
Omni1-
Quad v1-0 
B 
BeadStudio 
v3.1.3.0 
call rate ≤ 98%; 
MAF: n.a.; 
pHWE< 1E-4 
call rate ≤ 98% 
BEAGLE 
v3.3.1 
1000Genomes 
global panel phase 
1 release v3 (build 
37) 
8.905.697 lm.R - 
WHI – MOPMAP 
Affymetrix 
Axiom 
Genome-
Wide 
Human 
CEU I 
Birdseed 
call rate ≤ 90%; 
MAF <0.5%; 
pHWE< 1E-06 
call rate ≤ 95% 
MaCH 
minimac 
HapMap Phase II 
data in the CEU 
individuals release 
22 (build36) 
2.543.886 lm.R - 
WHII 
Illumina 
Metabochip 
GenomeStudio call rate< 0.95 
call rate< 0.95, sex 
mismatch, duplicates 
Minimac 
1000 Genomes 
global panel phase 
1 release v3 (build 
37) 
1.217.802 PLINK - 
STAGE 3 LOOKUP COHORTS OF OTHER ETHNICITY 
HCHS/SOL 
Illumina 
HumanOmni
2.5-8v1-1 + 
custom 
content 
GenomeStudio 
v2011.1 
call rate: 98%; 
MAF: n.a.; 
pHWE< 1E-05 
sex mismatch; 
unexpected duplicates 
IMPUTEv2 
1000Genomes 
global panel phase 
1 release v3 (build 
37) 
25.568.744 
R/Biocondu
ctor 
GENESIS 
package 
- 
MRS 
Illumina 
HumanOmni
ExpressExom
e array 
(HOEE 
12v1.0) 
Genome Studio 
call rate: 95%; 
MAF: n.a.; 
pHWE< 5E-08 
call rate <98%; 
heterozygosity <0.211 
or >0.302; non-
Hispanics 
IMPUTEv2 
1000Genomes 
global panel phase 
1 release v3 (build 
37) 
32.179.008 
SNPTEST 
v2.4.1 
- 
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ARIC 
Affymetrix 
GeneChip 
SNP Array 
6.0 
Birdseed 
call rate ≤ 90%; 
MAF <1%; 
pHWE: n.a. 
call rate <95% 
MaCH 
v1.0.16 
HapMap Phase II 
data in the 
YRI+CEU 
individuals release 
22 (build36) 
2.653.878 Probabel - 
HANDLS 
Illumina 
genotyping 
arrays 
including 1M 
and 1Mduo 
Illumina 
BeadStudio 
Genotype call 
rate <95%; 
HWE p-value < 
1.0E-7; MAF < 
0.01;  
Sample call rate < 
95%; excess 
heterozygosity > 
3SD from the 
mean; Ethnic 
outliers, Cryptic 
relatedness; Sex 
mismatch 
MACH/min
imac 
HapMap Phase 
II data in the 
YRI+CEU 
individuals 
release 22 
(build36) 
2.939.993 
MACH2QT
Lv1.08 
- 
MESA 
Affymetrix 
6.0 
Birdseed v2 
call rate < 95%; 
MAF: n.a.; 
pHWE: n.a; 
heterozygosity 
> 53%. 
sex mismatches, 
expected and 
unexpected 
duplicates, call rate 
< 95% 
IMPUTE 
v2.2.2 
1000Genomes 
global panel 
phase 1 release 
v3 (build 37) 
39.295.080 R - 
MRS 
Illumina 
HumanOmni
ExpressExom
e array 
(HOEE 
12v1.0) 
Genome Studio 
call rate ≤ 95%; 
MAF: n.a.; 
pHWE< 5E-08 
call rate <98%; 
heterozygosity 
<0.211 or >0.302; 
non-African-
Americans 
IMPUTEv2 
1000Genomes 
global panel 
phase 1 release 
v3 (build 37) 
32.179.008 
SNPTEST 
v2.4.1 
- 
WHI – SHARe 
Affymetrix 
GeneChip 
SNP Array 
6.0 
Birdseed 
call rate ≤ 95%; 
MAF <1%; 
pHWE< 1E-06 
call rate ≤ 95% 
MaCH 
v1.0.16 
HapMap Phase 
II data in the 
YRI+CEU 
individuals 
release 22 
(build36) 
2.203.608 lm.R - 
POST-GWAS COHORTS                  
ABCD 
Illumina 
HumanCoreE
xomeChip 
GenomeStudio 
call rate ≤ 95%; 
MAF <1%; 
pHWE< 1E-06 
Call rate <95%; 
heterozygosity, 
gender check and 
relatedness 
IMPUTE 
v2 
1000Genomes 
global panel 
phase 1 release 
v3 (build 37) 
27.448.454 
GTOOL; 
PLINK 
- 
MAF: minor allele frequency; HWE: Hardy-Weinberg Equilibrium   
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Supplementary Table 5: Conditional analyses of the SNPs on chromosomes 14 and 15 for 
confirmation of independent secondary signals within these loci using (a) individual data from 
Lifelines Cohort Study (n=12,101) and (b) using the joint-and-conditional analysis in the 
Genome-wide Complex Trait Analysis software package of the stage 1 summary statistics. 
(a) conditioned on SDNN   RMSSD 
SNP locus SNP locus PCondLL POrigLL   PCondLL POrigLL 
rs2052015 14b rs4899412 14b 1.2E-02 4.7E-05   2.1E-02 1.2E-04 
rs2529471 14c rs4899412 14b 2.5E-05 4.7E-06   2.3E-05 4.6E-06 
rs36423 14a rs4899412 14b 2.1E-03 1.3E-04   2.3E-02 2.4E-03 
rs4899412 14b rs2052015 14b 8.5E-01 1.3E-03   7.8E-01 1.9E-03 
rs2529471 14c rs2052015 14b 6.1E-05 4.7E-06   5.2E-05 4.6E-06 
rs36423 14a rs2052015 14b 1.4E-02 1.3E-04   9.0E-02 2.4E-03 
rs4899412 14b rs2529471 14c 7.8E-03 1.3E-03   1.1E-02 1.9E-03 
rs2052015 14b rs2529471 14c 6.3E-04 4.7E-05   1.4E-03 1.2E-04 
rs36423 14a rs2529471 14c 7.8E-04 1.3E-04   1.0E-02 2.4E-03 
rs4899412 14b rs36423 14a 2.4E-02 1.3E-03   1.8E-02 1.9E-03 
rs2052015 14b rs36423 14a 4.7E-03 4.7E-05   3.5E-03 1.2E-04 
rs2529471 14c rs36423 14a 2.7E-05 4.7E-06   1.8E-05 4.6E-06 
rs2680344 15a rs1812835 15b 4.0E-02 4.0E-03   1.9E-02 9.1E-04 
rs1812835 15b rs2680344 15a 2.7E-02 2.8E-03   8.7E-03 4.3E-04 
 
PCondLL=p-value of the SNP in Lifelines when conditioned on other SNP;  
POrigLL=original p-value of the SNP in Lifelines when not conditioned on any 
other SNP. 
         (b) 
  
conditional p-value 
GCTA 
     SNP locus SDNN RMSSD 
     rs4899412 14b 3.1E-04 9.4E-03 
     rs2052015 14b 2.0E-03 4.6E-09
a
 
     rs2529471 14c 9.0E-07
b
 4.1E-05 
     rs36423 14a 1.0E-07
b
 2.7E-03 
     rs2680344 15a 1.1E-07
c
 7.6E-04 
     rs1812835 15b 1.3E-03 6.6E-07
d
 
     
 
a
 rs2052015 was identified as the independent SNP associated with RMSSD in the locus on 
chromosome 14. The p-value given for this SNP is the unconditioned one. The p-values for the 
other three SNPs in this locus are p-values conditioned on rs2052015. 
b
 rs2529471 and rs36423 were identified as independent SNP associated with SDNN in the locus 
on chromosome 14. The p-values given for these two SNPs are the p-values from the model that 
contained both SNPs. The p-values for the other two SNPs in this locus are p-values conditioned 
on rs2529471 and rs36423. 
c
 rs2680344 was identified as independent SNP associated with SDNN in the locus on 
chromosome 15. The p-value given for this SNP is the unconditioned one. The p-value for the 
other SNP in this locus is the p-value conditioned on rs2680344. 
d
 rs1812835 was identified as independent SNP associated with RMSSD in the locus on 
chromosome 15. The p-value given for this SNP is the unconditioned one. The p-value for the 
other SNP in this locus is the p-value conditioned on rs1812835.
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Supplementary Table 6: Sex-stratified stage 1+2 meta-analysis results for SDNN, RMSSD, and pvRSA/HF for all SNPs that were 
genome-wide significant (p<5x10
-8
/3) in the overall analysis. SNPs are sorted as in Table 1. 
Locus Chr SNP 
Position 
(bp) 
(b36) 
Trait 
Men 
  
Women 
  
N EAF β SE p-value 
  
N EAF β SE p-value 
  
1 19 
rs12974991 5845584 RMSSD 18966 0.078 -0.121 0.012 5.54E-23   24172 0.078 -0.108 0.011 2.69E-23 
rs12974440 5845386 pvRSA/HF† 13625 0.074 -0.246 0.027 1.87E-20   15033 0.074 -0.241 0.029 6.88E-20 
rs12980262 5844058 SDNN 20270 0.076 -0.065 0.009 4.79E-13   25690 0.077 -0.055 0.008 1.36E-11 
2 12 rs10842383 24663234 
SDNN 21606 0.866 -0.048 0.006 2.98E-14   26116 0.865 -0.051 0.006 1.35E-18 
RMSSD 18979 0.865 -0.060 0.009 3.90E-12   24175 0.864 -0.068 0.008 8.14E-19 
pvRSA/HF† 14855 0.868 -0.105 0.019 5.50E-09   15362 0.869 -0.152 0.019 1.04E-17 
3 6 rs236349 36928543 
SDNN 22771 0.650 -0.036 0.005 1.17E-14   28524 0.653 -0.029 0.004 8.53E-12 
RMSSD 20144 0.655 -0.040 0.006 8.13E-10   26025 0.657 -0.033 0.006 9.11E-09 
pvRSA/HF† 16119 0.644 -0.074 0.013 1.27E-10   16666 0.648 -0.058 0.014 3.04E-05 
4 12 
rs7980799 33468257 RMSSD 18979 0.394 -0.041 0.006 1.40E-10   25229 0.391 -0.037 0.006 2.44E-11 
rs1351682 33490042 pvRSA/HF† 14702 0.436 -0.082 0.013 5.67E-09   15074 0.440 -0.063 0.014 1.48E-06 
rs1384598 33514166 SDNN 20223 0.432 -0.027 0.005 2.64E-08   27132 0.433 -0.020 0.004 1.81E-06 
5 7 
rs4262 93389364 
SDNN 21606 0.391 -0.028 0.005 1.81E-08   27314 0.389 -0.028 0.004 3.68E-10 
pvRSA/HF† 14955 0.391 -0.067 0.014 9.44E-08   15457 0.387 -0.042 0.015 6.15E-05 
rs180238 93388383 RMSSD 18979 0.337 -0.037 0.006 1.77E-08   25373 0.335 -0.033 0.006 5.12E-09 
6 
14b 
rs4899412 71534015 SDNN 20723 0.253 -0.024 0.005 5.80E-06   27443 0.252 -0.027 0.005 1.54E-08 
rs2052015 71556806 RMSSD 19526 0.166 -0.033 0.009 1.28E-04   25339 0.164 -0.038 0.008 9.30E-07 
14c rs2529471 71883022 SDNN 21439 0.428 -0.024 0.005 9.07E-08   28095 0.428 -0.019 0.004 1.83E-06 
14a rs36423 71422955 
SDNN 20652 0.129 -0.032 0.007 4.93E-06   27445 0.130 -0.035 0.006 1.05E-08 
RMSSD 19422 0.127 -0.042 0.009 6.88E-06   25373 0.129 -0.039 0.008 2.15E-06 
7 
15a rs2680344 71440538 SDNN 22768 0.777 -0.023 0.005 2.64E-05   28517 0.778 -0.025 0.005 4.42E-07 
15b rs1812835 71294557 RMSSD 18979 0.416 -0.025 0.006 4.51E-05   25374 0.419 -0.026 0.005 1.53E-06 
8 20 rs6123471 36273570 RMSSD 20144 0.532 -0.029 0.006 6.45E-06   26025 0.536 -0.019 0.006 5.10E-04 
Chr: chromosome; bp: base pair position; N: sample size; EAF: effect allele frequency; β: beta/effect size; SE: standard error of β.  
†p-value, allele, EAF, N from p-value weighted meta-analysis of all cohorts using METAL and β, SE from inverse-variance meta-
analysis of only HF cohorts using GWAMA.
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Supplementary Table 7: Comparison of the meta-analysis results for the four stage 1 cohorts with ambulatory ECG measurements 
(CHS, FHS, FINGESTURE, ULSAM ) versus those for the other stage 1 cohorts with HRV at rest in a laboratory setting for the 17 
genome-wide significantly associated HRV SNPs identified in this study. SNPs are sorted as in Table 1. 
Locus Chr SNP Trait 
Laboratory rest 
  
Ambulatory 
  Difference in β's 
between 
laboratory rest 
and ambulatory 
    
N β SE p-value I2 
  
N β SE p-value I2 
  
p-value I
2
 
    
1 19 
rs12974991 RMSSD 23646 -0.119 0.011 7.75E-27 40%   2703 -0.094 0.024 1.13E-04 82%   3.34E-01 0% 
rs12974440 pvRSA/HF† 20705 -0.241 0.024 7.64E-30 39%   2770 -0.272 0.045 2.73E-09 34%   5.40E-01 0% 
rs12980262 SDNN 24480 -0.055 0.008 2.08E-12 59%   2770 -0.037 0.016 2.46E-02 75%   2.92E-01 10% 
2 12 rs10842383 
SDNN 24487 -0.055 0.006 4.56E-22 15%   2770 -0.029 0.011 8.62E-03 54%   3.41E-02 78% 
RMSSD 23664 -0.074 0.008 9.57E-22 0%   2703 -0.041 0.016 1.25E-02 54%   6.24E-02 71% 
pvRSA/HF† 20705 -0.137 0.017 1.78E-20 48%   2770 -0.100 0.030 1.01E-03 5%   2.79E-01 15% 
3 6 rs236349 
SDNN 24487 -0.031 0.004 1.84E-12 17%   2770 -0.017 0.008 4.67E-02 0%   1.25E-01 57% 
RMSSD 23662 -0.034 0.007 1.48E-06 9%   2703 -0.013 0.015 3.93E-01 42%   2.05E-01 38% 
pvRSA/HF† 20705 -0.075 0.013 9.61E-11 33%   2770 -0.056 0.024 2.27E-02 0%   4.84E-01 0% 
4 12 
rs7980799 RMSSD 23453 -0.043 0.006 7.13E-14 0%   2703 -0.026 0.013 4.02E-02 0%   2.20E-01 34% 
rs1351682 pvRSA/HF† 20263 -0.072 0.012 1.19E-09 4%   2770 -0.075 0.023 3.52E-03 0%   8.88E-01 0% 
rs1384598 SDNN 22839 -0.025 0.004 2.97E-08 0%   2770 -0.021 0.008 1.10E-02 9%   7.17E-01 0% 
5 7 
rs4262 
SDNN 24486 -0.030 0.004 9.91E-12 25%   2770 -0.020 0.009 2.71E-02 0%   2.89E-01 11% 
pvRSA/HF† 20704 -0.050 0.012 4.12E-08 14%   2770 -0.045 0.025 7.05E-02 0%   8.55E-01 0% 
rs180238 RMSSD 23663 -0.044 0.006 7.35E-14 25%   2703 -0.016 0.013 2.00E-01 0%   5.28E-02 73% 
6 
14b 
rs4899412 SDNN 24485 -0.027 0.005 2.25E-08 46%   2770 -0.014 0.010 1.52E-01 0%   2.55E-01 23% 
rs2052015 RMSSD 23663 -0.046 0.008 1.57E-08 7%   1944 -0.033 0.022 1.32E-01 n.a.   5.77E-01 0% 
14c rs2529471 SDNN 24487 -0.021 0.004 6.54E-07 6%   2770 -0.017 0.008 4.17E-02 0%   6.38E-01 0% 
14a rs36423 
SDNN 24482 -0.029 0.006 1.95E-06 54%   2703 -0.045 0.013 7.09E-04 0%   2.62E-01 20% 
RMSSD 23659 -0.042 0.008 4.14E-07 32%   2703 -0.025 0.020 2.13E-01 17%   4.37E-01 0% 
7 
15a rs2680344 SDNN 24485 -0.028 0.005 5.39E-08 0%   2770 -0.010 0.010 3.25E-01 0%   1.10E-01 61% 
15b rs1812835 RMSSD 23664 -0.027 0.006 1.30E-06 0%   2703 -0.016 0.012 1.97E-01 0%   4.12E-01 0% 
8 20 rs6123471 RMSSD 23664 -0.024 0.006 3.75E-05 14%   2703 -0.048 0.012 6.49E-05 0%   7.09E-02 69% 
Chr: chromosome; bp: base pair position; N: sample size; EAF: effect allele frequency; β: beta/effect size; SE: standard error of β. †p-
value, allele, EAF, N from p-value weighted meta-analysis of all cohorts using METAL and β, SE from inverse-variance meta-analysis 
of only HF cohorts using GWAMA.
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Supplementary Table 8: Analyses of the 17 HRV top SNPs on HRV traits corrected for heart rate.  
We performed three corrections: (1) analytical construction of a meta-analysis of the log-transformed coefficients of variation (CV) of 
SDNN  - ln ((SDNN/mean heart period)*100%) and RMSSD- ln ((RMSSD/mean heart period)*100%) using GWIS on  the HRV and 
heart rate GWASs summary statistics; (2) meta-analysis of  SNP associations with the log-transformed CV(SDNN) and CV(RMSSD) 
in Lifelines, NESDA, and TRAILS-Pop; (3) mediation analysis using Sobel's test testing whether heart rate mediates the SNP 
association with HRV in a meta-analysis of HRV traits and heart rate in LifeLines, NESDA, and TRAILS-Pop. For the mediation 
analysis for pvRSA/HF only data of NESDA and TRAILS-Pop were available. Significant p-values after Bonferroni correction for 11 
independent SNPs (<0.0045) are shown in bold. 
        
    
  
  
GWIS  
log-transformed 
CV(SDNN) and 
CV(RMSSD)   
SNP associations 
  log-transformed 
CV(SDNN) and 
CV(RMSSD)   
Mediation analysis  
(HRV SNPs -> HR -> HRV traits) 
 
   HRV 
HR  
p-value 
 
  
Meta-analysis of three 
cohorts
#
   
Meta-analysis of three cohorts
#
  
 
Locus Chr HRV SNP HRV Trait β p-value   β (SE) p-value   β (SE) p-value 
  
p-value 
p-value 
HR 
corrected 
%media
ted 
Sobel 
p-
value
*
 
1 19 
rs12974991 RMSSD -0.116 4.6E-46 1.8E-01 -0.113 (0.010) 9.5E-29   -0.129 (0.012) 6.8E-27   9.5E-22 4.4E-31 1.0% 4.8E-01 
rs12974440 pvRSA/HF -0.244 1.9E-41 1.8E-01 n.a.  n.a.   2.9E-13 1.2E-16 -13.5% 2.9E-01 
rs12980262 SDNN -0.060 2.3E-23 1.8E-01 -0.050 (0.007) 4.8E-12   -0.085 (0.011) 1.3E-15   7.3E-14 8.1E-16 4.9% 4.1E-01 
2 12 rs10842383 
SDNN -0.049 9.3E-31 
1.5E-10 
-0.042 (0.005) 1.3E-16   -0.049 (0.008) 1.3E-09   2.0E-11 1.7E-08 26.1% 3.7E-04 
RMSSD -0.065 2.5E-29 -0.061 (0.007) 3.4E-18   -0.060 (0.009) 1.8E-10   4.5E-11 1.8E-08 30.2% 3.4E-04 
pvRSA/HF -0.124 1.2E-25 n.a.  n.a.   1.3E-04 5.1E-03 26.8% 3.1E-03 
3 6 rs236349 
SDNN -0.033 3.7E-25 
4.0E-05 
-0.025 (0.004) 8.6E-10   -0.031 (0.006) 7.1E-07   2.0E-07 1.0E-06 17.7% 1.4E-01 
RMSSD -0.035 9.1E-17 -0.027 (0.005) 6.3E-07   -0.039 (0.007) 1.3E-07   2.8E-07 1.9E-07 17.1% 9.3E-02 
pvRSA/HF -0.069 3.2E-15 n.a.  n.a.   7.5E-02 1.7E-01 23.8% 2.8E-01 
4 12 
rs7980799 RMSSD -0.039 3.2E-20 1.2E-12 -0.034 (0.005) 5.5E-11 
 
-0.032 (0.007) 1.7E-06   6.1E-08 1.6E-04 43.0% 5.9E-06 
rs1351682 pvRSA/HF -0.073 5.7E-15 6.7E-09 n.a.  n.a.   8.4E-05 1.1E-04 1.5% 1.0E-01 
rs1384598 SDNN -0.023 7.4E-13 5.5E-08 -0.019 (0.004) 8.8E-07   -0.012 (0.006) 3.2E-02   2.9E-03 6.6E-02 45.7% 9.8E-05 
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5 7 
rs4262 
SDNN -0.028 4.3E-17 
3.1E-05 
-0.025 (0.004) 1.1E-09   -0.025 (0.006) 4.7E-05   5.2E-06 9.8E-04 36.6% 4.4E-04 
pvRSA/HF -0.05 1.8E-11 n.a.  n.a.   2.9E-05 3.9E-03 31.0% 9.2E-04 
rs180238 RMSSD -0.034 8.0E-16 5.1E-06 -0.035 (0.005) 4.9E-11   -0.029 (0.007) 3.7E-05   1.9E-05 1.3E-03 38.5% 1.8E-03 
6 
14b 
rs4899412 SDNN -0.026 3.1E-13 1.7E-02 -0.022 (0.004) 3.1E-07   -0.017 (0.006) 9.0E-03   1.7E-03 1.5E-02 31.9% 9.4E-03 
rs2052015 RMSSD -0.036 3.6E-10 7.2E-02 -0.042 (0.004) 3.0E-08   -0.031 (0.009) 6.6E-04   1.4E-04 1.2E-02 46.1% 1.7E-03 
14c rs2529471 SDNN -0.021 1.9E-12 1.3E-02 -0.018 (0.004) 1.6E-06   -0.022 (0.006) 1.0E-04   5.5E-06 2.5E-04 29.1% 1.2E-03 
14a rs36423 
SDNN -0.033 6.3E-13 
3.5E-03 
-0.028 (0.006) 4.0E-07   -0.030 (0.009) 1.0E-03   4.9E-04 3.2E-03 25.5% 2.2E-01 
RMSSD -0.04 5.4E-11 -0.036 (0.008) 2.4E-06   -0.028 (0.010) 7.0E-03   7.5E-03 2.6E-02 32.0% 2.2E-01 
7 
15a rs2680344 SDNN -0.024 4.9E-11 3.8E-09 -0.019 (0.005) 4.2E-05   -0.026 (0.007) 1.7E-04   6.2E-05 3.4E-04 21.5% 1.2E-02 
15b rs1812835 RMSSD -0.025 5.2E-10 1.1E-06 -0.021 (0.005) 3.1E-05   -0.024 (0.007) 2.3E-04   2.2E-03 1.3E-02 33.8% 1.4E-02 
8 20 rs6123471 RMSSD -0.024 1.3E-08 1.6E-20 -0.022 (0.005) 4.2E-05   -0.015 (0.008) 4.5E-02   6.3E-03 6.8E-01 87.8% 2.2E-05 
Chr: chromosome; HR: heart rate; CV: coefficient of variation; SE: standard error. 
#
Lifelines (N=12,101), NESDA (N=2,118), TRAILS-Pop (N=1,191). 
*Sobel p-values of the meta-analyses are calculated from meta z-scores that are determined using a sqrt(sample size) weighted z-score 
meta-analysis. 
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Supplementary Table 9: Association between HRV SNPs and heart rate. 
Results in (a) are the look-up results of the 17 HRV SNPs identified in this study in the meta-
analysis of heart rate (Den Hoed et al., 2013). Panels (b) and (c) present the explained variances 
in heart rate  in the Lifelines (n=12,101), NESDA (n=2,118), TRAILS-Pop (n=1,191), and 
ABCD (n=1,094) cohorts by (b) the weighted multi-SNP genetic risk score based on the 
independent genome-wide significant HRV SNPs in the stage 1+2 meta-analysis, and (c) the 
optimal polygenic risk scores computed at the p-value threshold that explained the largest 
percentage of phenotypic variance. ΔR2 is the difference in percentage of explained variance by 
the multi-SNP genetic or polygenic risk score between the models with and without the risk score 
while adjusting both for age, sex, and principal components. The maximum number of overlap 
between the HRV and heart rate meta-analysis was N=10,612. 
 
a) Look-up results 
Identified heart rate variability SNPs Heart rate lookup   
Locus Chr HRV SNP Position (bp) HRV Trait β# SE N p-value* 
1 19 
rs12974991 5845584 RMSSD 0.1521 0.1072 80077.3 1.77E-01 
rs12974440 5845386 pvRSA/HF 0.1505 0.1072 80091.2 1.77E-01 
rs12980262 5844058 SDNN 0.1486 0.1072 80091.3 1.77E-01 
2 12 rs10842383 24663234 
SDNN, RMSSD, 
pvRSA/HF 
0.4922 0.0731 87263.7 1.52E-10 
3 6 rs236349 36928543 
SDNN, RMSSD, 
pvRSA/HF 
0.2583 0.0598 67947 3.95E-05 
4 12 
rs7980799 33468257 RMSSD 0.4052 0.0542 85488.7 1.19E-12 
rs1351682 33490042 pvRSA/HF 0.3136 0.0514 93068.9 6.72E-09 
rs1384598 33514166 SDNN 0.305 0.0534 87057.3 5.52E-08 
5 7 
rs4262 93389364 
SDNN, 
pvRSA/HF 
0.2514 0.0574 82597.3 3.13E-05 
rs180238 93388383 RMSSD 0.2788 0.0581 86814.9 5.08E-06 
6 
14b 
rs4899412 71534015 SDNN 0.1485 0.0594 89581.2 1.73E-02 
rs2052015 71556806 RMSSD 0.1473 0.0778 86557.5 7.19E-02 
14c rs2529471 71883022 SDNN 0.1325 0.0505 93152.6 1.26E-02 
14a rs36423 71422955 SDNN, RMSSD 0.2357 0.0767 90388.5 3.49E-03 
7 
15a rs2680344 71440538 SDNN 0.3787 0.0611 91249.2 3.80E-09 
15b rs1812835 71294557 RMSSD 0.2745 0.0536 84616.4 1.09E-06 
8 20 rs6123471 36273570 RMSSD 0.5012 0.0513 89348.2 1.56E-20 
Chr: chromosome; bp: base pair position based on build 36 (hg18); SE: standard error of β; N: 
sample size.  
# Effect size is shown for the allele increasing the risk of low levels of HRV.  
* P-values from the discovery stage using only Europeans. Significant p-values <0.05/11 
(independent SNPs) are shown in bold. 
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b) Multi-SNP genetic risk scores 
         Multi-SNP genetic risk score* 
    Lifelines   NESDA   TRAILS-Pop   ABCD 
trait risk score 
N 
SNPs 
p-value ΔR2   
N 
SNPs 
p-value ΔR2   
N 
SNPs 
p-value ΔR2   
N 
SNPs 
p-value ΔR2 
Heart rate SDNN 9 3.70E-08 0.23%   9 1.40E-03 0.39%   10 1.40E-02 0.55%   10 2.70E-01 0.11% 
Heart rate RMSSD 7 1.90E-05 0.14% 
 
11 1.60E-03 0.38% 
 
11 3.50E-04 1.07% 
 
11 1.90E-01 0.16% 
Heart rate pvRSA/HF 5 5.20E-04 0.09%   5 4.20E-02 0.13%   5 2.90E-04 1.13%   4 3.10E-01 0.10% 
n.a.=not available. 
* For Lifelines, NESDA, and TRAILS-Pop the weights (i.e. effects sizes) and number of genome-wide significant SNPs included in 
the risk score were adjusted by analytically extracting the cohort's effect size and standard error from the meta effect size and standard 
error, respectively, and recalculating the p-value based on these adjusted effect sizes and standard errors, since these cohorts were 
included in stage 1 and/or 2. 
 
c) Polygenic risk scores                  
  Polygenic risk score* 
  Lifelines   NESDA   TRAILS-Pop   ABCD 
risk score p cutoff 
N 
SNPs 
p-value ΔR2   p cutoff 
N 
SNPs 
p-value ΔR2   p cutoff 
N 
SNPs 
p-value ΔR2   p cutoff 
N 
SNPs 
p-value ΔR2 
SDNN <5E-3 3186 2.30E-08 0.25% 
 
<5E-8 6 9.00E-03 0.29% 
 
<5E-8 7 5.60E-03 0.69% 
 
<5E-5 71 1.80E-02 0.51% 
RMSSD <5E-5 80 1.30E-10 0.34% 
 
<5E-3 3341 1.70E-03 0.43% 
 
<5E-7 11 5.80E-04 0.99% 
 
<5E-4 466 5.80E-02 0.33% 
pvRSA/HF <0.05 20747 5.90E-06 0.17%   <5E-4 399 8.10E-04 0.50%   <5E-7 6 5.80E-03 0.68%   <5E-5 67 6.50E-02 0.31% 
* Weighted polygenic risk score were determined based on independent SNPs in the stage 1 meta-analysis. For NESDA and TRAILS-
Pop the weights (i.e. effects sizes) and p-values were adjusted by analytically extracting the cohort's effect size and standard error from 
the meta effect size and standard error, respectively, and recalculating the p-value based on these adjusted effect size and standard 
error, since these cohorts were included in stage 1.
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Supplementary Table 10: Association between heart rate SNPs and the three HRV traits. 
Look-up of the 21 heart rate SNPs identified in the GWAS meta-analysis of heart rate by Den 
Hoed et al.
14
 in the current study's meta-analyses results for the three HRV traits (a). The effects 
of the genetic risk score for the heart rate SNPs on SDNN, RMSSD, and pvRSA/HF (b).  
Explained variance in HRV traits in the Lifelines (n=12,101), NESDA (n=2,118), TRAILS-Pop 
(n=1,191), and ABCD (n=1,094) cohorts by the weighted multi-SNP genetic risk score based on 
the 21 heart rate SNPs (c), and the optimal polygenic risk scores for heart rate computed at the p-
value threshold that explained the largest percentage of phenotypic variance in the HRV traits (d). 
(a) Look-up of previously identified heart rate loci HRV look-up 
Locus Chr HR SNP Position (bp) HRV Trait β# SE N p-value* 
1 14 rs365990 22931651 
SDNN -0.0132 0.0039 27257 8.08E-04 
RMSSD -0.0153 0.0053 26367 4.28E-03 
pvRSA/HF† -0.0189 0.0109 20660 2.18E-01 
2 6 rs1015451 122173184 
pvRSA/HF† 0.0353 0.0180 18020 8.27E-02 
SDNN -0.0041 0.0059 24617 4.92E-01 
RMSSD -0.0116 0.0086 23727 1.83E-01 
3 7 rs13245899 100335067 
SDNN -0.0116 0.0046 27256 1.23E-02 
pvRSA/HF† 0.0158 0.0131 20659 8.31E-02 
RMSSD 0.0011 0.0063 26366 8.58E-01 
4 1 rs11118555 206007476 
SDNN -0.0130 0.0057 25873 2.46E-02 
RMSSD -0.0091 0.0081 24984 2.62E-01 
pvRSA/HF† -0.0099 0.0167 19277 9.06E-01 
5 11 rs174549 61327958 
pvRSA/HF† -0.0204 0.0114 20660 8.18E-02 
RMSSD -0.0052 0.0055 26367 3.49E-01 
SDNN -0.0024 0.0040 27257 5.54E-01 
6 6 rs11153730 118774215 
pvRSA/HF† 0.0226 0.0108 19277 4.10E-03 
SDNN 0.0019 0.0039 25041 6.29E-01 
RMSSD 0.0015 0.0052 24984 7.78E-01 
7 12 rs17287293 24662145 
pvRSA/HF† -0.1263 0.0152 19081 3.59E-21 
SDNN -0.0488 0.0052 25873 5.46E-21 
RMSSD -0.0670 0.0071 24984 1.25E-20 
8 20 rs6127471 36277452 
RMSSD -0.0283 0.0052 26367 5.83E-08 
SDNN -0.0160 0.0038 27257 2.58E-05 
pvRSA/HF† -0.0299 0.0107 20660 6.84E-04 
9 2 rs17362588 179429291 
RMSSD -0.0376 0.0089 24981 2.75E-05 
pvRSA/HF† -0.0560 0.0184 19274 7.16E-05 
SDNN -0.0233 0.0062 25871 1.91E-04 
10 12 rs7980799 33468257 
RMSSD -0.0402 0.0052 26156 1.92E-14 
pvRSA/HF† -0.0719 0.0111 20464 1.29E-11 
SDNN -0.0232 0.0038 26992 1.80E-09 
11 15 rs4489968 71452559 
SDNN -0.0242 0.0050 27256 1.94E-06 
RMSSD -0.0309 0.0071 26366 1.47E-05 
pvRSA/HF† -0.0469 0.0144 20659 3.97E-04 
12 3 rs7612445 180655673 
SDNN -0.0233 0.0048 27251 1.60E-06 
RMSSD -0.0295 0.0067 26366 1.13E-05 
pvRSA/HF† -0.0333 0.0136 20659 5.68E-03 
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13 14 rs17796783 84879664 
RMSSD -0.0121 0.0055 26153 3.00E-02 
SDNN -0.0046 0.0041 26989 2.63E-01 
pvRSA/HF† 0.0042 0.0113 20657 6.39E-01 
14 7 rs2350782 136293174 
pvRSA/HF† -0.0387 0.0189 17983 5.57E-03 
RMSSD -0.0156 0.0095 23691 1.04E-01 
SDNN -0.0100 0.0066 24514 1.28E-01 
15 5 rs6882776 172596769 
pvRSA/HF† 0.0209 0.0134 18716 3.14E-02 
RMSSD 0.0054 0.0065 24212 4.10E-01 
SDNN 0.0031 0.0047 25048 5.09E-01 
16 7 rs180242 93387532 
RMSSD -0.0417 0.0061 22345 1.44E-11 
SDNN -0.0284 0.0044 23235 1.27E-10 
pvRSA/HF† -0.0499 0.0127 16638 1.56E-07 
17 2 rs13030174 231979528 
RMSSD -0.0034 0.0057 26363 5.54E-01 
pvRSA/HF† -0.0028 0.0118 20656 8.29E-01 
SDNN 0.0004 0.0042 27253 9.28E-01 
18 3 rs9647379 173267862 
SDNN -0.0073 0.0041 25874 7.54E-02 
RMSSD -0.0094 0.0057 24984 9.92E-02 
pvRSA/HF† -0.0071 0.0116 19277 1.69E-01 
19 12 rs2067615 105673552 
SDNN 0.0024 0.0038 25874 5.31E-01 
RMSSD -0.0010 0.0051 24984 8.45E-01 
pvRSA/HF† -0.0018 0.0110 19081 8.88E-01 
20 12 rs826838 37392998 
pvRSA/HF† -0.0470 0.0108 20464 2.84E-09 
RMSSD -0.0290 0.0050 26367 1.04E-08 
SDNN -0.0172 0.0037 27257 3.36E-06 
21 2 rs4140885 188041309 
pvRSA/HF† 0.0109 0.0115 20660 1.56E-01 
SDNN -0.0005 0.0040 27257 9.00E-01 
RMSSD -0.0001 0.0056 26367 9.82E-01 
Chr: chromosome; bp: base pair position based on build 36 (hg18); HR: heart rate; SE: standard 
error of β; N: sample size. 
# Effect size is shown for the allele increasing the heart rate. 
*P-values from the discovery stage using only Europeans. Significant p-values <0.05/21 are 
shown in bold. 
 
†p-value, allele, EAF, N from p-value weighted meta-analysis of all cohorts using METAL and 
β, SE from inverse-variance meta-analysis of only HF cohorts using GWAMA.
(b) effect of the multi-SNP genetic risk score of heart rate composed of all genome-wide significant SNPs 
based on summary statistics 
   
genetic risk score heart rate 
HRV 
parameter 
Sample size N SNPs Effect size (95% CI) p-value* 
SDNN 27257 20 -0.032 (-0.04,-0.03) 1.7E-37 
RMSSD 26367 21 -0.043 (-0.05,-0.04) 1.0E-38 
pvRSA/HF 20660 21 -0.05 (-0.06,-0.04) 1.6E-13 
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* For Lifelines, NESDA, and TRAILS-Pop the weights (i.e. effects sizes) and number of genome-wide significant SNPs included in 
the risk score were adjusted by analytically extracting the cohort's effect size and standard error from the meta effect size and standard 
error, respectively, and recalculating the p-value based on these adjusted effect sizes and standard errors, since these cohorts were 
included in stage 1 and/or 2. 
 
 
* Weighted polygenic risk score were determined based on independent SNPs in the stage 1 meta-analysis. For NESDA and TRAILS-
Pop the weights (i.e. effects sizes) and p-values were adjusted by analytically extracting the cohort's effect size and standard error from 
the meta effect size and standard error, respectively, and recalculating the p-value based on these adjusted effect size and standard 
error, since these cohorts were included in stage 1. 
 
 
(c) effects of the multi-SNP genetic risk score of heart rate based on individual level data 
 
Multi-SNP genetic risk score* 
 
Lifelines NESDA TRAILS-Pop ABCD 
Trait N SNPs p-value ΔR2 N SNPs p-value ΔR2 N SNPs p-value ΔR2 N SNPs p-value ΔR2 
SDNN 15 3.30E-09 0.24% 21 4.60E-07 0.90% 21 6.00E-02 0.29% 20 4.90E-02 0.35% 
RMSSD 15 3.20E-15 0.44% 21 2.70E-07 0.90% 21 1.50E-02 0.49% 20 1.70E-02 0.52% 
pvRSA/HF 15 n.a. n.a. 21 2.10E-06 0.64% 21 5.40E-02 0.31% 20 6.70E-02 0.31% 
heart rate 15 3.30E-41 1.44% 21 2.50E-10 1.69% 21 7.30E-05 1.25% 20 4.60E-03 0.73% 
(d) effects of the polygenic risk score of heart rate based on individuals level data 
  Polygenic risk score* 
  Lifelines NESDA TRAILS-Pop ABCD 
Trait 
p cut-
off 
N 
SNPs 
p-value ΔR2 
p cut-
off 
N 
SNPs 
p-value ΔR2 
p cut-
off 
N 
SNPs 
p-value ΔR2 
p cut-
off 
N 
SNPs 
p-value ΔR2 
SDNN <5E-8 19 1.20E-09 0.26% <5E-4 430 5.00E-06 0.78% <5E-5 97 1.80E-02 0.46% <5E-4 438 1.30E-02 0.57% 
RMSSD <5E-8 19 3.50E-16 0.48% <5E-4 430 1.90E-06 0.82% <5E-8 18 8.20E-03 0.58% <5E-4 438 3.80E-02 0.39% 
pvRSA/
HF 
n.a. n.a. n.a. n.a. <5E-4 430 1.50E-06 0.70% <5E-5 97 2.70E-02 0.41% <5E-2 18305 1.50E-01 0.19% 
heart 
rate 
<5E-7 28 3.50E-42 1.50% <5E-8 21 8.10E-10 1.66% <5E-8 18 3.10E-06 1.73% <5E-4 438 1.40E-04 1.32% 
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Supplementary Table 11: Look-up results of genome-wide association consortia targeting cardiometabolic outcomes. 
In panel (a) results are shown for the associations with the genetic risk scores composed of the HRV SNPs identified in this study. 
Panel (b) shows the genetic correlations with the HRV traits are shown as computed using LD Score regression based on GWAS 
summary statistics. 
(a)     SDNN   RMSSD   pvRSA/HF
*
 
Trait or disease Reference  Sample 
size 
Effect size
#
   
(95% CI) 
p-value   Effect size
#
 
(95% CI) 
p-value   Effect size
#
  
(95% CI) 
p-value 
Heart rate Den Hoed et al., 2013
14
 93153 8.65 (7.35,9.94) 3.7E-39 
 
6.93 (6.02,7.83) 1.5E-50 2.66 (2.10,3.23) 2.2E-20 
Systolic blood pressure Ehret et al., 2011
15
 69616 1.64 (-0.79,4.08) 1.9E-01 
 
0.94 (-0.78,2.65) 2.8E-01 0.16 (-0.90,1.22) 7.7E-01 
Diastolic blood pressure Ehret et al., 2011
15
 69604 -0.37 (-1.91,1.17) 6.4E-01 
 
-0.83 (-1.91,0.25) 1.3E-01 -0.22 (-0.89,0.45) 5.2E-01 
Heart failure Smith et al., 2010
16
 20926 0.58 (0.27,1.23) 1.6E-01 
 
0.69 (0.41,1.16) 1.6E-01 0.90 (0.66,1.25) 5.2E-01 
Coronary Artery Disease Deloukas et al., 2013
17
 83174 1.04 (0.72,1.52) 8.3E-01 
 
1.08 (0.83,1.37) 6.0E-01 0.96 (0.82,1.12) 6.4E-01 
Atrial fibrillation Ellinor et al., 2012
18
 59133 0.62 (0.38,1.02) 5.8E-02 
 
0.72 (0.51,1.02) 6.7E-02 1.15 (0.93,1.43) 2.1E-01 
Sudden cardiac death 
SCD consortium, 
unpublished 
29928 1.10 (0.52,2.33) 8.0E-01 
 
1.37 (0.81,4.55) 2.4E-01 0.95 (0.68,1.32) 7.6E-01 
Type 2 diabetes Morris et al., 2012
19
 69033 0.99 (0.86,1.14) 9.1E-01 
 
1.01 (0.90,1.11) 9.2E-01 0.96  (0.83,1.11) 6.1E-01 
Body mass index Locke et al., 2015
20
 233947 -0.0052 (-0.10,0.09) 9.1E-01 
 
0.01 (-0.05,0.07) 7.3E-01 -0.0074 (-0.035,0.03) 7.2E-01 
eGFR for creatinin Pattaro et al., 2016
21
 74354 0.02 (-0.01,0.05) 1.7E-01 
 
0.005 (-0.02,0.03) 6.3E-01 0.001 (-0.01,0.01) 9.4E-01 
Urinary albumin 
excretion(UACR) 
Teumer et al., 2016
22
 31077 0.11 (-0.13,0.34) 4.2E-01 
 
0.10 (-0.06,0.27) 2.2E-01 0.08 (-0.03,0.18) 1.4E-01 
* p-value from z-score weighted meta-analysis of all cohorts using METAL and β and standard error from inverse-variance meta-
analysis of only HF cohorts using GWAMA were used 
# Effect size is either the incremental change in the phenotype for quantitative traits or the odds ratio for binary traits when the multi-
SNP genetic risk score of HRV decreases by one unit.  
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(b)     SDNN   RMSSD   pvRSA/HF
*
 
Trait or disease Reference  Sample 
size 
genetic 
correlation 
(SE) 
p-value   genetic 
correlation 
(SE) 
p-value   genetic 
correlation 
(SE) 
p-value 
Heart rate Den Hoed et al., 2013
14
 93153 -0.656 (0.09) 1.0E-12 
 
-0.738 (0.10) 1.3E-14 
 
-0.548 (0.11) 2.2E-07 
Systolic blood pressure Ehret et al., 2011
15
 69616 -0.204 (0.08) 8.4E-03 
 
-0.230 (0.08) 6.4E-03 
 
-0.314 (0.10) 2.1E-03 
Diastolic blood pressure Ehret et al., 2011
15
 69604 -0.267 (0.08) 4.0E-04 
 
-0.271 (0.08) 4.0E-04 
 
-0.349 (0.10) 3.0E-04 
Heart failure Smith et al., 2010
16
 20926 -0.291 (0.20) 1.5E-01 
 
-0.095 (0.19) 6.1E-01 
 
-0.281 (0.20) 1.5E-01 
Coronary Artery Disease Deloukas et al., 2013
17
 83174 -0.133 (0.09) 1.2E-01 
 
-0.113 (0.09) 2.3E-01 
 
-0.116 (0.10) 2.3E-01 
Atrial fibrillation Ellinor et al., 2012
18
 59133 0.050 (0.13) 7.0E-01 
 
0.058 (0.13) 1.3E-01 
 
-0.019 (0.12) 8.8E-01 
Sudden cardiac death 
SCD consortium, 
unpublished 
29928 -0.123(0.23) 5.9E-01 
 
0.080(0.22) 7.2E-01 
 
-0.100 (0.26) 7.0E-01 
Type 2 diabetes Morris et al., 2012
19
 69033 -0.263 (0.11) 1.2E-02 
 
-0.209 (0.13) 1.2E-01 
 
-0.160 (0.13) 2.1E-01 
Body mass index Locke et al., 2015
20
 233947 -0.085 (0.04) 4.5E-02 
 
0.042 (0.05) 3.6E-01 
 
-0.036 (0.05) 4.5E-01 
eGFR for creatinin Pattaro et al., 2016
21
 175579 -0.011 (0.07) 8.7E-01 
 
-0.017 (0.07) 8.1E-01 
 
-0.031 (0.07) 6.6E-01 
Urinary albumin 
excretion(UACR) 
Teumer et al., 2016
22
 51886 0.002 (0.13) 9.9E-01 
 
-0.055 (0.14) 6.9E-01 
 
-0.183 (0.15) 2.1E-01 
* p-value from z-score weighted meta-analysis of all cohorts using METAL and β and standard error from inverse-variance meta-
analysis of only HF cohorts using GWAMA were used. 
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Supplementary Table 12: Effects of the HRV SNPs identified in this study on atrial fibrillation 
(N=59,133). 
Odds ratios (OR) with confidence intervals (95%CI) are given for the HRV decreasing allele. 
Significantly associated SNPs (p-value <0.0045) are shown in bold. 
Locus Chr SNP Position (bp) HRV trait OR (95%CI) p-value 
1 19 
rs12974440 5845584 RMSSD 1.00 (0.92-1.07) 9.2E-01 
rs12974991 5845386 pvRSA/HF 1.00 (0.92-1.07) 9.2E-01 
rs12980262 5844058 SDNN 1.00 (0.92-1.07) 9.3E-01 
2 12 rs10842383 24663234 SDNN, RMSSD, pvRSA/HF 1.16 (1.10-1.23) 3.5E-07 
3 6 rs236349 36928543 SDNN, RMSSD, pvRSA/HF 0.94 (0.91-0.98) 5.3E-03 
4 12 
rs1351682 33468257 pvRSA/HF 0.98 (0.95-1.03) 4.5E-01 
rs1384598 33490042 SDNN 0.99 (0.95-1.03) 6.4E-01 
rs7980799 33514166 RMSSD 0.99 (0.95-1.03) 6.5E-01 
5 7 
rs180238 93389364 RMSSD 1.00 (0.96-1.05) 8.7E-01 
rs4262  93388383 SDNN, pvRSA/HF 1.02 (0.98-1.06) 3.8E-01 
6 
14b 
rs2052015 71534015 RMSSD 1.00 (0.94-1.07) 9.7E-01 
rs2529471 71556806 SDNN, RMSSD 0.96 (0.92-0.99) 2.3E-02 
14c rs36423 71883022 SDNN, RMSSD 0.94 (0.88-1.00) 4.2E-02 
14a rs4899412 71422955 SDNN 0.98 (0.94-1.03) 5.0E-01 
7 
15a rs1812835 71440538 SDNN, RMSSD 0.95 (0.92-0.99) 2.2E-02 
15b rs2680344 71294557 SDNN, RMSSD 0.89 (0.84-0.93) 4.3E-07 
8 20 rs6123471 36273570 RMSSD 0.99 (0.95-1.02) 4.5E-01 
Chr: chromosome; bp: base pair position (build 36).  
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Supplementary Table 13: RegulomeDB main results of functional variant analysis. 
HRV SNP Chr Position 
(bp; b37) 
RegulomeDB score 
rs12980262 19 5893057 TF binding + any motif + DNase Footprint + DNase peak 
rs12974440 19 5894385 TF binding + any motif + DNase peak 
rs12974991 19 5894583 TF binding + DNase peak 
rs236349 6 36820564 TF binding + DNase peak 
rs180238 7 93550446 TF binding + DNase peak 
rs4262 7 93551427 TF binding + DNase peak 
rs36423 14 72353201 TF binding or DNase peak 
rs2529471 14 72813268 TF binding or DNase peak 
rs2680344 15 73653484 TF binding or DNase peak 
rs6123471 20 36840155 TF binding or DNase peak 
rs7980799 12 33576989 other 
rs1351682 12 33598774 other 
rs1384598 12 33622898 other 
rs2052015 14 72487052 other 
rs1812835 15 73507503 other 
rs10842383 12 24771966 NA 
rs4899412 14 72464261 NA 
TF binding: the variant is located at a site where transcription factors are anticipated to bind.
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Supplementary Table 14: eQTL analysis. (a) The 17 HRV SNPs were assessed in the NESDA-NTR eQTL database
23, 24
. Only SNPs 
with a significant cis effect on gene expression are shown. All HRV SNPs with significant results in the NESDA/NTR eQTL 
database
23, 24
 were looked up in several other eQTL databases for multiple tissues: (b) a second 
25
 and (c) third independent whole 
blood eQTL database 
26
, (d) lymphoblastoid cell lines
27
, (e) eQTLs for ten different regions of the brain 
28
, (f) GTex, and (g) a heart 
eQTL database 
29
. 
(a) Association between HRV SNP 
 and gene expression in 
NESDA/NTR 
  Top eQTL with strongest  
association with gene expression 
p-value 
HRV SNP 
conditional 
on top 
eQTL HRV SNP Gene chr:bp_allele ; Probeset_id p-value FDR Beta    SNP & Allele p-value 
LD HRV 
SNP 
rs4262 GNG11 7:93551428_C ; 11722379_at 2.35E-07 1.75E-03 -0.100 
 
7:93540958_C 1.48E-08 0.797 >0.05 
rs180238 GNG11 7:93550447_C ; 11722379_at 6.00E-08 5.26E-04 -0.109 
 
7:93540958_C 1.48E-08 0.971 >0.05 
rs4899412 RGS6 14:72464262_T ; 11752774_a_at 2.71E-06 1.60E-02 0.097 
 
14:72465028_C 2.35E-06 0.999 >0.05 
rs4899412 RGS6 14:72464262_T ; 11750930_a_at 4.63E-07 3.50E-03 0.108 
 
14:72425522_T 1.86E-07 0.896 >0.05 
rs1812835 NEO1 15:73507504_A ; 11717210_a_at 1.65E-07 1.37E-03 -0.106 
 
15:73420724_A 3.12E-09 0.775 >0.05 
rs1812835 NEO1 15:73507504_A ; 11717212_a_at 5.91E-11 <1.34e-05 -0.131   15:73377436:G_GT_I 2.89E-13 0.743 >0.05 
           (b) Association between HRV SNP and 
expression in whole blood  
Top eQTL  in BIOS whole blood 
 HRV SNP Gene chr:bp_allele p-value Z-score   SNP p-value LD HRV SNP 
 rs4262 GNG11 7:93551428_C NS NS 
 
rs180279 1.45E-19 0.002 
 rs180238 GNG11 7:93550447_C NS NS 
 
rs180279 1.45E-19 0.001 
 rs4899412 (by its proxy 
rs1987722 [r
2
=0.99]) RGS6 14:72465028_C 1.27E-36 12.64 
 
rs1987722  1.27E-36 0.99 
 rs1812835 NEO1 15:73507504_A 4.93E-80 -18.944   rs1038137 1.72E-119 0.75 
 
           (c)  Association between HRV SNP and 
expression in whole blood   
Top eQTL in Westra et al. whole blood 
 HRV SNP Gene chr:bp_allele p-value Z-score   SNP p-value LD HRV SNP 
 rs4262 (by its proxy 
rs180236 r
2
=0.77) GNG11 7:93391277_A 1.12E-04 3.86 
 
rs180275 7.16E-09 0.002 
 rs180238 (by its proxy 
rs180236 r
2
=0.32) GNG11 7:93391277_A 1.12E-04 3.86 
 
rs180275 7.16E-09 0.001 
 rs4899412 RGS6 n.a. n.a. n.a. 
 
rs8008967 6.83E-04 0.002 
 rs1812835 NEO1 15:73507504_A 5.60E-04 -3.45   rs3784801 1.63E-04 0.92 
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(d) 
    
Association between HRV SNP and 
expression in Geuvadis    Top eQTL in Geuvadis 
 HRV SNP Gene chr:bp_allele p-value Beta   SNP  p-value LD HRV SNP 
 rs4262 GNG11 7:93551428_C NS NS 
 
NS NS NS 
 rs180238 GNG11 7:93550447_C NS NS 
 
NS NS NS 
 rs4899412 RGS6 14:72464262_T NS NS 
 
rs1548687 3.44E-07 0.002 
 rs1812835 NEO1 15:73507504_A 1.39E-17 n.a.   rs62016808 4.18E-25 0.75 
 
           (e)  Association between HRV SNP and 
expression in Braineac  (tissue) 
 
Top eQTL in Braineac 
  
 HRV SNP Gene chr:bp_allele p-value Beta   SNP  p-value LD HRV SNP 
 rs4262 GNG11 7:93551428_C 2.8E-04 (medulla) n.a. 
 
rs4266  1.20E-05 1 
 rs180238 GNG11 7:93550447_C 0.0013 (medulla) n.a. 
 
rs4266  1.20E-05 0.047 
 rs4899412 RGS6 14:72464262_T NS n.a. 
 
NS 
   rs1812835 NEO1 15:73507504_A NS n.a.   NS     
 
  
        
 
      
 (f) 
    
Association between HRV SNP and 
expression in GTEx (tissue)   Top eQTL  in GTEx 
 HRV SNP Gene chr:bp_allele  p-value  Beta    SNP p-value LD HRV SNP 
 
rs4262 GNG11 7:93551428_C 
8.10E-09  
(Tibial artery) -0.21 
 
rs4262 8.10E-09 1 
 rs180238 GNG11 7:93550447_C NS NS 
 
rs4262 8.10E-09 0.81 
 rs4899412 RGS6 14:72464262_T NS NS 
 
rs2108469 4.10E-10 0.006 
 
rs1812835 NEO1 15:73507504_A 
4.4E-06 (EBV- lympho-
blastoid cell line) -0.62   rs2169951 NS 0.84 
             
 
      
 (g) Association between HRV SNP and 
expression in Koopmans Heart eQTL  
database   Top eQTL in Heart eQTL database 
 HRV SNP Gene chr:bp_allele p-value  Beta    SNP p-value LD HRV SNP 
 rs4262 GNG11 7:93551428_C NS NS 
  
NS 
  rs180238 GNG11 7:93550447_C NS NS 
  
NS 
  rs4899412 RGS6 14:72464262_T NS NS 
  
NS 
  rs1812835 NEO1 15:73507504_A NS NS     NS   
 chr: chromosome; bp: base pair position (build 37); FDR: false discovery rate; LD: linkage disequilibrium (r2). 
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Supplementary Table 15: mQTL analysis using the BIOS (cis) mQTL database
30
 to assess the effect of the 17 HRV SNPs on 
methylation in nearby genes. 
      mQTL   Top mQTL  
HRV SNP Chr:bp 
Effect 
allele 
Methylation 
Site 
Gene(s) 
Position 
methylation 
site (bp) 
Location in 
gene region 
Relation to 
UCSC CpG 
Island 
p-value Beta   SNP p-value 
LD 
HRV 
SNP 
rs12974440 19:5894386 A cg22854549 
VMAC; 
NDUFA11 
5904785 
TSS200; 
TSS1500 
Island 5.72E-82 -19.18 
 
rs55660714 1.71E-103 0.73 
rs12974440 19:5894386 A cg03715305 NDUFA11 5894715 3'UTR S_Shelf 1.63E-25 -10.44 
 
rs17271904 3.89E-26 0.98 
rs12974440 19:5894386 A cg19211619 CAPS 5913923 TSS1500 N_Shore 8.07E-07 4.93 
 
rs12982903 1.76E-07 0.95 
rs12974991 19:5894584 A cg22854549 
VMAC; 
NDUFA11 
5904785 
TSS200; 
TSS1500 
Island 8.38E-83 -19.28 
 
rs55660714 1.71E-103 0.71 
rs12974991 19:5894584 A cg03715305 NDUFA11 5894715 3'UTR S_Shelf 4.21E-26 -10.57 
 
rs17271904 3.89E-26 1.00 
rs12974991 19:5894584 A cg19211619 CAPS 5913923 TSS1500 N_Shore 3.47E-07 5.10 
 
rs12982903 1.76E-07 0.97 
rs12980262 19:5893058 A cg22854549 
VMAC; 
NDUFA11 
5904785 
TSS200; 
TSS1500 
Island 9.98E-82 -19.15 
 
rs55660714 1.71E-103 0.73 
rs12980262 19:5893058 A cg03715305 NDUFA11 5894715 3'UTR S_Shelf 1.52E-25 -10.45 
 
rs17271904 3.89E-26 0.98 
rs12980262 19:5893058 A cg19211619 CAPS 5913923 TSS1500 N_Shore 7.94E-07 4.94 
 
rs12982903 1.76E-07 0.95 
rs7980799 12:33576990 A cg21043657 SYT10 33590837 Body N_Shore 1.72E-23 9.99 
 
rs6488162 2.92E-25 0.90 
rs1351682 12:33598775 G cg21043657 SYT10 33590837 Body N_Shore 5.52E-21 9.40 
 
rs6488162 2.92E-25 0.80 
rs1384598 12:33622899 T cg21043657 SYT10 33590837 Body N_Shore 9.71E-21 9.34 
 
rs6488162 2.92E-25 0.80 
rs4262 7:93551428 C cg08038054 GNG11 93550781 TSS1500 
 
5.22E-51 -15.02 
 
rs180236 2.60E-55 0.87 
rs4262 7:93551428 C cg06439941 GNG11 93550756 TSS1500 
 
3.63E-30 -11.41 
 
rs180236 9.11E-36 0.87 
rs2529471 14:72813269 C cg17922283 RGS6 72799938 Body 
 
2.84E-14 7.61 
 
rs2090737 3.74E-19 0.71 
rs4899412 14:72464262 T cg19493789 RGS6 72396233 
 
N_Shelf NS NS 
 
rs2238280 4.16E-07 0.88 
rs1812835 15:73507504 A cg11357013 NEO1 73588054 Body 
 
6.18E-30 -11.37 
 
rs62016851 1.15E-31 0.93 
rs1812835 15:73507504 A cg19281068 NEO1 73345607 Body S_Shore 3.88E-17 8.42 
 
rs4609810 7.37E-22 0.78 
rs1812835 15:73507504 A cg11552023 NEO1 73595120 3'UTR 
 
7.39E-10 -6.16 
 
rs4132536 2.28E-17 0.77 
rs1812835 15:73507504 A cg17150474 NEO1 73343980 TSS1500 Island 3.29E-09 5.92 
 
rs1023924 1.31E-11 0.83 
Chr: chromosome; bp: base pair position (build 37); LD: linkage disequilibrium (r2). TSS200= methylation site is located within 200 
bp of a transcription start site; TSS1500= methylation site is located within 1500 bp of a transcription start site; 3’UTR= methylation 
site is located in the 3’untranslated region; Body= methylation site is located within a gene (gene body); Island= methylation site is 
located in a CpG island; S_Shelf= methylation site is located in the south shelf of a CpG island; N_Shelf= methylation site is located 
in the north shelf of a CpG island; S_Shore= methylation site is located in the south shore of a CpG island; N_Shore= methylation site 
is located in the north shore of a CpG island 
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Supplementary Table 16: DEPICT tissue enrichment analysis summarized by tissue or cell type. 
Genes were considered to be enriched for certain tissues or cell-types if they showed a Z-score for enrichment > 2.0 in Supplementary 
Data 3. 
 
Enriched tissue or cell type 
Gene Blood 
Central 
Nervous 
System 
Respiratory 
Salivary/ 
mucosa 
Immuno 
logical 
Stem 
cells 
Heart Muscle Sensory Epithelium 
Endo 
crine 
(Embryonic)  
membrane 
Vasculature 
C6orf89 x 
   
x x 
 
x 
     
CAPS 
  
x x 
    
x x 
   
CPNE5 x x x 
 
x 
        
FUT5 x 
  
x 
   
x 
     
GNG11 x 
        
x 
 
x x 
GNGT1 x 
  
x 
    
x 
  
x 
 
HCN4 x 
 
x x 
 
x x 
      
KIAA1755 
 
x 
    
x 
      
LINC00477 x 
 
x 
 
x 
  
x 
     
NDUFA11 
      
x 
 
x 
 
x 
  
NEO1 
 
x 
           
PPIL1 x 
   
x x 
       
RANBP3 
 
x 
        
x 
  
RGS6 x x 
   
x 
       
Sum 9 5 4 4 4 4 3 3 3 2 2 2 1 
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Supplementary Table 17: Results of VEGAS showing gene-based significance based on the stage 1 GWAS meta-analyses results for 
SDNN, RMSSD, and pvRSA/HF. Genes are shown for which the i-value was significant at the multiple testing correction level of 
2.5x10
-6
 (bolded) for at least one of the HRV traits. Genes in red italics were newly detected compared to the SNP-based analysis. 
    SDNN   RMSSD   pvRSA/HF 
Chr Gene nSNPs p-value Best-SNP 
SNP-  
p-value   nSNPs p-value Best-SNP 
SNP-  
p-value   nSNPs p-value Best-SNP 
SNP-  
p-value 
2 CCDC141 149 2.01E-03 rs17362588 0.000191   149 <1.0E-06 rs13004438 1.58E-07   149 5.41E-04 rs12693173 1.05E-05 
7 TFPI2 133 <1.0E-06 rs4262 1.56E-12 
 
110 <1.0E-06 rs180238 2.24E-13 
 
134 <1.0E-06 rs4262 7.41E-09 
7 GNGT1 120 <1.0E-06 rs4262 1.56E-12 
 
102 <1.0E-06 rs180238 2.24E-13 
 
121 <1.0E-06 rs4262 7.41E-09 
7 GNG11 120 <1.0E-06 rs4262 1.56E-12 
 
106 <1.0E-06 rs180238 2.24E-13 
 
121 <1.0E-06 rs4262 7.41E-09 
12 C12orf67 98 <1.0E-06 rs10842383 1.51E-22 
 
95 <1.0E-06 rs10842383 2.61E-22 
 
98 <1.0E-06 rs10842383 7.61E-23 
12 SYT10 181 <1.0E-06 rs1384598 1.20E-09 
 
176 <1.0E-06 rs7980799 1.92E-14 
 
176 <1.0E-06 rs6488162 2.42E-12 
12 ALG10 80 1.74E-03 rs1705748 0.000109 
 
78 3.00E-06 rs1705748 6.80E-09 
 
79 2.00E-06 rs4001713 4.52E-09 
12 ALG10B 101 4.45E-04 rs11183514 4.69E-05 
 
90 <1.0E-06 rs4575342 1.34E-08 
 
101 <1.0E-06 rs4575342 9.55E-10 
12 CPNE8 289 1.27E-04 rs826879 2.74E-06 
 
272 <1.0E-06 rs826879 8.41E-09 
 
284 <1.0E-06 rs11168761 6.08E-10 
14 RGS6 1243 1.00E-06 rs36423 1.03E-08 
 
1216 4.00E-06 rs2052015 5.97E-09 
 
1236 1.85E-02 rs17108294 0.0001619 
15 HCN4 110 <1.0E-06 rs2680344 1.26E-07 
 
109 <1.0E-06 rs7173389 1.16E-06 
 
110 3.60E-05 rs2680344 4.23E-06 
19 NRTN 56 6.00E-05 rs8108862 4.03E-12 
 
54 <1.0E-06 rs8108862 2.77E-28 
 
55 <1.0E-06 rs8108862 1.81E-37 
19 FUT6 58 1.10E-05 rs8108862 4.03E-12 
 
57 <1.0E-06 rs8108862 2.77E-28 
 
57 <1.0E-06 rs8108862 1.81E-37 
19 FUT3 74 <1.0E-06 rs12980262 3.00E-13 
 
72 <1.0E-06 rs12974991 7.80E-30 
 
73 <1.0E-06 rs12974440 9.09E-38 
19 FUT5 75 2.00E-06 rs12980262 3.00E-13 
 
73 <1.0E-06 rs12974991 7.80E-30 
 
74 <1.0E-06 rs12974440 9.09E-38 
19 NDUFA11 72 1.00E-06 rs12980262 3.00E-13 
 
68 <1.0E-06 rs12974991 7.80E-30 
 
70 <1.0E-06 rs12974440 9.09E-38 
19 VMAC 71 3.00E-06 rs12980262 3.00E-13 
 
66 <1.0E-06 rs12974991 7.80E-30 
 
69 <1.0E-06 rs12974440 9.09E-38 
19 CAPS 72 1.00E-06 rs12980262 3.00E-13 
 
67 <1.0E-06 rs12974991 7.80E-30 
 
70 <1.0E-06 rs12974440 9.09E-38 
19 RANBP3 94 3.00E-06 rs12980262 3.00E-13 
 
89 <1.0E-06 rs12974991 7.80E-30 
 
93 <1.0E-06 rs12974440 9.09E-38 
19 RFX2 101 2.82E-03 rs7258475 2.11E-12 
 
98 5.00E-06 rs7258475 3.50E-26 
 
102 2.00E-06 rs7258475 3.46E-30 
20 KIAA1755 147 9.00E-06 rs6127466 1.53E-05   144 <1.0E-06 rs6123471 5.15E-08   143 2.85E-03 rs6123471 0.0003297 
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Supplementary Table 18: Common SNP and narrow-sense heritabilities of the HRV traits and 
heart rate as calculated (a) by genomic restricted maximum likelihood analysis in 9,571 unrelated 
individuals from the Lifelines Cohort Study, (b) by LD Score regression on the stage 1 meta-
analysis results and (c) from classical biometrical modeling in the Oman Family Study.  
For (a): Common SNP heritabilities are shown on the diagonal, genetic correlations above the 
diagonal. For (b): Narrow-sense heritabilities are shown on the diagonal, genetic correlations 
above the diagonal. For (c): Narrow-sense heritabilities are shown on the diagonal, genetic 
correlations above the diagonal, and environmental correlations below the diagonal. The p-values 
(between brackets) indicate whether the genetic correlation is different from 1. 
(a) SDNN RMSSD pvRSA/HF 
SDNN 0.1076 0.98 (n.s.) n.a. 
RMSSD 
 
0.1319 n.a. 
pvRSA/HF 
  
n.a. 
n.a.: not applicable. 
  
    
(b) SDNN RMSSD pvRSA/HF 
SDNN 0.1112 1.00 (n.s.) 1.00 (n.s.) 
RMSSD 
 
0.1125 1.00 (n.s.) 
pvRSA/HF 
  
0.1177 
    
(c) SDNN RMSSD HF 
SDNN 0.1521 0.71 (2.5E-06) 0.73 (1.7E-05) 
RMSSD 0.74 0.1989 0.90 (n.s.) 
HF 0.74 0.80 0.1723 
Heart Rate -0.61 -0.69 -0.64 
n.s.: not significant. 
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Supplementary Table 19: Prioritization of genes in HRV GWAS-identified loci (±40 kb of lead SNPs) using MetaRanker, 
ToppGene, Endeavour, and DEPICT. 
HRV SNP Chr Gene p-value for the gene being causal* Prioritized for 
functional 
follow-up 
MetaRanker ToppGene Endeavour DEPICT
#
 
SDNN RMSSD pvRSA/HF 
rs10842383 12 LINC00477 6.2E-13 - - 0.53 0.43 0.07 1 
rs12974991, rs12974440, rs12980262 19 AC024592.9 - 0.06 - - - - 0 
rs12974991, rs12974440, rs12980262 19 CAPS 7.5E-13 - - 0.30 0.64 0.58 1 
rs12974991, rs12974440, rs12980262 19 FUT5 3.2E-13 0.07 0.56 0.78 0.35 0.52 1 
rs12974991, rs12974440, rs12980262 19 NDUFA11 7.7E-14 0.06 - 0.52 0.54 0.42 1 
rs12974991, rs12974440, rs12980262 19 RANBP3 - - - 0.86 0.76 0.71 1 
rs12974991, rs12974440, rs12980262 19 VMAC 7.7E-13 - - - - - 0 
rs236349 6 C6orf89 2.1E-13 0.14 0.78 0.97 0.81 0.45 1 
rs236349 6 CPNE5 2.5E-13 - - 0.42 0.14 0.17 1 
rs236349 6 PPIL1 1.1E-13 - - 0.12 0.26 0.78 1 
rs2680344, rs1812835 15 HCN4 4.9E-15 - - 0.45 0.09 0.09 1 
rs2680344, rs1812835 15 NEO1 - - - 0.58 0.21 - 1 
rs4262, rs180238 7 GNG11 4.5E-13 - - 0.74 0.30 0.24 1 
rs4262, rs180238 7 GNGT1 1.5E-13 2.3E-03 0.19 0.84 0.32 0.51 1 
rs4262, rs180238 7 TFPI2 5.7E-13 - - - - - 0 
rs4899412, rs2052015, rs2529471, rs36423 14 RGS6 - - - 0.69 0.43  1 
rs6123471 20 KIAA1755 - - -  0.71 - 1 
rs7980799 12 SYT10 2.7E-13 0.02 0.16 - - - 1 
* Caution should be exercised when using the p-value as a measure of confidence that the highlighted genes are indeed causal for the 
associations identified by GWAS, or as a means to compare evidence across tools. Each tool uses different databases and algorithms to 
generate these p-values and as such, p-values cannot necessarily be compared across tools. We advise to use the presence of a p-value 
as an indication that the respective tool identifies a gene as potentially being causal. 
# DEPICT is considered to be the most advanced tool since it uses the most up-to-date information to derive which genes are likely to 
be causal. For DEPICT, only identified genes that were located within ±40 kb of GWAS lead SNPs are reported. 
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Supplementary Table 20: Network and functional enrichment analyses. 
Gene ontology (GO) terms related to cell membrane signal transduction are highlighted in 
yellow; GO terms related to cellular anabolic, catabolic, and respiratory processes are highlighted 
in green. Significant false discovery rate q-values are shown in red font, suggestive ones in 
purple. 
GO id Description q-value 
Occurrences 
in Sample 
Occurrences 
in Genome 
GO:0071377 cellular response to glucagon stimulus 3.01E-13 10 33 
GO:0033762 response to glucagon 3.01E-13 10 33 
GO:0036065 fucosylation 1.90E-11 7 11 
GO:0008417 fucosyltransferase activity 7.35E-11 7 13 
GO:0006004 fucose metabolic process 1.67E-08 6 13 
GO:0006112 energy reserve metabolic process 5.55E-07 10 143 
GO:0015980 energy derivation by oxidation of organic compounds 3.00E-05 11 285 
GO:0071375 cellular response to peptide hormone stimulus 7.32E-05 10 244 
GO:1901653 cellular response to peptide 7.32E-05 10 247 
GO:0043434 response to peptide hormone 8.89E-05 10 255 
GO:1901652 response to peptide 9.70E-05 10 260 
GO:0043413 macromolecule glycosylation 1.65E-04 9 209 
GO:0070085 glycosylation 2.02E-04 9 216 
GO:0016758 transferase activity, transferring hexosyl groups 3.49E-04 7 113 
GO:0019320 hexose catabolic process 4.23E-04 6 72 
GO:0046365 monosaccharide catabolic process 4.67E-04 6 74 
GO:0003924 GTPase activity 1.01E-03 7 136 
GO:0006486 protein glycosylation 1.39E-03 8 208 
GO:0008277 
regulation of G-protein coupled receptor protein 
signaling pathway 
1.53E-03 6 93 
GO:0044724 single-organism carbohydrate catabolic process 1.86E-03 6 97 
GO:0016757 transferase activity, transferring glycosyl groups 2.15E-03 7 157 
GO:0016052 carbohydrate catabolic process 2.27E-03 6 102 
GO:0009101 glycoprotein biosynthetic process 6.01E-03 8 262 
GO:0031305 integral component of mitochondrial inner membrane 1.21E-02 3 13 
GO:0031304 intrinsic component of mitochondrial inner membrane 1.47E-02 3 14 
GO:0006626 protein targeting to mitochondrion 2.74E-02 4 49 
GO:0070585 protein localization to mitochondrion 3.09E-02 4 51 
GO:0019318 hexose metabolic process 4.84E-02 6 182 
GO:0005834 heterotrimeric G-protein complex 5.25E-02 3 22 
GO:0005996 monosaccharide metabolic process 9.49E-02 6 209 
GO:0030695 GTPase regulator activity 9.49E-02 5 132 
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SUPPLEMENTARY NOTES 
1. Gene-based GWAS (VEGAS) 
The results of the VEGAS gene-based GWAS analysis corroborate those of the SNP-based 
analysis (Supplementary Table 17). In seven of our eight loci with genome-wide significant SNPs 
(Table 1) the closest gene or other nearby genes also emerged from VEGAS as significantly 
associated with at least one of the HRV traits. Only the loci on chromosome 6 (PPIL) and 15 
(NEO1) were not represented. In addition, a few new genes close to the top hits in our SNP-based 
analyses emerged: TFPI2 and GNGT1 (both on chromosome 7), ALG10, ALG10B, and CPNE8 
(all on chromosome 12), and NRTN, FUT6, FUT3, FUT5, VMAC, CAPS, RANBP3, and RFX2 
(all on chromosome 19). Only one gene in a new locus was identified: CCDC141 (on 
chromosome 2, next to TTN coding for the titin protein, a key determinant of myocardial passive 
stiffness). CCDC141 and CPNE8 have previously been reported to be associated in a GWAS for 
heart rate
14
. 
 
2. Heritability and genetic correlations  
The common SNP heritability estimated by Genomic Restricted Maximum Likelihood (GREML) 
analysis was 10.8% and 13.2% for SDNN and RMSSD in the Lifelines cohort (Supplementary 
Table 18, panel a). Applying LD score regression analysis on the summary statistics of the stage 
1 meta-analysis suggested a common SNP heritability of 11.1% for SDNN, 11.2% for RMSSD, 
and 11.8% for pvRSA/HF (Supplementary Table 18, panel b). Classical modeling on family data 
from the Oman Family Study yielded heritability estimates between 15.2 and 20.0%. 
Previous studies showed high phenotypic correlation between pvRSA/HF and RMSSD
31, 
32
 and suggested a large overlap in their genetic architecture
33, 34
. We confirmed the phenotypic 
correlations in the TRAILS-Pop, NESDA, and Lifelines cohorts where they ranged from 0.70 
(SDNN-pvRSA/HF) to 0.96 (RMSSD-pvRSA/HF). Bivariate analysis using GREML and LD 
score regression analysis further showed genetic correlations of unity between pvRSA/HF and 
RMSSD, but also with SDNN, indicating complete overlap between the genetic variants 
influencing all three HRV traits (Supplementary Table 18, panel a+b). Modeling of the family 
data from the Oman Family Study confirmed high genetic correlation between the HRV traits, 
including SDNN (0.71-0.90) (Supplementary Table 18, panel c). This shows that SDNN, 
notwithstanding its different etiology, is influenced by sets of genetic variants that also influence 
the RMSSD and pvRSA/HF traits. 
We observed large negative genetic correlations (between -0.74 and -0.55) of SDNN, 
RMSSD, and pvRSA/HF with heart rate (Supplementary Table 11, panel b). High genetic overlap 
between heart rate and HRV fits the notion that HRV increases with a net increase of the tonic 
vagal effects on the sinoatrial node, which in turn reduces average heart rate. However, we note 
that the full relationship between HRV and heart rate is more complex because heart rate is under 
parallel sympathetic control, changes in which are not captured well by the HRV measures used 
35, 36
 and because changes in heart rate can lead to lower HRV, even at unchanged vagal input 
37
. 
 
3. Association between heart rate SNPs and HRV 
After establishing the effects of HRV SNPs on the variance in heart rate we also examined the 
reverse question, i.e. whether SNPs known to be associated with heart rate accounted for part of 
the variance in HRV. The reverse association of the 21 heart rate SNPs identified by a GWAS 
58 
 
 
 
study for heart rate
14
 with the three HRV traits showed that nine heart rate SNPs were associated 
with HRV, all in the expected direction, after correction for multiple testing (Supplementary 
Table 10, panel a)). Using gtx, a multi-SNP genetic risk scores for heart rate was associated with 
the three HRV traits (Supplementary Table 10, panel b). 
In the Lifelines, NESDA, TRAILS-Pop, and ABCD cohorts, a multi-SNP genetic risk 
score for heart rate explained 0.2 to 0.9% of HRV variance in the four cohorts (Supplementary 
Table 10, panel c). The full polygenic risk score for heart rate explained a similar amount of the 
variance in the three HRV traits: 0.2 to 0.8% (Supplementary Table 10, panel d).  
 
4. Network and functional enrichment analyses  
Based on our 17 HRV SNPs, we selected candidate genes as input for the interaction network 
analysis with the GeneMANIA algorithm to prioritize potentially causal genes 
38
 with additional 
input from the VEGAS analyses (Supplementary Table 17) and four publicly available 
bioinformatics tools (Supplementary Table 19). As one of the genes (LINC00477) could not be 
found by GeneMANIA, 24 query genes were used as input. Functional network and enrichment 
analysis on these genes resulted in 31 significantly enriched gene ontology terms of which 23 had 
false discovery rate ≤ 0.01 (Supplementary Table 20). These 23 gene ontology terms showed that 
the genes near our hits were broadly related to two categories of significantly enriched biological 
processes, namely: (1) cellular signaling and cellular responses, including G-protein coupled 
receptor protein signaling and the responses to glucagon and peptides, and (2) metabolic 
processes in the cell (e.g. fucosylation and glycosylation) (Supplementary Fig. 10).  
 
5. Tissue and gene-set enrichment analyses  
In silico tissue enrichment analysis using DEPICT
6
 highlights a role for hormones in HRV 
regulation, with enrichment for the adrenal cortex, endocrine glands, gonads, gastrointestinal tract 
and female reproductive organs (Supplementary Fig. 8a,c,e). Gene-set enrichment analysis using 
DEPICT highlights the importance of cardiac development (Supplementary Fig. 8b,d,f).  
 
6. Known biological functions of the genes closest to the HRV SNPs 
Here we describe the known biological functions of the genes closest to the eight HRV lead SNPs 
identified in the two-stage meta-analysis. 
NDUFA11 (Chr 19, full name: NADH dehydrogenase (ubiquinone) 1 alpha sub-complex, 11, 
also known as B14.7 and Cl-B14.7) encodes a subunit of the membrane-bound mitochondrial 
complex I involved in mitochondrial respiration and electron transport. NDUFA11’s cDNA 
was cloned and sequenced from human heart mitochondria. The non-synonymous lead SNP in 
our meta-analysis induces a change in the structure of this complex with as yet unknown 
functional effects. Clinically, five phenotypes are frequently seen with homozygous mutations 
of this gene: severe neonatal lactic acidosis, cardiomyopathy-encephalopathy, hepatopathy-
tubulopathy, leukodystrophy with macrocephaly, and Leigh’s and Leigh-like 
neurodegenerative disorder, which are the most common presentations of complex I 
deficiency at a young age 
39, 40
. 
LINC00477 (C12orf67) (Chr 12, full name: long intergenic non-protein coding RNSA 477) is 
of unknown biological function but the locus has also been associated with resting heart rate 
14
 
and PR interval 
41
. 
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PPIL1 (Chr 6, full name: peptidylprolyl isomerase (cyclophilin)-like 1) is a member of the 
cyclophilin family. After being recruited by Ski interaction protein (SKIP) PPIL1 participates 
in the activation of spliceosomes and thereby facilitates the folding of proteins in the 
spliceosomes 
42, 43
. No relation with heart rate or HRV has been described but PPIL1 has been 
reported to be one of two key driver genes involved in coronary artery disease networks 
44
. 
SYT10 (Chr 12, full name: synaptotagmin-10) has a role in the regulation of calcium 
dependent exocytosis, including calcium regulated release of neurotransmitter from 
presynaptic nerve terminals 
45, 46
. SYT10 has been previously identified as being associated 
with heart rate 
14
. Synaptotagmin-1 plays a known role in calcium-triggered acetylcholine 
release from the neuromuscular junction 
47
. Our meta-analyses results hint at a possible role 
for synaptotagmin-10 in sinoatrial acetylcholine release but this remains to be tested.  
GNG11 (Chr 7, full name: guanine nucleotide binding protein (G protein, gamma 11) which is 
also a previously identified heart rate gene 
14
 encodes the γ11 subunit of Gαβγ heterotrimers. 
GNG11 is one of 12 genes encoding the Gγ subunits that all undergo post-translational 
isoprenylation of their C termini, in case of γ11 by a farnesyl 48. Because the γ subunits have 
lower amino acid sequence homology then the β subunits, they are thought to be the main 
determinant of signaling diversity and fidelity of the Gβγ components 49, 50. γ11 shows a 
unique pattern of expression compared to the other 11 γ subunits in that it is abundantly 
expressed in the heart but poorly in the brain
50
. 
RGS6 (Chr 14, full name: regulator of G-protein signaling 6) is a large gene coding one of the 
RGS superfamily that act as GTPase-activating proteins (GAPs) for the α subunit of Gαβγ 
heterotrimers by accelerating their intrinsic GTPase activity. This ends both Gα and Gβγ 
mediated cellular signaling. RGS6 exhibits a uniquely robust expression in the heart 
10
. RGS6 
is known to reduce parasympathetic signaling through the M2R in the sinoatrial node as well 
as Gαo coupled adenosine A1 receptors 
10, 51, 52
.  
HCN4 (Chr 15, full name: hyperpolarization activated cyclic nucleotide gated potassium 
channel 4) codes for a non-GIRK potassium channel in the sinoatrial node that is a core part of 
the ‘clock circuit’ generating the pacemaker potential. HCN4 is expressed abundantly in the 
heart from the early embryonic phase onward 
12
. HCN4 was previously found to be associated 
with heart rate 
14
. Depending on total load and severity, loss-of-function mutations in HCN4 
can lead to asymptomatic bradycardia, Brugada syndrome and Sick Sinus Syndrome, atrial 
fibrillation and possibly left ventricular noncompaction cardiomyopathy 
53, 54
. 
NEO1 (Chr 15, full name: neogenin 1, aka HsT16534, IGDCC2, NGN or NTN1R2) is a 
multifunctional transmembrane receptor closely related to the immunoglobulin (Ig) 
superfamily and is a netrin receptor 
55
. Neogenin plays a role in early cerebellar neurite out-
growth and projection in chicken and quail 
56, 57
 and is known to be a regulator of axonal 
guidance in the nervous system 
58
. No role in HRV or heart rate has been described previously. 
KIAA1755 (Chr 20, no full name in Ensembl or at NCBI) which has also been associated with 
heart rate 
14
. Effects of the non-synonymous lead SNP (rs6123471) is unclear as the function 
of this gene remains unknown. 
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7. Software and internet databases used 
Annovar URL: http://annovar.openbioinformatics.org/en/latest/  
DEPICT URL: http://www.broadinstitute.org/mpg/depict/  
Endeavour URL: http://homes.esat.kuleuven.be/~bioiuser/endeavour/index.php  
GeneMANIA URL: http://genemania.org/  
Genome-wide Complex 
Trait Analysis (GCTA) 
version 1.24.4 
URL: http://cnsgenomics.com/software/gcta/  
gtx (R package) URL: https://cran.r-project.org/web/packages/gtx/index.html  
GWAMA URL: http://www.well.ox.ac.uk/gwama/  
LD score regression URL: https://github.com/bulik/ldsc 
LocusZoom URL: http://locuszoom.sph.umich.edu/locuszoom/  
METAL URL: http://csg.sph.umich.edu//abecasis/Metal/index.html  
MetaRanker URL: http://www.cbs.dtu.dk/services/MetaRanker/  
PriorityPruner version 
0.1.1 
URL: http://prioritypruner.sourceforge.net/  
PLINK version 1.07 URL: http://pngu.mgh.harvard.edu/purcell/plink/  
PolyPhen URL: http://genetics.bwh.harvard.edu/pph2/  
RegulomeDB URL: http://regulomedb.org/  
SIFT URL: http://sift.jcvi.org/  
SNP annotation and 
proxy search (SNAP) 
URL: https://www.broadinstitute.org/mpg/snap/  
SOLAR URL: http://solar-eclipse-genetics.org/  
ToppGene URL: https://toppgene.cchmc.org/  
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on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced 
Computational Science (UPPMAX) under Project b2011036. Genotyping was funded by the 
Wellcome Trust under award WT064890. Analysis of genetic data was funded by the Wellcome 
Trust under awards WT098017 and WT090532.  
Written informed consent was obtained from all participants of the PIVUS study. The protocols 
were approved by the Ethics Committee of Uppsala University. 
 
PREVEND: PREVEND genetics is supported by the Dutch Kidney Foundation (Grant E033), the 
EU project grant GENECURE (FP-6 LSHM CT 2006 037697), the National Institutes of Health 
(grant 2R01LM010098), The Netherlands organization for health research and development 
(NWO-Groot grant 175.010.2007.006, NWO VENI grant 916.761.70, ZonMw grant 90.700.441), 
and the Dutch Inter University Cardiology Institute Netherlands (ICIN). 
All participants of the PREVEND study provided informed consent. This study has been 
approved by the review board of the University Medical Center Groningen. This study adheres to 
the principles expressed in the Declaration of Helsinki. 
 
RS: We are grateful to the study participants, the staff from the Rotterdam Study and the 
participating general practitioners and pharmacists. Furthermore, we thank Pascal Arp, Mila 
Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina Medina-
Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii 
Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed 
data. The generation and management of GWAS genotype data for the Rotterdam Study (RS I, 
RS II) was executed by the Human Genotyping Facility of the Genetic Laboratory of the 
Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS 
datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments 
(nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal 
Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), 
the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research 
(NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. The 
Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, 
Netherlands Organization for the Health Research and Development (ZonMw), the Research 
Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the 
Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the 
Municipality of Rotterdam. 
The Rotterdam study has been approved by the Medical Ethics Committee of the Erasmus MC 
and by the Ministry of Health, Welfare and Sport of the Netherlands, on the basis of the Wet 
Bevolkingsonderzoek ERGO. All participants provided written informed consent.  
 
TRAILS: This research is part of the TRacking Adolescents' Individual Lives Survey (TRAILS), 
which includes the TRAILS population cohort (TRAILS-Pop) and the TRAILS clinical cohort 
(TRAILS-CC). Participating centers of TRAILS include the University Medical Center and 
University of Groningen, the Erasmus University Medical Center Rotterdam, the University of 
65 
 
 
 
Utrecht, the Radboud Medical Center Nijmegen, and the Parnassia Bavo group, all in the 
Netherlands. We are grateful to everyone who participated in this research or worked on this 
project to make it possible. TRAILS has been financially supported by various grants from the 
Netherlands Organization for Scientific Research NWO (Medical Research Council program 
grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and 
Dependence grants 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social 
Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-
07-001; Social Sciences Council project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-
004; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel 
Funding 481-08-013 and 481-11-001), the Dutch Ministry of Justice (WODC), the European 
Science Foundation (EuroSTRESS project FP-006), Biobanking and Biomolecular Resources 
Research Infrastructure BBMRI-NL (CP 32), and the participating universities. Part of statistical 
analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org) 
hosted by SURFsara and financially supported by the Netherlands Scientific Organization (NWO 
480-05-003) along with a supplement from the Dutch Brain Foundation and the VU University 
Amsterdam. 
TRAILS was approved by Dutch Central Committee on Research Involving Human Subjects 
(CCMO); www.ccmo.nl. If both parents and children agreed to participate, parental written 
informed consent was obtained after the procedures had been fully explained. 
 
ULSAM: We thank the SNP&SEQ Technology Platform (www.genotyping.se), which is part of 
the National Genomics Infrastructure hosted by Science for Life laboratory at Uppsala University 
for excellent genotyping. This project was supported by Knut and Alice Wallenberg Foundation 
(Wallenberg Academy Fellow), European Research Council (ERC Starting Grant), Swedish 
Diabetes Foundation (2013-024), Swedish Research Council (2012-1397, 2012-1727, and 2012-
2215), Marianne and Marcus Wallenberg Foundation, County Council of Dalarna, Dalarna 
University, and Swedish Heart-Lung Foundation (20120197). The computations were performed 
on resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced 
Computational Science (UPPMAX) under Project b2011036. Genotyping was funded by the 
Wellcome Trust under award WT064890. Analysis of genetic data was funded by the Wellcome 
Trust under awards WT098017 and WT090532. Andrew P Morris is a Wellcome Trust Senior 
Fellow in Basic Biomedical Science (award WT098017). 
Written informed consent was obtained from all ULSAM participants. The study was approved 
by the ethics committee at Uppsala University (IRB numbers 251/90 and 2013/350). 
 
YFS: We gratefully acknowledge the expert technical assistance in the statistical analyses by 
Irina Lisinen. The Young Finns Study has been financially supported by the Academy of Finland: 
grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 
41071 (Skidi); the Social Insurance Institution of Finland; Kuopio, Tampere and Turku 
University Hospital Medical Funds (grant X51001); Juho Vainio Foundation; Paavo Nurmi 
Foundation; Finnish Foundation of Cardiovascular Research ; Finnish Cultural Foundation; 
Tampere Tuberculosis Foundation ; Emil Aaltonen Foundation ; and Yrjö Jahnsson Foundation.  
The Young Finns Study was approved by the local ethics committees (University Hospitals of 
Helsinki, Turku, Tampere, Kuopio and Oulu) and was conducted following the guidelines of the 
Declaration of Helsinki. All participants gave their written informed consent. 
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Stage 2 cohorts 
CARLA: This study was funded by a grant from the Deutsche Forschungsgemeinschaft (DFG, 
German Research Foundation) as part of the Collaborative Research Center 598 ‘‘Heart failure in 
the elderly–cellular mechanisms and therapy’’ at the Medical Faculty of the Martin-Luther-
University Halle-Wittenberg; by a grant of the Wilhelm-Roux Programme of the Martin-Luther-
University Halle-Wittenberg; by the Federal Employment Office; and by the Ministry of 
Education and Cultural Affairs of Saxony-Anhalt. 
Written informed consent was obtained from all CARLA participants. The study was approved 
by the Ethics Committee of The Medical Faculty of the Martin-Luther University Halle-
Wittenberg and by the State Data Privacy Commissioner of Saxony-Anhalt, Germany. 
 
FINCAVAS: We thank the staff of the Department of Clinical Physiology for collecting the 
exercise test data. The Finnish Cardiovascular Study (FINCAVAS) has been financially 
supported by the Competitive Research Funding of the Tampere University Hospital (Grant 
9M048 and 9N035), the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular 
Research, the Emil Aaltonen Foundation, Finland, and the Tampere Tuberculosis Foundation. 
The FINCAVAS study protocol was approved by the Ethical Committee of the Hospital District 
of Pirkanmaa, Finland, and all patients have given informed consent prior to the interview and 
measurements as stipulated in the Declaration of Helsinki. 
 
HANDLS: The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) 
study was supported by the Intramural Research Program of the NIH, National Institute on Aging 
and the National Center on Minority Health and Health Disparities (project # Z01-AG000513 and 
human subject’s protocol number 09-AG-N248). We thank the HANDLS study participants, staff 
and field workers for their contribution to this work. Data analyses for the HANDLS study 
utilized the high-performance computational resources of the Biowulf Linux cluster at the 
National Institutes of Health, Bethesda, MD, (http://hpc.nih.gov). 
HANDLS is reviewed and approved by the National Institute of Environmental Health Sciences 
Institutional Review Board at NIH 
 
HCHS/SOL: We thank the staff and participants of HCHS/SOL for their important contributions. 
A complete list of staff and investigators is available on the study website 
http://www.cscc.unc.edu/hchs/. The Hispanic Community Health Study/Study of Latinos was 
carried out as a collaborative study supported by contracts from the National Heart, Lung, and 
Blood Institute (NHLBI) to the University of North Carolina (N01-HC65233), University of 
Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern 
University (N01-HC65236), and San Diego State University (N01-HC65237). The following 
Institutes/Centers/Offices contribute to the HCHS/SOL through a transfer of funds to the NHLBI: 
National Center on Minority Health and Health Disparities, the National Institute of Deafness and 
Other Communications Disorders, the National Institute of Dental and Craniofacial Research, the 
National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of 
Neurological Disorders and Stroke, and the Office of Dietary Supplements. The Genetic Analysis 
Center at University of Washington was supported by NHLBI and NIDCR contracts 
(HHSN268201300005C AM03 and MOD03). Genotyping efforts were supported by NHLBI 
HSN 26220/20054C, NCATS CTSI grant UL1TR000124, and NIDDK Diabetes Research Center 
(DRC) grant DK063491. 
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Written informed consent was provided by all HCHS/SOL participants; IRB approvals were 
obtained by all field sites recruiting participants:  Bronx Site at Albert Einstein College of 
Medicine, Yeshiva University (FWA00000140) and Montifiore Medical Center (FWA0000258); 
Chicago Site at University of Illinois, Chicago (FWA00000083, IRB00000117  IRB#3); San 
Diego Site at San Diego State University:  (IORG0000333, IRB00000576); Miami site at 
University of Miami, Florida (FWA00002247). 
 
Lifelines: We wish to acknowledge the services of the Lifelines Cohort Study, the contributing 
research centers delivering data to Lifelines, and all the study participants. The Lifelines Cohort 
Study, and generation and management of GWAS genotype data for the Lifelines Cohort Study is 
supported by the Netherlands Organization of Scientific Research NWO (grant 
175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the 
Ministry of Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for 
Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), the 
Province of Groningen, University Medical Center Groningen, the University of Groningen, 
Dutch Kidney Foundation and Dutch Diabetes Research Foundation. Part of the statistical 
analyses were carried out on the Genetic Cluster Computer (http://www.geneticcluster.org) 
hosted by SURFsara and financially supported by the Netherlands Scientific Organization (NWO 
480-05-003) along with a supplement from the Dutch Brain Foundation and the VU University 
Amsterdam. 
All participants signed an informed consent form before they received an invitation for the 
physical examination. The LifeLines Cohort Study is conducted according to the principles of 
the Declaration of Helsinki and in accordance with research code University Medical Center 
Groningen (UMCG). The LifeLines study is approved by the medical ethical committee of the 
UMCG, the Netherlands (METc 2007/152). 
 
MRC NSHD: We are very grateful to the members of this birth cohort for their continuing 
interest and participation in the study. We would like to acknowledge the Swallow group, UCL, 
who performed the DNA extractions (Rousseau, et al 2006). DOI: 10.1111/j.1469-
1809.2006.00250.x MRC NSHD was funded by the Medical Research Council 
(MC_UU_12019/1); doi: 10.5522/NSHD/Q102. 
Written informed consent was obtained from all NSHD study members.  Ethical approval was 
given by the Central Manchester Research Ethics Committee (07/H1008/168, 07/H1008/245) and 
the Scottish A Research Ethics Committee (08/MRE00/12). 
 
NFBC 1966: We thank the late Professor Paula Rantakallio (launch of NFBCs), and Ms Outi 
Tornwall, Ms Minttu Jussila (DNA biobanking), Ms Nelli Perkiömäki (HRV analysis), the 
participants in the 46y study and the NFBC project center. The authors would like to 
acknowledge the contribution of the late Academian of Science Leena Peltonen. The DNA 
extractions, sample quality controls, biobank up-keeping and aliquotting was performed in the 
National Public Health Institute, Biomedicum Helsinki, Finland and supported financially by the 
Academy of Finland and Biocentrum Helsinki. NFBC1966 received financial support from the 
Academy of Finland (project grants 104781, 120315, 129269, 1114194, 24300796, 267435, 
285547 Center of Excellence in Complex Disease Genetics and SALVE), University of Oulu, 
Oulu University Hospital and Biocenter, Oulu, Finland [grant numbers 24301140, 24000692, 
75617], European Regional Development Fund [grant number 539/2010 A31592], NHLBI grant 
5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH 
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(5R01MH63706:02), ENGAGE project and grant agreement HEALTH-F4-2007-201413, EU 
FP7 EurHEALTHAgeing -277849, the Medical Research Council, UK (G0500539, G0600705, 
G1002319, PrevMetSyn/SALVE), the MRC, Centenary Early Career Award, the Sigrid Juselius 
Foundation and the Finnish Foundation for Cardiovascular Research. The program is currently 
being funded by the H2020-633595 DynaHEALTH action and the Academy of Finland EGEA-
project. 
Written informed consent was obtained from all NFBC1966 participants. The study was 
approved by the Regional Ethics Committee of the Northern Ostrobothnia Hospital District, 
Oulu, Finland (IRB number 94/2011). 
 
UCSD TWINS: We wish to dedicate this work to the memory Daniel T. O’Connor, whose body 
of work, particularly with the University of California San Diego Twins cohort, and passion for 
new knowledge were unprecedented. This study was supported by P30 DK079337 and U01 
HL69758-01. 
Written informed consent was obtained from all UCSD twin participants. The study was 
approved by the University of California-San Diego Institutional Review Board (IRB number 
120582). 
WHI: We thank all contributors to WHI science, which are listed at 
https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator
%20Long%20List.pdf.  
The Women’s Health Initiative study was approved by the human subjects review committee at 
each participating institution and all participants provided written informed consent.    
 
WHI CT – GARNET: The Women’s Health Initiative clinical trials were funded by the National 
Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and 
Human Services through contracts HHSN268201100046C, HHSN268201100001C, 
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and 
HHSN271201100004C. Within the Genomics and Randomized Trials Network, a GWAS of 
Hormone Treatment and CVD and Metabolic Outcomes in the WHI was funded by the National 
Human Genome Research Institute, National Institutes of Health, U.S. Department of Health and 
Human Services through cooperative agreement U01HG005152 (Reiner). 
The Women’s Health Initiative study was approved by the human subjects review committee at 
each participating institution and all participants provided written informed consent.    
 
WHI CT – MOPMAP: The Women’s Health Initiative clinical trials were funded by the National 
Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and 
Human Services through contracts HHSN268201100046C, HHSN268201100001C, 
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and 
HHSN271201100004C. The Modification of PM-Mediated Arrhythmogenesis in Populations 
was funded by the National Institute of Environmental Health Sciences, National Institutes of 
Health, U.S. Department of Health and Human Services through grant R01ES017794 (Whitsel). 
The Women’s Health Initiative study was approved by the human subjects review committee at 
each participating institution and all participants provided written informed consent.    
 
WHI - SHARe: The Women’s Health Initiative clinical trials were funded by the National Heart, 
Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human 
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Services through contracts HHSN268201100046C, HHSN268201100001C, 
HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and 
HHSN271201100004C. The SNP Health Association Resource project was funded by the 
National Heart, Lung and Blood Institute, National Institutes of Health, U.S. Department of 
Health and Human Services through contract N02HL64278 (Kooperberg). 
The Women’s Health Initiative study was approved by the human subjects review committee at 
each participating institution and all participants provided written informed consent.    
 
WHII: The Whitehall II study is supported by grants from the Medical Research Council 
(G0902037), British Heart Foundation (RG/07/008/23674), Stroke Association, National Heart 
Lung and Blood Institute (5RO1 HL036310) and National Institute on Aging (5RO1AG13196 
and 5RO1AG034454). 
Ethical approval for the Whitehall II study was obtained from University College London 
Medical School committee on the ethics of human research (reference number 85/0938), and the 
London-Harrow and Scotland A Research Ethics Committees on Ethics of Human Research. All 
participants provided written informed consent. 
 
Post-GWAS cohorts and consortia performing post-GWAS analyses and lookups 
ABCD: We thank all participating hospitals, obstetric clinics, general practitioners and primary 
schools for their assistance in implementing the ABCD study. We also gratefully acknowledge all 
the women and children who participated in this study for their cooperation. The ABCD study 
has been supported by grants from The Netherlands Organisation for Health Research and 
Development (ZonMW) and The Netherlands Heart Foundation. Genotyping was funded by the 
BBMRI-NL grant CP2013-50. Dr M.H. Zafarmand was supported by BBMRI-NL (CP2013-50). 
Dr. T.G.M. Vrijkotte was supported by ZonMW (TOP 40–00812–98–11010). 
All ABCD participants gave written informed consent  for themselves and their children. 
Approval was obtained from the Central Ethics Committee on Research Involving Human 
Subjects of the Academic Medical Centre (AMC), Amsterdam and the Registration Committee of 
Amsterdam (IRB number: MEC 02/039#07.17.1039) . 
 
AFGen consortium: See PMID 22544366 for contributors and funding information. Dr. Lubitz is 
further supported by NIH K23HL114724 and a Doris Duke Charitable Foundation Clinical 
Scientist Development Award 2014105.  
 
BIOS (Biobank-based Integrative Omics Study) consortium: eQTL and mQTL results were 
provided by the Biobank-based Integrative Omics Study (BIOS) Consortium, which is funded by 
the Biobanking and Biomolecular Research Infrastructure (BBMRI-NL, NWO project 
184.021.007).  
Management Team: Bastiaan T. Heijmans (chair), Peter A.C. ’t Hoen, Joyce van Meurs, Aaron 
Isaacs, Rick Jansen, Lude Franke. Cohort collection: Dorret I. Boomsma, René Pool, Jenny van 
Dongen, Jouke J. Hottenga (Netherlands Twin Register); Marleen MJ van Greevenbroek, Coen 
D.A. Stehouwer, Carla J.H. van der Kallen, Casper G. Schalkwijk (Cohort study on Diabetes and 
Atherosclerosis Maastricht); Cisca Wijmenga, Lude Franke, Sasha V. Zhernakova, Ettje F. 
Tigchelaar (Lifelines Deep); P. Eline Slagboom, Marian Beekman, Joris Deelen, Diana van 
Heemst (Leiden Longevity Study); Jan H. Veldink, Leonard H. van den Berg (Prospective ALS 
Study Netherlands); Cornelia M. van Duijn, Bert A. Hofman, Aaron Isaacs, André G. 
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Uitterlinden3 (Rotterdam Study). Data Generation Joyce van Meurs (Chair), P. Mila Jhamai, 
Michael Verbiest, H. Eka D. Suchiman, Marijn Verkerk, Ruud van der Breggen, Jeroen van 
Rooij, Nico Lakenberg. Data management and computational infra-structure Hailiang Mei 
(Chair), Maarten van Iterson, Michiel van Galen, Jan Bot, Sasha V. Zhernakova, Rick Jansen, 
Peter van ’t Hof, Patrick Deelen, Irene Nooren, Peter A.C. ’t Hoen, Bastiaan T. Heijmans, 
Matthijs Moed. Data Analysis Group Lude Franke (Co-Chair), Martijn Vermaat, Sasha V. 
Zhernakova, René Luijk, Marc Jan Bonder, Maarten van Iterson, Patrick Deelen, Freerk van Dijk, 
Michiel van Galen, Wibowo Arindrarto, Szymon M. Kielbasa, Morris A. Swertz, Erik. W van 
Zwet, Rick Jansen, Peter-Bram ’t Hoen (Co-Chair), Bastiaan T. Heijmans (Co-Chair). 
 
CHARGE-HF consortium: For a full list of CHARGE - Heart Failure Working Group members 
contributing to this work funding sources, and further acknowledgements, please see PMID 
20445134.  
 
CHARGE-SCD consortium: Foram N. Ashar, Christine M. Albert, Christopher Newton-Cheh, 
Jennifer A. Brody, Martina Muller-Nurasyid, Anna Moes, Angel Mak, Heikki Huikuri, M Juhani 
Junttila, Philippe Goyette, Sara L. Pulit, Aravinda Chakravarti, Georg Ehret, Josef Coresh, Man 
Li, Ronald J. Prineas, Catherine O. Johnson, Oscar H. Franco, Pui-Yan Kwok, Thomas Lumley, 
Florence Dumas, Barbara McKnight, Jerome I. Rotter, Rozenn N. Lemaitre, Susan Heckbert, 
Christopher J. O’Donnell, Shih-Jen Hwang, Jean-Claude Tardif, Marja-Leena Kortelainen, 
Martin VanDenBurgh, Andre G Uitterlinden, Albert Hofman, Bruno H. C. Stricker, Thomas 
Meitinger, Mark Eijgelsheim, John D. Rioux, Ken Rice, Xavier Jouven, Stefan Kaab, Bruce M. 
Psaty, David S. Siscovick, Dan E. Arking, Nona Sotoodehnia, for the SCD working group of the 
CHARGE Consortium. 
 
CKDGen consortium: We thank all members of the CKDGen Consortium for the sharing of 
summary statistics. 
 
Lifelines Cohort Study: Behrooz Z. Alizadeh, H. Marike Boezen, Lude Franke, Pim van der 
Harst, Gerjan Navis, Marianne Rots, Harold Snieder, Morris Swertz, Bruce H.R. Wolffenbuttel, 
Cisca Wijmenga.  
 
OFS: We thank the people of the Taimsa, Birkat AI-Moz, Radat Al-Busaidi, Karsha, and Farq 
villages for their continuous encouragement and participation. We thank the Ministry of Health 
and the Wali (Governor) of Nizwa District and the H. M. Sultan Qaboos Strategic Research Trust 
Fund (Grant SR/MED/PHYS/ O4/01) for supporting this work. 
The Oman Family Study (OFS) was approved by the Research and Ethics Committee of College 
of Medicine and Health Sciences at Sultan Qaboos University, Muscat Oman  under the title 
"Hypertension and the metabolic syndrome in Oman  intervention clinical trial  and mapping of 
genes" (SR/MED/PHYS/01/01  and  SR/MED/PHYS/04/01). All participants fully consented to 
the study by signing the written consent form or by thumb stamping for those who were 
illiterate.  
 
N. Sotoodehnia was supported by grants R01HL116747 and R01HL111089.  
M. den Hoed was supported by the Swedish research Council (2015-03657) and Swedish Heart-
Lung Foundation (20140543). 
71 
 
 
 
S.W. van der Laan was funded through grants from the Netherlands CardioVascular Research 
Initiative (“GENIUS”, CVON2011-19), the Interuniversity Cardiology Institute of the 
Netherlands (ICIN, 09.001), and through the FP7 EU project CVgenes@target (HEALTH-F2-
2013-601456) 
  
72 
 
 
 
SUPPLEMENTARY REFERENCES 
 
 1.      Kumar,P., Henikoff,S., & Ng,P.C. Predicting the effects of coding non-
synonymous variants on protein function using the SIFT algorithm. Nature Protocols 4, 
1073-1081 (2009). 
 2.      Adzhubei,I.A. et al. A method and server for predicting damaging missense 
mutations. Nature Methods 7, 248-249 (2010). 
 3.      Boyle,A.P. et al. Annotation of functional variation in personal genomes using 
RegulomeDB. Genome Research 22, 1790-1797 (2012). 
 4.      Liu,J.Z. et al. A versatile gene-based test for genome-wide association studies. 
American Journal of Human Genetics 87, 139-145 (2010). 
 5.      Pers,T.H., Dworzynski,P., Thomas,C.E., Lage,K., & Brunak,S. MetaRanker 2.0: a 
web server for prioritization of genetic variation data. Nucleic Acids Research 41, 
W104-W108 (2013). 
 6.      Pers,T.H. et al. Biological interpretation of genome-wide association studies using 
predicted gene functions. Nature Communications 6, 5890 (2015). 
 7.      Chen,J., Xu,H., Aronow,B.J., & Jegga,A.G. Improved human disease candidate 
gene prioritization using mouse phenotype. BMC Bioinformatics 16, 392 (2007). 
 8.      Arena,J. et al. Complex I defect in muscle from patients with Huntington's 
disease. Annals of Neurology 43, 398-400 (1998). 
 9.      Mostafavi,S., Debajyoti,R., Warde-Farley,D., Grouios,C., & Morris,Q. 
GeneMANIA: a real-time multiple association network integration algorithm for 
prediciting gene function. Genome Biology 9, S4 (2008). 
 10.      Stewart,A., Huang,J., & Fisher,R.A. RGS proteins in heart brakes on the vagus. 
Frontiers in Physiology 3, (2012). 
 11.      Posokhova,E., Wydeven,N., Allen,K.L., Wickman,K., & Martemyanov,K.A. 
RGS6/Gbeta5 complex accelerates IKACh gating kinetics in atrial myocytes and 
modulates parasympathetic regulation of heart rate. Circulation Research 107, 1350-
1354 (2010). 
 12.      Baruscotti,M., Barbuti,A., & Bucchi,A. The cardiac pacemaker current. Journal of 
Molecular and Cellular Cardiology 48, 55-64 (2010). 
 13.      Baruscotti,M., Bottelli,G., Milanesi,R., DiFrancesco,J.C., & DiFrancesco,D. 
HCN-related channelopathies. Pflugers Archiv-European Journal of Physiology 460, 
405-415 (2010). 
73 
 
 
 
 14.      den Hoed M. et al. Identification of heart rate-associated loci and their effects on 
cardiac conduction and rhythm disorders. Nature Genetics 45, 621-631 (2013). 
 15.      International Consortium for Blood Pressure Genome-Wide Association Studies et 
al. Genetic variants in novel pathways influence blood pressure and cardiovascular 
disease risk. Nature 478, 103-109 (2011). 
 16.      Smith,N.L. et al. Assocation of genome-wide variation with the risk of incident 
heart failure in adults of European and African ancestry: a prospective meta-analysis 
from the cohorts for heart and aging research in genomic epidemiolgy (CHARGE) 
consortium. Circulation Cardiovascular Genetics 3, 256-266 (2010). 
 17.      Deloukas,P. et al. Large-scale association analysis identifies new risk loci for 
coronary artery disease. Nature Genetics 45, 25-33 (2013). 
 18.      Ellinor,P.T. et al. Meta-analysis identifies six new susceptibility loci for atrial 
fibrililation. Nature Genetics 44, 670-675 (2012). 
 19.      Morris,A.P. et al. Large-scale association analysis provides insights into the 
genetic architecture and pathophysiology of type 2 diabetes. Nature 44, 981-990 (2012). 
 20.      Locke,A.E. et al. Genetic studies of body mass index yield new insights for 
obesity biology. Nature 518, 197-206 (2015). 
 21.      Pattaro,C. et al. Genetic associations at 53 loci highlight cell types and biological 
pathways relevant for kidney function. Nat. Commun. 7, 10023 (2016). 
 22.      Teumer,A. et al. Genome-wide Association Studies Identify Genetic Loci 
Associated With Albuminuria in Diabetes. Diabetes 65, 803-817 (2016). 
 23.      Jansen,R. et al. Sex differences in the human peripheral blood transcriptome. 
BMC Genomics 15, 33 (2014). 
 24.      Wright,F.A. et al. Heritability and genomics of gene expression in peripheral 
blood. Nature Genetics 46, 430-437 (2014). 
 25.      Zhernakova,D.V. et al. Identification of context-dependent expression quantitative 
trait loci in whole blood. Nat. Genet. 49, 139-145 (2017). 
 26.      Westra,H.J. et al. Systematic identification of trans eQTLs as putative drivers of 
known disease assocations. Nature Genetics 1238-1243, (2013). 
 27.      Lappalainen,T. et al. Transcriptome and genome sequencing uncovers functional 
variation in humans. Nature 501, 506-511 (2013). 
 28.      Ramasamy,A. et al. Genetic variability in the regulation of gene expression in ten 
regions of the human brain. Nature Neuroscience 17, 1418-1428 (2014). 
74 
 
 
 
 29.      Koopmann,T.T. et al. Genome-wide identification of expression quantitative trait 
loci (eQTLs) in human heart. PLoS ONE 9, e97380 (2014). 
 30.      Bonder,M.J. et al. Disease variants alter transcription factor levels and 
methylation of their binding sites. Nat. Genet. 49, 131-138 (2017). 
 31.      Goedhart,A.D., van der Sluis,S., Houtveen,J.H., Willemsen,G., & de Geus,E.J. 
Comparison of time and frequency domain measures of RSA in ambulatory recordings. 
Psychophysiology 44, 203-215 (2007). 
 32.      Grossman,P., van Beek,J., & Wientjes,C. A comparison of three quantification 
methods for estimation of respiratory sinus arrhythmia. Psychophysiology 27, 702-714 
(1990). 
 33.      Wang,X., Thayer,J.F., Treiber,F., & Snieder,H. Ethnic differences and heritability 
of heart rate variability in African- and European American youth. The American 
Journal of Cardiology 96, 1166-1172 (2005). 
 34.      Neijts,M. et al. Heritability of cardiac vagal control in 24-h heart rate variability 
recordings: influence of ceiling effects at low heart rates. Psychophysiology 51, 1023-
1036 (2014). 
 35.      Goedhart,A.D., Willemsen,G., Houtveen,J.H., Boomsma,D.I., & de Geus,E.J. 
Comparing low frequency heart rate variability and preejection period: two sides of a 
different coin. Psychophysiology 45, 1086-1090 (2008). 
 36.      Reyes Del Paso,G.A., Langewitz,W., Mulder,L.J., van Roon,A., & Duschek,S. 
The utility of low frequency heart rate variability as an index of sympathetic cardiac 
tone: a review with emphasis on a reanalysis of previous studies. Psychophysiology 50, 
477-487 (2013). 
 37.      Monfredi,O. et al. Biophysical Characterization of the Underappreciated and 
Important Relationship Between Heart Rate Variability and Heart Rate. Hypertension 
64, 1334-U386 (2014). 
 38.      Vaez,A. et al. An in silico post-GWAS analysis of C-reactive proteing loci 
suggests an important role for interferons. Circulation: Cardiovascular Genetics 8, 487-
497 (2015). 
 39.      Berger,I. et al. Mitochondrial complex deficiency caused by a deleterious 
NDUFA11 mutation. Annals of Neurology 63, 405-408 (2008). 
 40.      Finsterer,J. Leigh and Leigh-like syndrome in children and adults. Pediatric 
Neurology 39, 223-235 (2008). 
 41.      Pfeufer,A. et al. Genome-wide association study of PR interval. Nature Genetics 
42, 153-159 (2010). 
75 
 
 
 
 42.      Folk,P., Puta,F., & Skruzny,M. Transcriptional coregulator SNW/SKIP: the 
concealed tie of dissimilar pathways. Cellular and Molecular Life Sciences 61, 629-640 
(2004). 
 43.      Xu,C. et al. Solution structure of human peptidyl prolyl isomerase-like protein 1 
and insights into its interaction with SKIP. The Journal of Biological Chemistry 281, 
15900-15908 (2006). 
 44.      Makinen,V.P. et al. Integrative genomics reveals novel molecular pathways and 
gene networks for coronary artery disease. PLoS Genetics 10, e1004502 (2014). 
 45.      Cao,P., Maximov,A., & Sudhof,T.C. Activity-dependent IGF-1 exocytosis is 
controlled by the Ca(2+)-sensor synaptotagmin-10. Cell 145, 300-311 (2011). 
 46.      Sudhof,T.C. Calcium control of neurotransmitter release. Cold Spring Harb 
Perspectives in Biology 4, a011353 (2012). 
 47.      Dunant,Y. & Cordeiro,J.M. Presynaptic K(+) channels, vesicular Ca(2+)/H (+) 
antiport--synaptotagmin, and acetylcholinesterase, three mechanisms cutting short the 
cholinergic signal at neuromuscular and nerve-electroplaque junctions. Journal of 
Molecular Neuroscience 53, 377-386 (2014). 
 48.      Oldham,W.M. & Hamm,H.E. Heterotrimeric G protein activation by G-protein-
coupled receptors. Nature Reviews Molecular Cell Biology 9, 60-71 (2008). 
 49.      Hossain,M.N., Sakemura,R., Fujii,M., & Ayusawa,D. G-protein gamma subunit 
GNG11 strongly regulates cellular senescence. Biochemical and Biophysical Research 
Communications 351, 645-650 (2006). 
 50.      Balcueva,E.A. et al. Human G protein gamma(11) and gamma(14) subtypes 
define a new functional subclass. Experimental Cell Research 257, 310-319 (2000). 
 51.      Yang,J. et al. RGS6, a modulator of parasympathetic activation in heart. 
Circulation Research 107, 1345-1349 (2010). 
 52.      Wydeven,N., Posokhova,E., Xia,Z., Martemyanov,K.A., & Wickman,K. RGS6, 
but not RGS4, is the dominant regulator of G protein signaling (RGS) modulator of the 
parasympathetic regulation of mouse heart rate. The Journal of Biological Chemistry 
289, 2440-2449 (2014). 
 53.      Milanesi,R., Bucchi,A., & Baruscotti,M. The genetic basis for inherited forms of 
sinoatrial dysfunction and atrioventricular node dysfunction. Journal of Interventional 
Cardiac Electrphysiology 43, 121-134 (2015). 
 54.      Milano,A. et al. HCN4 mutations in multiple families with bradycardia and left 
ventricular noncompaction cardiomyopathy. Journal of the American College of 
Cardiology 64, 745-756 (2014). 
76 
 
 
 
 55.      Wilson,N.H. & Key,B. Neogenin: one receptor, many functions. International 
Journal of Biochemistry and Cellular Biology 39, 874-878 (2007). 
 56.      Le Douarin,N.M. Embryonic neural chimaeras in the study of brain development. 
Trends in Neurosciences 16, 64-72 (1993). 
 57.      Vielmetter,J., Kayyem,J.F., Roman,J.M., & Dreyer,W.J. Neogenin, an avian cell 
surface protein expressed during terminal neuronal differentiation, is closely related to 
the human tumor suppressor molecule deleted in colorectal cancer. The Journal of Cell 
Biology 127, 2009-2020 (1994). 
 58.      Slorach,E.M. & Werb,Z. Epithelial morphogenesis: Netrin comes to a sticky and 
terminal end. Current Biology 13, R491-R493 (2003). 
 
 
Reviewer #1 (Remarks to the Author):  
 
The authors have done a comprehensive study of collecting and analyzing heart rate variability (HRV) 
data and further downstream bioinformatic analyses. They identified 17 independent SNPs in 8 loci. 
It comes as no surprise that the heart rate variability loci overlap considerably with heart rate loci. 
The multi-SNP risk score analysis showed that lower HRV predicted lower risk of atrial fibrillation 
(AF) and type 2 diabetes (T2D).  
 
Some questions that I would like answered in the discussion perhaps:  
1. The opening comment on how reduced vagal control (low HRV) is associated with increased risk 
for cardiac morbidity & mortality. I am not sure if I could get any sense if it is true towards the end of 
the paper. For most cardiometabolic traits (where public data is available), the risk score analysis is 
negative. The 2 significant findings were: multi-snp risk score for HRV SNPs (lower RMSSD & SDNN) 
show lower risk of atrial fibrillation (AF) and lower HRV was associated with lower risk of T2D. Later 
on, the authors mention a higher HRV in Rgs6-/- mice increased susceptibility to AV block & AF. It is a 
bit confusing.  
2. The variability in heart rate is when the control of sympathetic and/or para-sympathetic nervous 
system gets disturbed. Both these autonomic fibres are tonically active and there are many factors 
which affect this fine tuning and thereby variation in heart rate. There is mention that the cohorts in 
this study were healthy and did not take any medication affecting heart rate. How about caffeine 
intake before the time of measurements? This will increase the basal heart rate and dampen the 
variation in heart rate. Do you have any data to confirm ?  
3. The variation in SDNN is pretty vast (average ranges from ~20 to 760?) TRAILS-CC shows the 
maximum. The forest plot does not show the study as an outlier so probably it is not alarming?  
4. How relevant is blood as a cell type to make any conclusions on functional gene?  
5. I personally find forest plots easier to follow if they are sorted by effect size.  
6. I know that UK Biobank are measuring ECG and numerous other heart metrics but am not aware 
whether the data on heart rate variability is available yet or not? It will certainly add a lot of power 
to your results (with the unfortunate cost of delaying this paper).  
 
 
 
 
Reviewer #2 (Remarks to the Author):  
 The presented study contains a meta-analysis of genome-wide association studies for heart rate 
variability. In a two-stage procedure, the authors identify eight chromosomal loci associated with at 
least one of the three investigated heart rate variability traits, i.e., standard deviation of the normal-
to-normal inter beat intervals, root mean square of the successive differences of inter beat intervals, 
and peak-valley respiratory sinus arrhythmia or high frequency power. As proteins encoded by genes 
that have been identified in this analysis are involved in cardiac pacemaker function, the authors 
claim to provide mechanistic insight into the functional biology underlying the genetic association.  
 
The study is the result of a large effort. The authors are well qualified for this type of analysis and 
the analysis plan is linearly conceived. There are, however, a few issues that need to be addressed.  
 
Major comments  
1. This study is the thus far largest meta-analysis on this topic. To this reviewer, no comparable 
study is known. The primary claims, i.e., the association of the reported chromosomal loci with heart 
rate variability measures, are convincing. In this light, further analyses aiming to elucidate a 
functional role of the detected variants are speculative and of uncertain value (e.g., blood eQTLs 
rather than cardiomyocyte eQTLs). Thus, the “Potential functional HRV variants“ and “Network and 
functional enrichment analyses” sections as well as the corresponding Discussion sections should be 
shortened.  
2. The authors mention the association of heart rate variability with a number of diseases. 
Here, a heart rate variability loci multi-SNP risk score was only associated with atrial fibrillation but 
not coronary artery disease, type 2 diabetes… In this reviewer’s opinion, this indicates that heart 
rate variability changes are indeed rather a consequence of the particular diseases. This should be 
briefly discussed.  
3. The most interesting finding in this study to this reviewer is the association of variants in the 
GNG11, RGS6, and HCN4 genes with heart rate variability. The paper would be strengthened by 
functional data directly investigating a mechanistic role of the identified SNPs as discussed by the 
authors (p12, l273-p13, l281).  
4. The Discussion is very much focused on the potential pathophysiological influence of the 
variants. The Discussion would benefit from a focus on rather the genetic findings than speculative 
implications.  
 
 
Minor comments  
1. Clear written English. Many abbreviations making the paper difficult to read. Careful revision 
suggested.  
2. Clear tables. Figure 1 ok. Figure 2 confusing, speculative, should be revised.  
 
 
Reviewer #3 (Remarks to the Author):  
 
This manuscript details a large scale, two stage GWAS of three heart rate variability (HRV) traits 
followed by some in silico functional annotation. HRV is associated with increased risk of sudden 
cardiac death and all-cause mortality, and has previously been shown to be heritable, suggesting an 
important genetic component but a large scale GWAS of these traits has not been previously 
conducted. The authors perform a large number of statistical analyses and find associations in 8 loci, 
several of which have been previously associated with heart rate and are biologically plausible 
candidates for regulating HRV, but additional ones that may be independent of HR.  
 
The strengths of the study are in the very large sample size (up to N=53000) with a two-staged 
discovery and validation and subsequent meta-analysis approach, the somewhat novel phenotype 
that has been incompletely evaluated at a genetic level, evaluation in non-Caucasian populations, 
triangulating results to assess prediction of GWAS identified loci with incident events using genotype 
risk scores, and some in silico functional analysis (with the caveats that that information was not 
particularly informative).  
 
There are however, several issues that temper enthusiasm for the study. The results are likely only 
incremental in our understanding of cardiac sinus node regulation as many of the loci have already 
been shown to be associated with heart rate itself and thus the results likely represent the fact that 
these variants regulate heart rate and it is known that resting heart rate is correlated with HRV. 
Thus, the authors should adjust for resting heart rate in all of their analyses to provide a context for 
true novel findings for HRV vs. those known to affect sinus node regulation through their known 
effects on resting HR. The authors did do a “look up” in GWAS of heart rate to pull p-values for their 
HRV loci, but this is insufficient to address this issue. The other major concern is the heterogeneity of 
the ways HRV was assessed in each cohort including cohorts that included very short tracings. At the 
minimum, sensitivity analyses of cohorts that have a full 24 hours of tracings to determine HRV 
should be done. More minor issues are the lack of functional data, particularly for the novel loci and 
the large number of analyses that make the manuscript somewhat difficult to follow (adding a figure 
of study flow with what adjustments for multiple comparisons were made at each stage would be 
helpful to address this). 
Some more minor questions/issues:  
1) The authors need to provide justification for their p-value threshold which is not corrected for the 
number of traits analyzed.  
2) How correlated were the three HRV traits in their data?  
3) What was were the imputation scores for the top loci?  
4) Only a small amount of variance in the trait is explained by their loci; although not unexpected the 
authors should comment on the clinical significance of that.  
5) Please include OR for prediction of risk for incident events.  
6) The first paragraph on page 10 is difficult to understand and it is not clear what set of analyses 
those represent. Was the GSEA done using the RNA microarray data from the subset that had that 
done on whole blood for HRV traits themselves?  
7) Given the linear models used, did the HRV traits meet critera for parametric analyses after log 
transformation? This is particularly necessary for the SOLAR analyses that are very sensitive to 
deviations in normality.  
8) Was the genomic inflation rate for each stage?  
9) Please include a reference for the “double genomic control correction”  
10)  
 
 
 
 
Rebecca Furlong 
Senior Editor 
Nature Communications 
 
Dear Dr. Furlong, 
 
Thank you for the invitation to revise and resubmit our manuscript “Identification of genetic 
loci associated with heart rate variability and their effects on heart rate and cardiac disease 
risk.” to Nature Communications. We were very pleased with the overall positive reception of 
this first ever GWA meta-analysis (N=53,174) on heart rate variability (HRV), a trait widely 
used in cardiology to characterize vagal control of heart rate for which no robustly associated 
loci had previously been identified. 
 
The reviewers’ comments have provided excellent guidance and we believe this revised 
version is a clear improvement over the original. We are grateful to the reviewers for their 
constructive comments.  
 
Three major changes were made that can be summarized as: 
 
- As suggested by the reviewers, we reduced the sections on functional in silico annotations of 
the HRV variants as well as the corresponding Discussion sections. These were indeed 
inherently somewhat speculative. 
- We added a number of additional analyses to address reviewers’ concerns, including the full 
genetic correlations between HRV and the disease risk factors/endpoints [by going back to the 
various consortia and retrieving their full GWAS summary stats], a series of analyses 
addressing the dependency of HRV on HR, and a sensitivity analysis testing potential 
laboratory/ambulatory heterogeneity in the HRV phenotypes across participating cohorts. 
- We have improved our discussion on the potential functional relevance of the genetic 
variants and illustrated in Figure 2 by better indicating which elements were based on existing 
knowledge on sinoatrial node signalling and which on the new hypothesized effects of the 
three genetic variants that were identified in the current study. 
 
Many additional changes were made in this revision. A full point-by-point reply to the 
reviewers and your editorial request is given in a separate document. Resulting changes in the 
manuscript have all been highlighted.  
 
We again thank you for handling our manuscript and your willingness to consider it for 
publication after satisfactory revision. 
 
Yours sincerely, 
 
Ilja Nolte, Harold Snieder and Eco de Geus 
on behalf of the VgHRV consortium  
EDITORIAL REQUEST 
Please ensure that the following requirements are met, and any relevant checklist is completed 
and uploaded as a Related Manuscript file type with the revised article. 
 
REPLY 
The revision closely follows the reporting requirements in:  
http://www.nature.com/article-assets/npg/ncomms/authors/ncomms_lifesciences_checklist.pdf  
and the format requirements in: 
http://www.nature.com/article-assets/npg/ncomms/authors/ncomms_manuscript_checklist.pdf 
 
 
REVIEWERS REMARKS TO THE AUTHORS 
 
Reviewer #1  
 
The authors have done a comprehensive study of collecting and analysing heart rate 
variability (HRV) data and further downstream bioinformatics analyses. They identified 17 
independent SNPs in 8 loci. It comes as no surprise that the heart rate variability loci overlap 
considerably with heart rate loci. The multi-SNP risk score analysis showed that lower HRV 
predicted lower risk of atrial fibrillation (AF) and type 2 diabetes (T2D). 
Some questions that I would like answered in the discussion perhaps: 
 
COMMENT 
1. The opening comment on how reduced vagal control (low HRV) is associated with 
increased risk for cardiac morbidity & mortality. I am not sure if I could get any sense 
if it is true towards the end of the paper. For most cardiometabolic traits (where public 
data is available), the risk score analysis is negative.  
REPLY 
You are correct; this was confusing. Absence of an association likely arose because 
we only requested the consortia to lookup effects on the disease phenotypes for our 17 
genome-wide SNPs for HRV. Although this risk score analysis makes good sense, the 
variance explained in HRV by these top SNPs is small, and HRV will only be one of 
many risk factors for these disease outcomes. This approach therefore has modest 
power to detect an association between the HRV SNPs and the disease outcomes, and 
failure to find the association is not prove of its absence. For the revision we re-
contacted the original consortia for these disease risk factors and endpoints with a 
request to provide us with the full GWAS summary statistics so that we could 
compute the genetic correlation between HRV and these disease risk factors/endpoints 
using LD Score regression. We have added the genetic correlations to the results 
section with full details in Supplementary Table 11. As you will see the genetic 
correlations systematically pointed to an overlap in the genetic variants causing low 
HRV and increased risk for disease (i.e., negative correlations with e.g. SBP, DBP, 
Coronary Artery Disease, Heart Failure, Sudden Cardiac Death, BMI, and T2D) 
although significance was reached only for blood pressure after correction for number 
of outcomes tested. Atrial fibrillation was still positively correlated to low HRV, but 
we find the correlation unconvincing. Also the heterogeneity tests in gtx are now 
considered suboptimal, and we removed these tests. LD Score regression results are 
more telling than just the plots of the non-heterogeneous top SNPs in previous 
Supplementary Figures 7 and 8. We removed these figures and had to retrace our steps 
regarding a clear AF – HRV connection, which we now consider too weak to interpret. 
We adapted the discussion to reflect this developing wisdom.  
“Using LD Score regression on meta-GWAS summary statistics from various risk 
factors and endpoints we find some evidence for overlap in the genetic variants 
causing low HRV and increased risk for disease, but significance was reached only for 
systolic and diastolic blood pressure after correction for multiple outcomes tested. 
These genetic correlations are compatible with causal effects of cardiac vagal control 
in the etiology of disease, but they could also be ascribed to reversed causality, where 
the disease process leads to lower cardiac vagal control. A strength of this study in 
this regard is that analyses were confined to individuals in good cardiac health, i.e. 
cohorts excluded patients with existing cardiovascular diseases or medication 
potentially impacting HRV. Because we selected individuals in good cardiac health 
reverse effects of disease on HRV seems less likely, although some latent pathology 
could have been present. However, an alternative explanation that is harder to rule 
out is that the genetic correlation derives from pleiotropic effects of genetic variants 
common to both outcomes.” 
 
COMMENT 
The 2 significant findings were: multi-snp risk score for HRV SNPs (lower RMSSD & 
SDNN) show lower risk of atrial fibrillation (AF) and lower HRV was associated with 
lower risk of T2D. Later on, the authors mention a higher HRV in Rgs6-/- mice 
increased susceptibility to AV block & AF. It is a bit confusing. 
REPLY 
Based on the added results on the disease risk factors/endpoints using LD Score 
regression we can no longer maintain that there is a clear AF – HRV connection. The 
results of the genetic correlation between HRV and T2D, although only marginally 
significant for SDNN (r=-0.26, p=0.01), are now much more in line with the 
expectation based on the studies showing a phenotype of lower HRV in diabetes 
patients.  
 
COMMENT 
2. The variability in heart rate is when the control of sympathetic and/or para-
sympathetic nervous system gets disturbed. Both these autonomic fibres are tonically 
active and there are many factors which affect this fine tuning and thereby variation in 
heart rate. There is mention that the cohorts in this study were healthy and did not take 
any medication affecting heart rate. How about caffeine intake before the time of 
measurements? This will increase the basal heart rate and dampen the variation in 
heart rate. Do you have any data to confirm?  
REPLY 
Systematic information on pre-experimental use of either caffeine or nicotine was not 
gathered by all cohorts. We acknowledge potential effects of these substances on HRV 
but also note that the basal idea of GWAS meta-analysis is to be robust against 
differences in exact phenotyping. Furthermore, caffeine seems to influence heart rate 
mainly through sympathetic (and not vagal) effects, illustrated amongst others by 
direct sympathetic nerve recordings after caffeine infusion1. Nonetheless, to address 
the concern of the reviewer we added the lack of strict pre-recording standardization 
on caffeine use, alcohol, smoking, and physical activity as a limitation of this study. 
“Finally, instructions on pre-ECG recording behaviors like physical activity, and 
caffeine, alcohol, or nicotine use were not rigorously standardized across cohorts.” 
 
COMMENT 
3. The variation in SDNN is pretty vast (average ranges from ~20 to 760?) TRAILS-CC 
shows the maximum. The forest plot does not show the study as an outlier so probably 
it is not alarming? 
REPLY 
This is an astute observation by the reviewer and we apologize for our own oversight. 
It led us to revisit the TRAILS-CC cohort. An unfortunate mistake was made in the 
prepared data by this cohort where we misplaced the decimal point for SDNN, which 
means it was a factor 10 too high. The cohort means have now been corrected in the 
Supplementary Table 3. 
Note that this had no effect on the GWA results because we used log SDNN in this 
analysis. The factor 10 disappears in the intercept: 
log(10*SDNN)=log(10)+log(SDNN), leaving estimates of betas as reported in Tables 
and Forest plots correct.  
 
COMMENT 
4. How relevant is blood as a cell type to make any conclusions on functional gene? 
REPLY 
This is of course a valid point, and only future research will provide the answer in full. 
We certainly do not contest that large eQTL databases on heart tissue, or ideally SA 
and AV nodes would certainly have been preferred, but such databases are currently 
small (for heart, see our Koopmans and GTEx analysis in Supplementary Table 15) or 
non-existent (for SA node). That does not, however, mean that the identified eQTLs in 
blood cannot reflect the presence of an eQTL in another more relevant tissue. For 
many disease traits, including psychiatric disorders2, 3, the SNPs identified with 
GWAS do contain eQTLs in blood even if the primary organ affected is clearly not 
hematological. In keeping, it has been shown that eQTLs are only partly tissue 
specific: almost 55% of blood eQTLs are also heart eQTLs for example4 (see Figure 
2B from this reference below).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B from4. From the legend: 'Dendrogram 
and heat map of pairwise eQTL sharing ... π1 = 
Pr(eQTL in tissue i given an eQTL in tissue j)'  
 
Our whole blood eQTL examinations in three different independent databases were 
well powered as these make up the largest eQTL databases in humans. Please note in 
Supplementary Table 15 that we detect eQTLs for RGS6, HCN and GNG11 in the 
discovery database (NESDA/NTR) and then replicate all three in either a second 
(BIOS) or third (Westra et al.) blood eQTL database. We also replicate the GNG11 
blood eQTL in two other tissues (tibial artery and medulla).  
 
COMMENT 
5. I personally find forest plots easier to follow if they are sorted by effect size. 
REPLY 
We did consider various ways of sorting and believe the one used here is optimal. A 
clear disadvantage of the proposed ordering by the reviewer is that the cohorts would 
be ranked differently for each SNP. This makes it, e.g. much harder to detect whether 
a single cohort or cohorts with a specific choice of HRV phenotyping (for instance 
using 24-hours) somehow stand out from all other cohorts across more than one of the 
lead SNPs. 
 
COMMENT 
6. I know that UK Biobank are measuring ECG and numerous other heart metrics but am 
not aware whether the data on heart rate variability is available yet or not? It will 
certainly add a lot of power to your results (with the unfortunate cost of delaying this 
paper).  
REPLY 
Indeed, UKB has not done this and de novo scoring of the raw ECG data files to 
obtain the HRV metrics used in our own cohorts is non-trivial. Even so, our more 
important concern is that the UKB measured the ECG only during a bicycle exercise 
test, and its recovery phase, which are inherently poorly standardized. Unfortunately, 
no clearly defined sitting/supine resting ECG recordings are available. We could 
extract ~15 secs of stable ECGs before biking onset in some subjects suggesting that 
they were seated on the bike before actual pedaling started. Such a baseline is known 
to contain a strong anticipatory (fight-flight) activation of the autonomic nervous 
system and can be expected to deviate rather strongly from our resting ECG 
phenotype.  
 
 
Reviewer #2  
 
COMMENT 
The presented study contains a meta-analysis of genome-wide association studies for heart 
rate variability. In a two-stage procedure, the authors identify eight chromosomal loci 
associated with at least one of the three investigated heart rate variability traits, i.e., standard 
deviation of the normal-to-normal inter beat intervals, root mean square of the successive 
differences of inter beat intervals, and peak-valley respiratory sinus arrhythmia or high 
frequency power. As proteins encoded by genes that have been identified in this analysis are 
involved in cardiac pacemaker function, the authors claim to provide mechanistic insight into 
the functional biology underlying the genetic association. 
The study is the result of a large effort. The authors are well qualified for this type of analysis 
and the analysis plan is linearly conceived. There are, however, a few issues that need to be 
addressed. 
 
COMMENT 
1. This study is the thus far largest meta-analysis on this topic. To this reviewer, no 
comparable study is known. The primary claims, i.e., the association of the reported 
chromosomal loci with heart rate variability measures, are convincing. In this light, 
further analyses aiming to elucidate a functional role of the detected variants are 
speculative and of uncertain value (e.g., blood eQTLs rather than cardiomyocyte 
eQTLs). Thus, the “Potential functional HRV variants” and “Network and functional 
enrichment analyses” sections as well as the corresponding Discussion sections should 
be shortened. 
REPLY 
Given similar concerns of the other reviewers we have trimmed the “Potential 
functional HRV variants” section removing previous Supplementary tables 16 and 17. 
We also moved the “Network and functional enrichment analyses” section in its 
entirety from the main text to the Supplementary Note. The corresponding Discussion 
sections were trimmed accordingly. With regard to the eQTL (and also mQTL) 
analyses we beg to differ. We certainly do not contest that large eQTL databases on 
heart tissue, or ideally SA and AV nodes would certainly have been preferred but such 
databases are currently small (for heart, see our Koopmans and GTEx analysis in 
Supplementary Table 15) or non-existent (for SA node). That does not however mean 
that the identified eQTLs in blood cannot reflect the presence of an eQTL in another 
more relevant tissue. For many disease traits, including psychiatric disorders2, 3, the 
SNPs identified with GWAS do contain eQTLs in blood even if the primary organ 
affected is clearly not haematological. In keeping, it has been shown that eQTLs are 
only partly tissue specific: almost 55% of blood eQTLs are also heart eQTLs for 
example4 (see Figure 2B from this reference below).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2B from4. From the legend: 'Dendrogram and 
heat map of pairwise eQTL sharing ... π1 = Pr(eQTL 
in tissue i given an eQTL in tissue j)'  
 
Our whole blood eQTL examinations in three different independent databases were 
well powered as these make up the largest eQTL databases in humans. Please note in 
Supplementary Table 15 that we detect eQTLS for RGS6, HCN and GNG11 in the 
discovery database (NESDA/NTR) and then replicate all three in either a second 
(BIOS) or third (Westra et al.) blood eQTL database. We also replicate the GNG11 
blood eQTL in two other tissues (tibial artery and medulla). 
 
COMMENT 
2. The authors mention the association of heart rate variability with a number of diseases. 
Here, a heart rate variability loci multi-SNP risk score was only associated with atrial 
fibrillation but not coronary artery disease, type 2 diabetes… In this reviewer’s 
opinion, this indicates that heart rate variability changes are indeed rather a 
consequence of the particular diseases. This should be briefly discussed. 
REPLY 
We fear that absence of the expected associations arose because we only requested the 
consortia to lookup effects on the disease phenotypes for our 17 genome-wide SNPs for 
HRV. Although this makes good sense, the variance explained in HRV by these top SNPs 
is small, and HRV will only be one of many risk factors for these disease outcomes. This 
approach, therefore, has modest power to detect an association between the HRV SNPs 
and the disease outcomes, and failure to find the association is not prove of its absence. 
For the revision we re-contacted the original consortia for these disease risk factors and 
endpoints with a request to provide us with the full GWAS summary statistics so that we 
could compute the genetic correlation between HRV and these disease risk 
factors/endpoints using LD Score regression.  
We have added the genetic correlations to the results section with full details in 
Supplementary Table 11. As you will see the genetic correlations systematically pointed 
to an overlap in the genetic variants causing low HRV and increased risk for disease (i.e., 
negative correlations with e.g. SBP, DBP, Coronary Artery Disease, Heart Failure, 
Sudden Cardiac Death, BMI, and T2D) although significance was reached only for blood 
pressure after correction for number of outcomes tested. The genetic correlations could of 
course still be caused by genetic variants for disease as the primary driver, with disease 
causing low HRV. A strength of this study in this regard is that analyses were confined to 
individuals in good cardiac health, i.e. cohorts excluded patients with existing 
cardiovascular diseases or medication potentially impacting HRV. Therefore, our results 
are compatible with reduced vagal control as a potential risk factor for detrimental 
cardiovascular outcomes. Even so, the text of our revised discussion still allows for 
pleiotropy and latent pathology as potential alternatives: “Using LD Score regression on 
meta-GWAS summary statistics from various risk factors and endpoints we find some 
evidence for overlap in the genetic variants causing low HRV and increased risk for 
disease, but significance was reached only for systolic and diastolic blood pressure after 
correction for multiple outcomes tested. These genetic correlations are compatible with 
causal effects of cardiac vagal control in the etiology of disease, but they could also be 
ascribed to reversed causality, where the disease process leads to lower cardiac vagal 
control. A strength of this study in this regard is that analyses were confined to 
individuals in good cardiac health, i.e. cohorts excluded patients with existing 
cardiovascular diseases or medication potentially impacting HRV. Because we selected 
individuals in good cardiac health reverse effects of disease on HRV seems less likely, 
although some latent pathology could have been present. However, an alternative 
explanation that is harder to rule out is that the genetic correlation derives from 
pleiotropic effects of genetic variants common to both outcomes.” 
 
Please note that atrial fibrillation was still positively correlated to low HRV, but we find 
the correlation unconvincing. LD Score regression results are more telling than just the 
plots of the non-heterogeneous top SNPs in previous Supplementary Figures 7 and 8. We 
removed these figures and had to retrace our steps regarding a clear AF – HRV connection 
after removal of the two heterogeneous SNPs, a connection we now consider too weak to 
interpret. We adapted the discussion by removing the previous emphasis on AF to reflect 
this developing wisdom. 
 
COMMENT 
3. The most interesting finding in this study to this reviewer is the association of variants 
in the GNG11, RGS6, and HCN4 genes with heart rate variability. The paper would be 
strengthened by functional data directly investigating a mechanistic role of the 
identified SNPs as discussed by the authors (p12, l273-p13, l281).  
REPLY 
To inspire further experimental work to elucidate the mechanistic role of the identified 
loci we performed post-GWAS annotation of the HRV SNPs for which we added a 
flow chart in Supplementary Figure 7 describing the various steps. However, in view 
of the non-experimental and therefore speculative nature of these analyses we 
removed them from the main text, adding them to the Supplementary Note. 
 
COMMENT 
4. The Discussion is very much focused on the potential pathophysiological influence of 
the variants. The Discussion would benefit from a focus on rather the genetic findings 
than speculative implications. 
REPLY 
We beg to differ of opinion. Much of our discussion is based on Figure 2 that may 
erroneously have been conceived by the reviewer to have been ‘made up’ based on the 
current findings. That is not correct. On the contrary, Figure 2 is for the most part 
based on a very extensive well-established body of knowledge on SA-node signalling 
pathways– our only addition is the potential effects of the newly identified genetic 
variants for HRV. We believe these fit and extend this existing body of knowledge in 
a rather convincing way, although we agree that these hypothesized effects of the 
HRV variants should be confirmed by experimental evidence, using e.g. knock down 
variants in valid animal models of HRV.  
We take responsibility for inviting this concern from the reviewer by citing 
only a tiny fragment of the extant literature that supports Figure 2 (so as to comply 
with the limit placed by the author guidelines on references). We have tried to amend 
this in the revised version of the legend of the Figure and in the substantially revised 
version of the discussion.  
 
MINOR COMMENTS 
1. Clear written English. Many abbreviations making the paper difficult to read. Careful 
revision suggested. 
REPLY 
 More of the abbreviations (unless they are used more than 10 times like HRV, or 
commonly accepted like eQTL) are now spelled out in full. All abbreviations are now 
defined before they are used and an abbreviation list is added to the Supplementary 
Information. 
 
2. Clear tables. Figure 1 ok. Figure 2 confusing, speculative, should be revised. 
REPLY 
Please see our response to your comment 4 above. 
 
 
Reviewer #3  
 
This manuscript details a large scale, two stage GWAS of three heart rate variability (HRV) 
traits followed by some in silico functional annotation. HRV is associated with increased risk 
of sudden cardiac death and all-cause mortality, and has previously been shown to be 
heritable, suggesting an important genetic component but a large scale GWAS of these traits 
has not been previously conducted. The authors perform a large number of statistical analyses 
and find associations in 8 loci, several of which have been previously associated with heart 
rate and are biologically plausible candidates for regulating HRV, but additional ones that 
may be independent of HR.  
The strengths of the study are in the very large sample size (up to N=53000) with a two-
staged discovery and validation and subsequent meta-analysis approach, the somewhat novel 
phenotype that has been incompletely evaluated at a genetic level, evaluation in non-
Caucasian populations, triangulating results to assess prediction of GWAS identified loci with 
incident events using genotype risk scores, and some in silico functional analysis (with the 
caveats that that information was not particularly informative). There are however, several 
issues that temper enthusiasm for the study. 
 
COMMENT 
“.. and some in silico functional analysis (with the caveats that that information was not 
particularly informative) “ 
REPLY  
Given similar concerns of the other reviewers we have removed the “Network and 
functional enrichment analyses” sections from the main text. It was reorganized, 
shortened, and placed in the Supplementary Note. 
 
COMMENT 
The results are likely only incremental in our understanding of cardiac sinus node regulation 
as many of the loci have already been shown to be associated with heart rate itself and thus 
the results likely represent the fact that these variants regulate heart rate and it is known that 
resting heart rate is correlated with HRV. Thus, the authors should adjust for resting heart rate 
in all of their analyses to provide a context for true novel findings for HRV vs. those known to 
affect sinus node regulation through their known effects on resting HR. The authors did do a 
“look up” in GWAS of heart rate to pull p-values for their HRV loci, but this is insufficient to 
address this issue.  
REPLY 
With this comment the reviewer addresses the complexity of the heart rate – HRV 
relationship, and we begin by admitting that we clearly did not address this important 
issue in a satisfactory way in the previous version. However, the solution by the 
reviewer – to correct HRV association analyses for the resting heart rate as a covariate 
- may also not give sufficient credit to this complex relationship. Indeed, all three 
measures used by us (SDNN, RMSSD, and pvRSA/HF) are known to be inversely 
proportional to heart rate. Two parallel mechanisms account for this. The first is 
unrelated to the underlying biology but simply reflects the definition of HRV. That is, 
the slower the heart rate, the longer the inter beat interval, and therefore, any 
proportionally minor beat-to-beat differences in inter beat interval are more 
pronounced at slower heart rates. Hence the strong inverse correlation between 
measures of HRV and heart rate are at least in part due to the manner in which HRV is 
defined 5-7 . This alone will cause significant overlap between the genetics of HRV and 
genetics of heart rate. At the same time, a host of evidence shows that an increase in 
vagal tone (e.g. by pharmacological means) leads to both decreased heart rate and 
increased HRV 8-13. This fits with current biological understanding of the autonomic 
regulation of the pacemaker frequency where increased vagal activity, for which HRV 
is a valid index, is known to causally reduce heart rate.  
The complexity that arises in the HRV – heart rate relationship is twofold: 
- If that relationship would be dominated by a causal effect of heart rate on HRV, all 
SNPs for heart rate should have an effect on HRV. They clearly do not (see 
Supplementary Table 21). 
- If that relationship would be dominated by a causal effect of vagal activity on both 
HRV and heart rate, under the strong assumption that HRV is a perfect index of 
cardiac vagal activity, all HRV SNPs should influence heart rate. Most do but 
certainly not all (see Supplementary Table 10). However, we already know that the 
strong assumption that HRV perfectly indexes cardiac vagal activity is violated, 
because as we point out in the discussion, HRV also reflects “ individual 
differences in: (i) resting respiration rate and depth 14; (ii) the amplitude of the 
intrinsic 0.1 Hz oscillations related to both vagal and sympathetic blood pressure 
regulation through the baroreflex loops 15; (iii) mechanotransduction or 
intracellular pathways stimulated by sinoatrial stretch 16 or (iv) the efficiency of 
the actual respiratory-vagal gating process 17, 18.” 
 
So, we are faced with the conundrum that HRV is a good measure of vagal activity but 
not a perfect one. Focusing on SNPs that influence HRV only (but not heart rate) may 
lead us to biology that is actually unrelated to cardiac vagal activity, our main trait of 
interest. However, simply correcting HRV for heart rate may “throw out the baby with 
the bathwater” because a substantial part of the genetic variants for cardiac vagal 
activity will take the brunt (because they influence heart rate through vagal activity).  
 
With this caveat in mind, the revised version reports on three additional analyses that 
correct HRV for resting heart rate. First, we used the coefficient of variation of SDNN 
and RMMSD that corrects for its dependency on the mean heart rate (or more 
correctly inter beat interval). The coefficient of variation is a measure of spread that 
describes the amount of inter beat interval variability relative to the mean inter beat 
interval of each subject, and was recently revived by us to get rid of the 
proportionality-based dependence of HRV and heart rate19. Using the coefficients of 
variation we corrected the meta-analytic results of SDNN and RMSSD with the meta-
analytic summary statistics from the resting heart rate meta-analysis, using GWIS20, an 
analytical approach that can compute the GWAS summary statistics for a 
mathematical equation-derived variable using the summary statistics of the 
constituting variables used in the equation. The equations we used to correct HRV for 
heart rate were 
- (SDNN/X)*100%  
- (RMSSD/X)*100% 
where X is the mean resting inter beat interval which we define as: X=60000/heart 
rate, because the resting heart rate GWAS meta-analysis used heart rate in beats per 
minute, not the inter beat interval. As the coefficients of variation were skewed we 
used a natural logarithm transformation. Genome-wide significant results of the 
analyses of these log-transformed coefficients of variation are in the new 
Supplementary Table 9.Similar analyses could not be performed for pvRSA/HF as 
effect sizes for pvRSA and HF were not comparable for this combination measure (for 
this reason we conducted a z-score based meta-analysis for pvRSA/HF). 
Secondly, we established the effect of the 17 genome-wide significant SNPs on 
ln((SDNN/mean inter beat interval)*100%) and ln((RMSSD/mean inter beat 
interval)*100%) in Lifelines, NESDA, and TRAILS-Pop, and meta-analyzed the 
results. 
Thirdly, we established the effect of the 17 genome-wide significant SNPs using heart 
rate as a covariate as suggested by the reviewer in Lifelines, NESDA and TRAILS-
Pop, and meta-analyzed the results. As part of this analysis we also calculated the % of 
the SNP effects on HRV mediated by heart rate and the significance of this mediation 
using a Sobel test. 
 
We now compared the effect sizes and significance before and after these different 
corrections for heart rate in the new Supplementary Table 9. The overarching 
conclusion is that we indeed attenuate some of the HRV SNP effects (in part by 
overcorrecting a true vagal effect on heart rate and HRV) on average by ~28% 
(according to the Sobel test of mediation) but the correction for heart rate does not 
remove the significance of the HRV SNP effects on HRV.  
 
We have added a new section “Correcting HRV for heart rate” to the Results to 
describe these three additional analyses. 
 
 
COMMENT 
The other major concern is the heterogeneity of the ways HRV was assessed in each cohort 
including cohorts that included very short tracings. At the minimum, sensitivity analyses of 
cohorts that have a full 24 hours of tracings to determine HRV should be done.  
REPLY 
We performed the requested sensitivity analyses for our 17 top SNPs. That is, we 
conducted analyses on only the 4 cohorts (CHS, FHS, FINGESTURE, ULSAM) using 
2-24-hour ambulatory recordings in which posture and activity was not carefully 
standardized, and compared the results with those from all other cohorts that used 
laboratory rest recordings. We added these results to a new Supplementary Table 8. 
We can now report that “Separately meta-analyzing across cohorts with short 
laboratory rest recordings versus longer term ambulatory recordings did not suggest 
sensitivity of the results to these different recording methods (Supplementary Table 
8).” 
 
In addition we point the reviewer to the large correspondence in effect sizes across the 
various cohorts as shown in the forest plots (Supplementary Information) for our top 
SNPs and we added the (generally low) I2 values of the meta-analysis to 
Supplementary Table 5 confirming that there was little heterogeneity across cohorts. 
 
MINOR COMMENTS 
More minor issues are the lack of functional data, particularly for the novel loci  
and the large number of analyses that make the manuscript somewhat difficult to follow 
(adding a figure of study flow with what adjustments for multiple comparisons were made at 
each stage would be helpful to address this). 
REPLY 
To inspire further experimental work to elucidate the functional impact of the 
identified loci we performed post-GWAS annotation of the HRV SNPs for which we 
added a flow chart in Supplementary Figure 7 describing the various steps. However, 
in view of the non-experimental and therefore speculative nature of these analyses we 
removed the gene network and tissue enrichment analyses from the main text, adding 
them to the Supplementary Note. 
We further simplified the analytical approach using headers in the main text to 
guide the readership through the main steps: New loci associated with HRV; Variance 
explained; Generalization to other ethnicities; Association of the HRV variants with 
resting heart rate; Correcting HRV for heart rate; Association with cardiometabolic 
traits and diseases; Potential functional impact of the HRV variants”. 
 
Some more minor questions/issues: 
1) The authors need to provide justification for their p-value threshold which is not corrected 
for the number of traits analysed. 
REPLY 
Because the HRV traits are highly correlated (please see below), Bonferroni 
adjustment for multiple testing should be considered too strict. Even so, using this 
correction all genome-wide signals remain significant and we have adjusted the text 
and footnote to Table 1 accordingly.  
 
2) How correlated were the three HRV traits in their data? 
REPLY 
An oversight. Possibly induced by the fact that there are many publications addressing 
the phenotypic correlations between these measures. They seldom reported lower 
correlations than 0.721-23. For completeness we now report in the Supplementary Note 
the correlations in three of our larger cohorts covering all possible combinations of 
pvRSA or HF with SDNN and RMSSD: “We confirmed the phenotypic correlations 
in the TRAILS-Pop, NESDA, and Lifelines cohorts where they ranged from 0.70 
(SDNN-pvRSA/HF) to 0.96 (RMSSD-pvRSA/HF).” 
 
3) What were the imputation scores for the top loci? 
REPLY 
We added the imputation scores (median [interquartile range]) to Supplementary 
Table 5. 
 
4) Only a small amount of variance in the trait is explained by their loci; although not 
unexpected the authors should comment on the clinical significance of that. 
REPLY 
We added this caveat to the discussion: “Direct clinical relevance of most current 
GWAS findings is still low and our study is no exception.” 
 
5) Please include OR for prediction of risk for incident events. 
REPLY 
With the exception of HF, we did not perform lookups in GWAS for incident disease 
(only prevalent for AF, CAD, SCD, T2D). ORs and betas for continuous outcomes are 
reported for the GRSs based on the SNP lookups in Supplementary Table 11. Please 
note, we now also report in the same table the genetic correlations based on LD score 
regression of the full GWAS summary statistics of all clinical outcomes.  
 
6) The first paragraph on page 10 is difficult to understand and it is not clear what set of 
analyses those represent. Was the GSEA done using the RNA microarray data from the subset 
that had that done on whole blood for HRV traits themselves? 
REPLY 
We rephrased this paragraph as it clearly led to misunderstanding. Here we did not use 
RNA microarray data of subjects involved in the cohorts of the HRV meta-analysis. 
DEPICT works based on existing in silico databases. The corrected text now reads: 
“In silico tissue enrichment analysis using DEPICT24highlights a role for hormones in 
HRV regulation, with enrichment for the adrenal cortex, endocrine glands, gonads, 
gastrointestinal tract and female reproductive organs (Supplementary Fig. 9a,c,e). 
Gene-set enrichment analysis using DEPICT highlights the importance of cardiac 
development (Supplementary Fig. 9b,d,f)."  
 
7) Given the linear models used, did the HRV traits meet criteria for parametric analyses after 
log transformation? This is particularly necessary for the SOLAR analyses that are very 
sensitive to deviations in normality. 
REPLY 
In the description of the Oman family study we now made clear that we used a log 
transformation for all three HRV measures. To allay the reviewers’ concern: after log 
transformation values for skewness and kurtosis for SDNN (skewness = 0.08; kurtosis 
= 3.81), RMSSD (skewness = -0.34; kurtosis = 3.00) and HF (skewness = 0.05; 
kurtosis = 3.25) closely resembled those of a normal distribution (skewness = 0; 
kurtosis = 3.0). 
 
8) Was the genomic inflation rate for each stage? 
REPLY 
We added the per-cohort genomic control lambda to Supplementary Table 4. 
 
9) Please include a reference for the “double genomic control correction” 
REPLY 
We added a reference on double genomic control correction25, which was earlier 
applied in a GWAS meta-analysis for body mass26. 
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Reviewer #1 (Remarks to the Author):  
 
Thank you for addressing the comments and updating the draft accordingly. I just have a couple 
minor comments.  
Lines 15,16 in abstract gets repeated in lines 54,55 and by the time one reaches the end of 
introduction, there is no data/result to back up this statement.  
Lines 248-250: Not sure if I understand the phrase "sort their effect"?  
 
 
 
Reviewer #2 (Remarks to the Author):  
 
The authors have adressed my concerns. No further commen 
 
 
 
REVIEWERS' COMMENTS: 
 
Reviewer #1 (Remarks to the Author): 
 
Thank you for addressing the comments and updating the draft accordingly. I just have a 
couple minor comments. 
COMMENT 
Lines 15,16 in abstract gets repeated in lines 54,55 and by the time one reaches the end of 
introduction, there is no data/result to back up this statement. 
REPLY  
 Lines 15.16: In the abstract we now refer back to the found genes so as to connect this 
 statement with the reported results, i.e. the sentence was changed to ‘with a key role 
 for genetic variants (GNG11, RGS6) that influence G-protein heterotrimer action in 
 GIRK- channel induced pacemaker membrane hyperpolarization.’ 
 Lines 54,55 : If the reviewer means that we provide a summary of the main results at 
 the end of the  introduction before full disclosure of the actual results then we must 
 point out this was per the request of Nature Communications to add such a 
 summary. If the reviewer means that the link to the GIRK-channel induced 
 pacemaker membrane hyperpolarization  comes a bit out of the blue, we can 
 agree. Again we solve this by referring back to the found genes (GNG11,  RGS6) ”for 
 two proteins well-known to regulate GIRK-channel induced pacemaker membrane 
 hyperpolarization”. 
 
COMMENT 
Lines 248-250: Not sure if I understand the phrase "sort their effect"?  
REPLY 
 We have rephrased to: ‘exert their effect’. 
 
 
 
No other comments remained. 
 
 
 
Effect Other N EAF β SE p-value I2 imp.qual.*
RMSSD 26349 0,079 -0,115 0,010 7,80E-30 47% 0.99 [0.57-1.00]
SDNN 27239 0,078 -0,051 0,007 5,20E-13 60% 0.97 [0.49-1.00]
pvRSA/HF† 23652 0,078 -0,244 0,021 1,12E-37 54% 0.97 [0.49-1.00]
pvRSA/HF† 23671 0,077 -0,248 0,021 9,09E-38 54% 0.97 [0.49-1.00]
RMSSD 26367 0,078 -0,117 0,010 8,15E-30 46% 0.98 [0.57-1.00]
SDNN 27257 0,077 -0,052 0,007 3,42E-13 61% 0.94 [0.49-1.00]
SDNN 27250 0,079 -0,052 0,007 3,00E-13 60% 0.97 [0.49-1.00]
RMSSD 26367 0,078 -0,116 0,010 1,52E-29 46% 0.98 [0.57-1.00]
pvRSA/HF† 23664 0,077 -0,246 0,021 1,19E-37 54% 0.98 [0.49-1.00]
SDNN 27257 0,863 -0,049 0,005 1,51E-22 34% 1.00 [0.81-1.02]
RMSSD 26367 0,863 -0,068 0,007 2,61E-22 10% 1.00 [0.85-1.02]
pvRSA/HF† 23475 0,865 -0,128 0,015 7,61E-23 47% 1.00 [0.81-1.02]
SDNN 27257 0,653 -0,028 0,004 8,65E-13 13% 1.00 [0.62-1.00]
RMSSD 26367 0,653 -0,031 0,005 1,43E-08 46% 0.99 [0.62-1.00]
pvRSA/HF† 23671 0,652 -0,071 0,011 2,78E-12 24% 0.99 [0.62-1.00]
RMSSD 26156 0,401 -0,040 0,005 1,92E-14 0% 0.93 [0.86-0.99]
SDNN 26992 0,401 -0,023 0,004 1,80E-09 0% 0.94 [0.87-1.00]
pvRSA/HF† 23036 0,402 -0,072 0,011 1,29E-11 40% 0.94 [0.87-1.00]
pvRSA/HF† 23033 0,436 -0,072 0,011 1,86E-11 36% 0.99 [0.90-1.00]
RMSSD 26153 0,436 -0,038 0,005 9,67E-14 0% 0.99 [0.91-1.00]
SDNN 26989 0,436 -0,022 0,004 8,23E-09 0% 0.99 [0.91-1.00]
SDNN 25609 0,436 -0,024 0,004 1,20E-09 0% 0.94 [0.87-1.03]
RMSSD 24773 0,436 -0,039 0,005 1,67E-13 0% 0.94 [0.87-0.98]
pvRSA/HF† 21653 0,436 -0,073 0,011 7,73E-11 0% 0.95 [0.86-1.03]
SDNN 27256 0,390 -0,028 0,004 1,56E-12 16% 0.88 [0.68-1.00]
RMSSD 26366 0,390 -0,040 0,005 2,27E-13 50% 0.88 [0.68-1.00]
1 19
rs12974991 5845584
rs12974440
Stage 1 Discovery
Supplementary Data 1:  Stage 1, stage 2, and combined stage 1+2 meta-analysis results for SDNN, RMSSD, and pvRSA/HF for the 23 SNPs that were genome-wide 
suggestive (p<1x10-6) after stage 1 in the meta-analysis for any of the traits.
NOTE : SNPs are sorted according to p -value  of the combined meta-analysis per locus. Results for SNP-trait combinations not initially selected at stage 1 are in 
red italics . 
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pvRSA/HF† 23670 0,390 -0,049 0,011 7,41E-09 20% 0.88 [0.69-1.00]
RMSSD 26366 0,339 -0,039 0,005 2,24E-13 31% 0.99 [0.85-1.00]
SDNN 27250 0,338 -0,027 0,004 3,50E-12 6% 1.00 [0.85-1.00]
pvRSA/HF† 23664 0,339 -0,051 0,011 7,72E-09 0% 1.00 [0.86-1.00]
SDNN 27255 0,247 -0,025 0,004 1,59E-08 38% 0.95 [0.65-1.00]
RMSSD 26366 0,247 -0,030 0,006 4,34E-07 29% 0.92 [0.65-1.00]
pvRSA/HF† 23669 0,246 -0,048 0,012 3,56E-04 34% 0.93 [0.65-1.00]
RMSSD 25607 0,162 -0,044 0,008 5,97E-09 2% 0.80 [0.67-0.98]
SDNN 26497 0,163 -0,031 0,005 1,67E-08 52% 0.83 [0.71-1.01]
pvRSA/HF† 22911 0,163 -0,063 0,016 4,51E-04 53% 0.82 [0.67-1.01]
SDNN 27257 0,417 -0,020 0,004 8,94E-08 0% 1.00 [0.94-1.03]
RMSSD 26367 0,416 -0,024 0,005 1,67E-06 37% 1.00 [0.94-1.03]
pvRSA/HF† 23671 0,417 -0,029 0,010 9,00E-03 0% 1.00 [0.94-1.00]
SDNN 27185 0,132 -0,032 0,005 1,03E-08 51% 0.95 [0.73-0.99]
RMSSD 26362 0,133 -0,040 0,008 2,61E-07 28% 0.95 [0.73-0.99]
pvRSA/HF† 23599 0,131 -0,055 0,016 6,32E-04 58% 0.95 [0.72-1.00]
SDNN 27255 0,783 -0,025 0,005 1,26E-07 0% 0.88 [0.73-1.00]
RMSSD 26365 0,784 -0,030 0,006 2,38E-06 15% 0.88 [0.73-1.00]
pvRSA/HF† 23669 0,784 -0,052 0,013 4,23E-06 0% 0.89 [0.73-1.00]
RMSSD 26367 0,417 -0,025 0,005 7,99E-07 0% 1.00 [0.88-1.02]
SDNN 27257 0,417 -0,018 0,004 2,50E-06 0% 1.00 [0.88-1.02]
pvRSA/HF† 23671 0,420 -0,036 0,010 3,69E-05 0% 1.00 [0.89-1.01]
RMSSD 26367 0,534 -0,029 0,005 5,15E-08 21% 0.99 [0.35-1.03]
SDNN 27254 0,534 -0,016 0,004 2,42E-05 0% 0.99 [0.35-1.03]
pvRSA/HF† 23668 0,535 -0,031 0,011 3,30E-04 42% 0.99 [0.35-1.01]
RMSSD 26367 0,572 -0,027 0,005 1,58E-07 28% 0.96 [0.80-0.99]
SDNN 27257 0,571 -0,012 0,004 2,50E-03 45% 0.96 [0.80-1.00]
pvRSA/HF† 23671 0,570 -0,022 0,011 2,25E-03 20% 0.96 [0.80-1.00]
SDNN 27256 0,717 -0,023 0,004 1,69E-07 0% 0.83 [0.67-1.00]
RMSSD 26366 0,718 -0,025 0,006 4,37E-05 7% 0.82 [0.67-1.00]
pvRSA/HF† 23670 0,715 -0,030 0,012 4,30E-04 21% 0.83 [0.67-1.00]
RMSSD 26366 0,107 -0,040 0,008 5,91E-07 19% 0.97 [0.70-1.03]
SDNN 27256 0,108 -0,019 0,006 9,77E-04 0% 0.98 [0.70-1.10]
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pvRSA/HF† 23670 0,110 -0,062 0,016 7,44E-06 15% 0.98 [0.68-1.10]
SDNN 27250 0,136 -0,030 0,006 2,97E-07 0% 0.99 [0.42-1.00]
RMSSD 26361 0,137 -0,038 0,008 3,84E-06 4% 0.99 [0.42-1.00]
pvRSA/HF† 23664 0,140 -0,047 0,017 3,76E-04 9% 0.99 [0.42-1.00]
SDNN 17523 0,217 -0,028 0,006 5,98E-07 0% 0.93 [0.74-1.00]
RMSSD 16636 0,215 -0,033 0,008 1,89E-05 0% 0.95 [0.74-1.00]
pvRSA/HF† 15295 0,215 -0,048 0,019 3,37E-03 0% 0.92 [0.74-1.00]
SDNN 16897 0,031 -0,072 0,014 2,59E-07 29% 0.46 [0.31-0.61]
RMSSD 16064 0,030 -0,058 0,030 5,38E-02 0% 0.45 [0.37-0.52]
pvRSA/HF† 12930 0,029 -0,074 0,061 1,38E-01 25% 0.46 [0.31-0.61]
86059258 A G
LEGEND: Chr: chromosome;  SNP: single nucleotide polymorphism; bp: base pair position based on build 36 (hg18); N: sample size; EAF: effect 
allele frequency; β: beta/effect size; SE: standard error of β; I2: measure of heterogeneity; imp.qual.: imputation quality.
*median [range] over all cohorts passing the quality control criteria for the particular SNP.
†p-value, allele, EAF, N from p-value weighted meta-analysis of all cohorts using METAL and β, SE, I2 from inverse-variance meta-analysis of only 
HF cohorts using GWAMA.
C14 11 rs677652 117541921 T
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21336411 T
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13 9 rs3858083 95923978 T G
12 18 rs8093402
Stage 2 Replication
N EAF β SE p-value I2 imp.qual.* N EAF β SE p-value
16856 0,077 -0,118 0,014 8,70E-18 0% 0.93 [0.36-1.00] 43205 0,078 -0,117 0,008 4,57E-46
18796 0,074 -0,083 0,012 6,40E-13 60% 0.98 [0.57-1.00] 46035 0,077 -0,059 0,006 5,60E-23
5856 0,059 -0,226 0,046 3,37E-06 0% 0.93 [0.36-0.97] 29508 0,074 -0,241 0,019 1,75E-41
5856 0,060 -0,223 0,046 4,22E-06 0% 0.93 [0.39-0.97] 29527 0,073 -0,244 0,019 1,91E-41
16856 0,077 -0,117 0,014 7,20E-18 0% 0.96 [0.39-1.00] 43223 0,077 -0,117 0,008 3,92E-46
18796 0,075 -0,083 0,012 4,94E-13 61% 0.97 [0.57-1.00] 46053 0,076 -0,060 0,006 2,42E-23
18796 0,074 -0,083 0,012 5,55E-13 61% 0.98 [0.57-1.00] 46046 0,076 -0,060 0,006 2,30E-23
16856 0,077 -0,117 0,014 1,27E-17 0% 0.97 [0.36-1.00] 43223 0,077 -0,117 0,008 1,29E-45
5856 0,059 -0,225 0,046 3,86E-06 0% 0.94 [0.36-0.97] 29520 0,073 -0,243 0,019 2,20E-41
20551 0,864 -0,050 0,008 8,00E-10 34% 1.00 [0.81-1.02] 47808 0,863 -0,049 0,004 9,33E-31
16856 0,862 -0,058 0,010 1,07E-08 0% 0.98 [0.64-1.00] 43223 0,863 -0,065 0,006 2,45E-29
7610 0,868 -0,111 0,028 5,29E-05 0% 0.99 [0.64-1.12] 31085 0,865 -0,124 0,013 1,20E-25
24122 0,649 -0,041 0,005 6,80E-15 13% 0.99 [0.62-1.00] 51379 0,651 -0,033 0,003 3,70E-25
20428 0,657 -0,043 0,007 2,65E-10 0% 1.00 [0.81-1.00] 46795 0,655 -0,035 0,004 9,10E-17
9983 0,627 -0,064 0,016 1,02E-04 0% 1.00 [0.91-1.00] 33654 0,645 -0,069 0,009 3,16E-15
18054 0,379 -0,036 0,007 2,07E-07 0% 0.98 [0.97-1.00] 44210 0,392 -0,039 0,004 3,19E-20
21749 0,385 -0,021 0,005 6,40E-05 0% 0.95 [0.87-1.00] 48741 0,394 -0,022 0,003 8,66E-13
7610 0,397 -0,065 0,018 1,34E-04 0% 0.99 [0.89-1.00] 30646 0,401 -0,070 0,009 1,53E-14
7610 0,442 -0,075 0,018 3,33E-05 0% 0.96 [0.94-1.04] 30643 0,437 -0,073 0,009 5,70E-15
18054 0,423 -0,032 0,007 2,61E-06 0% 0.99 [0.94-1.00] 44207 0,430 -0,036 0,004 2,26E-18
21748 0,429 -0,020 0,005 1,01E-04 0% 0.99 [0.91-1.00] 48737 0,433 -0,021 0,003 6,02E-12
21749 0,427 -0,020 0,005 7,70E-05 0% 0.94 [0.87-1.03] 47358 0,432 -0,023 0,003 7,37E-13
18054 0,422 -0,032 0,007 1,64E-06 0% 0.98 [0.93-1.00] 42827 0,430 -0,037 0,004 2,55E-18
7610 0,436 -0,076 0,018 3,01E-05 0% 0.96 [0.93-1.03] 29263 0,436 -0,074 0,010 2,14E-14
21749 0,390 -0,027 0,006 3,54E-06 17% 0.88 [0.68-1.00] 49005 0,390 -0,028 0,003 4,26E-17
18054 0,393 -0,021 0,007 1,65E-03 0% 0.97 [0.79-1.00] 44420 0,391 -0,033 0,004 1,89E-14
Stage 1 + 2  combined
7611 0,383 -0,054 0,019 3,08E-04 28% 0.91 [0.79-1.00] 31281 0,388 -0,050 0,010 1,84E-11
18054 0,328 -0,026 0,007 2,07E-04 0% 0.99 [0.93-1.00] 44420 0,334 -0,034 0,004 7,99E-16
21749 0,322 -0,026 0,006 4,97E-06 7% 1.00 [0.85-1.00] 48999 0,330 -0,027 0,003 1,33E-16
7611 0,316 -0,048 0,019 1,55E-03 1% 0.95 [0.91-1.00] 31275 0,333 -0,050 0,010 9,05E-11
20997 0,258 -0,029 0,006 2,16E-06 39% 0.94 [0.65-1.00] 48252 0,252 -0,026 0,004 3,13E-13
19057 0,262 -0,026 0,008 3,91E-04 0% 0.99 [0.57-1.00] 45423 0,254 -0,028 0,005 1,19E-09
6858 0,245 -0,027 0,021 5,05E-02 0% 0.99 [0.57-1.00] 30527 0,245 -0,043 0,010 8,81E-05
19885 0,169 -0,025 0,009 2,76E-03 65% 0.96 [0.79-1.00] 45492 0,165 -0,036 0,006 3,56E-10
21825 0,170 -0,029 0,007 2,07E-05 52% 0.82 [0.71-1.01] 48322 0,166 -0,030 0,004 2,60E-12
7687 0,170 -0,017 0,023 1,53E-01 58% 0.94 [0.75-1.00] 30598 0,165 -0,048 0,013 3,85E-04
22362 0,442 -0,024 0,005 2,25E-06 0% 1.00 [0.94-1.03] 49619 0,428 -0,021 0,003 1,88E-12
20423 0,436 -0,029 0,006 1,82E-06 32% 1.00 [0.66-1.00] 46790 0,425 -0,026 0,004 2,83E-11
8223 0,445 -0,022 0,017 3,98E-02 14% 1.00 [0.66-1.05] 31894 0,424 -0,027 0,009 1,69E-03
20997 0,125 -0,036 0,008 7,15E-06 51% 0.95 [0.73-0.99] 48182 0,129 -0,033 0,005 6,25E-13
19057 0,122 -0,042 0,010 2,88E-05 0% 0.92 [0.54-1.00] 45419 0,128 -0,040 0,006 5,36E-11
6859 0,134 -0,025 0,028 1,40E-01 41% 0.95 [0.54-1.00] 30458 0,132 -0,048 0,014 4,31E-04
24115 0,772 -0,023 0,006 5,30E-05 0% 0.88 [0.73-1.00] 51370 0,778 -0,024 0,004 4,88E-11
20998 0,777 -0,034 0,008 6,25E-06 0% 0.97 [0.78-1.00] 47363 0,781 -0,032 0,005 1,16E-10
9976 0,757 -0,036 0,018 5,99E-02 0% 0.98 [0.89-1.00] 33645 0,776 -0,046 0,011 2,54E-06
18054 0,419 -0,026 0,007 9,60E-05 35% 1.00 [0.98-1.01] 44421 0,418 -0,025 0,004 5,18E-10
21748 0,412 -0,016 0,005 1,20E-03 0% 1.00 [0.88-1.02] 49005 0,414 -0,017 0,003 1,92E-08
7609 0,389 -0,036 0,018 1,30E-02 0% 0.99 [0.95-1.00] 31280 0,413 -0,036 0,009 2,77E-06
20422 0,534 -0,015 0,007 1,54E-02 0% 1.00 [0.68-1.00] 46789 0,534 -0,024 0,004 1,30E-08
24116 0,534 -0,011 0,005 1,87E-02 0% 0.99 [0.35-1.03] 51370 0,534 -0,014 0,003 3,22E-06
9978 0,530 -0,015 0,015 1,00E-01 0% 1.00 [0.97-1.01] 33646 0,533 -0,026 0,009 2,09E-04
19222 0,566 -0,009 0,007 8,80E-02 0% 0.97 [0.90-1.00] 45589 0,569 -0,020 0,004 5,63E-07
22916 0,567 -0,005 0,005 1,75E-01 45% 0.96 [0.80-1.00] 50173 0,569 -0,009 0,003 2,71E-03
9976 0,565 -0,011 0,016 2,58E-01 0% 0.97 [0.90-1.00] 33647 0,568 -0,019 0,009 3,54E-03
22362 0,703 -0,003 0,006 2,99E-01 0% 0.83 [0.67-1.00] 49618 0,711 -0,016 0,003 7,02E-06
20422 0,707 0,001 0,007 4,58E-01 20% 1.00 [0.52-1.00] 46788 0,713 -0,014 0,005 2,22E-03
8224 0,690 -0,011 0,018 2,74E-01 20% 1.00 [0.52-1.00] 31894 0,709 -0,024 0,010 5,69E-03
20423 0,112 -0,004 0,010 3,56E-01 0% 0.99 [0.97-1.00] 46789 0,109 -0,026 0,006 3,01E-05
24118 0,116 -0,005 0,008 2,69E-01 0% 0.98 [0.70-1.10] 51374 0,112 -0,014 0,005 2,53E-03
8614 0,112 0,002 0,024 5,49E-01 20% 0.99 [0.92-1.00] 32284 0,113 -0,042 0,013 1,61E-04
22359 0,105 0,006 0,009 2,35E-01 0% 0.99 [0.42-1.00] 49609 0,122 -0,019 0,005 4,55E-04
20419 0,106 0,012 0,010 1,27E-01 0% 0.99 [0.42-1.00] 46780 0,123 -0,019 0,006 3,07E-03
8221 0,106 0,038 0,028 8,44E-01 0% 1.00 [0.42-1.00] 31885 0,131 -0,023 0,015 1,08E-02
22924 0,238 0,003 0,006 3,18E-01 0% 0.93 [0.74-1.00] 40447 0,229 -0,014 0,004 8,16E-04
19229 0,236 0,005 0,008 2,49E-01 0% 1.00 [0.89-1.00] 35865 0,226 -0,014 0,005 5,08E-04
9754 0,240 0,002 0,018 5,81E-01 0% 0.99 [0.88-1.00] 25049 0,225 -0,022 0,013 3,05E-02
6647 0,017 0,107 0,059 3,49E-02 30% 0.47 [0.37-0.61] 23544 0,027 -0,063 0,014 3,70E-06
4707 0,013 0,092 0,089 1,48E-01 0% 0.65 [0.38-1.00] 20771 0,026 -0,043 0,028 1,32E-01
5680 0,013 -0,091 0,183 5,63E-01 40% 0.49 [0.24-1.00] 18610 0,024 -0,076 0,058 1,86E-01
rs12974991 19 5894584 RMSSD rs12974991 5894584 G A 0,0974 1 intronic
non-synonymous rs12982903 5872403 G A 0,0974 0,957064 intergenic
rs12984289 5872968 G A 0,0984 0,946586 intergenic
rs34971496 5873282 A G 0,0974 0,957064 intergenic
rs8108862 5873728 C T 0,0974 0,957064 intergenic
rs12973503 5875892 T G 0,0974 0,957064 intergenic
rs55800071 5878583 A G 0,0994 0,978852 intergenic
rs35103346 5878684 A T 0,0994 0,978852 intergenic
rs34568271 5879711 C T 0,0964 0,946208 intergenic
rs34505898 5882857 G A 0,0954 0,957049 intergenic
rs12974377 5883973 C T 0,0984 0,989332 intergenic
rs74174353 5886666 A T 0,0994 0,979317 intergenic
rs17271897 5886764 C T 0,0964 0,967735 intergenic
rs35952442 5889071 C T 0,0974 1 intergenic
rs34860663 5890655 T C 0,0974 1 downstream
rs55928223 5890670 T C 0,0974 1 downstream
rs17271904 5892274 C G 0,0974 1 UTR3
rs12980262 5893058 G A 0,0974 1 exonic
rs12974440 5894386 G A 0,0974 1 intronic
rs12975210 5894645 G C 0,0954 0,978604 intronic
rs702064 5896766 C T 0,0974 0,852338 intronic
rs778800 5900247 T C 0,1014 0,814503 intronic
rs12974440 19 5894386 pvRSA/HF rs12974440 5894386 G A 0,0974 1 intronic
non-synonymous rs12982903 5872403 G A 0,0974 0,957064 intergenic
rs12984289 5872968 G A 0,0984 0,946586 intergenic
rs34971496 5873282 A G 0,0974 0,957064 intergenic
rs8108862 5873728 C T 0,0974 0,957064 intergenic
rs12973503 5875892 T G 0,0974 0,957064 intergenic
rs55800071 5878583 A G 0,0994 0,978852 intergenic
Supplementary Data 2: In silico annotation and GWAS catalog lookup results of the 17 HRV SNPs identified in this study. 
NOTE:  All SNPs are shown that are in high linkage disequilibrium with the HRV lead SNPs (r
2
>0.5 for non-synonymous variants and r
2
>0.8 for 
other variants). SNPs that are interesting because of exonic details are depicted in red; SNPs that are interesting because of associated 
disease/trait are depicted in blue.
Lead SNP Chr pos (b37) HRV trait Variant typeLD SNP pos (B37) ref 
allele
AF (other 
allele)
other 
allele
LD
rs35103346 5878684 A T 0,0994 0,978852 intergenic
rs34568271 5879711 C T 0,0964 0,946208 intergenic
rs34505898 5882857 G A 0,0954 0,957049 intergenic
rs12974377 5883973 C T 0,0984 0,989332 intergenic
rs74174353 5886666 A T 0,0994 0,979317 intergenic
rs17271897 5886764 C T 0,0964 0,967735 intergenic
rs35952442 5889071 C T 0,0974 1 intergenic
rs34860663 5890655 T C 0,0974 1 downstream
rs55928223 5890670 T C 0,0974 1 downstream
rs17271904 5892274 C G 0,0974 1 UTR3
rs12980262 5893058 G A 0,0974 1 exonic
rs12974991 5894584 G A 0,0974 1 intronic
rs12975210 5894645 G C 0,0954 0,978604 intronic
rs702064 5896766 C T 0,0974 0,852338 intronic
rs778800 5900247 T C 0,1014 0,814503 intronic
rs12980262 19 5893058 SDNN rs12980262 5893058 G A 0,0974 1 exonic
non-synonymous rs12982903 5872403 G A 0,0974 0,957064 intergenic
rs12984289 5872968 G A 0,0984 0,946586 intergenic
rs34971496 5873282 A G 0,0974 0,957064 intergenic
rs8108862 5873728 C T 0,0974 0,957064 intergenic
rs12973503 5875892 T G 0,0974 0,957064 intergenic
rs55800071 5878583 A G 0,0994 0,978852 intergenic
rs35103346 5878684 A T 0,0994 0,978852 intergenic
rs34568271 5879711 C T 0,0964 0,946208 intergenic
rs34505898 5882857 G A 0,0954 0,957049 intergenic
rs12974377 5883973 C T 0,0984 0,989332 intergenic
rs74174353 5886666 A T 0,0994 0,979317 intergenic
rs17271897 5886764 C T 0,0964 0,967735 intergenic
rs35952442 5889071 C T 0,0974 1 intergenic
rs34860663 5890655 T C 0,0974 1 downstream
rs55928223 5890670 T C 0,0974 1 downstream
rs17271904 5892274 C G 0,0974 1 UTR3
rs12974440 5894386 G A 0,0974 1 intronic
rs12974991 5894584 G A 0,0974 1 intronic
rs12975210 5894645 G C 0,0954 0,978604 intronic
rs702064 5896766 C T 0,0974 0,852338 intronic
rs778800 5900247 T C 0,1014 0,814503 intronic
rs10842383 12 24771967 RMSSD, SDNN, pvRSA/HF rs10842383 24771967 C T 0,1551 1 intergenic
intergenic rs4963772 24758480 G A 0,1551 0,985088 intergenic
rs34219605 24760456 A G 0,1551 0,985088 intergenic
rs11047527 24762501 A C 0,1551 0,985088 intergenic
rs17287293 24770878 A G 0,1551 1 intergenic
rs12829213 24773562 G A 0,1551 1 intergenic
rs112630705 24773919 G A 0,1551 1 intergenic
rs111504119 24774691 A G 0,1789 0,833094 intergenic
rs137913153 24776752 A G 0,1551 1 intergenic
rs12826024 24776799 G A 0,1551 1 intergenic
rs4963776 24779491 G T 0,1789 0,834831 intergenic
rs11047539 24781446 A G 0,1551 1 intergenic
rs4246224 24784139 G A 0,1551 1 intergenic
rs11047543 24788339 G A 0,1551 1 intergenic
rs4963778 24800607 A G 0,1402 0,820263 intergenic
rs4963779 24800775 T G 0,1402 0,820263 intergenic
rs4963780 24801081 A T 0,1412 0,813096 intergenic
rs236349 6 36820565 RMSSD, SDNN, pvRSA/HF rs236349 36820565 A G 0,6531 1 intergenic
intronic rs236352 36817113 A G 0,6541 0,995531 intergenic
rs4594944 36840767 G A 0,6899 0,831809 intronic
rs7980799 12 33576990 RMSSD rs7980799 33576990 A C 0,6243 1 intronic
intronic rs4244865 33511917 G A 0,6252 0,937035 intergenic
rs4244866 33511983 G C 0,6352 0,897268 intergenic
rs1905408 33516963 G A 0,6252 0,937035 intergenic
rs7312012 33517984 A G 0,6252 0,937035 intergenic
rs4931717 33521151 G A 0,6262 0,941245 intergenic
rs2389194 33529164 A G 0,6262 0,941245 UTR3
rs9888363 33529288 T C 0,6262 0,941245 UTR3
rs10732554 33533374 C T 0,6262 0,941245 intronic
rs1905427 33534368 T C 0,6262 0,941245 intronic
rs12301124 33543024 T C 0,6252 0,94532 intronic
rs2892701 33547395 T C 0,6243 0,949431 intronic
rs7294492 33548530 C T 0,6243 0,949431 intronic
rs7315695 33551841 G C 0,6272 0,953779 intronic
rs10772076 33553574 A C 0,6262 0,958014 intronic
rs10844580 33553867 G A 0,6272 0,953779 intronic
rs10844582 33560873 A G 0,6262 0,958014 intronic
rs7971226 33586881 A G 0,6243 1 intronic
rs11052705 33588388 T C 0,6243 1 intronic
rs6488162 33593127 T C 0,5954 0,859743 upstream
rs1351682 12 33598775 pvRSA/HF rs1351682 33598775 G A 0,5626 1 intergenic
intergenic rs1482993 33594515 G A 0,5636 0,995895 intergenic
rs1351683 33598563 G A 0,5636 0,995895 intergenic
rs4931719 33602986 G A 0,5636 0,995895 intergenic
rs10844611 33603544 T C 0,5626 1 intergenic
rs10844612 33603676 T C 0,5636 0,995895 intergenic
rs10844613 33605362 A G 0,5686 0,975785 intergenic
rs10844614 33605702 A C 0,5706 0,967757 intergenic
rs1601007 33609675 G C 0,5626 1 intergenic
rs1601008 33611352 A G 0,5626 1 intergenic
rs1842885 33613317 A G 0,5626 1 intergenic
rs1482987 33614283 G C 0,5626 1 intergenic
rs1447873 33615236 A G 0,5626 1 intergenic
rs1580396 33615841 C A 0,5616 0,995895 intergenic
rs2200156 33618048 C A 0,5626 1 intergenic
rs1384598 33622899 T A 0,5626 1 intergenic
rs10161311 33623204 G A 0,5636 0,995895 intergenic
rs10161491 33623806 T C 0,5636 0,995895 intergenic
rs1384599 33624579 G A 0,5636 0,995895 intergenic
rs10844618 33625010 A G 0,5626 1 intergenic
rs12319055 33626509 C T 0,5616 0,995916 intergenic
rs11052722 33626530 G A 0,5447 0,923009 intergenic
rs1601006 33629519 C T 0,5616 0,987689 intergenic
rs61927702 33631695 A G 0,5606 0,991832 intergenic
rs7303356 33633599 G C 0,5447 0,923009 intergenic
rs1601005 33634658 A G 0,5626 1 intergenic
rs7138529 33634855 T C 0,5636 0,995895 intergenic
rs10437795 33635336 C G 0,5636 0,995895 intergenic
rs7311794 33635630 C T 0,5626 1 intergenic
rs111940785 33646586 C A 0,5706 0,960176 intergenic
rs1839062 33646892 G A 0,5706 0,960176 intergenic
rs2389214 33647406 C A 0,5706 0,960176 intergenic
rs4348988 33647529 A T 0,5706 0,960176 intergenic
rs2200159 33648544 G C 0,5706 0,960176 intergenic
rs2220059 33648630 C T 0,5706 0,960176 intergenic
rs11535974 33649029 A G 0,5706 0,960176 intergenic
rs11559754 33649229 G A 0,5706 0,960176 intergenic
rs2389215 33649457 C T 0,5706 0,960176 intergenic
rs2220060 33650463 G A 0,5706 0,960176 intergenic
rs11052731 33651637 G A 0,5706 0,960176 intergenic
rs7972688 33653477 T C 0,5716 0,956169 intergenic
rs7965096 33655082 A G 0,5706 0,960176 intergenic
rs2084391 33655419 C T 0,5706 0,960176 intergenic
rs11052732 33657801 A G 0,5716 0,956169 intergenic
rs10772088 33663849 A T 0,5716 0,956169 intergenic
rs11052736 33669583 T C 0,4274 0,952179 intergenic
rs138585668 33677966 T C 0,4284 0,956169 intergenic
rs2389218 33680929 C A 0,4284 0,956169 intergenic
rs1994135 33682405 T C 0,4463 0,87965 intergenic
rs12819439 33684509 A C 0,4284 0,956169 intergenic
rs12820541 33684754 G A 0,4284 0,956169 intergenic
rs1601003 33689436 A T 0,4284 0,956169 intergenic
rs1482983 33690326 A C 0,4284 0,956169 intergenic
rs1384598 12 33622899 SDNN rs1384598 33622899 T A 0,5626 1 intergenic
intergenic rs1482993 33594515 G A 0,5636 0,995895 intergenic
rs1351683 33598563 G A 0,5636 0,995895 intergenic
rs1351682 33598775 G A 0,5626 1 intergenic
rs4931719 33602986 G A 0,5636 0,995895 intergenic
rs10844611 33603544 T C 0,5626 1 intergenic
rs10844612 33603676 T C 0,5636 0,995895 intergenic
rs10844613 33605362 A G 0,5686 0,975785 intergenic
rs10844614 33605702 A C 0,5706 0,967757 intergenic
rs1601007 33609675 G C 0,5626 1 intergenic
rs1601008 33611352 A G 0,5626 1 intergenic
rs1842885 33613317 A G 0,5626 1 intergenic
rs1482987 33614283 G C 0,5626 1 intergenic
rs1447873 33615236 A G 0,5626 1 intergenic
rs1580396 33615841 C A 0,5616 0,995895 intergenic
rs2200156 33618048 C A 0,5626 1 intergenic
rs10161311 33623204 G A 0,5636 0,995895 intergenic
rs10161491 33623806 T C 0,5636 0,995895 intergenic
rs1384599 33624579 G A 0,5636 0,995895 intergenic
rs10844618 33625010 A G 0,5626 1 intergenic
rs12319055 33626509 C T 0,5616 0,995916 intergenic
rs11052722 33626530 G A 0,5447 0,923009 intergenic
rs1601006 33629519 C T 0,5616 0,987689 intergenic
rs61927702 33631695 A G 0,5606 0,991832 intergenic
rs7303356 33633599 G C 0,5447 0,923009 intergenic
rs1601005 33634658 A G 0,5626 1 intergenic
rs7138529 33634855 T C 0,5636 0,995895 intergenic
rs10437795 33635336 C G 0,5636 0,995895 intergenic
rs7311794 33635630 C T 0,5626 1 intergenic
rs111940785 33646586 C A 0,5706 0,960176 intergenic
rs1839062 33646892 G A 0,5706 0,960176 intergenic
rs2389214 33647406 C A 0,5706 0,960176 intergenic
rs4348988 33647529 A T 0,5706 0,960176 intergenic
rs2200159 33648544 G C 0,5706 0,960176 intergenic
rs2220059 33648630 C T 0,5706 0,960176 intergenic
rs11535974 33649029 A G 0,5706 0,960176 intergenic
rs11559754 33649229 G A 0,5706 0,960176 intergenic
rs2389215 33649457 C T 0,5706 0,960176 intergenic
rs2220060 33650463 G A 0,5706 0,960176 intergenic
rs11052731 33651637 G A 0,5706 0,960176 intergenic
rs7972688 33653477 T C 0,5716 0,956169 intergenic
rs7965096 33655082 A G 0,5706 0,960176 intergenic
rs2084391 33655419 C T 0,5706 0,960176 intergenic
rs11052732 33657801 A G 0,5716 0,956169 intergenic
rs10772088 33663849 A T 0,5716 0,956169 intergenic
rs11052736 33669583 T C 0,4274 0,952179 intergenic
rs138585668 33677966 T C 0,4284 0,956169 intergenic
rs2389218 33680929 C A 0,4284 0,956169 intergenic
rs1994135 33682405 T C 0,4463 0,87965 intergenic
rs12819439 33684509 A C 0,4284 0,956169 intergenic
rs12820541 33684754 G A 0,4284 0,956169 intergenic
rs1601003 33689436 A T 0,4284 0,956169 intergenic
rs1482983 33690326 A C 0,4284 0,956169 intergenic
rs4262 7 93551428 SDNN, pvRSA/HF rs4262 93551428 C T 0,5954 1 UTR5
5 'UTR rs180236 93553341 A G 0,6322 0,844759 intronic
rs180238 7 93550447 RMSSD rs180238 93550447 C T 0,6779 1 upstream
upstream rs180274 93537158 C T 0,6581 0,895205 intronic
rs180271 93539479 G A 0,663 0,922627 intronic
rs180270 93539490 A T 0,663 0,922627 intronic
rs180269 93539527 A T 0,663 0,922627 intronic
rs2798 93540348 T G 0,6769 0,970211 UTR3
rs180267 93540542 T C 0,6769 0,970211 downstream
rs28438575 93540958 C T 0,675 0,970372 downstream
rs180265 93541129 C A 0,6769 0,970211 downstream
rs180262 93542743 A G 0,6769 0,970211 intergenic
rs180261 93543481 C G 0,6769 0,970211 intergenic
rs180260 93543861 A T 0,6769 0,970211 intergenic
rs180259 93544357 G A 0,6769 0,970211 intergenic
rs180258 93544393 A G 0,6759 0,966148 intergenic
rs180257 93544520 T A 0,6769 0,970211 intergenic
rs180255 93545351 G A 0,6779 0,965876 intergenic
rs180253 93545777 G A 0,663 0,913072 intergenic
rs180251 93546256 C T 0,6769 0,970211 intergenic
rs180250 93547331 C A 0,6769 0,970211 intergenic
rs180249 93547512 G A 0,6769 0,970211 intergenic
rs180248 93547596 T G 0,6769 0,970211 intergenic
rs180247 93548608 A G 0,6789 0,978627 intergenic
rs180245 93549271 G C 0,6769 0,987152 intergenic
rs180244 93549363 G C 0,6759 0,991471 intergenic
rs180242 93549596 T A 0,6759 0,991471 intergenic
rs180240 93550207 G C 0,6769 0,987183 upstream
rs180239 93550415 G C 0,6759 0,991471 upstream
rs4899412 14 72464262 SDNN rs4899412 72464262 T C 0,7266 1 intronic
intronic rs2238280 72425522 T C 0,7346 0,86417 intronic
rs11623535 72462381 G A 0,7237 0,97703 intronic
rs4350510 72463936 C T 0,7237 0,97703 intronic
rs4354860 72464107 C T 0,7237 0,97703 intronic
rs4243640 72464141 G A 0,7237 0,97703 intronic
rs4902966 72464278 A T 0,7247 0,990737 intronic
rs2010846 72464810 G A 0,7266 0,981452 intronic
rs2010850 72464881 C T 0,7237 0,97703 intronic
rs1987723 72464890 A G 0,7266 0,981452 intronic
rs1987722 72465028 C T 0,7237 0,97703 intronic
rs8013467 72465579 C T 0,7256 0,976972 intronic
rs699358 72465969 T G 0,7256 0,976972 intronic
rs1009017 72466285 T C 0,7266 0,963078 intronic
rs2332707 72471862 A G 0,7157 0,874836 intronic
rs12897386 72472263 C T 0,7157 0,874836 intronic
rs12883063 72473230 G A 0,7157 0,874836 intronic
rs8008678 72473655 C T 0,7157 0,874836 intronic
rs35727014 72474545 G T 0,7157 0,874836 intronic
rs6574037 72475353 T C 0,7177 0,882355 intronic
rs4048388 72475398 G C 0,7167 0,870485 intronic
rs2215132 72475789 G A 0,7137 0,840678 intronic
rs2052015 14 72487053 RMSSD rs2052015 72487053 C T 0,172 1 intronic
intronic rs78352915 72395663 T A 0,175 0,806356 intergenic
rs72734102 72409999 A G 0,175 0,806356 intronic
rs56743778 72414393 G T 0,175 0,806356 intronic
rs17093750 72414804 A T 0,175 0,806356 intronic
rs11158920 72415811 A G 0,175 0,806356 intronic
rs72735921 72421687 G A 0,175 0,806356 intronic
rs72735923 72421729 A G 0,175 0,806356 intronic
rs4902958 72427325 G A 0,1759 0,826779 intronic
rs2238277 72434662 G C 0,1789 0,848998 intronic
rs4899409 72438375 G A 0,1779 0,829766 intronic
rs200753739 72445706 T C 0,1789 0,848998 intronic
rs3784056 72449351 A G 0,1779 0,855017 intronic
rs3784055 72449568 C T 0,1779 0,855017 intronic
rs2332705 72451966 G A 0,174 0,878805 intronic
rs17105346 72452471 C G 0,174 0,878805 intronic
rs11627768 72453599 C G 0,173 0,885175 intronic
rs60503142 72454200 C G 0,173 0,885175 intronic
rs76309583 72454445 C G 0,173 0,885175 intronic
rs11622507 72456250 A G 0,173 0,885175 intronic
rs72735952 72460289 A G 0,173 0,885175 intronic
rs11623492 72462557 A G 0,173 0,898322 intronic
rs72735955 72463283 A G 0,173 0,898322 intronic
rs72735956 72463537 A C 0,174 0,892685 intronic
rs11620690 72463740 T C 0,174 0,892685 intronic
rs11625937 72463990 G A 0,173 0,898322 intronic
rs17105566 72465202 G T 0,173 0,898322 intronic
rs11158927 72466149 G C 0,1759 0,906167 intronic
rs17105606 72466936 G T 0,173 0,924907 intronic
rs59631889 72467308 G A 0,173 0,924907 intronic
rs58890880 72467516 G A 0,173 0,924907 intronic
rs11628133 72471630 A G 0,172 0,918723 intronic
rs12148043 72472427 G A 0,171 0,924747 intronic
rs11628574 72485195 T G 0,171 0,993067 intronic
rs7494103 72485244 A C 0,171 0,993067 intronic
rs2529471 14 72813269 SDNN rs2529471 72813269 A C 0,4016 1 intronic
intronic rs2529475 72803242 A C 0,3996 0,885287 intronic
rs1915132 72805490 T C 0,4066 0,980833 intronic
rs2681771 72806117 C A 0,4036 0,992293 intronic
rs2239243 72806264 G A 0,4036 0,992293 intronic
rs2239241 72807042 G A 0,4026 0,988379 intronic
rs2681769 72807278 T C 0,4036 0,992293 intronic
rs2681768 72807405 C T 0,4036 0,992293 intronic
rs2079506 72807559 A G 0,4036 0,992293 intronic
rs2681767 72807622 G A 0,4036 0,992293 intronic
rs2079505 72807663 A G 0,4036 0,992293 intronic
rs2079504 72807682 C T 0,4036 0,992293 intronic
rs8019358 72807815 T A 0,4036 0,992293 intronic
rs8019371 72807845 T C 0,4056 0,984637 intronic
rs8018393 72807860 C T 0,4056 0,984637 intronic
rs2079503 72807872 A T 0,4056 0,984637 intronic
rs10711066 72807901 G T 0,4046 0,988457 intronic
rs8003559 72808083 T C 0,4036 0,992293 intronic
rs8022956 72808138 G A 0,4036 0,992293 intronic
rs8003591 72808157 T C 0,4036 0,992293 intronic
rs8022859 72808321 A G 0,4036 0,992293 intronic
rs2239239 72808692 A G 0,4036 0,992293 intronic
rs2239238 72808848 G A 0,4036 0,992293 intronic
rs2283388 72809040 A G 0,4006 0,996134 intronic
rs929413 72810140 T C 0,4016 1 intronic
rs1812041 72810256 G A 0,4016 1 intronic
rs2877805 72810345 T C 0,4016 1 intronic
rs2247090 72810384 C G 0,4016 1 intronic
rs886826 72810663 C T 0,4016 1 intronic
rs2239235 72811156 T C 0,4036 0,992293 intronic
rs2681727 72811484 A C 0,4016 1 intronic
rs2681730 72811992 A G 0,3877 0,947856 intronic
rs2681731 72812162 G A 0,4016 1 intronic
rs2681733 72812219 A G 0,3877 0,940554 intronic
rs8016719 72812230 T A 0,3877 0,940554 intronic
rs8016720 72812231 T A 0,3877 0,940554 intronic
rs8015917 72812274 G A 0,3877 0,947856 intronic
rs2681734 72812326 T G 0,4016 1 intronic
rs2681735 72812525 A G 0,3877 0,947856 intronic
rs2681736 72812684 G T 0,3877 0,947856 intronic
rs2529472 72812723 T C 0,4036 0,992293 intronic
rs2681737 72812724 G A 0,3907 0,958868 intronic
rs2529470 72813592 T C 0,4016 1 intronic
rs2529469 72813721 T C 0,4016 1 intronic
rs2239234 72813956 G A 0,4016 1 intronic
rs2239232 72814130 G A 0,4016 1 intronic
rs1356841 72814415 T C 0,4016 1 intronic
rs1356843 72814653 G T 0,4016 1 intronic
rs2681741 72814857 A G 0,4046 0,988457 intronic
rs2681743 72815145 T C 0,4046 0,988457 intronic
rs2681744 72815284 C A 0,4046 0,988457 intronic
rs2681745 72815405 T G 0,4056 0,984637 intronic
rs2681746 72815641 A G 0,4046 0,988457 intronic
rs2681747 72815787 G A 0,4036 0,961634 intronic
rs2529468 72815824 T G 0,4036 0,961634 intronic
rs2214965 72816393 A T 0,3986 0,965295 intronic
rs2681749 72816626 T C 0,3986 0,965295 intronic
rs2529467 72816875 T C 0,3986 0,965295 intronic
rs2681751 72817005 T C 0,3986 0,965295 intronic
rs2681752 72817160 T G 0,3996 0,961396 intronic
rs2681753 72817512 G A 0,3986 0,965295 intronic
rs2239230 72818033 A G 0,3986 0,965295 intronic
rs2239229 72818218 T C 0,3986 0,965295 intronic
rs2681757 72821317 A G 0,3946 0,950209 intronic
rs1072166 72823173 A G 0,3917 0,962062 intronic
rs2176841 72824475 A C 0,3946 0,950209 intronic
rs10129799 72826071 A G 0,3946 0,950209 intronic
rs2529457 72826550 T C 0,3946 0,950209 intronic
rs1099968 72826595 A C 0,3847 0,914462 intronic
rs2190508 72834466 A G 0,3847 0,914462 intronic
rs2283385 72841851 C T 0,3946 0,950209 intronic
rs2332832 72844369 A C 0,3638 0,852819 intronic
rs7151325 72845263 T A 0,3628 0,857102 intronic
rs7150465 72845655 A T 0,3628 0,857102 intronic
rs10137579 72846021 G A 0,3658 0,844842 intronic
rs10138152 72846658 G A 0,3668 0,840622 intronic
rs7140973 72847555 A G 0,3857 0,910409 intronic
rs2680344 15 73653485 SDNN rs2680344 73653485 A G 0,2445 1 intronic
intronic rs3784813 73663040 C T 0,7535 0,970897 intergenic
rs7178084 73668046 T C 0,2465 0,942481 intergenic
rs1812835 15 73507504 RMSSD rs1812835 73507504 C A 0,3907 1 intronic
intronic rs62016797 73352037 A G 0,3857 0,802972 intronic
rs80158392 73387930 A C 0,3787 0,822117 intronic
rs76985330 73398013 T C 0,3797 0,825616 intronic
rs62016806 73399528 A G 0,3797 0,825616 intronic
rs56377702 73400276 A C 0,3797 0,825616 intronic
rs2169951 73410811 A G 0,3797 0,825616 intronic
rs55836604 73413375 G T 0,3797 0,825616 intronic
rs62016811 73414131 A G 0,3797 0,825616 intronic
rs9972347 73419767 A G 0,3797 0,825616 intronic
rs11072403 73426298 A G 0,3807 0,829147 intronic
rs75487461 73430761 A G 0,3827 0,828476 intronic
rs112752532 73431021 T C 0,3837 0,824261 intronic
rs112593508 73431106 A C 0,3807 0,829147 intronic
rs62016849 73432610 A G 0,3817 0,832709 intronic
rs4545783 73438225 A G 0,3837 0,825019 intronic
rs1023924 73438622 T C 0,3877 0,817703 intronic
rs62016851 73441915 A G 0,4105 0,91147 intronic
rs7172021 73449003 A G 0,4115 0,907581 intronic
rs7172396 73449208 A G 0,4105 0,902872 intronic
rs58060856 73449348 A G 0,4115 0,907581 intronic
rs12050658 73451781 G C 0,3569 0,840418 intronic
rs12050774 73453815 G A 0,3897 0,995708 intronic
rs62016853 73458455 A G 0,3897 0,995708 intronic
rs62016854 73459671 G A 0,3887 0,991456 intronic
rs59066156 73462022 G T 0,3777 0,945678 intronic
rs62016856 73465002 T C 0,3738 0,921185 intronic
rs62016857 73469918 C T 0,3598 0,859829 intronic
rs62016858 73471810 G A 0,3728 0,917338 intronic
rs74025262 73472096 C T 0,3897 0,995708 intronic
rs1479340 73472887 G A 0,4115 0,907581 intronic
rs1479339 73473036 C T 0,3897 0,995708 intronic
rs17829830 73474643 G A 0,3907 0,991451 intronic
rs17829836 73474669 A G 0,4115 0,907581 intronic
rs79478409 73475366 T G 0,3897 0,995708 intronic
rs1479338 73476100 A G 0,3897 0,995708 intronic
rs7497992 73477039 T C 0,3598 0,859829 intronic
rs12050685 73477482 G A 0,3598 0,859829 intronic
rs3985588 73482002 G A 0,3767 0,941713 intronic
rs7169083 73482258 C T 0,3986 0,851127 intronic
rs17762516 73484270 A T 0,3946 0,983041 intronic
rs2899784 73485117 G A 0,4125 0,911878 intronic
rs17829957 73485897 G A 0,3907 1 intronic
rs2127277 73486051 T C 0,4125 0,911878 intronic
rs17762600 73488753 G T 0,3917 0,995698 intronic
rs55646651 73489157 C G 0,3907 1 intronic
rs9806496 73490182 T C 0,3946 0,983041 intronic
rs78750912 73493396 G A 0,3907 1 intronic
rs62017774 73494036 A G 0,3907 1 intronic
rs148855211 73494324 G A 0,3907 0,991396 intronic
rs74022925 73495625 G A 0,3907 1 intronic
rs62017776 73495724 G A 0,3897 0,995708 intronic
rs1564345 73497874 T C 0,4125 0,911878 intronic
rs55868723 73498363 C T 0,3787 0,941193 intronic
rs56215298 73498371 C G 0,3907 1 intronic
rs55939596 73502892 T C 0,3907 1 intronic
rs1116880 73507321 G A 0,3787 0,941193 intronic
rs56348595 73512648 T G 0,3907 1 intronic
rs62015460 73518606 G A 0,3738 0,921185 intronic
rs2415148 73546319 G A 0,3897 0,995708 intronic
rs113826883 73555727 G A 0,3728 0,917116 intronic
rs62015484 73587174 C T 0,3728 0,917116 intronic
rs62015499 73602108 G A 0,3708 0,909237 intergenic
rs62015500 73602729 G A 0,3728 0,91693 intergenic
rs62015502 73616744 C T 0,3728 0,908499 intronic
rs55848419 73619134 A T 0,3867 0,924408 intronic
rs4777598 73620572 G A 0,3837 0,953532 intronic
rs55853625 73621532 G A 0,3837 0,953532 intronic
rs3985587 73622444 G A 0,3837 0,953532 intronic
rs62015504 73623193 C T 0,3708 0,893173 intronic
rs11634084 73623462 A C 0,3708 0,893173 intronic
rs11634147 73623537 C T 0,3837 0,953532 intronic
rs3784801 73623782 G A 0,3827 0,957753 intronic
rs76789737 73624849 C A 0,3708 0,893173 intronic
rs56118677 73627723 A G 0,3668 0,814632 intronic
rs36423 14 72353202 RMSSD rs36423 72353202 T G 0,8996 1 intergenic
intergenic rs36418 72353731 T G 0,8817 0,831288 intergenic
rs6123471 20 36840156 RMSSD rs6123471 36840156 T C 0,4314 1 UTR3
non-synonymous rs6023939 36832526 C A 0,4264 0,954965 intergenic
rs4811583 36833268 T A 0,4264 0,954965 intergenic
rs2881138 36834862 A G 0,4274 0,950984 intergenic
rs2345386 36835420 C T 0,4264 0,954965 intergenic
rs2881139 36835636 C T 0,4264 0,954965 intergenic
rs2881140 36835654 T C 0,4264 0,954965 intergenic
rs1534966 36837296 A G 0,4264 0,963115 intergenic
rs4550723 36838101 T C 0,4314 1 downstream
rs6127448 36838422 T C 0,4344 0,987553 downstream
rs3746467 36839297 T C 0,4314 1 UTR3
rs6127461 36840458 G C 0,4314 1 UTR3
rs6069225 36840877 G T 0,4314 1 UTR3
rs1053932 36841251 A G 0,4344 0,987553 UTR3
rs1053931 36841293 G A 0,4344 0,987553 UTR3
rs1534967 36841756 T C 0,4344 0,987553 exonic
rs3746471 36841914 G A 0,4235 0,942489 exonic
rs6123474 36842782 C G 0,4344 0,987553 intronic
rs6024001 36842836 C T 0,4344 0,987553 intronic
rs6127466 36842883 A G 0,4235 0,942489 intronic
rs6069232 36843256 T C 0,4344 0,987553 intronic
rs6127467 36843334 A T 0,4344 0,987553 intronic
rs6069234 36843992 A G 0,4344 0,987553 intronic
rs6127471 36844038 C T 0,4344 0,987553 intronic
rs5026717 36844116 C T 0,4344 0,987553 intronic
rs760998 36845738 C T 0,2982 0,549508 exonic
rs4811601 36849007 C T 0,4324 0,946201 intronic
rs4811602 36849088 G A 0,4364 0,963009 intronic
LEGEND : total number of LD SNPs: 469; non-synonymous: 4; upstream: 1; UTR5: 1; intronic: 7; intergenic: 4.   
*Explanation of SIFT score: D=deleterious (sift score<=0.05); T: tolerated (sift score>0.05).   
#Explanation of Polyphen score: D=probably damaging (0.957<=pp2hdiv<=1); P: possibly damaging (0.453<=pp2hdiv<0.957); B: benign (pp2hdiv<0.453).
 score pred  score pred
NDUFA11
FUT5(dist=1852),NDUFA11(dist=18884)
FUT5(dist=2417),NDUFA11(dist=18319)
FUT5(dist=2731),NDUFA11(dist=18005)
FUT5(dist=3177),NDUFA11(dist=17559)
FUT5(dist=5341),NDUFA11(dist=15395)
FUT5(dist=8032),NDUFA11(dist=12704)
FUT5(dist=8133),NDUFA11(dist=12603)
FUT5(dist=9160),NDUFA11(dist=11576)
FUT5(dist=12306),NDUFA11(dist=8430)
FUT5(dist=13422),NDUFA11(dist=7314)
FUT5(dist=16115),NDUFA11(dist=4621)
FUT5(dist=16213),NDUFA11(dist=4523)
FUT5(dist=18520),NDUFA11(dist=2216)
NDUFA11
NDUFA11
NDUFA11(NM_001193375:c.*654G>C)
NDUFA11 nonsynonymous 0,01 D 0,753 P
NDUFA11
NDUFA11
NDUFA11
NDUFA11
NDUFA11
FUT5(dist=1852),NDUFA11(dist=18884)
FUT5(dist=2417),NDUFA11(dist=18319)
FUT5(dist=2731),NDUFA11(dist=18005)
FUT5(dist=3177),NDUFA11(dist=17559)
FUT5(dist=5341),NDUFA11(dist=15395)
FUT5(dist=8032),NDUFA11(dist=12704)
exonic details Associated  disease/trait SIFT PolyphenGene name(s)
FUT5(dist=8133),NDUFA11(dist=12603)
FUT5(dist=9160),NDUFA11(dist=11576)
FUT5(dist=12306),NDUFA11(dist=8430)
FUT5(dist=13422),NDUFA11(dist=7314)
FUT5(dist=16115),NDUFA11(dist=4621)
FUT5(dist=16213),NDUFA11(dist=4523)
FUT5(dist=18520),NDUFA11(dist=2216)
NDUFA11
NDUFA11
NDUFA11(NM_001193375:c.*654G>C)
NDUFA11 nonsynonymous 0,01 D 0,753 P
NDUFA11
NDUFA11
NDUFA11
NDUFA11
NDUFA11 nonsynonymous 0,01 D 0,753 P
FUT5(dist=1852),NDUFA11(dist=18884)
FUT5(dist=2417),NDUFA11(dist=18319)
FUT5(dist=2731),NDUFA11(dist=18005)
FUT5(dist=3177),NDUFA11(dist=17559)
FUT5(dist=5341),NDUFA11(dist=15395)
FUT5(dist=8032),NDUFA11(dist=12704)
FUT5(dist=8133),NDUFA11(dist=12603)
FUT5(dist=9160),NDUFA11(dist=11576)
FUT5(dist=12306),NDUFA11(dist=8430)
FUT5(dist=13422),NDUFA11(dist=7314)
FUT5(dist=16115),NDUFA11(dist=4621)
FUT5(dist=16213),NDUFA11(dist=4523)
FUT5(dist=18520),NDUFA11(dist=2216)
NDUFA11
NDUFA11
NDUFA11(NM_001193375:c.*654G>C)
NDUFA11
NDUFA11
NDUFA11
NDUFA11
NDUFA11
LINC00477(dist=34865),BCAT1(dist=190991)
LINC00477(dist=21378),BCAT1(dist=204478)
LINC00477(dist=23354),BCAT1(dist=202502)
LINC00477(dist=25399),BCAT1(dist=200457)
LINC00477(dist=33776),BCAT1(dist=192080)
LINC00477(dist=36460),BCAT1(dist=189396)
LINC00477(dist=36817),BCAT1(dist=189039)
LINC00477(dist=37589),BCAT1(dist=188267)
LINC00477(dist=39650),BCAT1(dist=186206)
LINC00477(dist=39697),BCAT1(dist=186159)
LINC00477(dist=42389),BCAT1(dist=183467)
LINC00477(dist=44344),BCAT1(dist=181512)
LINC00477(dist=47037),BCAT1(dist=178819) Heart rate
LINC00477(dist=51237),BCAT1(dist=174619) PR interval
LINC00477(dist=63505),BCAT1(dist=162351)
LINC00477(dist=63673),BCAT1(dist=162183)
LINC00477(dist=63979),BCAT1(dist=161877)
CPNE5(dist=13345),PPIL1(dist=2041) Heart rate
CPNE5(dist=9893),PPIL1(dist=5493)
C6orf89,PPIL1
SYT10
PKP2(dist=462137),SYT10(dist=16431)
PKP2(dist=462203),SYT10(dist=16365)
PKP2(dist=467183),SYT10(dist=11385)
PKP2(dist=468204),SYT10(dist=10364)
PKP2(dist=471371),SYT10(dist=7197)
SYT10(NM_198992:c.*601T>C)
SYT10(NM_198992:c.*477A>G)
SYT10
SYT10
SYT10
SYT10
SYT10
SYT10
SYT10
SYT10
SYT10
SYT10
SYT10 Heart rate
SYT10
SYT10(dist=6021),ALG10(dist=576441)
SYT10(dist=1761),ALG10(dist=580701)
SYT10(dist=5809),ALG10(dist=576653)
SYT10(dist=10232),ALG10(dist=572230)
SYT10(dist=10790),ALG10(dist=571672)
SYT10(dist=10922),ALG10(dist=571540)
SYT10(dist=12608),ALG10(dist=569854)
SYT10(dist=12948),ALG10(dist=569514)
SYT10(dist=16921),ALG10(dist=565541)
SYT10(dist=18598),ALG10(dist=563864)
SYT10(dist=20563),ALG10(dist=561899)
SYT10(dist=21529),ALG10(dist=560933)
SYT10(dist=22482),ALG10(dist=559980)
SYT10(dist=23087),ALG10(dist=559375)
SYT10(dist=25294),ALG10(dist=557168)
SYT10(dist=30145),ALG10(dist=552317)
SYT10(dist=30450),ALG10(dist=552012)
SYT10(dist=31052),ALG10(dist=551410)
SYT10(dist=31825),ALG10(dist=550637)
SYT10(dist=32256),ALG10(dist=550206)
SYT10(dist=33755),ALG10(dist=548707)
SYT10(dist=33776),ALG10(dist=548686)
SYT10(dist=36765),ALG10(dist=545697)
SYT10(dist=38941),ALG10(dist=543521)
SYT10(dist=40845),ALG10(dist=541617)
SYT10(dist=41904),ALG10(dist=540558)
SYT10(dist=42101),ALG10(dist=540361)
SYT10(dist=42582),ALG10(dist=539880)
SYT10(dist=42876),ALG10(dist=539586) Heart rate
SYT10(dist=53832),ALG10(dist=528630)
SYT10(dist=54138),ALG10(dist=528324)
SYT10(dist=54652),ALG10(dist=527810)
SYT10(dist=54775),ALG10(dist=527687)
SYT10(dist=55790),ALG10(dist=526672)
SYT10(dist=55876),ALG10(dist=526586)
SYT10(dist=56275),ALG10(dist=526187)
SYT10(dist=56475),ALG10(dist=525987)
SYT10(dist=56703),ALG10(dist=525759)
SYT10(dist=57709),ALG10(dist=524753)
SYT10(dist=58883),ALG10(dist=523579)
SYT10(dist=60723),ALG10(dist=521739)
SYT10(dist=62328),ALG10(dist=520134)
SYT10(dist=62665),ALG10(dist=519797)
SYT10(dist=65047),ALG10(dist=517415)
SYT10(dist=71095),ALG10(dist=511367)
SYT10(dist=76829),ALG10(dist=505633)
SYT10(dist=85212),ALG10(dist=497250)
SYT10(dist=88175),ALG10(dist=494287)
SYT10(dist=89651),ALG10(dist=492811)
SYT10(dist=91755),ALG10(dist=490707)
SYT10(dist=92000),ALG10(dist=490462)
SYT10(dist=96682),ALG10(dist=485780)
SYT10(dist=97572),ALG10(dist=484890)
SYT10(dist=30145),ALG10(dist=552317)
SYT10(dist=1761),ALG10(dist=580701)
SYT10(dist=5809),ALG10(dist=576653)
SYT10(dist=6021),ALG10(dist=576441)
SYT10(dist=10232),ALG10(dist=572230)
SYT10(dist=10790),ALG10(dist=571672)
SYT10(dist=10922),ALG10(dist=571540)
SYT10(dist=12608),ALG10(dist=569854)
SYT10(dist=12948),ALG10(dist=569514)
SYT10(dist=16921),ALG10(dist=565541)
SYT10(dist=18598),ALG10(dist=563864)
SYT10(dist=20563),ALG10(dist=561899)
SYT10(dist=21529),ALG10(dist=560933)
SYT10(dist=22482),ALG10(dist=559980)
SYT10(dist=23087),ALG10(dist=559375)
SYT10(dist=25294),ALG10(dist=557168)
SYT10(dist=30450),ALG10(dist=552012)
SYT10(dist=31052),ALG10(dist=551410)
SYT10(dist=31825),ALG10(dist=550637)
SYT10(dist=32256),ALG10(dist=550206)
SYT10(dist=33755),ALG10(dist=548707)
SYT10(dist=33776),ALG10(dist=548686)
SYT10(dist=36765),ALG10(dist=545697)
SYT10(dist=38941),ALG10(dist=543521)
SYT10(dist=40845),ALG10(dist=541617)
SYT10(dist=41904),ALG10(dist=540558)
SYT10(dist=42101),ALG10(dist=540361)
SYT10(dist=42582),ALG10(dist=539880)
SYT10(dist=42876),ALG10(dist=539586) Heart rate
SYT10(dist=53832),ALG10(dist=528630)
SYT10(dist=54138),ALG10(dist=528324)
SYT10(dist=54652),ALG10(dist=527810)
SYT10(dist=54775),ALG10(dist=527687)
SYT10(dist=55790),ALG10(dist=526672)
SYT10(dist=55876),ALG10(dist=526586)
SYT10(dist=56275),ALG10(dist=526187)
SYT10(dist=56475),ALG10(dist=525987)
SYT10(dist=56703),ALG10(dist=525759)
SYT10(dist=57709),ALG10(dist=524753)
SYT10(dist=58883),ALG10(dist=523579)
SYT10(dist=60723),ALG10(dist=521739)
SYT10(dist=62328),ALG10(dist=520134)
SYT10(dist=62665),ALG10(dist=519797)
SYT10(dist=65047),ALG10(dist=517415)
SYT10(dist=71095),ALG10(dist=511367)
SYT10(dist=76829),ALG10(dist=505633)
SYT10(dist=85212),ALG10(dist=497250)
SYT10(dist=88175),ALG10(dist=494287)
SYT10(dist=89651),ALG10(dist=492811)
SYT10(dist=91755),ALG10(dist=490707)
SYT10(dist=92000),ALG10(dist=490462)
SYT10(dist=96682),ALG10(dist=485780)
SYT10(dist=97572),ALG10(dist=484890)
GNG11(NM_004126:c.-22C>T) Heart rate
GNG11 Pulmonary function decline
GNG11 Heart rate
GNGT1
GNGT1
GNGT1
GNGT1
GNGT1(NM_021955:c.*118T>G)
GNGT1
GNGT1
GNGT1
GNGT1(dist=2258),GNG11(dist=8273)
GNGT1(dist=2996),GNG11(dist=7535)
GNGT1(dist=3376),GNG11(dist=7155)
GNGT1(dist=3872),GNG11(dist=6659)
GNGT1(dist=3908),GNG11(dist=6623)
GNGT1(dist=4035),GNG11(dist=6496)
GNGT1(dist=4866),GNG11(dist=5665)
GNGT1(dist=5292),GNG11(dist=5239)
GNGT1(dist=5771),GNG11(dist=4760)
GNGT1(dist=6846),GNG11(dist=3685)
GNGT1(dist=7027),GNG11(dist=3504)
GNGT1(dist=7111),GNG11(dist=3420)
GNGT1(dist=8123),GNG11(dist=2408)
GNGT1(dist=8786),GNG11(dist=1745)
GNGT1(dist=8878),GNG11(dist=1653)
GNGT1(dist=9111),GNG11(dist=1420)
GNG11
GNG11 Pulmonary function decline
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
SIPA1L1(dist=187717),RGS6(dist=3154)
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6 Smoking cessation
RGS6 Antibody status in 
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
RGS6
HCN4 Atrial fibrillation
HCN4(dist=1435),REC114(dist=72459) Heart rate
HCN4(dist=6441),REC114(dist=67453)
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1
NEO1(dist=4561),HCN4(dist=10092)
NEO1(dist=5182),HCN4(dist=9471)
HCN4
HCN4
HCN4
HCN4
HCN4
HCN4
HCN4
HCN4
HCN4
HCN4
HCN4
SIPA1L1(dist=145256),RGS6(dist=45615)
SIPA1L1(dist=145785),RGS6(dist=45086)
KIAA1755(NM_001029864:c.*1288A>G)
TGM2(dist=38826),KIAA1755(dist=6381)
TGM2(dist=39568),KIAA1755(dist=5639)
TGM2(dist=41162),KIAA1755(dist=4045)
TGM2(dist=41720),KIAA1755(dist=3487)
TGM2(dist=41936),KIAA1755(dist=3271)
TGM2(dist=41954),KIAA1755(dist=3253)
TGM2(dist=43596),KIAA1755(dist=1611)
KIAA1755
KIAA1755
KIAA1755(NM_001029864:c.*2147A>G)
KIAA1755(NM_001029864:c.*986C>G)
KIAA1755(NM_001029864:c.*567C>A) Heart rate
KIAA1755(NM_001029864:c.*193T>C)
KIAA1755(NM_001029864:c.*151C>T)
KIAA1755 synonymous
KIAA1755 nonsynonymous 0,17 T 0,003 B
KIAA1755
KIAA1755
KIAA1755
KIAA1755
KIAA1755
KIAA1755
KIAA1755
KIAA1755
KIAA1755 nonsynonymous 1 T 0 B
KIAA1755
KIAA1755
LEGEND : total number of LD SNPs: 469; non-synonymous: 4; upstream: 1; UTR5: 1; intronic: 7; intergenic: 4.   
*Explanation of SIFT score: D=deleterious (sift score<=0.05); T: tolerated (sift score>0.05).   
#Explanation of Polyphen score: D=probably damaging (0.957<=pp2hdiv<=1); P: possibly damaging (0.453<=pp2hdiv<0.957); B: benign (pp2hdiv<0.453).
Gene
A11.063 Cells Antibody-Producing Cells Antibody Producing Cells C6orf89
A15.145.229.637.555.567.562.725 Hemic and Immune Systems Blood Plasma Cells C6orf89
A15.145.693 Hemic and Immune Systems Blood Plasma C6orf89
A15.145.846 Hemic and Immune Systems Blood Serum C6orf89
A11.118.637.555.567.562 Cells Blood Cells B Lymphocytes C6orf89
A11.118.637.415 Cells Blood Cells Granulocytes C6orf89
A11.118.637 Cells Blood Cells Leukocytes C6orf89
A07.231 Cardiovascular System Blood Vessels Blood Vessels C6orf89
A07.231.908.670 Cardiovascular System Blood Vessels Portal System C6orf89
A07.231.908.670.874 Cardiovascular System Blood Vessels Umbilical Veins C6orf89
A07.231.908 Cardiovascular System Blood Vessels Veins C6orf89
A07.231.114 Cardiovascular System Blood Vessels Arteries C6orf89
A08.186.211.730.317.357.352 Nervous System Central Nervous System Hypothalamus  Middle C6orf89
A08.186.211.730.317.357.352.435 Nervous System Central Nervous System Hypothalamo Hypophyseal System C6orf89
A10.165.450 Tissues Connective Tissue Granulation Tissue C6orf89
A10.165.450.300 Tissues Connective Tissue Cicatrix C6orf89
A10.165.450.300.425 Tissues Connective Tissue Keloid C6orf89
A10.165.114.830.500 Tissues Connective Tissue Abdominal Fat C6orf89
A10.165.114.830.500.750 Tissues Connective Tissue Subcutaneous Fat  Abdominal C6orf89
A11.329.830 Cells Connective Tissue Cells Stromal Cells C6orf89
A11.329.171 Cells Connective Tissue Cells Chondrocytes C6orf89
A11.329.228 Cells Connective Tissue Cells Fibroblasts C6orf89
A11.329 Cells Connective Tissue Cells Connective Tissue Cells C6orf89
A11.329.114 Cells Connective Tissue Cells Adipocytes C6orf89
Supplementary Data 3: DEPICT tissue enrichment analysis. 
NOTE: The table shows genes in GWAS identified loci and the tissues in which they are highly expressed. The Z-score indicates the level of tissue specific 
expression (Pers et al., 2015).
MeSH MeSH 1st level MeSH 2nd level Tissue/Cell type 
A11.329.372.600 Cells Connective Tissue Cells Macrophages  Alveolar C6orf89
A11.382.625 Cells Endocrine Cells Enteroendocrine Cells C6orf89
A11.436.397 Cells Epithelial Cells Keratinocytes C6orf89
A11.436.348 Cells Epithelial Cells Hepatocytes C6orf89
A11.436.275 Cells Epithelial Cells Endothelial Cells C6orf89
A11.436.294.064 Cells Epithelial Cells Glucagon Secreting Cells C6orf89
A10.272 Tissues Epithelium Epithelium C6orf89
A07.541.560 Cardiovascular System Heart Heart Ventricles C6orf89
A07.541 Cardiovascular System Heart Heart C6orf89
A15.378.316.378.590.837.250 Hemic and Immune Systems Hematopoietic System Erythroid Precursor Cells C6orf89
A15.378 Hemic and Immune Systems Hematopoietic System Hematopoietic System C6orf89
A15.378.316 Hemic and Immune Systems Hematopoietic System Bone Marrow Cells C6orf89
A15.382.490.315.583 Hemic and Immune Systems Immune System Neutrophils C6orf89
A15.382.812.522 Hemic and Immune Systems Immune System Macrophages C6orf89
A15.382.680 Hemic and Immune Systems Immune System Phagocytes C6orf89
A15.382.490.555.567.622 Hemic and Immune Systems Immune System Lymphocytes  Null C6orf89
A15.382.490.555.567 Hemic and Immune Systems Immune System Lymphocytes C6orf89
A15.382 Hemic and Immune Systems Immune System Immune System C6orf89
A10.615.284 Tissues Membranes Extraembryonic Membranes C6orf89
A10.615.284.473 Tissues Membranes Chorion C6orf89
A10.615.550.599 Tissues Membranes Mouth Mucosa C6orf89
A10.615 Tissues Membranes Membranes C6orf89
A10.615.550 Tissues Membranes Mucous Membrane C6orf89
A14.549.167 Stomatognathic System Mouth Dentition C6orf89
A11.620 Cells Muscle Cells Muscle Cells C6orf89
A11.620.520 Cells Muscle Cells Myocytes  Smooth Muscle C6orf89
A10.690.467 Tissues Muscles Muscle  Smooth C6orf89
A11.627.624.249 Cells Myeloid Cells Monocyte Macrophage Precursor Cells C6orf89
A11.627.635 Cells Myeloid Cells Myeloid Progenitor Cells C6orf89
A11.627 Cells Myeloid Cells Myeloid Cells C6orf89
A08.713 Nervous System Neurosecretory Systems Neurosecretory Systems C6orf89
A03.734.414 Digestive System Pancreas Islets of Langerhans C6orf89
A03.734 Digestive System Pancreas Pancreas C6orf89
A02.835.583 Musculoskeletal System Skeleton Joints C6orf89
A02.835.583.443 Musculoskeletal System Skeleton Joint Capsule C6orf89
A02.835.583.443.800 Musculoskeletal System Skeleton Synovial Membrane C6orf89
A02.835.583.443.800.800 Musculoskeletal System Skeleton Synovial Fluid C6orf89
A11.872.378.590.817 Cells Stem Cells Megakaryocyte Erythroid Progenitor Cells C6orf89
A11.872.378.590.635 Cells Stem Cells Granulocyte Macrophage Progenitor Cells C6orf89
A11.872.378 Cells Stem Cells Hematopoietic Stem Cells C6orf89
A11.872.580 Cells Stem Cells Mesenchymal Stem Cells C6orf89
A11.872.653 Cells Stem Cells Neural Stem Cells C6orf89
A11.872 Cells Stem Cells Stem Cells C6orf89
A15.145.229.188 Hemic and Immune Systems Blood Blood Platelets CAPS
A15.145.229.637.555.567.569.200 Hemic and Immune Systems Blood CD4 Positive T Lymphocytes CAPS
A11.118.637.555.567.569.200.700 Cells Blood Cells T Lymphocytes  Regulatory CAPS
A08.186.211.730.885.287.249 Nervous System Central Nervous System Basal Ganglia CAPS
A08.186.211.730.317 Nervous System Central Nervous System Diencephalon CAPS
A08.186.211.730.317.357 Nervous System Central Nervous System Hypothalamus CAPS
A08.186.211.730.317.357.352 Nervous System Central Nervous System Hypothalamus  Middle CAPS
A08.186.211.730.317.357.352.435 Nervous System Central Nervous System Hypothalamo Hypophyseal System CAPS
A08.186.211.730.885.287.500.670 Nervous System Central Nervous System Parietal Lobe CAPS
A08.186.211.464.405 Nervous System Central Nervous System Hippocampus CAPS
A08.186.211.653 Nervous System Central Nervous System Mesencephalon CAPS
A08.186.211.730 Nervous System Central Nervous System Prosencephalon CAPS
A08.186.211.464 Nervous System Central Nervous System Limbic System CAPS
A08.186.211.730.885 Nervous System Central Nervous System Telencephalon CAPS
A08.186.211.730.885.287 Nervous System Central Nervous System Cerebrum CAPS
A08.186.211.730.885.287.500 Nervous System Central Nervous System Cerebral Cortex CAPS
A08.186.211.464.710 Nervous System Central Nervous System Parahippocampal Gyrus CAPS
A08.186.211.464.710.225 Nervous System Central Nervous System Entorhinal Cortex CAPS
A08.186.211.730.885.287.500.863 Nervous System Central Nervous System Temporal Lobe CAPS
A08.186.211.132 Nervous System Central Nervous System Brain Stem CAPS
A08.186 Nervous System Central Nervous System Central Nervous System CAPS
A08.186.211.865 Nervous System Central Nervous System Rhombencephalon CAPS
A08.186.211.865.428 Nervous System Central Nervous System Metencephalon CAPS
A08.186.211.132.810.428.200 Nervous System Central Nervous System Cerebellum CAPS
A11.329.629 Cells Connective Tissue Cells Osteoblasts CAPS
A06.407.312 Endocrine System Endocrine Glands Gonads CAPS
A06.407.900 Endocrine System Endocrine Glands Thyroid Gland CAPS
A06.407 Endocrine System Endocrine Glands Endocrine Glands CAPS
A11.436 Cells Epithelial Cells Epithelial Cells CAPS
A10.272 Tissues Epithelium Epithelium CAPS
A03.556.500.760 Digestive System Gastrointestinal Tract Salivary Glands CAPS
A03.556.500.760.464 Digestive System Gastrointestinal Tract Parotid Gland CAPS
A03.556.875.875 Digestive System Gastrointestinal Tract Stomach CAPS
A05.360.319.679.490 Urogenital System Genitalia Endometrium CAPS
A05.360.490.690 Urogenital System Genitalia Ovum CAPS
A05.360.319.679 Urogenital System Genitalia Uterus CAPS
A05.360.490 Urogenital System Genitalia Germ Cells CAPS
A05.360.319 Urogenital System Genitalia Genitalia  Female CAPS
A05.360.319.114.373 Urogenital System Genitalia Fallopian Tubes CAPS
A05.360 Urogenital System Genitalia Genitalia CAPS
A05.360.319.114 Urogenital System Genitalia Adnexa Uteri CAPS
A05.360.319.114.630 Urogenital System Genitalia Ovary CAPS
A11.497.497.600 Cells Germ Cells Oocytes CAPS
A10.615.550.760 Tissues Membranes Respiratory Mucosa CAPS
A10.615.550 Tissues Membranes Mucous Membrane CAPS
A10.615 Tissues Membranes Membranes CAPS
A10.615.789 Tissues Membranes Serous Membrane CAPS
A08.713 Nervous System Neurosecretory Systems Neurosecretory Systems CAPS
A04.531.520 Respiratory System Nose Nasal Mucosa CAPS
A09.531 Sense Organs Nose Nose CAPS
A05.810.890 Urogenital System Urinary Tract Urinary Bladder CAPS
A11.063 Cells Antibody-Producing Cells Antibody Producing Cells CPNE5
A15.145.229.637.555.567.562.725 Hemic and Immune Systems Blood Plasma Cells CPNE5
A15.145.693 Hemic and Immune Systems Blood Plasma CPNE5
A15.145.229.188 Hemic and Immune Systems Blood Blood Platelets CPNE5
A15.145.229.637.555 Hemic and Immune Systems Blood Leukocytes  Mononuclear CPNE5
A15.145.229 Hemic and Immune Systems Blood Blood Cells CPNE5
A15.145 Hemic and Immune Systems Blood Blood CPNE5
A11.118.637.555.567.562 Cells Blood Cells B Lymphocytes CPNE5
A11.118.637 Cells Blood Cells Leukocytes CPNE5
A11.118.637.555.567.562.440 Cells Blood Cells Precursor Cells  B Lymphoid CPNE5
A07.231.908 Cardiovascular System Blood Vessels Veins CPNE5
A07.231.908.670 Cardiovascular System Blood Vessels Portal System CPNE5
A07.231.908.670.874 Cardiovascular System Blood Vessels Umbilical Veins CPNE5
A08.186.211.730.885.287.500.270 Nervous System Central Nervous System Frontal Lobe CPNE5
A08.186.211.730.885.287.249 Nervous System Central Nervous System Basal Ganglia CPNE5
A08.186.211.464.710 Nervous System Central Nervous System Parahippocampal Gyrus CPNE5
A08.186.211.464.710.225 Nervous System Central Nervous System Entorhinal Cortex CPNE5
A08.186.211.730.885.287.500.670 Nervous System Central Nervous System Parietal Lobe CPNE5
A08.186.211.730.885.287.500.863 Nervous System Central Nervous System Temporal Lobe CPNE5
A08.186.211.730.885.287.249.487 Nervous System Central Nervous System Corpus Striatum CPNE5
A08.186.211.730.885.287 Nervous System Central Nervous System Cerebrum CPNE5
A08.186.211.464 Nervous System Central Nervous System Limbic System CPNE5
A08.186.211.730.885 Nervous System Central Nervous System Telencephalon CPNE5
A08.186.211.730.885.287.500 Nervous System Central Nervous System Cerebral Cortex CPNE5
A08.186.211.730 Nervous System Central Nervous System Prosencephalon CPNE5
A08.186.211 Nervous System Central Nervous System Brain CPNE5
A08.186 Nervous System Central Nervous System Central Nervous System CPNE5
A08.186.211.464.405 Nervous System Central Nervous System Hippocampus CPNE5
A08.186.211.730.885.287.500.571 Nervous System Central Nervous System Occipital Lobe CPNE5
A08.186.211.730.885.287.500.571.735 Nervous System Central Nervous System Visual Cortex CPNE5
A08.186.211.653 Nervous System Central Nervous System Mesencephalon CPNE5
A08.186.211.730.317.357 Nervous System Central Nervous System Hypothalamus CPNE5
A08.186.211.132 Nervous System Central Nervous System Brain Stem CPNE5
A08.186.211.865 Nervous System Central Nervous System Rhombencephalon CPNE5
A08.186.211.865.428 Nervous System Central Nervous System Metencephalon CPNE5
A08.186.211.132.810.428.200 Nervous System Central Nervous System Cerebellum CPNE5
A10.165 Tissues Connective Tissue Connective Tissue CPNE5
A07.541.560 Cardiovascular System Heart Heart Ventricles CPNE5
A07.541 Cardiovascular System Heart Heart CPNE5
A07.541.358 Cardiovascular System Heart Heart Atria CPNE5
A15.382.520.604.800 Hemic and Immune Systems Immune System Palatine Tonsil CPNE5
A15.382.490.555.567 Hemic and Immune Systems Immune System Lymphocytes CPNE5
A15.382.520 Hemic and Immune Systems Immune System Lymphatic System CPNE5
A15.382.216 Hemic and Immune Systems Immune System Bone Marrow CPNE5
A15.382 Hemic and Immune Systems Immune System Immune System CPNE5
A15.382.520.604.700 Hemic and Immune Systems Immune System Spleen CPNE5
A10.549 Tissues Lymphoid Tissue Lymphoid Tissue CPNE5
A10.549.400 Tissues Lymphoid Tissue Lymph Nodes CPNE5
A04.623.603 Respiratory System Pharynx Oropharynx CPNE5
A14.724 Stomatognathic System Pharynx Pharynx CPNE5
A14.724.557 Stomatognathic System Pharynx Nasopharynx CPNE5
A02.835 Musculoskeletal System Skeleton Skeleton CPNE5
A02.835.232 Musculoskeletal System Skeleton Bone and Bones CPNE5
A02.835.583.443.800.800 Musculoskeletal System Skeleton Synovial Fluid CPNE5
A11.872.653 Cells Stem Cells Neural Stem Cells CPNE5
A11.872.378.294 Cells Stem Cells Lymphoid Progenitor Cells CPNE5
A11.063 Cells Antibody-Producing Cells Antibody Producing Cells FUT5
A11.066 Cells Antigen-Presenting Cells Antigen Presenting Cells FUT5
A15.145.229.188 Hemic and Immune Systems Blood Blood Platelets FUT5
A15.145.229.637.555.567.562.725 Hemic and Immune Systems Blood Plasma Cells FUT5
A15.145.693 Hemic and Immune Systems Blood Plasma FUT5
A15.145.229.334 Hemic and Immune Systems Blood Erythrocytes FUT5
A15.145.229.637.555.567.569.200 Hemic and Immune Systems Blood CD4 Positive T Lymphocytes FUT5
A15.145.300 Hemic and Immune Systems Blood Fetal Blood FUT5
A15.145.229.637.555 Hemic and Immune Systems Blood Leukocytes  Mononuclear FUT5
A15.145 Hemic and Immune Systems Blood Blood FUT5
A15.145.229 Hemic and Immune Systems Blood Blood Cells FUT5
A11.118.637.555.567.562 Cells Blood Cells B Lymphocytes FUT5
A11.118.637.555.567.569.200.700 Cells Blood Cells T Lymphocytes  Regulatory FUT5
A11.118.637.415 Cells Blood Cells Granulocytes FUT5
A11.118.637 Cells Blood Cells Leukocytes FUT5
A11.118.637.555.567.569 Cells Blood Cells T Lymphocytes FUT5
A11.118.637.555.567.562.440 Cells Blood Cells Precursor Cells  B Lymphoid FUT5
A02.165 Musculoskeletal System Cartilage Cartilage FUT5
A08.186.211.730.885.287.249.487 Nervous System Central Nervous System Corpus Striatum FUT5
A08.186.211.730.885.287.249 Nervous System Central Nervous System Basal Ganglia FUT5
A08.186.211.730.885.287.500.571.735 Nervous System Central Nervous System Visual Cortex FUT5
A08.186.211.730.885.287.500.571 Nervous System Central Nervous System Occipital Lobe FUT5
A08.186.211.132.810.428.200 Nervous System Central Nervous System Cerebellum FUT5
A08.186.211.865 Nervous System Central Nervous System Rhombencephalon FUT5
A08.186.211.865.428 Nervous System Central Nervous System Metencephalon FUT5
A10.165 Tissues Connective Tissue Connective Tissue FUT5
A06.407.900 Endocrine System Endocrine Glands Thyroid Gland FUT5
A11.443 Cells Erythroid Cells Erythroid Cells FUT5
A03.556.500.760.464 Digestive System Gastrointestinal Tract Parotid Gland FUT5
A03.556.500.760 Digestive System Gastrointestinal Tract Salivary Glands FUT5
A03.556.124.369 Digestive System Gastrointestinal Tract Intestinal Mucosa FUT5
A03.556.124.526.767 Digestive System Gastrointestinal Tract Rectum FUT5
A03.556.249.124 Digestive System Gastrointestinal Tract Ileum FUT5
A03.556.124.684 Digestive System Gastrointestinal Tract Intestine  Small FUT5
A03.556 Digestive System Gastrointestinal Tract Gastrointestinal Tract FUT5
A03.556.124 Digestive System Gastrointestinal Tract Intestines FUT5
A03.556.249 Digestive System Gastrointestinal Tract Lower Gastrointestinal Tract FUT5
A03.556.249.249.356.668 Digestive System Gastrointestinal Tract Colon  Sigmoid FUT5
A03.556.249.249 Digestive System Gastrointestinal Tract Intestine  Large FUT5
A03.556.249.249.356 Digestive System Gastrointestinal Tract Colon FUT5
A05.360.319.679.256 Urogenital System Genitalia Cervix Uteri FUT5
A07.541.358.100 Cardiovascular System Heart Atrial Appendage FUT5
A15.378.316.580 Hemic and Immune Systems Hematopoietic System Monocytes FUT5
A15.378 Hemic and Immune Systems Hematopoietic System Hematopoietic System FUT5
A15.378.316 Hemic and Immune Systems Hematopoietic System Bone Marrow Cells FUT5
A15.382.216 Hemic and Immune Systems Immune System Bone Marrow FUT5
A15.382.490.315.583 Hemic and Immune Systems Immune System Neutrophils FUT5
A15.382 Hemic and Immune Systems Immune System Immune System FUT5
A15.382.490.555.567 Hemic and Immune Systems Immune System Lymphocytes FUT5
A15.382.680 Hemic and Immune Systems Immune System Phagocytes FUT5
A15.382.812.260 Hemic and Immune Systems Immune System Dendritic Cells FUT5
A15.382.812 Hemic and Immune Systems Immune System Mononuclear Phagocyte System FUT5
A15.382.490.555.567.537 Hemic and Immune Systems Immune System Killer Cells  Natural FUT5
A15.382.520.604.800 Hemic and Immune Systems Immune System Palatine Tonsil FUT5
A15.382.520 Hemic and Immune Systems Immune System Lymphatic System FUT5
A03.620 Digestive System Liver Liver FUT5
A10.549 Tissues Lymphoid Tissue Lymphoid Tissue FUT5
A10.549.400 Tissues Lymphoid Tissue Lymph Nodes FUT5
A10.615.550.599 Tissues Membranes Mouth Mucosa FUT5
A10.615.550 Tissues Membranes Mucous Membrane FUT5
A14.549.885 Stomatognathic System Mouth Tongue FUT5
A14.549 Stomatognathic System Mouth Mouth FUT5
A14.549.167.646 Stomatognathic System Mouth Periodontium FUT5
A02.633.567.850 Musculoskeletal System Muscles Quadriceps Muscle FUT5
A10.690.552 Tissues Muscles Muscle  Striated FUT5
A10.690.552.500 Tissues Muscles Muscle  Skeletal FUT5
A10.690 Tissues Muscles Muscles FUT5
A11.627 Cells Myeloid Cells Myeloid Cells FUT5
A11.627.340.360 Cells Myeloid Cells Granulocyte Precursor Cells FUT5
A04.623.603 Respiratory System Pharynx Oropharynx FUT5
A02.835.232 Musculoskeletal System Skeleton Bone and Bones FUT5
A02.835 Musculoskeletal System Skeleton Skeleton FUT5
A11.872.378.294 Cells Stem Cells Lymphoid Progenitor Cells FUT5
A05.810.890 Urogenital System Urinary Tract Urinary Bladder FUT5
A15.145.229.188 Hemic and Immune Systems Blood Blood Platelets GNG11
A15.145.846 Hemic and Immune Systems Blood Serum GNG11
A15.145.300 Hemic and Immune Systems Blood Fetal Blood GNG11
A07.231.908.670 Cardiovascular System Blood Vessels Portal System GNG11
A07.231.908.670.874 Cardiovascular System Blood Vessels Umbilical Veins GNG11
A07.231 Cardiovascular System Blood Vessels Blood Vessels GNG11
A07.231.908 Cardiovascular System Blood Vessels Veins GNG11
A07.231.114 Cardiovascular System Blood Vessels Arteries GNG11
A10.165.114.830 Tissues Connective Tissue Adipose Tissue  White GNG11
A10.165.114.830.500 Tissues Connective Tissue Abdominal Fat GNG11
A10.165.114.830.500.750 Tissues Connective Tissue Subcutaneous Fat  Abdominal GNG11
A10.165.114.830.750 Tissues Connective Tissue Subcutaneous Fat GNG11
A10.165.114 Tissues Connective Tissue Adipose Tissue GNG11
A10.165.450 Tissues Connective Tissue Granulation Tissue GNG11
A10.165.450.300 Tissues Connective Tissue Cicatrix GNG11
A10.165.450.300.425 Tissues Connective Tissue Keloid GNG11
A11.329.114 Cells Connective Tissue Cells Adipocytes GNG11
A11.329.228 Cells Connective Tissue Cells Fibroblasts GNG11
A11.329.830 Cells Connective Tissue Cells Stromal Cells GNG11
A11.329.171 Cells Connective Tissue Cells Chondrocytes GNG11
A06.407.071 Endocrine System Endocrine Glands Adrenal Glands GNG11
A06.407.071.140 Endocrine System Endocrine Glands Adrenal Cortex GNG11
A06.407.312.782 Endocrine System Endocrine Glands Testis GNG11
A06.407.900 Endocrine System Endocrine Glands Thyroid Gland GNG11
A11.436.275 Cells Epithelial Cells Endothelial Cells GNG11
A10.272.497 Tissues Epithelium Epidermis GNG11
A10.336 Tissues Exocrine Glands Exocrine Glands GNG11
A10.336.707 Tissues Exocrine Glands Prostate GNG11
A03.556.875.875 Digestive System Gastrointestinal Tract Stomach GNG11
A03.556.875 Digestive System Gastrointestinal Tract Upper Gastrointestinal Tract GNG11
A05.360.319.679.690 Urogenital System Genitalia Myometrium GNG11
A05.360.490.690 Urogenital System Genitalia Ovum GNG11
A05.360.490 Urogenital System Genitalia Germ Cells GNG11
A05.360.319.679.490 Urogenital System Genitalia Endometrium GNG11
A05.360.319.679 Urogenital System Genitalia Uterus GNG11
A05.360.319.887 Urogenital System Genitalia Vulva GNG11
A05.360.444 Urogenital System Genitalia Genitalia  Male GNG11
A05.360.444.492 Urogenital System Genitalia Penis GNG11
A11.497.497.600 Cells Germ Cells Oocytes GNG11
A07.541.510 Cardiovascular System Heart Heart Valves GNG11
A07.541.510.110 Cardiovascular System Heart Aortic Valve GNG11
A07.541 Cardiovascular System Heart Heart GNG11
A15.382.520 Hemic and Immune Systems Immune System Lymphatic System GNG11
A15.382.520.604.700 Hemic and Immune Systems Immune System Spleen GNG11
A03.620 Digestive System Liver Liver GNG11
A04.411 Respiratory System Lung Lung GNG11
A10.549.400 Tissues Lymphoid Tissue Lymph Nodes GNG11
A10.549 Tissues Lymphoid Tissue Lymphoid Tissue GNG11
A10.615.284 Tissues Membranes Extraembryonic Membranes GNG11
A10.615.284.473 Tissues Membranes Chorion GNG11
A10.615.789 Tissues Membranes Serous Membrane GNG11
A10.615.550.599 Tissues Membranes Mouth Mucosa GNG11
A11.620 Cells Muscle Cells Muscle Cells GNG11
A11.620.520 Cells Muscle Cells Myocytes  Smooth Muscle GNG11
A10.690.467 Tissues Muscles Muscle  Smooth GNG11
A10.690 Tissues Muscles Muscles GNG11
A02.633.567.850 Musculoskeletal System Muscles Quadriceps Muscle GNG11
A10.690.552 Tissues Muscles Muscle  Striated GNG11
A10.690.552.500 Tissues Muscles Muscle  Skeletal GNG11
A03.734 Digestive System Pancreas Pancreas GNG11
A02.835.583 Musculoskeletal System Skeleton Joints GNG11
A02.835.583.443 Musculoskeletal System Skeleton Joint Capsule GNG11
A02.835.583.443.800 Musculoskeletal System Skeleton Synovial Membrane GNG11
A17.815 Integumentary System Skin Skin GNG11
A11.872.580 Cells Stem Cells Mesenchymal Stem Cells GNG11
A11.872.653 Cells Stem Cells Neural Stem Cells GNG11
A05.810.453.324 Urogenital System Urinary Tract Kidney Cortex GNG11
A05.810.453 Urogenital System Urinary Tract Kidney GNG11
A05.810 Urogenital System Urinary Tract Urinary Tract GNG11
A15.145.229.188 Hemic and Immune Systems Blood Blood Platelets GNGT1
A15.145.229.334 Hemic and Immune Systems Blood Erythrocytes GNGT1
A08.186.211.730.885.287.249.487 Nervous System Central Nervous System Corpus Striatum GNGT1
A11.382.625 Cells Endocrine Cells Enteroendocrine Cells GNGT1
A06.407.312 Endocrine System Endocrine Glands Gonads GNGT1
A06.407.312.782 Endocrine System Endocrine Glands Testis GNGT1
A06.407 Endocrine System Endocrine Glands Endocrine Glands GNGT1
A06.407.900 Endocrine System Endocrine Glands Thyroid Gland GNGT1
A11.436.294.064 Cells Epithelial Cells Glucagon Secreting Cells GNGT1
A11.436 Cells Epithelial Cells Epithelial Cells GNGT1
A11.443 Cells Erythroid Cells Erythroid Cells GNGT1
A10.336 Tissues Exocrine Glands Exocrine Glands GNGT1
A10.336.707 Tissues Exocrine Glands Prostate GNGT1
A09.371.729 Sense Organs Eye Retina GNGT1
A09.371 Sense Organs Eye Eye GNGT1
A09.371.060 Sense Organs Eye Anterior Eye Segment GNGT1
A09.371.337 Sense Organs Eye Eyelids GNGT1
A09.371.337.168 Sense Organs Eye Conjunctiva GNGT1
A03.556.875.500 Digestive System Gastrointestinal Tract Esophagus GNGT1
A03.556.124.526.767 Digestive System Gastrointestinal Tract Rectum GNGT1
A03.556.124.369 Digestive System Gastrointestinal Tract Intestinal Mucosa GNGT1
A03.556 Digestive System Gastrointestinal Tract Gastrointestinal Tract GNGT1
A03.556.124 Digestive System Gastrointestinal Tract Intestines GNGT1
A03.556.249 Digestive System Gastrointestinal Tract Lower Gastrointestinal Tract GNGT1
A03.556.249.249 Digestive System Gastrointestinal Tract Intestine  Large GNGT1
A03.556.249.249.356 Digestive System Gastrointestinal Tract Colon GNGT1
A03.556.249.249.209 Digestive System Gastrointestinal Tract Cecum GNGT1
A05.360.319.114.373 Urogenital System Genitalia Fallopian Tubes GNGT1
A05.360.319.114 Urogenital System Genitalia Adnexa Uteri GNGT1
A05.360.319.114.630 Urogenital System Genitalia Ovary GNGT1
A05.360.319.679.256 Urogenital System Genitalia Cervix Uteri GNGT1
A05.360.319 Urogenital System Genitalia Genitalia  Female GNGT1
A05.360 Urogenital System Genitalia Genitalia GNGT1
A05.360.319.679 Urogenital System Genitalia Uterus GNGT1
A15.378.316.378.590.837.250 Hemic and Immune Systems Hematopoietic System Erythroid Precursor Cells GNGT1
A15.382.520.604.700 Hemic and Immune Systems Immune System Spleen GNGT1
A04.411 Respiratory System Lung Lung GNGT1
A10.615.284 Tissues Membranes Extraembryonic Membranes GNGT1
A10.615.284.473 Tissues Membranes Chorion GNGT1
A14.549.885 Stomatognathic System Mouth Tongue GNGT1
A14.549 Stomatognathic System Mouth Mouth GNGT1
A03.734.414 Digestive System Pancreas Islets of Langerhans GNGT1
A03.734 Digestive System Pancreas Pancreas GNGT1
A02.835.232.043 Musculoskeletal System Skeleton Bones of Lower Extremity GNGT1
A02.835.232.043.300 Musculoskeletal System Skeleton Foot Bones GNGT1
A02.835.232.043.300.710 Musculoskeletal System Skeleton Tarsal Bones GNGT1
A11.872.378.590.817 Cells Stem Cells Megakaryocyte Erythroid Progenitor Cells GNGT1
A05.810 Urogenital System Urinary Tract Urinary Tract GNGT1
A05.810.453 Urogenital System Urinary Tract Kidney GNGT1
A05.810.890 Urogenital System Urinary Tract Urinary Bladder GNGT1
A11.063 Cells Antibody-Producing Cells Antibody Producing Cells HCN4
A11.066 Cells Antigen-Presenting Cells Antigen Presenting Cells HCN4
A15.145.229.637.555.567.562.725 Hemic and Immune Systems Blood Plasma Cells HCN4
A15.145.693 Hemic and Immune Systems Blood Plasma HCN4
A15.145.229.637.555 Hemic and Immune Systems Blood Leukocytes  Mononuclear HCN4
A15.145.229 Hemic and Immune Systems Blood Blood Cells HCN4
A15.145 Hemic and Immune Systems Blood Blood HCN4
A11.118.637.415 Cells Blood Cells Granulocytes HCN4
A11.118.637.555.567.562 Cells Blood Cells B Lymphocytes HCN4
A11.118.637 Cells Blood Cells Leukocytes HCN4
A08.186.211.653 Nervous System Central Nervous System Mesencephalon HCN4
A08.186.211.730.317 Nervous System Central Nervous System Diencephalon HCN4
A08.186.211.730.317.357 Nervous System Central Nervous System Hypothalamus HCN4
A08.186.211.730.317.357.352 Nervous System Central Nervous System Hypothalamus  Middle HCN4
A08.186.211.730.317.357.352.435 Nervous System Central Nervous System Hypothalamo Hypophyseal System HCN4
A08.186.211.132 Nervous System Central Nervous System Brain Stem HCN4
A10.165.450 Tissues Connective Tissue Granulation Tissue HCN4
A10.165.450.300 Tissues Connective Tissue Cicatrix HCN4
A10.165 Tissues Connective Tissue Connective Tissue HCN4
A10.165.450.300.425 Tissues Connective Tissue Keloid HCN4
A11.329.629 Cells Connective Tissue Cells Osteoblasts HCN4
A11.329.372.600 Cells Connective Tissue Cells Macrophages  Alveolar HCN4
A10.272.497 Tissues Epithelium Epidermis HCN4
A09.371.729 Sense Organs Eye Retina HCN4
A07.541.560 Cardiovascular System Heart Heart Ventricles HCN4
A07.541 Cardiovascular System Heart Heart HCN4
A07.541.358 Cardiovascular System Heart Heart Atria HCN4
A07.541.358.100 Cardiovascular System Heart Atrial Appendage HCN4
A15.378 Hemic and Immune Systems Hematopoietic System Hematopoietic System HCN4
A15.378.316 Hemic and Immune Systems Hematopoietic System Bone Marrow Cells HCN4
A15.378.316.580 Hemic and Immune Systems Hematopoietic System Monocytes HCN4
A15.382.490.315.583 Hemic and Immune Systems Immune System Neutrophils HCN4
A15.382 Hemic and Immune Systems Immune System Immune System HCN4
A15.382.216 Hemic and Immune Systems Immune System Bone Marrow HCN4
A15.382.680 Hemic and Immune Systems Immune System Phagocytes HCN4
A15.382.490.555.567 Hemic and Immune Systems Immune System Lymphocytes HCN4
A15.382.812 Hemic and Immune Systems Immune System Mononuclear Phagocyte System HCN4
A15.382.812.260 Hemic and Immune Systems Immune System Dendritic Cells HCN4
A15.382.812.522 Hemic and Immune Systems Immune System Macrophages HCN4
A15.382.520 Hemic and Immune Systems Immune System Lymphatic System HCN4
A15.382.520.604.800 Hemic and Immune Systems Immune System Palatine Tonsil HCN4
A10.549 Tissues Lymphoid Tissue Lymphoid Tissue HCN4
A10.549.400 Tissues Lymphoid Tissue Lymph Nodes HCN4
A11.620 Cells Muscle Cells Muscle Cells HCN4
A11.620.520 Cells Muscle Cells Myocytes  Smooth Muscle HCN4
A02.633.567.850 Musculoskeletal System Muscles Quadriceps Muscle HCN4
A10.690.552 Tissues Muscles Muscle  Striated HCN4
A10.690.552.500 Tissues Muscles Muscle  Skeletal HCN4
A10.690 Tissues Muscles Muscles HCN4
A11.627.340.360 Cells Myeloid Cells Granulocyte Precursor Cells HCN4
A11.627 Cells Myeloid Cells Myeloid Cells HCN4
A08.713 Nervous System Neurosecretory Systems Neurosecretory Systems HCN4
A14.724.557 Stomatognathic System Pharynx Nasopharynx HCN4
A14.724 Stomatognathic System Pharynx Pharynx HCN4
A04.623.603 Respiratory System Pharynx Oropharynx HCN4
A02.835.232.834 Musculoskeletal System Skeleton Spine HCN4
A02.835.232.834.151 Musculoskeletal System Skeleton Cervical Vertebrae HCN4
A02.835 Musculoskeletal System Skeleton Skeleton HCN4
A02.835.232 Musculoskeletal System Skeleton Bone and Bones HCN4
A11.872.700 Cells Stem Cells Pluripotent Stem Cells HCN4
A11.872.700.500 Cells Stem Cells Induced Pluripotent Stem Cells HCN4
A11.872.040 Cells Stem Cells Adult Stem Cells HCN4
A11.872.190 Cells Stem Cells Embryonic Stem Cells HCN4
A11.872.190.260 Cells Stem Cells Embryoid Bodies HCN4
A11.872 Cells Stem Cells Stem Cells HCN4
A07.231.114 Cardiovascular System Blood Vessels Arteries KIAA1755
A02.165 Musculoskeletal System Cartilage Cartilage KIAA1755
A08.186.211.653 Nervous System Central Nervous System Mesencephalon KIAA1755
A08.186.211.730.885.287.249.487 Nervous System Central Nervous System Corpus Striatum KIAA1755
A08.186.211.730.885.287.249 Nervous System Central Nervous System Basal Ganglia KIAA1755
A08.186.211.730.885.287.500.270 Nervous System Central Nervous System Frontal Lobe KIAA1755
A08.186.211.464.405 Nervous System Central Nervous System Hippocampus KIAA1755
A08.186.211.730.317 Nervous System Central Nervous System Diencephalon KIAA1755
A08.186.211.730.885.287.500.670 Nervous System Central Nervous System Parietal Lobe KIAA1755
A08.186.211.730 Nervous System Central Nervous System Prosencephalon KIAA1755
A08.186.211.730.885 Nervous System Central Nervous System Telencephalon KIAA1755
A08.186.211.730.885.287 Nervous System Central Nervous System Cerebrum KIAA1755
A08.186.211.730.885.287.500 Nervous System Central Nervous System Cerebral Cortex KIAA1755
A08.186.211.464 Nervous System Central Nervous System Limbic System KIAA1755
A08.186 Nervous System Central Nervous System Central Nervous System KIAA1755
A08.186.211 Nervous System Central Nervous System Brain KIAA1755
A08.186.211.730.885.287.500.863 Nervous System Central Nervous System Temporal Lobe KIAA1755
A08.186.211.464.710 Nervous System Central Nervous System Parahippocampal Gyrus KIAA1755
A08.186.211.464.710.225 Nervous System Central Nervous System Entorhinal Cortex KIAA1755
A08.186.211.730.885.287.500.571 Nervous System Central Nervous System Occipital Lobe KIAA1755
A08.186.211.730.885.287.500.571.735 Nervous System Central Nervous System Visual Cortex KIAA1755
A08.186.211.132 Nervous System Central Nervous System Brain Stem KIAA1755
A07.541.510 Cardiovascular System Heart Heart Valves KIAA1755
A07.541.510.110 Cardiovascular System Heart Aortic Valve KIAA1755
A11.063 Cells Antibody-Producing Cells Antibody Producing Cells LINC00477
A11.066 Cells Antigen-Presenting Cells Antigen Presenting Cells LINC00477
A15.145.229.637.555.567.562.725 Hemic and Immune Systems Blood Plasma Cells LINC00477
A15.145.693 Hemic and Immune Systems Blood Plasma LINC00477
A15.145.229.637.555 Hemic and Immune Systems Blood Leukocytes  Mononuclear LINC00477
A15.145 Hemic and Immune Systems Blood Blood LINC00477
A15.145.229 Hemic and Immune Systems Blood Blood Cells LINC00477
A15.145.229.637.555.567.569.200 Hemic and Immune Systems Blood CD4 Positive T Lymphocytes LINC00477
A15.145.846 Hemic and Immune Systems Blood Serum LINC00477
A11.118.637.555.567.562 Cells Blood Cells B Lymphocytes LINC00477
A11.118.637 Cells Blood Cells Leukocytes LINC00477
A11.118.637.555.567.562.440 Cells Blood Cells Precursor Cells  B Lymphoid LINC00477
A11.118.637.415 Cells Blood Cells Granulocytes LINC00477
A11.118.637.555.567.569 Cells Blood Cells T Lymphocytes LINC00477
A11.118.637.555.567.569.200.700 Cells Blood Cells T Lymphocytes  Regulatory LINC00477
A07.231.114 Cardiovascular System Blood Vessels Arteries LINC00477
A02.165 Musculoskeletal System Cartilage Cartilage LINC00477
A08.186.211.730.885.287.249 Nervous System Central Nervous System Basal Ganglia LINC00477
A10.165 Tissues Connective Tissue Connective Tissue LINC00477
A10.165.114 Tissues Connective Tissue Adipose Tissue LINC00477
A10.165.114.830 Tissues Connective Tissue Adipose Tissue  White LINC00477
A10.165.114.830.750 Tissues Connective Tissue Subcutaneous Fat LINC00477
A11.329.372.600 Cells Connective Tissue Cells Macrophages  Alveolar LINC00477
A11.329 Cells Connective Tissue Cells Connective Tissue Cells LINC00477
A06.407.900 Endocrine System Endocrine Glands Thyroid Gland LINC00477
A10.336 Tissues Exocrine Glands Exocrine Glands LINC00477
A10.336.707 Tissues Exocrine Glands Prostate LINC00477
A03.556.249.249.209 Digestive System Gastrointestinal Tract Cecum LINC00477
A03.556.124.684 Digestive System Gastrointestinal Tract Intestine  Small LINC00477
A03.556.249.249.356.668 Digestive System Gastrointestinal Tract Colon  Sigmoid LINC00477
A03.556.124 Digestive System Gastrointestinal Tract Intestines LINC00477
A03.556.124.526.767 Digestive System Gastrointestinal Tract Rectum LINC00477
A03.556.249.249 Digestive System Gastrointestinal Tract Intestine  Large LINC00477
A03.556.249 Digestive System Gastrointestinal Tract Lower Gastrointestinal Tract LINC00477
A03.556.249.249.356 Digestive System Gastrointestinal Tract Colon LINC00477
A03.556 Digestive System Gastrointestinal Tract Gastrointestinal Tract LINC00477
A03.556.124.369 Digestive System Gastrointestinal Tract Intestinal Mucosa LINC00477
A03.556.875.500 Digestive System Gastrointestinal Tract Esophagus LINC00477
A03.556.875 Digestive System Gastrointestinal Tract Upper Gastrointestinal Tract LINC00477
A05.360.319.679.256 Urogenital System Genitalia Cervix Uteri LINC00477
A05.360.319.679 Urogenital System Genitalia Uterus LINC00477
A05.360.444 Urogenital System Genitalia Genitalia  Male LINC00477
A15.378.316.580 Hemic and Immune Systems Hematopoietic System Monocytes LINC00477
A15.378 Hemic and Immune Systems Hematopoietic System Hematopoietic System LINC00477
A15.378.316 Hemic and Immune Systems Hematopoietic System Bone Marrow Cells LINC00477
A15.382.812.522 Hemic and Immune Systems Immune System Macrophages LINC00477
A15.382.812 Hemic and Immune Systems Immune System Mononuclear Phagocyte System LINC00477
A15.382.216 Hemic and Immune Systems Immune System Bone Marrow LINC00477
A15.382.680 Hemic and Immune Systems Immune System Phagocytes LINC00477
A15.382 Hemic and Immune Systems Immune System Immune System LINC00477
A15.382.490.555.567 Hemic and Immune Systems Immune System Lymphocytes LINC00477
A15.382.812.260 Hemic and Immune Systems Immune System Dendritic Cells LINC00477
A15.382.520 Hemic and Immune Systems Immune System Lymphatic System LINC00477
A15.382.490.555.567.537 Hemic and Immune Systems Immune System Killer Cells  Natural LINC00477
A15.382.520.604.800 Hemic and Immune Systems Immune System Palatine Tonsil LINC00477
A15.382.490.555.567.622 Hemic and Immune Systems Immune System Lymphocytes  Null LINC00477
A15.382.490.315.583 Hemic and Immune Systems Immune System Neutrophils LINC00477
A15.382.520.604.700 Hemic and Immune Systems Immune System Spleen LINC00477
A10.549.400 Tissues Lymphoid Tissue Lymph Nodes LINC00477
A10.549 Tissues Lymphoid Tissue Lymphoid Tissue LINC00477
A10.615.789 Tissues Membranes Serous Membrane LINC00477
A02.633.567.850 Musculoskeletal System Muscles Quadriceps Muscle LINC00477
A10.690.552 Tissues Muscles Muscle  Striated LINC00477
A10.690.552.500 Tissues Muscles Muscle  Skeletal LINC00477
A10.690 Tissues Muscles Muscles LINC00477
A11.627.340.360 Cells Myeloid Cells Granulocyte Precursor Cells LINC00477
A11.627 Cells Myeloid Cells Myeloid Cells LINC00477
A11.627.624.249 Cells Myeloid Cells Monocyte Macrophage Precursor Cells LINC00477
A04.623.603 Respiratory System Pharynx Oropharynx LINC00477
A14.724 Stomatognathic System Pharynx Pharynx LINC00477
A14.724.557 Stomatognathic System Pharynx Nasopharynx LINC00477
A02.835 Musculoskeletal System Skeleton Skeleton LINC00477
A02.835.232 Musculoskeletal System Skeleton Bone and Bones LINC00477
A02.835.583.443.800.800 Musculoskeletal System Skeleton Synovial Fluid LINC00477
A11.872.378.590.635 Cells Stem Cells Granulocyte Macrophage Progenitor Cells LINC00477
A11.872.378.294 Cells Stem Cells Lymphoid Progenitor Cells LINC00477
A11.872.378 Cells Stem Cells Hematopoietic Stem Cells LINC00477
A05.810.890 Urogenital System Urinary Tract Urinary Bladder LINC00477
A05.810 Urogenital System Urinary Tract Urinary Tract LINC00477
A05.810.453 Urogenital System Urinary Tract Kidney LINC00477
A08.186.211.730.317.357.352 Nervous System Central Nervous System Hypothalamus  Middle NDUFA11
A08.186.211.730.317.357.352.435 Nervous System Central Nervous System Hypothalamo Hypophyseal System NDUFA11
A08.186.211.653 Nervous System Central Nervous System Mesencephalon NDUFA11
A08.186.211.730.317.357 Nervous System Central Nervous System Hypothalamus NDUFA11
A08.186.211.730.317 Nervous System Central Nervous System Diencephalon NDUFA11
A08.186.211.730.885.287.500.270 Nervous System Central Nervous System Frontal Lobe NDUFA11
A08.186.211.464 Nervous System Central Nervous System Limbic System NDUFA11
A08.186.211.464.405 Nervous System Central Nervous System Hippocampus NDUFA11
A08.186.211.730 Nervous System Central Nervous System Prosencephalon NDUFA11
A08.186.211.464.710 Nervous System Central Nervous System Parahippocampal Gyrus NDUFA11
A08.186.211.464.710.225 Nervous System Central Nervous System Entorhinal Cortex NDUFA11
A08.186.211.730.885 Nervous System Central Nervous System Telencephalon NDUFA11
A08.186.211.730.885.287 Nervous System Central Nervous System Cerebrum NDUFA11
A08.186.211.730.885.287.500 Nervous System Central Nervous System Cerebral Cortex NDUFA11
A08.186.211.730.885.287.500.863 Nervous System Central Nervous System Temporal Lobe NDUFA11
A08.186 Nervous System Central Nervous System Central Nervous System NDUFA11
A08.186.211 Nervous System Central Nervous System Brain NDUFA11
A10.165.450.300.425 Tissues Connective Tissue Keloid NDUFA11
A11.329.171 Cells Connective Tissue Cells Chondrocytes NDUFA11
A11.329.228 Cells Connective Tissue Cells Fibroblasts NDUFA11
A11.382 Cells Endocrine Cells Endocrine Cells NDUFA11
A06.407.071.140 Endocrine System Endocrine Glands Adrenal Cortex NDUFA11
A06.407.071 Endocrine System Endocrine Glands Adrenal Glands NDUFA11
A06.407.312.497.535.300.500 Endocrine System Endocrine Glands Cumulus Cells NDUFA11
A06.407 Endocrine System Endocrine Glands Endocrine Glands NDUFA11
A11.436.329 Cells Epithelial Cells Granulosa Cells NDUFA11
A09.371.337 Sense Organs Eye Eyelids NDUFA11
A09.371.337.168 Sense Organs Eye Conjunctiva NDUFA11
A09.371.060 Sense Organs Eye Anterior Eye Segment NDUFA11
A09.371 Sense Organs Eye Eye NDUFA11
A03.556 Digestive System Gastrointestinal Tract Gastrointestinal Tract NDUFA11
A03.556.249.249 Digestive System Gastrointestinal Tract Intestine  Large NDUFA11
A03.556.249.249.209 Digestive System Gastrointestinal Tract Cecum NDUFA11
A03.556.249.249.356 Digestive System Gastrointestinal Tract Colon NDUFA11
A03.556.249 Digestive System Gastrointestinal Tract Lower Gastrointestinal Tract NDUFA11
A05.360.319.114.630.535 Urogenital System Genitalia Ovarian Follicle NDUFA11
A05.360.490.690 Urogenital System Genitalia Ovum NDUFA11
A05.360.490 Urogenital System Genitalia Germ Cells NDUFA11
A05.360.319.679 Urogenital System Genitalia Uterus NDUFA11
A05.360.319.679.490 Urogenital System Genitalia Endometrium NDUFA11
A05.360.319 Urogenital System Genitalia Genitalia  Female NDUFA11
A05.360.319.679.690 Urogenital System Genitalia Myometrium NDUFA11
A05.360.319.679.256 Urogenital System Genitalia Cervix Uteri NDUFA11
A05.360.319.887 Urogenital System Genitalia Vulva NDUFA11
A11.497.497.600 Cells Germ Cells Oocytes NDUFA11
A07.541.358.100 Cardiovascular System Heart Atrial Appendage NDUFA11
A07.541.358 Cardiovascular System Heart Heart Atria NDUFA11
A07.541 Cardiovascular System Heart Heart NDUFA11
A07.541.560 Cardiovascular System Heart Heart Ventricles NDUFA11
A15.382.490.555.567.622 Hemic and Immune Systems Immune System Lymphocytes  Null NDUFA11
A03.620 Digestive System Liver Liver NDUFA11
A10.615.550.599 Tissues Membranes Mouth Mucosa NDUFA11
A10.615.789 Tissues Membranes Serous Membrane NDUFA11
A14.549.885 Stomatognathic System Mouth Tongue NDUFA11
A14.549.167.646 Stomatognathic System Mouth Periodontium NDUFA11
A14.549 Stomatognathic System Mouth Mouth NDUFA11
A14.549.167 Stomatognathic System Mouth Dentition NDUFA11
A11.620 Cells Muscle Cells Muscle Cells NDUFA11
A11.620.520 Cells Muscle Cells Myocytes  Smooth Muscle NDUFA11
A02.633.567.850 Musculoskeletal System Muscles Quadriceps Muscle NDUFA11
A10.690.552 Tissues Muscles Muscle  Striated NDUFA11
A10.690.552.500 Tissues Muscles Muscle  Skeletal NDUFA11
A10.690 Tissues Muscles Muscles NDUFA11
A10.690.467 Tissues Muscles Muscle  Smooth NDUFA11
A11.627.624.249 Cells Myeloid Cells Monocyte Macrophage Precursor Cells NDUFA11
A11.627.340.360 Cells Myeloid Cells Granulocyte Precursor Cells NDUFA11
A11.627.635 Cells Myeloid Cells Myeloid Progenitor Cells NDUFA11
A08.713 Nervous System Neurosecretory Systems Neurosecretory Systems NDUFA11
A14.724.557 Stomatognathic System Pharynx Nasopharynx NDUFA11
A14.724 Stomatognathic System Pharynx Pharynx NDUFA11
A02.835.232.043 Musculoskeletal System Skeleton Bones of Lower Extremity NDUFA11
A02.835.232.043.300 Musculoskeletal System Skeleton Foot Bones NDUFA11
A02.835.232.043.300.710 Musculoskeletal System Skeleton Tarsal Bones NDUFA11
A02.835.232.834 Musculoskeletal System Skeleton Spine NDUFA11
A02.835.232.834.151 Musculoskeletal System Skeleton Cervical Vertebrae NDUFA11
A02.835.583.443.800.800 Musculoskeletal System Skeleton Synovial Fluid NDUFA11
A11.872.653 Cells Stem Cells Neural Stem Cells NDUFA11
A11.872.378.590.635 Cells Stem Cells Granulocyte Macrophage Progenitor Cells NDUFA11
A11.872 Cells Stem Cells Stem Cells NDUFA11
A05.810.453.324 Urogenital System Urinary Tract Kidney Cortex NDUFA11
A08.186.211.730.885.287.249.487 Nervous System Central Nervous System Corpus Striatum NEO1
A08.186.211.653 Nervous System Central Nervous System Mesencephalon NEO1
A08.186.211.730.885.287.249 Nervous System Central Nervous System Basal Ganglia NEO1
A08.186.211.464.405 Nervous System Central Nervous System Hippocampus NEO1
A08.186.211.730.317 Nervous System Central Nervous System Diencephalon NEO1
A08.186 Nervous System Central Nervous System Central Nervous System NEO1
A08.186.211 Nervous System Central Nervous System Brain NEO1
A08.186.211.132 Nervous System Central Nervous System Brain Stem NEO1
A08.186.211.730.317.357 Nervous System Central Nervous System Hypothalamus NEO1
A08.186.211.865 Nervous System Central Nervous System Rhombencephalon NEO1
A08.186.211.865.428 Nervous System Central Nervous System Metencephalon NEO1
A08.186.211.132.810.428.200 Nervous System Central Nervous System Cerebellum NEO1
A11.329.629 Cells Connective Tissue Cells Osteoblasts NEO1
A06.407.312 Endocrine System Endocrine Glands Gonads NEO1
A06.407 Endocrine System Endocrine Glands Endocrine Glands NEO1
A10.272.497 Tissues Epithelium Epidermis NEO1
A10.272 Tissues Epithelium Epithelium NEO1
A09.371.060 Sense Organs Eye Anterior Eye Segment NEO1
A09.371.337 Sense Organs Eye Eyelids NEO1
A09.371.337.168 Sense Organs Eye Conjunctiva NEO1
A09.371 Sense Organs Eye Eye NEO1
A03.556.124.369 Digestive System Gastrointestinal Tract Intestinal Mucosa NEO1
A03.556.124.526.767 Digestive System Gastrointestinal Tract Rectum NEO1
A03.556.124 Digestive System Gastrointestinal Tract Intestines NEO1
A03.556.249 Digestive System Gastrointestinal Tract Lower Gastrointestinal Tract NEO1
A03.556.249.249 Digestive System Gastrointestinal Tract Intestine  Large NEO1
A03.556.249.249.356 Digestive System Gastrointestinal Tract Colon NEO1
A03.556.249.249.356.668 Digestive System Gastrointestinal Tract Colon  Sigmoid NEO1
A03.556 Digestive System Gastrointestinal Tract Gastrointestinal Tract NEO1
A03.556.249.249.209 Digestive System Gastrointestinal Tract Cecum NEO1
A03.556.875.875 Digestive System Gastrointestinal Tract Stomach NEO1
A03.556.875 Digestive System Gastrointestinal Tract Upper Gastrointestinal Tract NEO1
A05.360.319.114.373 Urogenital System Genitalia Fallopian Tubes NEO1
A05.360.319.114 Urogenital System Genitalia Adnexa Uteri NEO1
A05.360.319.114.630 Urogenital System Genitalia Ovary NEO1
A05.360 Urogenital System Genitalia Genitalia NEO1
A05.360.319 Urogenital System Genitalia Genitalia  Female NEO1
A05.360.319.679 Urogenital System Genitalia Uterus NEO1
A10.615.550 Tissues Membranes Mucous Membrane NEO1
A10.615.550.760 Tissues Membranes Respiratory Mucosa NEO1
A10.615 Tissues Membranes Membranes NEO1
A04.531.520 Respiratory System Nose Nasal Mucosa NEO1
A09.531 Sense Organs Nose Nose NEO1
A02.835.232.043 Musculoskeletal System Skeleton Bones of Lower Extremity NEO1
A02.835.232.043.300 Musculoskeletal System Skeleton Foot Bones NEO1
A02.835.232.043.300.710 Musculoskeletal System Skeleton Tarsal Bones NEO1
A17.815 Integumentary System Skin Skin NEO1
A11.872.653 Cells Stem Cells Neural Stem Cells NEO1
A05.810.453 Urogenital System Urinary Tract Kidney NEO1
A15.145.229.334 Hemic and Immune Systems Blood Erythrocytes PPIL1
A15.145.846 Hemic and Immune Systems Blood Serum PPIL1
A07.231.908.670 Cardiovascular System Blood Vessels Portal System PPIL1
A07.231.908.670.874 Cardiovascular System Blood Vessels Umbilical Veins PPIL1
A07.231.908 Cardiovascular System Blood Vessels Veins PPIL1
A08.186.211.132.810.428.200 Nervous System Central Nervous System Cerebellum PPIL1
A08.186.211.865 Nervous System Central Nervous System Rhombencephalon PPIL1
A08.186.211.865.428 Nervous System Central Nervous System Metencephalon PPIL1
A11.329.228 Cells Connective Tissue Cells Fibroblasts PPIL1
A11.382 Cells Endocrine Cells Endocrine Cells PPIL1
A11.382.625 Cells Endocrine Cells Enteroendocrine Cells PPIL1
A06.407.071.140 Endocrine System Endocrine Glands Adrenal Cortex PPIL1
A06.407.071 Endocrine System Endocrine Glands Adrenal Glands PPIL1
A06.407.312.497.535.300.500 Endocrine System Endocrine Glands Cumulus Cells PPIL1
A06.407.312.782 Endocrine System Endocrine Glands Testis PPIL1
A06.407 Endocrine System Endocrine Glands Endocrine Glands PPIL1
A06.407.312 Endocrine System Endocrine Glands Gonads PPIL1
A11.436.348 Cells Epithelial Cells Hepatocytes PPIL1
A11.436.329 Cells Epithelial Cells Granulosa Cells PPIL1
A11.436.294.064 Cells Epithelial Cells Glucagon Secreting Cells PPIL1
A11.436.397 Cells Epithelial Cells Keratinocytes PPIL1
A11.436.275 Cells Epithelial Cells Endothelial Cells PPIL1
A11.436 Cells Epithelial Cells Epithelial Cells PPIL1
A11.443 Cells Erythroid Cells Erythroid Cells PPIL1
A09.371.729 Sense Organs Eye Retina PPIL1
A03.556.249.249.356 Digestive System Gastrointestinal Tract Colon PPIL1
A03.556 Digestive System Gastrointestinal Tract Gastrointestinal Tract PPIL1
A03.556.249 Digestive System Gastrointestinal Tract Lower Gastrointestinal Tract PPIL1
A03.556.249.249 Digestive System Gastrointestinal Tract Intestine  Large PPIL1
A03.556.124 Digestive System Gastrointestinal Tract Intestines PPIL1
A03.556.249.249.209 Digestive System Gastrointestinal Tract Cecum PPIL1
A05.360.490 Urogenital System Genitalia Germ Cells PPIL1
A05.360.490.690 Urogenital System Genitalia Ovum PPIL1
A05.360.319.114.630.535 Urogenital System Genitalia Ovarian Follicle PPIL1
A05.360.319.114.373 Urogenital System Genitalia Fallopian Tubes PPIL1
A05.360.319.114 Urogenital System Genitalia Adnexa Uteri PPIL1
A05.360.319.114.630 Urogenital System Genitalia Ovary PPIL1
A05.360.319.679.490 Urogenital System Genitalia Endometrium PPIL1
A05.360.319.887 Urogenital System Genitalia Vulva PPIL1
A05.360.319 Urogenital System Genitalia Genitalia  Female PPIL1
A05.360.319.679 Urogenital System Genitalia Uterus PPIL1
A05.360 Urogenital System Genitalia Genitalia PPIL1
A11.497.497.600 Cells Germ Cells Oocytes PPIL1
A07.541.560 Cardiovascular System Heart Heart Ventricles PPIL1
A07.541 Cardiovascular System Heart Heart PPIL1
A15.378.316.378.590.837.250 Hemic and Immune Systems Hematopoietic System Erythroid Precursor Cells PPIL1
A15.382.490.555.567.622 Hemic and Immune Systems Immune System Lymphocytes  Null PPIL1
A15.382.520.604.700 Hemic and Immune Systems Immune System Spleen PPIL1
A15.382.520 Hemic and Immune Systems Immune System Lymphatic System PPIL1
A04.411 Respiratory System Lung Lung PPIL1
A10.549 Tissues Lymphoid Tissue Lymphoid Tissue PPIL1
A10.615.284 Tissues Membranes Extraembryonic Membranes PPIL1
A10.615.284.473 Tissues Membranes Chorion PPIL1
A10.615.550.599 Tissues Membranes Mouth Mucosa PPIL1
A14.549.885 Stomatognathic System Mouth Tongue PPIL1
A14.549 Stomatognathic System Mouth Mouth PPIL1
A11.627.635 Cells Myeloid Cells Myeloid Progenitor Cells PPIL1
A11.627.624.249 Cells Myeloid Cells Monocyte Macrophage Precursor Cells PPIL1
A11.627.340.360 Cells Myeloid Cells Granulocyte Precursor Cells PPIL1
A03.734.414 Digestive System Pancreas Islets of Langerhans PPIL1
A02.835.232.834 Musculoskeletal System Skeleton Spine PPIL1
A02.835.232.834.151 Musculoskeletal System Skeleton Cervical Vertebrae PPIL1
A11.872.378.590.817 Cells Stem Cells Megakaryocyte Erythroid Progenitor Cells PPIL1
A11.872.700 Cells Stem Cells Pluripotent Stem Cells PPIL1
A11.872.700.500 Cells Stem Cells Induced Pluripotent Stem Cells PPIL1
A11.872.190 Cells Stem Cells Embryonic Stem Cells PPIL1
A11.872.040 Cells Stem Cells Adult Stem Cells PPIL1
A11.872.378.590.635 Cells Stem Cells Granulocyte Macrophage Progenitor Cells PPIL1
A11.872.378 Cells Stem Cells Hematopoietic Stem Cells PPIL1
A11.872.653 Cells Stem Cells Neural Stem Cells PPIL1
A11.872 Cells Stem Cells Stem Cells PPIL1
A11.872.190.260 Cells Stem Cells Embryoid Bodies PPIL1
A15.145.229.637.555.567.569.200 Hemic and Immune Systems Blood CD4 Positive T Lymphocytes RANBP3
A15.145.846 Hemic and Immune Systems Blood Serum RANBP3
A15.145.300 Hemic and Immune Systems Blood Fetal Blood RANBP3
A15.145.229.637.555 Hemic and Immune Systems Blood Leukocytes  Mononuclear RANBP3
A15.145 Hemic and Immune Systems Blood Blood RANBP3
A15.145.229 Hemic and Immune Systems Blood Blood Cells RANBP3
A11.118.637.555.567.569 Cells Blood Cells T Lymphocytes RANBP3
A11.118.637.555.567.569.200.700 Cells Blood Cells T Lymphocytes  Regulatory RANBP3
A11.118.637.415 Cells Blood Cells Granulocytes RANBP3
A11.118.637.555.567.562.440 Cells Blood Cells Precursor Cells  B Lymphoid RANBP3
A07.231 Cardiovascular System Blood Vessels Blood Vessels RANBP3
A08.186.211.730.317.357.352 Nervous System Central Nervous System Hypothalamus  Middle RANBP3
A08.186.211.730.317.357.352.435 Nervous System Central Nervous System Hypothalamo Hypophyseal System RANBP3
A08.186.211.730.317.357 Nervous System Central Nervous System Hypothalamus RANBP3
A08.186.211.730.317 Nervous System Central Nervous System Diencephalon RANBP3
A08.186.211.730.885.287.500.670 Nervous System Central Nervous System Parietal Lobe RANBP3
A08.186.211.464.405 Nervous System Central Nervous System Hippocampus RANBP3
A08.186.211.653 Nervous System Central Nervous System Mesencephalon RANBP3
A08.186.211.464 Nervous System Central Nervous System Limbic System RANBP3
A08.186.211.464.710 Nervous System Central Nervous System Parahippocampal Gyrus RANBP3
A08.186.211.464.710.225 Nervous System Central Nervous System Entorhinal Cortex RANBP3
A08.186.211.730.885.287.500.270 Nervous System Central Nervous System Frontal Lobe RANBP3
A08.186.211.730 Nervous System Central Nervous System Prosencephalon RANBP3
A08.186.211.730.885.287.500 Nervous System Central Nervous System Cerebral Cortex RANBP3
A08.186.211.730.885.287.500.863 Nervous System Central Nervous System Temporal Lobe RANBP3
A08.186.211.730.885 Nervous System Central Nervous System Telencephalon RANBP3
A08.186.211.730.885.287 Nervous System Central Nervous System Cerebrum RANBP3
A08.186.211.132 Nervous System Central Nervous System Brain Stem RANBP3
A08.186.211.132.810.428.200 Nervous System Central Nervous System Cerebellum RANBP3
A08.186.211.865 Nervous System Central Nervous System Rhombencephalon RANBP3
A08.186.211.865.428 Nervous System Central Nervous System Metencephalon RANBP3
A08.186 Nervous System Central Nervous System Central Nervous System RANBP3
A08.186.211 Nervous System Central Nervous System Brain RANBP3
A10.165.114.830.500 Tissues Connective Tissue Abdominal Fat RANBP3
A10.165.114.830.500.750 Tissues Connective Tissue Subcutaneous Fat  Abdominal RANBP3
A10.165.114.830 Tissues Connective Tissue Adipose Tissue  White RANBP3
A10.165.114.830.750 Tissues Connective Tissue Subcutaneous Fat RANBP3
A06.407.071.140 Endocrine System Endocrine Glands Adrenal Cortex RANBP3
A06.407.071 Endocrine System Endocrine Glands Adrenal Glands RANBP3
A11.436.348 Cells Epithelial Cells Hepatocytes RANBP3
A11.436.275 Cells Epithelial Cells Endothelial Cells RANBP3
A03.556.500.760.464 Digestive System Gastrointestinal Tract Parotid Gland RANBP3
A03.556.500.760 Digestive System Gastrointestinal Tract Salivary Glands RANBP3
A03.556.249.124 Digestive System Gastrointestinal Tract Ileum RANBP3
A03.556.875.875 Digestive System Gastrointestinal Tract Stomach RANBP3
A03.556.124.684 Digestive System Gastrointestinal Tract Intestine  Small RANBP3
A03.556.875 Digestive System Gastrointestinal Tract Upper Gastrointestinal Tract RANBP3
A03.556.124.526.767 Digestive System Gastrointestinal Tract Rectum RANBP3
A03.556.249.249.209 Digestive System Gastrointestinal Tract Cecum RANBP3
A15.382.490.555.567.622 Hemic and Immune Systems Immune System Lymphocytes  Null RANBP3
A15.382.490.555.567 Hemic and Immune Systems Immune System Lymphocytes RANBP3
A15.382.490.555.567.537 Hemic and Immune Systems Immune System Killer Cells  Natural RANBP3
A15.382.490.315.583 Hemic and Immune Systems Immune System Neutrophils RANBP3
A15.382.520.604.700 Hemic and Immune Systems Immune System Spleen RANBP3
A10.615.789 Tissues Membranes Serous Membrane RANBP3
A10.615.550.760 Tissues Membranes Respiratory Mucosa RANBP3
A02.633.567.850 Musculoskeletal System Muscles Quadriceps Muscle RANBP3
A10.690.552 Tissues Muscles Muscle  Striated RANBP3
A10.690.552.500 Tissues Muscles Muscle  Skeletal RANBP3
A11.627.624.249 Cells Myeloid Cells Monocyte Macrophage Precursor Cells RANBP3
A08.713 Nervous System Neurosecretory Systems Neurosecretory Systems RANBP3
A04.531.520 Respiratory System Nose Nasal Mucosa RANBP3
A09.531 Sense Organs Nose Nose RANBP3
A02.835.583 Musculoskeletal System Skeleton Joints RANBP3
A02.835.583.443 Musculoskeletal System Skeleton Joint Capsule RANBP3
A02.835.583.443.800 Musculoskeletal System Skeleton Synovial Membrane RANBP3
A02.835.583.443.800.800 Musculoskeletal System Skeleton Synovial Fluid RANBP3
A11.872.653 Cells Stem Cells Neural Stem Cells RANBP3
A11.872.700 Cells Stem Cells Pluripotent Stem Cells RANBP3
A11.872.700.500 Cells Stem Cells Induced Pluripotent Stem Cells RANBP3
A11.872.040 Cells Stem Cells Adult Stem Cells RANBP3
A11.872.190.260 Cells Stem Cells Embryoid Bodies RANBP3
A11.872.190 Cells Stem Cells Embryonic Stem Cells RANBP3
A11.872.378 Cells Stem Cells Hematopoietic Stem Cells RANBP3
A11.872.378.294 Cells Stem Cells Lymphoid Progenitor Cells RANBP3
A05.810.890 Urogenital System Urinary Tract Urinary Bladder RANBP3
A15.145.229.188 Hemic and Immune Systems Blood Blood Platelets RGS6
A15.145.229.334 Hemic and Immune Systems Blood Erythrocytes RGS6
A15.145.300 Hemic and Immune Systems Blood Fetal Blood RGS6
A08.186.211.653 Nervous System Central Nervous System Mesencephalon RGS6
A08.186.211.730.885.287.500.270 Nervous System Central Nervous System Frontal Lobe RGS6
A08.186.211.730.885.287.249 Nervous System Central Nervous System Basal Ganglia RGS6
A08.186.211.730.885.287.249.487 Nervous System Central Nervous System Corpus Striatum RGS6
A08.186.211.730.885.287.500.571 Nervous System Central Nervous System Occipital Lobe RGS6
A08.186.211.730.885.287.500.571.735 Nervous System Central Nervous System Visual Cortex RGS6
A08.186.211.730.885.287.500.863 Nervous System Central Nervous System Temporal Lobe RGS6
A08.186.211.464.710 Nervous System Central Nervous System Parahippocampal Gyrus RGS6
A08.186.211.464.710.225 Nervous System Central Nervous System Entorhinal Cortex RGS6
A08.186.211.730.317 Nervous System Central Nervous System Diencephalon RGS6
A08.186.211.730 Nervous System Central Nervous System Prosencephalon RGS6
A08.186.211.730.885 Nervous System Central Nervous System Telencephalon RGS6
A08.186.211.730.885.287 Nervous System Central Nervous System Cerebrum RGS6
A08.186.211.730.885.287.500 Nervous System Central Nervous System Cerebral Cortex RGS6
A08.186.211.132 Nervous System Central Nervous System Brain Stem RGS6
A08.186.211.730.317.357 Nervous System Central Nervous System Hypothalamus RGS6
A08.186.211.730.885.287.500.670 Nervous System Central Nervous System Parietal Lobe RGS6
A08.186.211.730.317.357.352 Nervous System Central Nervous System Hypothalamus  Middle RGS6
A08.186.211.730.317.357.352.435 Nervous System Central Nervous System Hypothalamo Hypophyseal System RGS6
A08.186 Nervous System Central Nervous System Central Nervous System RGS6
A08.186.211 Nervous System Central Nervous System Brain RGS6
A11.443 Cells Erythroid Cells Erythroid Cells RGS6
A08.713 Nervous System Neurosecretory Systems Neurosecretory Systems RGS6
A11.872.653 Cells Stem Cells Neural Stem Cells RGS6
MeSH: Medical Subject Heading
pvRSA/HF RMSSD SDNN
A11.063 1,5 1,5 1,5
A15.145.229.637.555.567.562.725 2,4 2,4 2,4
A15.145.693 2,4 2,4 2,4
A15.145.846 1,3 1,3 1,3
A11.118.637.555.567.562 1,5 1,5 1,5
A11.118.637.415 1,2 - -
A11.118.637 0,7 - -
A07.231 0,9 0,9 0,9
A07.231.908.670 0,6 - -
A07.231.908.670.874 0,6 - -
A07.231.908 0,5 - -
A07.231.114 0,3 - -
A08.186.211.730.317.357.352 0,8 - -
A08.186.211.730.317.357.352.435 0,8 - -
A10.165.450 1,4 1,4 1,4
A10.165.450.300 1,4 1,4 1,4
A10.165.450.300.425 1,3 - -
A10.165.114.830.500 -0,1 - -
A10.165.114.830.500.750 -0,1 - -
A11.329.830 1,6 1,6 1,6
A11.329.171 1,4 1,4 1,4
A11.329.228 1,2 1,2 1,2
A11.329 1,0 1,0 1,0
A11.329.114 0,6 - -
Z-scoreMeSH
A11.329.372.600 0,6 - -
A11.382.625 0,4 - -
A11.436.397 1,0 1,0 -
A11.436.348 0,8 - 0,8
A11.436.275 0,6 - -
A11.436.294.064 0,4 - -
A10.272 0,0 - -
A07.541.560 1,4 - -
A07.541 1,2 - -
A15.378.316.378.590.837.250 2,6 2,6 2,6
A15.378 0,9 - -
A15.378.316 0,9 - -
A15.382.490.315.583 1,4 - -
A15.382.812.522 1,1 1,1 -
A15.382.680 0,9 - -
A15.382.490.555.567.622 0,7 - -
A15.382.490.555.567 0,6 - -
A15.382 0,5 - -
A10.615.284 1,7 1,7 1,7
A10.615.284.473 1,7 1,7 1,7
A10.615.550.599 0,9 0,9 -
A10.615 0,4 - -
A10.615.550 0,2 - -
A14.549.167 0,8 0,8 -
A11.620 2,2 2,2 2,2
A11.620.520 2,2 2,2 2,2
A10.690.467 1,5 1,5 1,5
A11.627.624.249 2,3 2,3 2,3
A11.627.635 1,8 1,8 1,8
A11.627 0,9 - -
A08.713 0,8 - -
A03.734.414 0,6 - -
A03.734 0,2 - -
A02.835.583 1,1 1,1 -
A02.835.583.443 1,1 1,1 -
A02.835.583.443.800 1,1 1,1 -
A02.835.583.443.800.800 0,2 - -
A11.872.378.590.817 2,6 2,6 2,6
A11.872.378.590.635 1,5 1,5 1,5
A11.872.378 1,3 1,3 1,3
A11.872.580 0,9 0,9 -
A11.872.653 0,8 - -
A11.872 0,4 - -
A15.145.229.188 1,1 - -
A15.145.229.637.555.567.569.200 0,3 - -
A11.118.637.555.567.569.200.700 0,2 - -
A08.186.211.730.885.287.249 0,9 - -
A08.186.211.730.317 0,8 - -
A08.186.211.730.317.357 0,7 - -
A08.186.211.730.317.357.352 0,5 - -
A08.186.211.730.317.357.352.435 0,5 - -
A08.186.211.730.885.287.500.670 0,5 - -
A08.186.211.464.405 0,4 - -
A08.186.211.653 0,4 - -
A08.186.211.730 0,4 - -
A08.186.211.464 0,3 - -
A08.186.211.730.885 0,3 - -
A08.186.211.730.885.287 0,2 - -
A08.186.211.730.885.287.500 0,2 - -
A08.186.211.464.710 0,1 - -
A08.186.211.464.710.225 0,1 - -
A08.186.211.730.885.287.500.863 0,1 - -
A08.186.211.132 -0,1 - -
A08.186 -0,2 - -
A08.186.211.865 -0,3 - -
A08.186.211.865.428 -0,3 - -
A08.186.211.132.810.428.200 -0,6 - -
A11.329.629 0,5 - -
A06.407.312 0,8 0,8 0,8
A06.407.900 0,6 - -
A06.407 0,6 0,6 0,6
A11.436 0,9 0,9 0,9
A10.272 3,2 3,2 3,2
A03.556.500.760 1,3 - -
A03.556.500.760.464 1,3 - -
A03.556.875.875 0,2 - -
A05.360.319.679.490 3,2 3,2 3,2
A05.360.490.690 2,3 2,3 2,3
A05.360.319.679 2,2 2,2 2,2
A05.360.490 2,0 2,0 2,0
A05.360.319 1,4 1,4 1,4
A05.360.319.114.373 1,1 1,1 1,1
A05.360 0,9 0,9 0,9
A05.360.319.114 0,9 0,9 0,9
A05.360.319.114.630 0,9 0,9 0,9
A11.497.497.600 2,3 2,3 2,3
A10.615.550.760 5,6 5,6 5,6
A10.615.550 1,6 1,6 1,6
A10.615 1,3 1,3 1,3
A10.615.789 0,6 0,6 0,6
A08.713 0,5 - -
A04.531.520 5,6 5,6 5,6
A09.531 5,6 5,6 5,6
A05.810.890 1,6 1,6 1,6
A11.063 3,3 3,3 3,3
A15.145.229.637.555.567.562.725 3,8 3,8 3,8
A15.145.693 3,8 3,8 3,8
A15.145.229.188 2,7 - 2,7
A15.145.229.637.555 1,0 1,0 1,0
A15.145.229 0,8 0,8 0,8
A15.145 0,6 - -
A11.118.637.555.567.562 3,3 3,3 3,3
A11.118.637 0,8 - -
A11.118.637.555.567.562.440 0,6 - -
A07.231.908 0,6 - -
A07.231.908.670 0,6 - -
A07.231.908.670.874 0,6 - -
A08.186.211.730.885.287.500.270 2,4 2,4 2,4
A08.186.211.730.885.287.249 2,1 2,1 2,1
A08.186.211.464.710 2,0 2,0 2,0
A08.186.211.464.710.225 2,0 2,0 2,0
A08.186.211.730.885.287.500.670 2,0 2,0 2,0
A08.186.211.730.885.287.500.863 2,0 2,0 2,0
A08.186.211.730.885.287.249.487 1,8 - -
A08.186.211.730.885.287 1,7 1,7 1,7
A08.186.211.464 1,6 1,6 1,6
A08.186.211.730.885 1,6 1,6 1,6
A08.186.211.730.885.287.500 1,6 1,6 1,6
A08.186.211.730 1,5 1,5 1,5
A08.186.211 1,3 1,3 1,3
A08.186 1,2 1,2 1,2
A08.186.211.464.405 1,1 - -
A08.186.211.730.885.287.500.571 1,1 - -
A08.186.211.730.885.287.500.571.735 1,0 - -
A08.186.211.653 0,8 - -
A08.186.211.730.317.357 0,6 - -
A08.186.211.132 -0,1 - -
A08.186.211.865 -0,5 - -
A08.186.211.865.428 -0,5 - -
A08.186.211.132.810.428.200 -0,7 - -
A10.165 0,9 0,9 -
A07.541.560 1,5 - -
A07.541 1,3 - -
A07.541.358 1,1 - -
A15.382.520.604.800 2,3 2,3 2,3
A15.382.490.555.567 1,6 1,6 1,6
A15.382.520 1,3 1,3 1,3
A15.382.216 1,2 1,2 -
A15.382 0,9 0,9 -
A15.382.520.604.700 0,8 0,8 0,8
A10.549 1,3 1,3 1,3
A10.549.400 1,2 1,2 1,2
A04.623.603 2,3 2,3 2,3
A14.724 1,1 1,1 1,1
A14.724.557 0,3 - -
A02.835 1,0 1,0 -
A02.835.232 1,0 1,0 -
A02.835.583.443.800.800 0,2 - -
A11.872.653 1,4 1,4 1,4
A11.872.378.294 0,6 - -
A11.063 1,5 1,5 1,5
A11.066 0,9 - -
A15.145.229.188 4,6 4,6 4,6
A15.145.229.637.555.567.562.725 1,8 1,8 -
A15.145.693 1,8 1,8 -
A15.145.229.334 1,7 1,7 1,7
A15.145.229.637.555.567.569.200 1,6 - 1,6
A15.145.300 1,5 1,5 1,5
A15.145.229.637.555 1,1 1,1 1,1
A15.145 0,9 0,9 0,9
A15.145.229 0,7 0,7 0,7
A11.118.637.555.567.562 1,5 1,5 1,5
A11.118.637.555.567.569.200.700 1,2 - -
A11.118.637.415 1,1 - -
A11.118.637 1,1 1,1 1,1
A11.118.637.555.567.569 0,9 0,9 -
A11.118.637.555.567.562.440 0,5 - -
A02.165 1,5 1,5 1,5
A08.186.211.730.885.287.249.487 1,1 - -
A08.186.211.730.885.287.249 0,9 - -
A08.186.211.730.885.287.500.571.735 0,4 - -
A08.186.211.730.885.287.500.571 0,3 - -
A08.186.211.132.810.428.200 -0,2 - -
A08.186.211.865 -0,4 - -
A08.186.211.865.428 -0,4 - -
A10.165 1,1 1,1 1,1
A06.407.900 1,2 1,2 1,2
A11.443 1,7 1,7 1,7
A03.556.500.760.464 2,6 2,6 2,6
A03.556.500.760 2,4 2,4 2,4
A03.556.124.369 1,4 1,4 1,4
A03.556.124.526.767 1,2 1,2 1,2
A03.556.249.124 1,0 1,0 1,0
A03.556.124.684 0,7 0,7 0,7
A03.556 0,6 - -
A03.556.124 0,6 - 0,6
A03.556.249 0,4 - -
A03.556.249.249.356.668 0,4 - -
A03.556.249.249 0,3 - -
A03.556.249.249.356 0,3 - -
A05.360.319.679.256 0,4 - -
A07.541.358.100 1,1 - -
A15.378.316.580 1,0 - -
A15.378 1,0 1,0 -
A15.378.316 1,0 1,0 -
A15.382.216 1,4 1,4 1,4
A15.382.490.315.583 1,2 - -
A15.382 1,2 1,2 1,2
A15.382.490.555.567 1,2 1,2 1,2
A15.382.680 0,9 - -
A15.382.812.260 0,9 - -
A15.382.812 0,8 - -
A15.382.490.555.567.537 0,6 - -
A15.382.520.604.800 0,3 - -
A15.382.520 -0,1 - -
A03.620 0,2 - -
A10.549 -0,1 - -
A10.549.400 -0,2 - -
A10.615.550.599 0,3 - -
A10.615.550 0,2 - -
A14.549.885 1,3 - -
A14.549 0,7 - -
A14.549.167.646 0,6 - -
A02.633.567.850 2,7 2,7 2,7
A10.690.552 2,6 2,6 2,6
A10.690.552.500 2,6 2,6 2,6
A10.690 1,6 1,6 1,6
A11.627 0,9 - -
A11.627.340.360 0,5 - -
A04.623.603 0,3 - -
A02.835.232 1,2 1,2 1,2
A02.835 1,1 1,1 1,1
A11.872.378.294 0,5 - -
A05.810.890 1,2 1,2 1,2
A15.145.229.188 3,2 3,2 3,2
A15.145.846 1,8 1,8 1,8
A15.145.300 0,4 - -
A07.231.908.670 2,3 2,3 2,3
A07.231.908.670.874 2,3 2,3 2,3
A07.231 2,2 2,2 2,2
A07.231.908 2,2 2,2 2,2
A07.231.114 1,4 1,4 1,4
A10.165.114.830 2,1 2,1 2,1
A10.165.114.830.500 2,1 2,1 2,1
A10.165.114.830.500.750 2,1 2,1 2,1
A10.165.114.830.750 2,1 2,1 2,1
A10.165.114 1,9 1,9 1,9
A10.165.450 1,2 - -
A10.165.450.300 1,2 - -
A10.165.450.300.425 1,1 - -
A11.329.114 1,5 1,5 1,5
A11.329.228 1,5 1,5 1,5
A11.329.830 1,4 1,4 1,4
A11.329.171 0,6 - -
A06.407.071 0,6 - -
A06.407.071.140 0,6 - -
A06.407.312.782 0,6 - -
A06.407.900 0,3 - -
A11.436.275 2,2 2,2 2,2
A10.272.497 0,1 - -
A10.336 0,3 - -
A10.336.707 0,3 - -
A03.556.875.875 0,5 - -
A03.556.875 0,3 - -
A05.360.319.679.690 1,5 1,5 1,5
A05.360.490.690 1,2 - -
A05.360.490 1,1 - -
A05.360.319.679.490 0,8 - -
A05.360.319.679 0,6 - -
A05.360.319.887 0,4 - -
A05.360.444 0,4 - -
A05.360.444.492 0,3 - -
A11.497.497.600 1,2 - -
A07.541.510 1,2 1,2 -
A07.541.510.110 1,2 1,2 -
A07.541 1,0 - -
A15.382.520 0,1 - -
A15.382.520.604.700 0,1 - -
A03.620 0,4 - -
A04.411 0,7 0,7 0,7
A10.549.400 0,4 - -
A10.549 0,1 - -
A10.615.284 2,1 2,1 2,1
A10.615.284.473 2,1 2,1 2,1
A10.615.789 0,6 0,6 0,6
A10.615.550.599 0,3 - -
A11.620 1,8 1,8 1,8
A11.620.520 1,8 1,8 1,8
A10.690.467 1,7 1,7 1,7
A10.690 1,0 - -
A02.633.567.850 0,8 - -
A10.690.552 0,7 - -
A10.690.552.500 0,7 - -
A03.734 0,4 - -
A02.835.583 0,7 - -
A02.835.583.443 0,7 - -
A02.835.583.443.800 0,7 - -
A17.815 0,8 0,8 -
A11.872.580 0,9 0,9 -
A11.872.653 0,6 - -
A05.810.453.324 1,2 1,2 -
A05.810.453 0,9 0,9 0,9
A05.810 0,8 0,8 0,8
A15.145.229.188 2,6 - 2,6
A15.145.229.334 1,8 1,8 1,8
A08.186.211.730.885.287.249.487 1,2 - -
A11.382.625 1,9 1,9 1,9
A06.407.312 1,9 1,9 1,9
A06.407.312.782 1,9 1,9 1,9
A06.407 1,5 1,5 1,5
A06.407.900 0,6 - -
A11.436.294.064 1,9 1,9 1,9
A11.436 0,5 - -
A11.443 1,8 1,8 1,8
A10.336 0,4 - -
A10.336.707 0,4 - -
A09.371.729 7,5 7,5 7,5
A09.371 1,8 1,8 1,8
A09.371.060 0,5 - -
A09.371.337 0,5 - -
A09.371.337.168 0,5 - -
A03.556.875.500 1,1 1,1 1,1
A03.556.124.526.767 0,9 - -
A03.556.124.369 0,7 - -
A03.556 0,5 - -
A03.556.124 0,4 - -
A03.556.249 0,4 - -
A03.556.249.249 0,4 - -
A03.556.249.249.356 0,3 - -
A03.556.249.249.209 0,0 - -
A05.360.319.114.373 2,2 2,2 2,2
A05.360.319.114 1,9 1,9 1,9
A05.360.319.114.630 1,9 1,9 1,9
A05.360.319.679.256 1,3 1,3 1,3
A05.360.319 1,1 1,1 1,1
A05.360 0,9 0,9 0,9
A05.360.319.679 0,3 - -
A15.378.316.378.590.837.250 0,8 - -
A15.382.520.604.700 0,1 - -
A04.411 1,5 1,5 1,5
A10.615.284 3,6 3,6 3,6
A10.615.284.473 3,6 3,6 3,6
A14.549.885 2,7 2,7 2,7
A14.549 0,7 - -
A03.734.414 1,4 1,4 1,4
A03.734 0,2 - -
A02.835.232.043 0,5 - -
A02.835.232.043.300 0,5 - -
A02.835.232.043.300.710 0,5 - -
A11.872.378.590.817 0,8 - -
A05.810 1,5 1,5 1,5
A05.810.453 1,5 1,5 1,5
A05.810.890 1,0 1,0 1,0
A11.063 1,4 1,4 1,4
A11.066 0,7 - -
A15.145.229.637.555.567.562.725 2,2 2,2 2,2
A15.145.693 2,2 2,2 2,2
A15.145.229.637.555 0,7 - -
A15.145.229 0,5 - -
A15.145 0,4 - -
A11.118.637.415 1,4 1,4 -
A11.118.637.555.567.562 1,4 1,4 1,4
A11.118.637 0,9 - -
A08.186.211.653 1,0 - -
A08.186.211.730.317 1,0 - -
A08.186.211.730.317.357 0,7 - -
A08.186.211.730.317.357.352 0,5 - -
A08.186.211.730.317.357.352.435 0,5 - -
A08.186.211.132 -0,3 - -
A10.165.450 0,9 - -
A10.165.450.300 0,9 - -
A10.165 0,7 - -
A10.165.450.300.425 0,7 - -
A11.329.629 0,5 - -
A11.329.372.600 0,3 - -
A10.272.497 0,3 - -
A09.371.729 0,6 - -
A07.541.560 3,7 3,7 3,7
A07.541 3,2 3,2 3,2
A07.541.358 2,2 2,2 2,2
A07.541.358.100 2,0 - -
A15.378 0,9 - -
A15.378.316 0,9 - -
A15.378.316.580 0,9 - -
A15.382.490.315.583 1,5 1,5 -
A15.382 0,8 - -
A15.382.216 0,8 - -
A15.382.680 0,8 - -
A15.382.490.555.567 0,7 - -
A15.382.812 0,7 - -
A15.382.812.260 0,7 - -
A15.382.812.522 0,5 - -
A15.382.520 -0,1 - -
A15.382.520.604.800 -0,1 - -
A10.549 -0,1 - -
A10.549.400 -0,1 - -
A11.620 0,6 - -
A11.620.520 0,6 - -
A02.633.567.850 1,7 1,7 -
A10.690.552 1,6 1,6 -
A10.690.552.500 1,6 1,6 -
A10.690 1,2 - -
A11.627.340.360 1,1 1,1 -
A11.627 0,8 - -
A08.713 0,5 - -
A14.724.557 2,3 2,3 2,3
A14.724 1,3 1,3 1,3
A04.623.603 -0,1 - -
A02.835.232.834 0,9 0,9 0,9
A02.835.232.834.151 0,9 0,9 0,9
A02.835 0,8 - -
A02.835.232 0,8 - -
A11.872.700 3,9 3,9 3,9
A11.872.700.500 3,9 3,9 3,9
A11.872.040 2,5 2,5 2,5
A11.872.190 2,2 2,2 2,2
A11.872.190.260 0,8 - -
A11.872 0,7 0,7 -
A07.231.114 - 0,9 -
A02.165 - 3,0 -
A08.186.211.653 - 4,0 -
A08.186.211.730.885.287.249.487 - 3,6 -
A08.186.211.730.885.287.249 - 3,2 -
A08.186.211.730.885.287.500.270 - 2,5 -
A08.186.211.464.405 - 2,3 -
A08.186.211.730.317 - 2,3 -
A08.186.211.730.885.287.500.670 - 2,3 -
A08.186.211.730 - 2,2 -
A08.186.211.730.885 - 2,2 -
A08.186.211.730.885.287 - 2,2 -
A08.186.211.730.885.287.500 - 2,1 -
A08.186.211.464 - 2,0 -
A08.186 - 1,9 -
A08.186.211 - 1,9 -
A08.186.211.730.885.287.500.863 - 1,9 -
A08.186.211.464.710 - 1,8 -
A08.186.211.464.710.225 - 1,8 -
A08.186.211.730.885.287.500.571 - 1,7 -
A08.186.211.730.885.287.500.571.735 - 1,7 -
A08.186.211.132 - 1,4 -
A07.541.510 - 3,6 -
A07.541.510.110 - 3,6 -
A11.063 1,8 1,8 1,8
A11.066 1,1 1,1 -
A15.145.229.637.555.567.562.725 2,1 2,1 2,1
A15.145.693 2,1 2,1 2,1
A15.145.229.637.555 1,2 1,2 1,2
A15.145 0,8 0,8 0,8
A15.145.229 0,7 0,7 -
A15.145.229.637.555.567.569.200 0,4 - -
A15.145.846 0,4 - -
A11.118.637.555.567.562 1,8 1,8 1,8
A11.118.637 1,1 1,1 1,1
A11.118.637.555.567.562.440 0,9 0,9 -
A11.118.637.415 0,5 - -
A11.118.637.555.567.569 0,4 - -
A11.118.637.555.567.569.200.700 0,2 - -
A07.231.114 0,5 - -
A02.165 1,4 1,4 1,4
A08.186.211.730.885.287.249 0,9 - -
A10.165 1,0 1,0 -
A10.165.114 -0,2 - -
A10.165.114.830 -0,2 - -
A10.165.114.830.750 -0,2 - -
A11.329.372.600 2,5 2,5 2,5
A11.329 0,7 0,7 0,7
A06.407.900 1,3 1,3 1,3
A10.336 0,7 - -
A10.336.707 0,7 - -
A03.556.249.249.209 3,1 3,1 3,1
A03.556.124.684 1,5 1,5 1,5
A03.556.249.249.356.668 1,4 1,4 1,4
A03.556.124 1,0 1,0 1,0
A03.556.124.526.767 1,0 1,0 1,0
A03.556.249.249 1,0 1,0 1,0
A03.556.249 0,9 0,9 0,9
A03.556.249.249.356 0,9 0,9 0,9
A03.556 0,8 0,8 0,8
A03.556.124.369 0,7 - -
A03.556.875.500 0,6 0,6 -
A03.556.875 0,3 - -
A05.360.319.679.256 1,4 1,4 1,4
A05.360.319.679 0,5 - -
A05.360.444 0,3 - -
A15.378.316.580 1,2 1,2 -
A15.378 0,9 - -
A15.378.316 0,9 - -
A15.382.812.522 1,8 1,8 1,8
A15.382.812 1,4 1,4 1,4
A15.382.216 1,3 1,3 1,3
A15.382.680 1,3 1,3 1,3
A15.382 1,2 1,2 1,2
A15.382.490.555.567 1,2 1,2 1,2
A15.382.812.260 1,1 1,1 -
A15.382.520 1,1 1,1 1,1
A15.382.490.555.567.537 1,0 1,0 1,0
A15.382.520.604.800 0,8 - -
A15.382.490.555.567.622 0,5 - -
A15.382.490.315.583 0,4 - -
A15.382.520.604.700 0,1 - -
A10.549.400 1,4 1,4 1,4
A10.549 1,1 1,1 1,1
A10.615.789 0,6 - 0,6
A02.633.567.850 2,0 2,0 2,0
A10.690.552 1,6 1,6 -
A10.690.552.500 1,6 1,6 -
A10.690 1,1 - -
A11.627.340.360 1,7 1,7 1,7
A11.627 1,3 1,3 1,3
A11.627.624.249 0,6 - -
A04.623.603 0,8 - -
A14.724 0,8 - -
A14.724.557 0,8 - -
A02.835 1,0 1,0 -
A02.835.232 1,0 1,0 -
A02.835.583.443.800.800 0,4 - -
A11.872.378.590.635 0,9 - -
A11.872.378.294 0,9 0,9 -
A11.872.378 0,4 - -
A05.810.890 1,5 1,5 1,5
A05.810 1,2 1,2 1,2
A05.810.453 1,2 1,2 1,2
A08.186.211.730.317.357.352 1,1 1,1 -
A08.186.211.730.317.357.352.435 1,1 1,1 -
A08.186.211.653 0,9 - -
A08.186.211.730.317.357 0,9 - -
A08.186.211.730.317 0,8 - -
A08.186.211.730.885.287.500.270 0,7 - -
A08.186.211.464 0,2 - -
A08.186.211.464.405 0,2 - -
A08.186.211.730 0,2 - -
A08.186.211.464.710 0,1 - -
A08.186.211.464.710.225 0,1 - -
A08.186.211.730.885 0,1 - -
A08.186.211.730.885.287 0,1 - -
A08.186.211.730.885.287.500 0,1 - -
A08.186.211.730.885.287.500.863 0,1 - -
A08.186 0,0 - -
A08.186.211 0,0 - -
A10.165.450.300.425 0,7 - -
A11.329.171 1,0 1,0 -
A11.329.228 0,6 - -
A11.382 0,5 - -
A06.407.071.140 2,2 2,2 2,2
A06.407.071 1,9 1,9 1,9
A06.407.312.497.535.300.500 1,0 - -
A06.407 0,2 - -
A11.436.329 1,0 - -
A09.371.337 0,6 0,6 -
A09.371.337.168 0,6 0,6 -
A09.371.060 0,5 - -
A09.371 0,5 0,5 -
A03.556 0,3 - -
A03.556.249.249 0,2 - -
A03.556.249.249.209 0,2 - -
A03.556.249.249.356 0,2 - -
A03.556.249 0,1 - -
A05.360.319.114.630.535 1,0 - -
A05.360.490.690 0,9 - -
A05.360.490 0,8 - -
A05.360.319.679 0,7 - -
A05.360.319.679.490 0,7 - -
A05.360.319 0,3 - -
A05.360.319.679.690 0,3 - -
A05.360.319.679.256 0,2 - -
A05.360.319.887 0,0 - -
A11.497.497.600 0,9 - -
A07.541.358.100 3,1 3,1 3,1
A07.541.358 3,0 3,0 3,0
A07.541 1,5 - -
A07.541.560 1,5 - -
A15.382.490.555.567.622 0,6 - -
A03.620 0,2 - -
A10.615.550.599 0,9 - -
A10.615.789 0,6 - -
A14.549.885 2,4 2,4 2,4
A14.549.167.646 1,4 1,4 1,4
A14.549 1,3 1,3 1,3
A14.549.167 1,3 1,3 1,3
A11.620 0,6 - -
A11.620.520 0,6 - -
A02.633.567.850 1,0 - -
A10.690.552 0,9 - -
A10.690.552.500 0,9 - -
A10.690 0,8 - -
A10.690.467 0,5 - -
A11.627.624.249 1,0 1,0 -
A11.627.340.360 0,6 - -
A11.627.635 0,6 - -
A08.713 1,1 1,1 -
A14.724.557 0,3 - -
A14.724 0,1 - -
A02.835.232.043 0,5 - -
A02.835.232.043.300 0,5 - -
A02.835.232.043.300.710 0,5 - -
A02.835.232.834 0,5 - -
A02.835.232.834.151 0,5 - -
A02.835.583.443.800.800 0,0 - -
A11.872.653 1,0 - -
A11.872.378.590.635 0,9 - -
A11.872 0,3 - -
A05.810.453.324 1,7 1,7 1,7
A08.186.211.730.885.287.249.487 - 2,2 2,2
A08.186.211.653 - 1,9 1,9
A08.186.211.730.885.287.249 - 1,8 1,8
A08.186.211.464.405 - 1,6 1,6
A08.186.211.730.317 - 1,4 1,4
A08.186 - 1,2 1,2
A08.186.211 - 1,2 1,2
A08.186.211.132 - 1,1 -
A08.186.211.730.317.357 - 1,1 -
A08.186.211.865 - 0,7 -
A08.186.211.865.428 - 0,7 -
A08.186.211.132.810.428.200 - 0,6 -
A11.329.629 - 1,7 1,7
A06.407.312 - 0,9 0,9
A06.407 - 0,7 0,7
A10.272.497 - 2,2 2,2
A10.272 - 1,1 1,1
A09.371.060 - 0,7 0,7
A09.371.337 - 0,7 0,7
A09.371.337.168 - 0,7 0,7
A09.371 - 0,6 0,6
A03.556.124.369 - 1,8 1,8
A03.556.124.526.767 - 1,3 1,3
A03.556.124 - 1,1 1,1
A03.556.249 - 1,1 1,1
A03.556.249.249 - 1,1 1,1
A03.556.249.249.356 - 1,1 1,1
A03.556.249.249.356.668 - 1,1 1,1
A03.556 - 0,9 0,9
A03.556.249.249.209 - 0,9 0,9
A03.556.875.875 - 0,8 0,8
A03.556.875 - 0,6 0,6
A05.360.319.114.373 - 1,2 1,2
A05.360.319.114 - 1,0 1,0
A05.360.319.114.630 - 1,0 1,0
A05.360 - 0,8 0,8
A05.360.319 - 0,8 0,8
A05.360.319.679 - 0,7 0,7
A10.615.550 - 1,1 1,1
A10.615.550.760 - 0,9 -
A10.615 - 0,9 0,9
A04.531.520 - 0,9 -
A09.531 - 0,9 -
A02.835.232.043 - 0,6 0,6
A02.835.232.043.300 - 0,6 0,6
A02.835.232.043.300.710 - 0,6 0,6
A17.815 - 0,8 -
A11.872.653 - 1,3 1,3
A05.810.453 - - 0,5
A15.145.229.334 1,0 - -
A15.145.846 0,5 - -
A07.231.908.670 0,7 - -
A07.231.908.670.874 0,7 - -
A07.231.908 0,5 - -
A08.186.211.132.810.428.200 -0,4 - -
A08.186.211.865 -0,4 - -
A08.186.211.865.428 -0,4 - -
A11.329.228 0,5 - -
A11.382 1,2 1,2 1,2
A11.382.625 1,2 1,2 1,2
A06.407.071.140 1,4 1,4 1,4
A06.407.071 1,3 1,3 1,3
A06.407.312.497.535.300.500 1,2 1,2 -
A06.407.312.782 0,9 - -
A06.407 0,5 - -
A06.407.312 0,4 - -
A11.436.348 1,8 1,8 1,8
A11.436.329 1,2 1,2 -
A11.436.294.064 1,2 1,2 1,2
A11.436.397 0,8 - -
A11.436.275 0,7 - -
A11.436 0,6 0,6 -
A11.443 1,0 - -
A09.371.729 0,7 - -
A03.556.249.249.356 0,4 - -
A03.556 0,3 - -
A03.556.249 0,3 - -
A03.556.249.249 0,3 - -
A03.556.124 0,2 - -
A03.556.249.249.209 0,2 - -
A05.360.490 1,4 1,4 1,4
A05.360.490.690 1,4 1,4 1,4
A05.360.319.114.630.535 1,2 1,2 -
A05.360.319.114.373 0,5 - -
A05.360.319.114 0,4 - -
A05.360.319.114.630 0,4 - -
A05.360.319.679.490 0,4 - -
A05.360.319.887 0,4 0,4 -
A05.360.319 0,3 - -
A05.360.319.679 0,3 - -
A05.360 0,2 - -
A11.497.497.600 1,4 1,4 1,4
A07.541.560 1,7 - -
A07.541 1,5 - -
A15.378.316.378.590.837.250 3,0 3,0 3,0
A15.382.490.555.567.622 2,1 2,1 2,1
A15.382.520.604.700 0,1 - -
A15.382.520 -0,2 - -
A04.411 0,7 0,7 0,7
A10.549 -0,2 - -
A10.615.284 1,5 1,5 1,5
A10.615.284.473 1,5 1,5 1,5
A10.615.550.599 0,5 - -
A14.549.885 0,7 - -
A14.549 0,4 - -
A11.627.635 1,9 1,9 1,9
A11.627.624.249 1,8 1,8 1,8
A11.627.340.360 0,7 - -
A03.734.414 1,2 1,2 1,2
A02.835.232.834 0,8 0,8 0,8
A02.835.232.834.151 0,8 0,8 0,8
A11.872.378.590.817 3,0 3,0 3,0
A11.872.700 2,4 2,4 2,4
A11.872.700.500 2,4 2,4 2,4
A11.872.190 2,1 2,1 2,1
A11.872.040 1,9 1,9 1,9
A11.872.378.590.635 1,5 1,5 1,5
A11.872.378 1,4 1,4 1,4
A11.872.653 1,1 - -
A11.872 1,1 1,1 1,1
A11.872.190.260 0,8 0,8 -
A15.145.229.637.555.567.569.200 1,5 - 1,5
A15.145.846 1,0 1,0 -
A15.145.300 0,9 - -
A15.145.229.637.555 0,7 - -
A15.145 0,6 - -
A15.145.229 0,5 - -
A11.118.637.555.567.569 1,3 1,3 1,3
A11.118.637.555.567.569.200.700 1,1 - -
A11.118.637.415 0,3 - -
A11.118.637.555.567.562.440 0,2 - -
A07.231 0,6 - -
A08.186.211.730.317.357.352 3,1 3,1 3,1
A08.186.211.730.317.357.352.435 3,1 3,1 3,1
A08.186.211.730.317.357 2,7 2,7 2,7
A08.186.211.730.317 2,1 2,1 2,1
A08.186.211.730.885.287.500.670 1,3 1,3 1,3
A08.186.211.464.405 1,2 - -
A08.186.211.653 1,2 - -
A08.186.211.464 1,1 - -
A08.186.211.464.710 1,0 - -
A08.186.211.464.710.225 1,0 - -
A08.186.211.730.885.287.500.270 1,0 - -
A08.186.211.730 0,9 - -
A08.186.211.730.885.287.500 0,9 - -
A08.186.211.730.885.287.500.863 0,9 - -
A08.186.211.730.885 0,8 - -
A08.186.211.730.885.287 0,8 - -
A08.186.211.132 0,7 - -
A08.186.211.132.810.428.200 0,4 - -
A08.186.211.865 0,4 - -
A08.186.211.865.428 0,4 - -
A08.186 0,3 - -
A08.186.211 0,3 - -
A10.165.114.830.500 -0,1 - -
A10.165.114.830.500.750 -0,1 - -
A10.165.114.830 -0,3 - -
A10.165.114.830.750 -0,3 - -
A06.407.071.140 2,1 2,1 2,1
A06.407.071 1,9 1,9 1,9
A11.436.348 0,6 - -
A11.436.275 0,4 - -
A03.556.500.760.464 1,8 1,8 1,8
A03.556.500.760 1,7 1,7 1,7
A03.556.249.124 0,8 - 0,8
A03.556.875.875 0,6 0,6 -
A03.556.124.684 0,5 0,5 -
A03.556.875 0,4 - -
A03.556.124.526.767 0,2 - -
A03.556.249.249.209 0,1 - -
A15.382.490.555.567.622 1,0 1,0 -
A15.382.490.555.567 0,9 - -
A15.382.490.555.567.537 0,6 - -
A15.382.490.315.583 0,3 - -
A15.382.520.604.700 0,1 - -
A10.615.789 1,2 1,2 1,2
A10.615.550.760 0,4 - -
A02.633.567.850 0,5 - -
A10.690.552 0,4 - -
A10.690.552.500 0,4 - -
A11.627.624.249 0,9 - -
A08.713 3,1 3,1 3,1
A04.531.520 0,4 - -
A09.531 0,4 - -
A02.835.583 0,6 - -
A02.835.583.443 0,6 - -
A02.835.583.443.800 0,6 - -
A02.835.583.443.800.800 0,6 0,6 -
A11.872.653 1,6 1,6 1,6
A11.872.700 1,2 - -
A11.872.700.500 1,2 - -
A11.872.040 0,8 - -
A11.872.190.260 0,7 - -
A11.872.190 0,4 - -
A11.872.378 0,4 - -
A11.872.378.294 0,2 - -
A05.810.890 0,6 0,6 -
A15.145.229.188 - 5,3 5,3
A15.145.229.334 - 1,6 1,6
A15.145.300 - 1,1 1,1
A08.186.211.653 - 3,7 3,7
A08.186.211.730.885.287.500.270 - 2,5 2,5
A08.186.211.730.885.287.249 - 2,4 2,4
A08.186.211.730.885.287.249.487 - 2,4 2,4
A08.186.211.730.885.287.500.571 - 2,0 2,0
A08.186.211.730.885.287.500.571.735 - 1,9 1,9
A08.186.211.730.885.287.500.863 - 1,9 1,9
A08.186.211.464.710 - 1,8 1,8
A08.186.211.464.710.225 - 1,8 1,8
A08.186.211.730.317 - 1,8 1,8
A08.186.211.730 - 1,6 1,6
A08.186.211.730.885 - 1,5 1,5
A08.186.211.730.885.287 - 1,5 1,5
A08.186.211.730.885.287.500 - 1,5 1,5
A08.186.211.132 - 1,4 1,4
A08.186.211.730.317.357 - 1,3 -
A08.186.211.730.885.287.500.670 - 1,3 -
A08.186.211.730.317.357.352 - 1,1 -
A08.186.211.730.317.357.352.435 - 1,1 -
A08.186 - 1,1 1,1
A08.186.211 - 1,1 1,1
A11.443 - 1,6 1,6
A08.713 - 1,1 -
A11.872.653 - 3,8 3,8
MeSH: Medical Subject Heading
